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Background: Age-related macular degeneration is the most common cause of sight impairment in the UK.
In neovascular age-related macular degeneration (nAMD), vision worsens rapidly (over weeks) due to
abnormal blood vessels developing that leak fluid and blood at the macula.
Objectives: To determine the optimal role of optical coherence tomography (OCT) in diagnosing people
newly presenting with suspected nAMD and monitoring those previously diagnosed with the disease.
Data sources: Databases searched: MEDLINE (1946 to March 2013), MEDLINE In-Process & Other
Non-Indexed Citations (March 2013), EMBASE (1988 to March 2013), Biosciences Information Service
(1995 to March 2013), Science Citation Index (1995 to March 2013), The Cochrane Library (Issue 2 2013),
Database of Abstracts of Reviews of Effects (inception to March 2013), Medion (inception to March 2013),
Health Technology Assessment database (inception to March 2013).
Review methods: Types of studies: direct/indirect studies reporting diagnostic outcomes. Index test:
time domain optical coherence tomography (TD-OCT) or spectral domain optical coherence tomography
(SD-OCT). Comparators: clinical evaluation, visual acuity, Amsler grid, colour fundus photographs,
infrared reflectance, red-free images/blue reflectance, fundus autofluorescence imaging, indocyanine
green angiography, preferential hyperacuity perimetry, microperimetry. Reference standard: fundus
fluorescein angiography (FFA). Risk of bias was assessed using quality assessment of diagnostic accuracy
studies, version 2. Meta-analysis models were fitted using hierarchical summary receiver operating
characteristic curves. A Markov model was developed (65-year-old cohort, nAMD prevalence 70%), with
nine strategies for diagnosis and/or monitoring, and cost–utility analysis conducted. NHS and Personal
Social Services perspective was adopted. Costs (2011/12 prices) and quality-adjusted life-years (QALYs)
were discounted (3.5%). Deterministic and probabilistic sensitivity analyses were performed.
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Results: In pooled estimates of diagnostic studies (all TD-OCT), sensitivity and specificity [95% confidence
interval (CI)] was 88% (46% to 98%) and 78% (64% to 88%) respectively. For monitoring, the pooled
sensitivity and specificity (95% CI) was 85% (72% to 93%) and 48% (30% to 67%) respectively. The FFA
for diagnosis and nurse-technician-led monitoring strategy had the lowest cost (£39,769; QALYs 10.473)
and dominated all others except FFA for diagnosis and ophthalmologist-led monitoring (£44,649; QALYs
10.575; incremental cost-effectiveness ratio £47,768). The least costly strategy had a 46.4% probability
of being cost-effective at £30,000 willingness-to-pay threshold.
Limitations: Very few studies provided sufficient information for inclusion in meta-analyses. Only a few
studies reported other tests; for some tests no studies were identified. The modelling was hampered by a
lack of data on the diagnostic accuracy of strategies involving several tests.
Conclusions: Based on a small body of evidence of variable quality, OCT had high sensitivity and moderate
specificity for diagnosis, and relatively high sensitivity but low specificity for monitoring. Strategies involving
OCT alone for diagnosis and/or monitoring were unlikely to be cost-effective. Further research is required
on (i) the performance of SD-OCT compared with FFA, especially for monitoring but also for diagnosis;
(ii) the performance of strategies involving combinations/sequences of tests, for diagnosis and monitoring;
(iii) the likelihood of active and inactive nAMD becoming inactive or active respectively; and (iv) assessment
of treatment-associated utility weights (e.g. decrements), through a preference-based study.
Study registration: This study is registered as PROSPERO CRD42012001930.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
Case–control study This type of study compares a group of people who have the disease and a group
who do not have the disease.
Choroidal neovascularisation New blood vessels originating from the choroid. The choroid is a thin
layer of connective tissue that lies between the retina and the sclera and supplies blood to the outer layers
of the retina.
Diagnostic odds ratio The ratio of the odds of testing positive in those with the disease relative to the
odds of testing positive in those without the disease.
Direct head-to-head study A study in which people receive both index and comparator tests (i.e. tests
are evaluated in the same participants).
False negative/true negative/false positive/true positive In terms of diagnostic accuracy,
indicators of index test results as compared with the reference standard: negative index test, positive
reference standard/negative index test, negative reference standard/positive index test, negative reference
standard/positive index test, positive reference standard.
Fundus fluorescein angiography An invasive imaging test that examines the circulation of the retina
and choroid. A fluorescein dye is injected into a vein in the arm and a specialised camera photographs the
dye as it passes through the blood vessels in the eye.
Index test The diagnostic test which is being evaluated.
Likelihood ratio A description of how many times more likely it is that a person with the disease will
receive a particular test result than a person without the disease.
Macula The central part of the retina containing the xanthophyll pigment and two or more layers
of ganglion cells. Damage to the centre of the macula, the so-called fovea, often results in loss of
central vision.
Meta-analysis The quantitative pooling of data from two or more studies.
Negative predictive value The proportion of those with negative test results who do not have
the disease.
Neovascular age-related macular degeneration In neovascular or ‘wet’ age-related macular
degeneration, abnormal blood vessels grow into the macula and leak blood or fluid, leading to scarring of
the macula and rapid loss of central vision.
Optical coherence tomography A non-invasive imaging technology used to obtain high resolution
cross-sectional images of the retina.
Positive predictive value The proportion of those with positive test results who actually have
the disease.
Randomised controlled trial A study in which people are randomly allocated to receive – or not
receive – a particular treatment or intervention. This is said to be the best study type to determine
effectiveness of a treatment.
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Reference standard The best available test for establishing the presence or absence of the disease.
Retina The light-sensitive layer of tissue located in the back of the eye. The retina receives images via the
eye’s lens, converts them to electric signals and transmits them to the brain.
Sensitivity The proportion of those who actually have the disease and who are correctly identified with
positive test results.
Specificity The proportion of those who actually do not have the disease and who are correctly identified
with negative test results.
Visual acuity Sharpness of vision, which is tested by identifying characters on a chart from a set distance.
Normal visual acuity is usually referred to as 20/20 vision, meaning the detail that a person with normal
eyesight would see from 20 feet away.
Visual impairment ≤ 6/60 to > 3/60, severe visual impairment; ≤ 3/60, profound visual
impairment/blindness.
GLOSSARY
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AMD age-related macular degeneration
antiVEGF antivascular endothelial growth
factor
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and Ophthalmology
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CEAC cost-effectiveness acceptability
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CI confidence interval
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SD-OCT spectral domain optical coherence
tomography
SHTAC Southampton Health Technology
Assessments Centre
SLB slit-lamp biomicroscopy
SLO scanning laser ophthalmoscope
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SROC summary receiver operating
characteristic
subRPE subretinal pigment epithelium
TD-OCT time domain optical coherence
tomography
TN true negative
TP true positive
VA visual acuity
VEGF vascular endothelial growth factor
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Plain English summary
In wet age-related macular degeneration (AMD), abnormal blood vessels develop that leak fluid andblood in the back of the eye, causing central vision to worsen rapidly (over weeks). Optical coherence
tomography (OCT) is a non-invasive imaging test, widely used in the NHS, that can detect wet AMD.
The more recent spectral domain OCT contains improvements over time domain OCT. OCT is usually used
along with other tests, such as visual acuity. This review assessed the evidence for the usefulness of OCT in
diagnosing people newly presenting with suspected wet AMD, and in determining disease activity during
regular monitoring visits for those previously diagnosed with the condition. The date of the last literature
searches was March 2013. Twenty-two diagnostic and eight monitoring studies were included. The
evidence suggested that, for diagnosis, OCT had high sensitivity (very few people with wet AMD would be
wrongly diagnosed as not having it) and moderate specificity (around one-quarter of those without wet
AMD would be wrongly diagnosed as having it). For monitoring, OCT also had high sensitivity but low
specificity (half of those without active disease would be wrongly diagnosed as having it). Therefore,
although OCT is a sensitive test and would detect most people with wet AMD, if used as the only test to
guide treatment then, potentially, a considerable number of people with inactive disease would receive
treatment. However, these results should be interpreted with caution owing to the small number of studies
identified and their variable quality.
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Scientific summary
Background
Age-related macular degeneration is the most common cause of sight impairment in the UK.
In neovascular age-related macular degeneration (nAMD), vision worsens rapidly (over weeks) due to
abnormal blood vessels developing that leak fluid and blood at the macula. For patients with nAMD,
it is common practice to initiate treatment with three consecutive (monthly) injections of antivascular
endothelial growth factor therapy, and then the patient is reassessed to evaluate whether the disease is
active or inactive. Many patients require monthly monitoring and treatment over a period of several years.
Fundus fluorescein angiography (FFA), an invasive test, is considered the reference standard for detecting
nAMD at initial presentation and it is also used for detecting recurrent activity at some monitoring visits.
Optical coherence tomography (OCT) is a non-invasive test that can be used for detecting nAMD at initial
presentation and is often used as the only imaging test for detecting recurrent activity during monitoring
visits. The more recently introduced spectral domain optical coherence tomography (SD-OCT) incorporates
a number of improvements over time domain optical coherence tomography (TD-OCT).
Objectives
This review aims to determine the optimal role of OCT in (i) the diagnosis of people newly presenting with
suspected nAMD and (ii) in monitoring those previously diagnosed with the disease.
Methods
Electronic databases searched included MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations,
EMBASE, Bioscience Information Service, Science Citation Index, Cochrane Central Register of Controlled
Trials, Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects, Medion,
Health Technology Assessment database, PsycINFO, Applied Social Sciences Index and Abstracts,
conference abstracts from the American Academy of Ophthalmology, the Association for Research in
Vision and Ophthalmology, the European Association for Vision and Eye Research and current research
registers. Searches were carried out from 1995 to March 2013 other than for conference abstracts
(2009 to November 2012).
Types of studies considered included direct or indirect comparisons reporting diagnostic outcomes. The
population was people with newly suspected nAMD or those previously diagnosed with the disease and
under surveillance monitoring. The index test was TD-OCT or SD-OCT and comparator tests considered
were clinical evaluation, visual acuity (VA), Amsler grid, colour fundus photographs, infrared reflectance,
red-free images or blue reflectance, fundus autofluorescence (FAF) imaging, indocyanine green
angiography (ICGA), preferential hyperacuity perimetry (PHP) and microperimetry. The reference standard
was FFA.
Two reviewers independently screened the titles and abstracts of all reports identified by the search
strategy and full-text papers were obtained for assessment. Data extraction was undertaken by one
reviewer and checked by a second. Two reviewers independently assessed the risk of bias of the studies
using the quality assessment of diagnostic accuracy studies, version 2 instrument.
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The results of the individual studies were tabulated and sensitivity, specificity and their 95% confidence
intervals (CIs) presented for each test or combination of tests. The presence of heterogeneity was assessed
by visual examination of forest plots of sensitivity and specificity. Summary receiver operating characteristic
curves were derived. Meta-analysis models were fitted using hierarchical summary receiver operating
characteristic (HSROC) curves. Summary sensitivity, specificity, positive and negative likelihood ratios and
diagnostic odds ratios were reported as median and 95% CI.
An economic model was developed to assess the cost-effectiveness of different strategies for diagnosis and
monitoring of individuals with nAMD. Three strategies were selected for the diagnostic stage and three for
the monitoring stage, giving a total of nine diagnosis–monitoring combinations.
Diagnostic strategies
(a) Stereoscopic FFA interpreted by an ophthalmologist. If positive (i.e. presence of nAMD), treat and
monitor; if negative, discharge.
(b) OCT alone interpreted by an ophthalmologist. If positive, treat and monitor; if negative, discharge.
(c) VA, OCT and slit-lamp biomicroscopy (SLB) in all patients, performed/interpreted by an
ophthalmologist. If positive or unclear, arrange for a FFA. If negative, discharge. This is the diagnostic
strategy that best reflects standard practice.
Monitoring strategies
(a) OCT alone (interpreted by an ophthalmologist). If positive, treat. If negative or unclear, review in
1 month’s time.
(b) VA, SLB and OCT interpreted together by an ophthalmologist. If positive, treat; if negative, review in
1 month’s time. If unclear, then the ophthalmologist will arrange for a FFA. This is the monitoring
strategy that best reflects standard practice.
(c) VA and OCT interpreted by a technician or nurse. If negative, review in 1 month’s time. If positive or
unclear, refer to an ophthalmologist for assessment (e.g. SLB and ophthalmologist interpretation
of VA and SD-OCT test results). If positive, treat; if negative, review in 1 month’s time; if unclear,
arrange for a FFA.
The model was run for a cohort of 65-year-old men for a lifetime time horizon. A 1-month cycle length
was defined. Costs were expressed in 2011–12 pounds sterling and effectiveness in quality-adjusted
life-years (QALYs). Costs and QALYs were discounted at 3.5%. Cost-effectiveness analysis results were
reported using incremental cost-effectiveness ratios.
Uncertainty was explored by conducting one-way sensitivity analyses, scenario analysis and probabilistic
sensitivity analysis. One-way sensitivity analyses were conducted on test sensitivity and specificity for
diagnosis, the probability of ophthalmologist diagnosis or monitoring having unclear results, test sensitivity
and specificity for monitoring, the probability of the nurse or technician assessment being unclear, and unit
costs for OCT, FFA and ranibizumab [Lucentis®, Genentech Inc. (USA)/Novartis Pharmaceutical
Ltd] treatment.
In addition, three scenario analyses were tested. All of these incorporated data favouring OCT
(e.g. scenario 1 included the 95% CI upper limit for OCT sensitivity and specificity for diagnosis and
monitoring, with £20.90 and £139 unit costs for OCT and FFA respectively). Scenario 2 assumed a cost per
treatment injection of £50 instead of £742, and scenario 3 explored the effect of monitoring patients with
OCT only, within the community, with referral to secondary care only for treatment.
SCIENTIFIC SUMMARY
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Results
Number and quality of studies
Twenty-two diagnostic studies (20 full text, two abstracts) enrolling 2124 people and eight (full-text)
monitoring studies enrolling 463 people were included. Only full-text studies were assessed for risk of bias.
For both the diagnostic and monitoring studies, the domains in which the greatest number of studies were
judged to be at high risk of bias were the patient selection domain (55%, 11/20; 25%, 2/8) and flow and
timing domain (40%, 8/20; 25%, 2/8).
Summary of benefits and risks
Diagnostic studies
In a meta-analysis of diagnostic studies (four TD-OCT studies) sensitivity and specificity (95% CI) was 88%
(46% to 98%) and 78% (64% to 88%) respectively.
In descriptive analyses, across the studies reporting other tests, median sensitivity was high for ICGA
(93.2%, range 84.6–100.0%; four studies) and FAF (93.3%; one study), followed by PHP (81.5%,
range 50.0–84.8%; three studies), colour fundus photography (70.0%; one study) and lowest for Amsler
grid (41.7%; one study). Specificity was highest for colour fundus photography (95%; one study), followed
by PHP (84.6% and 87.7%; two studies), and was low for FAF (37.1%; one study) and ICGA (36.8%;
one study).
Monitoring studies
In a meta-analysis of monitoring studies (three TD-OCT, two SD-OCT studies), sensitivity and specificity
(95% CI) was 85% (72% to 93%) and 48% (30% to 67%) respectively. For TD-OCT, sensitivity and
specificity was 70% (56% to 80%) and 65% (48% to 79%) respectively. It was not possible to calculate
pooled estimates using HSROC methodology for the two SD-OCT monitoring studies due to insufficient
data. These studies reported high sensitivity of 94% and 90% but low specificity of 27% and 47%.
In the one monitoring study reporting ICGA, sensitivity of 75.9% and specificity of 88.0% was reported
for detecting nAMD activity.
Summary of cost-effectiveness
The strategy that based its diagnostic decision on the results of FFA only, combined with VA and OCT
interpreted together by a nurse or technician as a first monitoring step (‘FFA & Nurse’), had the lowest total
expected cost. This strategy dominated (i.e. lower total cost and higher QALYs) all others apart from one.
Diagnosis based on FFA only, followed by ophthalmologist-led monitoring (‘FFA & Ophthalmologist’),
had a higher total expected cost and also produced higher total expected QALYs but at a cost per additional
QALY > £30,000. Moreover, the ‘FFA & Nurse’ strategy had a 46.5% probability of being cost-effective at a
£30,000 threshold value of willingness to pay for an extra QALY. Strategies using OCT alone for diagnosis
or monitoring were unlikely to be cost-effective. This result seemed to be driven by the OCT low specificity
that resulted in a high number of false positives (FPs).
Discussion
Strengths, limitations of the analyses and uncertainties
In terms of strengths, a systematic literature search was undertaken and non-English language studies
were included. A HSROC model was applied, which takes account of the trade-off between true
positives/FPs and models between-study heterogeneity. The evidence for diagnosis and monitoring was
considered separately, as was the evidence for TD-OCT and SD-OCT. Regarding the economic model,
multiple different pathways were developed and evaluated. In terms of limitations, very few studies
provided sufficient information for inclusion in meta-analyses. Only a few studies meeting our inclusion
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criteria reported the performance of other diagnostic tests of interest; for some tests no studies were
identified. The modelling was hampered by a lack of data on the diagnostic accuracy of strategies
involving several tests (performed by ophthalmologists or other health professionals).
In terms of uncertainties, there was substantial disagreement between OCT and FFA specificity, especially
for monitoring. As FFA was considered the reference standard it was not possible to assess whether or not
OCT might have better sensitivity or specificity than FFA. It was unclear why the specificity was lower for
SD-OCT compared with TD-OCT.
The model was based on one eye status and outcomes, as this is the approach most commonly used in
this health area. The so named ‘one eye models’ can underestimate resources used due to a proportion of
nAMD individuals having active nAMD in both eyes in one particular visit. In the current model, this would
increase the cost for those strategies with a higher number of FPs (i.e. lower specificity) and therefore
would be unlikely to modify the general conclusions of this report. In addition, the model did not consider
effects on utility due to treatment injections and frequent monitoring. Anxiety in nAMD individuals was
believed to occur at each monitoring visit mainly due to uncertainty of the underlying condition rather than
the effects of treatment injections. Limited evidence was available on the probability of nAMD active
individuals becoming inactive when under treatment or inactive nAMD individuals becoming active.
Short-time follow-up data were extrapolated to a lifetime time horizon.
Generalisability of the findings
From the populations evaluated in the primary studies, the results of this report are broadly generalisable
to the NHS. One of the UK-based diagnostic studies evaluated a nurse-led, fast-track screening clinic,
which may not be representative of current UK practice. In addition, 55% of the diagnostic and 25%
of the monitoring studies were considered to be at risk of selection bias due to either pre-selection of
participants and/or inappropriate exclusions.
Conclusions
Implications for service provision
In terms of OCT test performance, this review found that, based on a relatively small body of evidence of
variable quality:
l For diagnosis of newly suspected nAMD, OCT had high sensitivity (88%) and moderate specificity
(78%) (meta-analysis).
l For monitoring of those previously diagnosed with nAMD, OCT had high sensitivity (85%) but low
specificity (48%) (meta-analysis).
l OCT had higher sensitivity than TD-OCT but lower specificity (monitoring studies).
The strategy that based its diagnostic decision on the results of FFA only, combined with a nurse- or
technician-led stepwise approach for monitoring, had the lowest expected total cost and a 47%
probability of being cost-effective at a £30,000 threshold value of willingness to pay for an extra QALY.
Strategies using OCT test results alone to make diagnosis and/or monitoring treatment decisions were
unlikely to be a cost-effective use of resources.
There has already been a shift in the diagnostic and monitoring pathways for nAMD caused by the
adoption of OCT. At the diagnostic stage, OCT is currently used in addition to FFA (reference standard),
whereas for monitoring it has virtually replaced FFA, which is only used in selected circumstances. The
evidence suggests that using OCT as the only test for monitoring patients with nAMD and detecting
activity would, potentially, result in a substantial proportion of patients receiving treatment unnecessarily.
SCIENTIFIC SUMMARY
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The continuing rise in the ageing population, with increasing numbers of people being diagnosed with
nAMD and moving on to monitoring for renewed disease activity, will continue to present challenges for
ophthalmology departments to have sufficient capacity to provide timely testing and treatment.
Suggested research priorities
l Regarding monitoring of nAMD, OCT is routinely used in current practice, while FFA is used only in
particular scenarios. There is a substantial disagreement between OCT and FFA. There is a need to
research that OCT (without FFA) is an acceptable way of detecting active nAMD and guiding
treatment. As there is the theoretical possibility of OCT being better in some cases than the current
reference standard, such studies might be designed to include a ‘fair umpire’ test, if available,
to examine differences between OCT and FFA, or be designed to incorporate sufficient follow-up to
assess the consequences of the tests in terms of clinical effectiveness outcomes (e.g. VA).
l Regarding diagnosis of nAMD, current practice consists of FFA (as reference standard) associated with
OCT. Further research should be considered to establish the added value of OCT, and whether OCT
(associated with SLB and VA) can fully replace FFA. As above, such studies might be designed to
include a ‘fair umpire’ test, or the evaluation of the consequences of the diagnostic intervention.
l Regarding the different phenotypes of nAMD, further evidence on the diagnostic performance of OCT
according to phenotype of nAMD is required.
l For both diagnosis and monitoring of nAMD, prospective studies are required to assess the diagnostic
accuracy and clinical effectiveness of strategies involving possible different combinations and sequences
of tests (e.g. VA, SLB, FAF imaging, OCT), including a comparison of their interpretation by
ophthalmologists compared with other health professionals.
l To strengthen the evidence base used to develop the economic model, it would be important to
explore the likelihood of active and inactive nAMD individuals becoming inactive or active respectively.
In addition, a preference-based study to assess utility weights (e.g. decrements) associated with
treatment and frequent monitoring is needed.
l Further research is needed to evaluate health status (utilities) in patients with nAMD, taking into
consideration the visual function and spectrum of disease in both eyes and exploring the value added
by inclusion of fellow eye information.
Study registration
This study is registered as CRD42012001930.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Description of health problem
Brief statement describing the health problem
Neovascular age-related macular degeneration (nAMD) causes severe visual loss and is the most common
cause of blindness in persons aged > 50 years in the Western world. In recent years, there have been
significant advances in the clinical management of patients with nAMD. For example, there are now
effective treatments, specifically antivascular endothelial growth factor (antiVEGF), and novel diagnostic
technologies, including both imaging and functional tests. Patients who are being treated for nAMD with
antiVEGF require frequent and long-term follow-up for treatment to be most effective.
The current reference standard for diagnosis of nAMD is fundus fluorescein angiography (FFA)1 which may
also be used to monitor the activity of the disease after treatment. However, FFA is time-consuming,
invasive and requires expert interpretation. Optical coherence tomography (OCT) is now widely used for
the diagnosis and management of nAMD. OCT is non-invasive, safer and more straightforward to do and
interpret than FFA. OCT may help clinicians to provide a more cost-effective service for people with nAMD
by potentially replacing the current reference standard of FFA and helping to distinguish between those
patients with active disease requiring treatment and those whose disease is not active at a particular point
in time and who do not require treatment. OCT might also lead to efficiencies by allowing other categories
of health professionals to become involved in the diagnosis and monitoring of patients.
Aetiology, pathology and prognosis
Neovascular age-related macular degeneration is a pathological process in which new blood vessels
arising from the choroid breach the normal tissue barriers and come to lie within the subretinal pigment
epithelium (subRPE) and/or subretinal spaces. These new vessels, commonly referred to as choroidal
neovascularisation (CNV) or choroidal neovascular membrane (CNVM), leak fluid, lipids and blood, elicit an
inflammatory response and, as part of their natural history, undergo a scarring process, all of which has a
deleterious effect on the visual cells of the retina (photoreceptors), leading to central loss of vision. Besides
CNV, there are two other recognised phenotypes of nAMD: (1) retinal angiomatous proliferation (RAP)
in which vascular complex seems to arise de novo from the retinal circulation, or results from CNV
anastomosing with the retinal circulation; and (2) intrachoroidal/subRPE aneurysmal dilatation(s) of the
choroidal vasculature, known as idiopathic polypoidal choroidal vasculopathy (IPCV).2 These phenotypes
may occur in isolation or be mixed with other phenotypes.3
The onset of nAMD results in progressive and unremitting loss of central vision in the affected eye, with
rare exceptions in cases of IPCV in which spontaneous improvement may be observed. A number of
studies have shown that extrafoveal CNV will grow towards the fovea. Once foveal involvement has
occurred, CNV will expand and involve ever-increasing areas of the macula. Thus, the majority of eyes will
experience acute visual loss, either moderate [defined as a doubling of the visual angle which equates to a
three-line worsening on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart] or
severe (defined as a quadrupling of the visual angle and which equates to a six-line worsening on the
ETDRS VA chart). However, some patients with a fellow eye with good vision will not notice any such
changes despite the onset of neovascularisation.
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Neovascular age-related macular degeneration is now treated with repeated intraocular injections of drugs
designed to antagonise vascular endothelial growth factor (antiVEGF). This will stabilise sight in most
patients (≈90%) and will improve vision in a smaller group (≈30%) during the first 2 years of treatment.1
Long-term (beyond 3–4 years) outcomes from randomised controlled trials (RCTs) using antiVEGF are,
however, not available. These drugs are administered monthly (often with a mandated minimum of three
injections for the first 3 months, and thereafter depending on whether or not active nAMD is present)
as intraocular injections until the macula is rendered fluid free. When the disease becomes quiescent,
treatment is stopped and patients are monitored for relapse, with treatment being restarted if needed,
by monthly intraocular injections based on findings of VA checks, clinical examination and OCT. FFA is
typically used to confirm the diagnosis of nAMD prior to initiating antiVEGF therapy, but it is used only in
selected circumstances for monitoring activity of nAMD after treatment. Relapse of nAMD is unpredictable
and can occur within weeks, months or even years after stopping treatment.
Epidemiology, incidence and prevalence
The prevalence of all forms of age-related macular degeneration (AMD) (including neovascular and
atrophic AMD), which affects more than 600,000 people in the UK, is expected to rise by a quarter to
nearly 756,000 by 2020. The estimated number of individuals with nAMD in the UK for 2011 is 368,000
and will increase substantially due to the ageing population.4–6 Estimates of incidence of nAMD in the UK
suggest that there are between 13,000 and 37,000 new cases annually.5 The National Institute for
Health and Care Excellence (NICE) guidance on ranibizumab [Lucentis®, Genentech Inc. (USA)/Novartis
Pharmaceutical Ltd] and pegaptanib (Macugen®, Pfizer Ltd) for the treatment of age-related macular
degeneration (AMD) (issued 2008 and modified 2012) estimated that there were about 26,000 new cases
of nAMD in the UK each year.7 Many of these individuals will require monthly monitoring and treatment
for several years. Relevant risk factors include age, cigarette smoking, nutritional factors, cardiovascular
diseases and genetic markers, including genes regulating complement, lipid, angiogenic and extracellular
matrix pathways.
Impact of health problem
Significance for patients in terms of ill-health (burden of disease);
significance for the NHS
Age-related macular degeneration is the most common cause of blindness and partial sighted registration
in the UK.1 As the incidence of AMD increases with age, the burden of disease to the NHS and society
is expected to increase with an ageing population. Furthermore, loss of vision contributes to a
psychological ill-health (depression, emotional distress) and reduced quality of life.
Ophthalmology accounts for 10% (5 million per year) of all outpatient attendances to the NHS and
AMD accounts for 15% of all ophthalmology outpatient attendances.1 Loss of VA is associated with a
profound impairment of quality of life. Visual loss increases the risk of frequent falls. Depression and visual
hallucinations (Charles Bonnet syndrome) are frequent accompaniments of severe central vision loss.
Patients with Charles Bonnet syndrome (associated with visual loss) and their family members should be
informed that visual symptoms are not unusual and are not a sign of psychosis or mental deterioration.
Measurement of disease
The spectrum of disease may be classified according to the reduction of VA (e.g. mild, moderate or
severe). In addition to this spectrum of disease, during monitoring of patients undergoing treatment with
antiVEGF drugs, it is important to determine whether or not the disease is active. Disease activity is typically
determined with imaging technologies, mainly FFA and OCT.
BACKGROUND
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Current service provision
Management of disease
Diagnosis of neovascular age-related macular degeneration and
care pathway
Typically, patients with possible AMD present to primary care (optometrists or general practitioners) with
non-specific symptoms (such as reduced, blurred and distorted vision). Some patients do not report
symptoms and are diagnosed at routine eye examination. Clinical examination of the retina reveals typical
changes associated with AMD such as drusen and irregularities in the appearance of the retinal pigment
epithelium (RPE), most commonly in both eyes. However, the presence of a neovascular component may
be difficult to detect clinically, especially early on in the course of its development. The diagnostic pathway
for nAMD and the management of patients with known disease include imaging technologies (Figure 1).
According to current guidelines from the Royal College of Ophthalmologists (RCO),1 FFA interpreted by an
ophthalmologist is the method of choice and reference standard test to diagnose nAMD. Occasionally,
indocyanine green angiography (ICGA) is associated with FFA as part of the reference standard when
particular phenotypes of nAMD are suspected, including RAP and IPCV (see above). FFA is an invasive and
time-consuming procedure, entailing the injection of a dye into a peripheral vein by a nurse and a trained
photographer to undertake the test (obtain the images of the CNV, RAP, IPCV lesions). In addition to FFA,
current guidelines recommend using OCT at diagnosis. Owing to recent developments in technology, it is
possible that in some cases OCT might be superior to FFA in detecting nAMD (Table 1).
Treatment and monitoring of neovascular age-related macular degeneration
When active nAMD is confirmed, treatment with antiVEGF therapy is initiated.8,9 For all patients
with nAMD it is common practice to use three consecutive (monthly) intravitreal injections of antiVEGF
therapy, and then the patient is reassessed to evaluate whether or not the disease is active
(i.e., neovascularisation leaking fluid/blood at the macula) or inactive (Figure 2). For this purpose,
both FFA and OCT may be used, although the latter more often than the former, according to the
guidelines of the RCO.1 Studies that have a large influence in current practice used VA and OCT at
Referral from primary care with suspected nAMD
• Visual acuity
• Slit-lamp biomicroscopy by ophthalmologist
Exam suggests possible
diagnosis of nAMD
Exam rules out possible
diagnosis of nAMD
Discharge
Treat and monitor
• Fluorescein angiography
• OCT
• ± Fundus autofluorescence
Discharge
+
+ –
–
FIGURE 1 Current diagnostic pathway of nAMD.
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monthly intervals and FFA at quarterly intervals to decide on the need for retreatment. In some units, OCT
is the only test performed to determine activity of the neovascular process in clinical practice; in some
centres FFA is performed in selected cases during the monitoring phase. Other technologies such as fundus
autofluorescence (FAF) may also be used at baseline and at variable intervals during the follow-up of these
patients as areas of atrophy in the RPE (difficult to detect clinically but easily observed on autofluorescence
images) could be associated with fluid in the retina in the absence of active nAMD.
If fluid is not seen intraretinally or subretinally, further treatment is not given and the patient is followed
thereafter regularly. The timing of follow-up visits is variable, typically every 4 weeks for the first year,
extending the intervals after the second year. Varying intervals have been proposed, such as ‘treat and
extend’ strategy, where if there is no active disease, no treatment is given and the monitoring intervals
are progressively extended. If the disease is judged to be active, further injections of antiVEGF are given.
Either a single injection or three injections are administered if activity is detected on follow-up and then
the patient returns to the monthly monitoring scheme. The possibility of using VA (without imaging tests)
as the only test to guide treatment during monitoring (i.e. treatment would be given if there is a loss of
five or more letters from best previously observed VA) has been modelled using data from published trials
for nAMD.10 The authors concluded that an individualised VA-guided regimen could sustain visual
outcomes and improve cost-effectiveness compared with current regimes.
TABLE 1 Apparent features of OCT and FFA for nAMD
Features OCT (index test) FFA (reference standard)
Accuracy High? Reference standard
Invasiveness Non-invasive Invasive
Knowledge and skills needed to interpret Moderate High
Interpretable Most tests Nearly all tests
Cost Low to moderate Moderate
Side effects None Allergy (rarely anaphylactic shock)
Initial treatment with three consecutive monthly injections of anti-VEGF
Inactive: no treatment Active: treatment given
Monitor
First year: ± monthly
Later: according to
clinician’s criteria
Monitor
First year: ± monthly
Later: according to
clinician’s criteria
Review by ophthalmologist:
• Visual acuity
• Slit-lamp biomicroscopy
• OCT ± FFA
• ± Autofluorescence
FIGURE 2 Current monitoring pathway of nAMD.
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Current service cost
Table 2 shows an estimation of unit costs associated with current diagnosis and monitoring care pathways.
A first referral visit to a hospital eye service will involve an eye examination and is costed at £106. In
addition, OCT and FFA tests can be indicated, with the overall cost for the first visits ascending to £274.71.
A follow-up monitoring visit can involve a face-to-face attendance with an ophthalmologist and an OCT
test only (£131). However, if a FFA is indicated, the monitoring visit will cost £248.27. Without doubt,
the major cost category is given by the treatment cost. There are two possible antiVEGF treatments:
ranibizumab and bevacizumab (Avastin®, Roche) at £742.17 and £50 per injection respectively. NICE
guidelines advocate for the use of ranibizumab unless individual sight is heavily deteriorated. It should be
noted that special cost arrangements are in place and a reduced cost for ranibizumab is agreed under a
Patient Access Scheme negotiated between the manufacturer and the Department of Health. Under this
agreement, the cost of ranibizumab to the UK NHS (confidential) is significantly lower than the list price
given above. The cost of bevacizumab is based on that of a compounded product as supplied by different
compounding pharmacies in the UK.
Variation in service and/or uncertainty about best practice
Once nAMD has been diagnosed, monotherapy with an antiVEGF drug (administered into the vitreous) is
the current standard of care. Ranibizumab is highly effective and recommended by current guidelines.
Bevacizumab remains unlicensed in the UK although its use worldwide reflects the fact that it is much
cheaper than ranibizumab (as currently supplied for intravitreal administration) with similar efficacy.8,9
Retinal imaging with OCT before and after intravitreal administration of antiVEGF therapy is regularly
used.13 Following antiVEGF therapy a reduction of intraretinal and subretinal fluid is typically observed,
often with rapid unification of the retinal layers and improvement/restoration of the anatomical contours.
This anatomical improvement is often accompanied by improvements in VA.
The ultimate treatment goal when nAMD has already developed is to achieve restoration of central vision
and prevent visual loss with normal or near normal foveal and macular anatomy. Complete cessation of
exudation can result in good unification of the tissue layers, but most patients report difficulty with reading
small print and other visually demanding tasks, even when tissue contours have been apparently restored.
High-resolution OCT scans obtained after antiVEGF treatment show persistent abnormalities of the outer
retina even though the tissues appear to be fluid free. In cases where localised atrophy and fibrosis have
already occurred, considerable impairment of central visual function can remain, despite the achievement
of a fluid free macula.
TABLE 2 Diagnosis and monitoring costs associated with nAMD health care
Intervention
Unit costs (£, 2011–12)
SourceDiagnosis Monitoring
Ophthalmologist
visit
£106.18 £79.74 NHS Reference Costs 2011–1211 (Ophthalmology – consultant led:
first attendance or follow-up non-admitted face to face)
FFA £117.26 £117.26 NHS Reference Costs 2011–1211 (HRG BZ23Z minor vitreous
retinal procedures)
OCT £51.27 £51.27 NHS Reference Costs 2011–1211 (HRG RA23Z ultrasound scan, less than
20 minutes)
Medication
ranibizumab
£742.17 Ranibizumab. Source: BNF12 (accessed 9 May 2013) [Lucentis® (Novartis)
solution for intravitreal injection, ranibizumab
10 mg/ml, net price 0.23-ml vial = £742.17]
Medication
bevacizumab
£50.00 As supplied by compounding pharmacies. Manufacturer’s list price
not applicable
BNF, British National Formulary; HRG, Healthcare Resource Group.
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Patients who have been treated with antiVEGF therapy should be examined at regular intervals. Although
most clinicians will use OCT for monitoring patients with nAMD, there is probably large variability on the
tests used (e.g. biomicroscopy of the fundus, FFA and fundus photography).
As explained above, patients treated with antiVEGF injection should receive injections monthly for the first
3 months and, thereafter, should be monitored monthly. If active nAMD is present, treatment should be
continued, and if there is no active exudative AMD, observation at monthly intervals is recommended.
The use of technologies, including OCT, FFA and FAF during the follow-up of these patients is variable as
it depends on clinical findings, the judgement of the treating ophthalmologist and the clinical pathways
established at different centres. The workload associated with such contemporary AMD services is
significant and is expected to increase, as the best outcomes are achieved with monthly follow-up visits.
It is expected that these follow-up visits may continue for as long as 4 years or longer. The pressure on
resources and service delivery in the AMD clinics is expected to become even more intense as many
patients cannot be discharged, and there is a need to accommodate new incident cases. The regular
monthly follow-up for AMD patients under treatment, in order to maintain efficacy, is demanding. This
situation is likely to be further aggravated by the impending treatments with intravitreal therapies of
macular oedema secondary to diabetic retinopathy and retinal vein occlusion. As such, the problem seems
more acute than was originally envisaged, and is expected to get worse. It has been suggested engaging
non-medical staff (optometrists, nurses, technicians) to undertake some of the duties in the AMD clinic in
order to increase capacity. Such roles include clinical assessments, especially retreatment decision-making.
Relevant national guidelines, including National Service Frameworks
Subsequent to the technology appraisal and issuing of guidance by NICE, ranibizumab has been
widely adopted as the treatment of choice for subfoveal nAMD in the UK.7 However, the high cost of
ranibizumab, along with the positive clinical experience with bevacizumab, has stimulated a debate on
whether or not bevacizumab could be used in practice.
In the UK, guidelines for the management and treatment of nAMD were published by the RCO in 2009
(and in 2013 were undergoing revision).1 According to the RCO guidelines, FFA interpreted by an
ophthalmologist is the method of choice and reference standard test to diagnose nAMD. Occasionally,
ICGA is associated with FFA as part of the reference standard when particular phenotypes of nAMD are
suspected, including RAP and IPCV. In addition to FFA, current guidelines recommend using OCT at
diagnosis. During follow-up and monitoring of disease activity, after treatment the current guidelines
recommend the use of OCT mainly, and FFA at the discretion of the clinician.
Description of technologies under assessment
Reference standard: fundus fluorescein angiography
Fundus fluorescein angiography is currently the reference standard for diagnosing CNV in AMD.
A fluorescein angiogram is a sequence of images captured of the fundus over a 10-minute period
after injection of the non-toxic dye fluorescein isothiocyanate into a suitable peripheral vein.
Neovascular lesions are classified by their location with reference to the foveal avascular zone – extrafoveal,
juxtafoveal or subfoveal. Lesions lying more than 200 μm from fixation are defined as extrafoveal and may
also be described as juxtafoveal or subfoveal when immediately adjacent to or involving the geometric
centre of the fovea respectively. Neovascular lesions located away from the macula are termed peripheral
and those around the optic nerve juxtapapillary. A more refined classification of the neovascular lesion is
obtained by describing the composition of the exudative lesion after stereoscopic review of the entire
sequence of the angiogram. The exudative lesion is defined as the area occupied by the neovascular
complex, any associated blood, thick exudate and pigment epithelial detachments (PEDs) that are
contiguous to the neovascular complex and obscure its margins. The neovascular complex can, therefore,
consist of RAP, CNV and IPCV.
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The classification of nAMD lesions is based on the temporal and spatial features of the patterns of
fluorescence as observed on the FFA. CNV lesions are classified according to their location relative
to the fovea (see above), and pattern of fluorescein angiographic leakage. The majority of CNVs
occur subfoveally.
Classic choroidal neovascularisation
Classic CNV is said to be present when an area of well-delineated hyperfluorescence appears in the early
phases of the FFA, usually before seconds have elapsed following injection of the fluorescent dye into a
peripheral vein. Most commonly, classic CNV represents new vessels that have breached the RPE and lie in
the subretinal space. Sometimes a typical lacy pattern of hyperfluorescence is observed in the very early
phase of the angiogram which corresponds to the vascular profiles before the fluorescein has leaked
out of these vessels and obscured the margins. Classic CNV also leaks aggressively and hence there is
considerable pooling of fluorescein dye in the subretinal space in late frames of the angiogram.
Occult choroidal neovascularisation
Occult CNV, as its name suggests, refers to the presence of leakage without clear evidence of neovascular
profiles in the early angiographic images. Two types of occult leakage are recognised. The first is a
characteristic stippled hyperfluorescence which occurs early and is located at the level of the RPE. The RPE
layer is elevated and in the later phases of the angiogram there is increasing hyperfluorescence and
pooling of dye in the subretinal pigment epithelial space. The pattern of leakage suggests new vessels
between Bruch’s membrane and the RPE and it is therefore considered to be a fibrovascular PED. The
second pattern of occult leakage is a more diffuse hyperfluorescence with poorly demarcated boundaries
which occurs late in the angiographic phase, generally after 2 minutes have elapsed since injection of dye.
There is no corresponding hyperfluorescence in the early frames and there is shallow elevation of the RPE.
This type of leakage is referred to as late leakage of indeterminate origin. Many lesions are mixed showing
combinations of classic and occult features. It is now common practice to classify lesions by presence or
absence of classic and/or occult CNV. In the absence of any occult CNV, lesions are termed classic with no
occult (100% classic) and conversely occult with no classic (0% classic).
When CNV is mixed, the lesion is classified by the proportion of classic. When the lesion is composed
primarily of classic CNV (i.e. classic > 50%), it is termed predominantly classic. When there is 1–49%
classic, the lesions are termed minimally classic.
Retinal angiomatous proliferation
One type of neovascularisation that has been well recognised by the use of high-speed video angiography
using the scanning laser ophthalmoscope (SLO) is the RAP lesion. RAP is seen commonly as a round area
of intraretinal telangiectatic, dilated blood vessels located juxta- or extrafoveally. On viewing stereo pairs of
images, the vessels are often seen to turn sharply from the inner retina towards the choroidal interface.
Except in early stages, RAPs are associated with PEDs. They leak and hence the adjacent retina is usually
disrupted with cystoid spaces. ICGA is a helpful test to determine the presence of RAP.
Idiopathic polypoidal choroidal vasculopathy
Polyps are seen as focal, round areas of abnormal dilated choroidal vessels, often associated with large
areas of lipid deposition and haemorrhage. The presence of haemorrhagic PED is highly suggestive of the
presence of this phenotype. These are best visualised by ICGA.
Optical coherence tomography
Optical coherence tomography was developed at the Michigan Institute of Technology, MI, USA in 1991.
It is a light-wave-based technology producing cross-sectional images of the retina with scan rates
and resolution parameters that have greatly improved over the last 10 years. OCT is a non-invasive,
non-contact visual test that requires around 5–10 minutes to assess both eyes.14 From the investigator’s
point of view, it is user friendly (e.g. OCT is easier to do than FFA), typically undertaken by trained medical
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photographers or ophthalmic imaging technicians, and interpreted by ophthalmologists. Automated
analysis can also be used.
There are two main types of OCT system. The earlier time domain optical coherence tomography
(TD-OCT) system, available from 1995, had an image rate of 100–400 scans per second and provided
information for a limited view of the retina by taking six scans radially-oriented 30 degrees from each
other with a resolution in the range of 10 to 20 µm.14 The newer system, spectral domain optical
coherence tomography (SD-OCT), has been available since 2006. Improvements with this system include
(i) a faster scan speed of approximately 27,000 scans per second, (ii) the ability to scan larger areas of the
retina by taking several horizontal line scans such that there are no ‘missed areas’, (iii) increased resolution
at 5 µm, and (iv) ‘real time registration’, which was not previously available with TD-OCT.14 The real-time
registration feature enables the identification of specific anatomical locations on the retina, against which
subsequent tests may be evaluated, which is of particular importance in the monitoring of patients.14
Compared with TD-OCT, the faster scan speed of SD-OCT enables the collection of additional information
on larger regions of the retina and eliminates image distortion arising from patient movement, while the
improved resolution allows for a clearer and more distinguishable view of retinal layers, with the possibility
of detecting earlier signs of disease.14
Identification of important subgroups
There are different subgroups of patients with nAMD. They are diagnosed according to FFA findings and
are described above. Subgroup classification depends on the location (extra-, juxta- and subfoveal) and
type of neovascularisation (classic and occult CNV, RAP, and IPCV), which could be mixed in different
combinations. Although the initial treatment is similar for all subgroups (with antiVEGF therapy), the
natural history and progression after treatment are different. It is also possible that the performance of
diagnostic technologies may be different among subtypes of nAMD. OCT is not currently used in isolation
to identify subgroups.
Current usage in the NHS
Both FFA and OCT are currently used in the NHS to diagnose and monitor patients with nAMD. They are
recommended technologies to provide standard care. FFA is essential for diagnosis of the condition.
Regarding monitoring, FFA is less commonly used than OCT.
Anticipated costs associated with intervention
Table 3 presents an estimation of the number of visits in a lifetime of the population. Based on census,
nAMD prevalence and Interim Life Table data, it is possible to estimate the number of visits for the
population lifetime. Calculations in Table 3 are for England and Wales, based on 2011 data and assumed
that every individual with nAMD would contact NHS services. This estimation resulted in 33.7 million visits.
If OCT was conducted at every monitoring visit, this would result in an undiscounted lifetime cost of above
£1.7B [i.e. £51.27 (see Table 2) multiplied by 33.7 million people].
Alternative tests
Clinical evaluation (with slit-lamp biomicroscopy with or without use of
diagnostic contact lens and evaluation of patients’ symptoms)
The onset of exudative AMD is heralded by the appearance of central visual blurring and distortion. Most
patients will complain that straight lines appear crooked or wavy. Sometimes patients do not notice visual
symptoms when the first eye is affected. When nAMD occurs in the second eye, patients suddenly become
limited in their daily activities, for example reading, driving and seeing fine detail such as facial expressions.
Examination of the macula usually reveals fluid and/or lipid (yellow deposition) and/or blood. Other features
of AMD such as drusen and pigmentary irregularities are most often present. Sometimes these latter
features are not observed once exudative AMD has supervened or in certain phenotypes such as IPCV.
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However, the fellow eye would usually exhibit some or all of these AMD early clinical signs (drusen and RPE
changes) and their presence is helpful in confirming that the neovascular lesion is due to AMD (again with
the exception of IPCV where the fellow eye may also be normal). Following slit-lamp biomicroscopy (SLB) the
presence or absence of the following signs should be noted:
l Subretinal or subRPE neovascularisation which may be visible as a dark grey lesion. Occasionally the
lesion will have a dark pigmented edge which is thought to be due to proliferation of the RPE at
the edge of the membrane.
l Serous detachment of the neurosensory retina.
l RPE detachment.
l Haemorrhages: subretinal pigment epithelial, subretinal, intraretinal or preretinal. Breakthrough
bleeding into the vitreous may also occur, indicating most often the presence of IPCV.
l Hard exudates (lipids) within the macular area related to any of the above and not related to other
retinal vascular disease.
l Epiretinal, intraretinal, subretinal or subpigment epithelial scar/glial tissue or fibrin-like deposits.
l RAPs: red, round, extra- or juxtafoveal lesions located within the retina.
l Polyps: red, round lesions located underneath the RPE or protruding through the RPE layer.
TABLE 3 Neovascular age-related macular degeneration prevalence and lifetime total number of monitoring visits
for England and Wales
Population by
gender and age
Population for
England and Wales,
2011 census-based
estimates15
nAMD
prevalence
rates, %6
nAMD
cases, n
Life
expectancy
(years)16
Total number of
monthly monitoring
visits (lifetime)
Men (age, years)
65–69 1,096,335 0.38 4166 16.64 833,215
70–74 1,027,959 1.40 14,391 13.06 2,259,454
75–79 810,590 2.63 21,319 9.87 2,515,585
80–84 557,203 5.56 30,980 7.16 2,664,322
85–89 295,680 5.56 16,440 5.07 1,002,828
90–99 333,448 5.56 18,540 3.00 667,430
Total males 9,942,833
Women (age, years)
65–69 1,154,292 0.92 10,619 19.15 2,442,482
70–74 1,140,959 1.42 16,202 15.20 2,948,694
75–79 976,657 2.17 21,193 11.59 2,945,891
80–84 788,087 10.50 82,749 8.46 8,440,412
85–89 532,677 10.50 55,931 5.95 3,971,107
90–99 717,989 10.50 75,389 3.36 3,015,554
Total females 23,764,139
Total overall
population
33,706,973
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Visual acuity (for monitoring)
Visual acuity is a measure of the spatial resolution of the visual processing system. VA is tested by requiring
the person whose vision is being tested to identify characters (like letters and numbers) on a chart from
a set distance. Chart characters are typically represented as black symbols against a white background
(for maximum contrast). The distance between the person’s eyes and the testing chart is set at a sufficient
distance to approximate infinity in the way the lens attempts to focus.
Amsler grid
The Amsler grid is a grid of horizontal and vertical lines used to monitor a person’s central visual field.
It is a diagnostic tool that aids in the detection of visual disturbances caused by changes in the retina,
particularly the macula (e.g. macular degeneration). In the test, the person looks with each eye separately
at the small dot in the centre of the grid. Patients with macular disease may see wavy lines or some lines
may be missing. Amsler grids are supplied by ophthalmologists, optometrists or from websites, and may be
used to test one’s vision at home.
Colour fundus photographs
Colour fundus photography provides a record of the appearance of the macular retina. Stereoscopic
images of the macula viewed appropriately can help localise pathology to the different tissue layers.
For the purposes of recording macular pathology, stereoscopic pairs of images taken at 35 degrees centred
on the macula are recommended. Red-free images (RFs) can help detect some features of the fundus
associated with nAMD, such as haemorrhages.
Infrared reflectance
Confocal near-infrared fundus reflectance is a non-invasive en-face imaging technique using an 830-nm
diode laser capable of visualising subretinal pathology. In contrast to visible wavelength illumination,
fundus reflectance may be up to 10 times higher in the near-infrared wavelength and is then largely
independent of melanin content, which advances the visibility of deep fundus structures.
Red-free images or blue reflectance
See Colour fundus photographs, above.
Fundus autofluorescence imaging or blue reflectance
This test can give an indication of the health of the RPE. The conventional FAF signal (obtained with
488 nm) originates, predominantly, from lipofuscin in RPE cells. The near-infrared autofluorescence (NIA)
signal originates, predominantly, from melanin in the RPE, with some contribution from choroidal melanin.
Increased FAF represents accumulation of lipofuscin and suggests that the RPE cells are beginning to fail.
Absence of a FAF and NIA signal, which appears as black areas in FAF and NIA images, is due to loss of
RPE cells. The finding of patches of absent autofluorescence may explain central scotoma patterns.
Although different patterns have been described in early and late AMD, the exact diagnostic performance
of autofluorescence is yet to be determined. The role of FAF may be more important in monitoring
patients undergoing antiVEGF therapy to evaluate atrophy (e.g. for potential discontinuation of treatment).
Indocyanine green angiography, dynamic high speed or digital subtraction
indocyanine green angiography
Indocyanine green (ICG) is an alternative dye to fluorescein which is used to visualise the choroidal
circulation. This dye binds to plasma protein and hence does not egress easily through the fenestrae of the
choroidal vessels, remaining within the vascular compartment. ICGA is obtained using longer wavelengths
than FFA and, thus, can penetrate through areas of fluid/blood, permitting visualisation of pathology in
circumstances where fluorescein may not. ICG also has some limitations and very thick blood or pigment
can reduce or block transmission of the ICG infra-red wavelength and the emitted light is of lower
intensity compared with that of fluorescein. The use of the SLO with video capture can, however, yield
images of high resolution. Video ICGA also allows better imaging of RAP. As ICG dye does not leak into
the subretinal and subpigment epithelial spaces to the same extent as fluorescein, the enhanced definition
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of the vascularised tissue as a hotspot is possible and a combination of FFA and ICGA can produce
complementary information. A dose of 25mg of ICG in aqueous solution is usually injected intravenously
and images acquired for up to 30 minutes.
Preferential hyperacuity perimetry
Preferential hyperacuity perimetry (PHP) is a psychophysical test of macular function that exploits the
ability of the human visual system to perceive even minute differences in the relative localisation of two
objects in space; a phenomenon termed hyperacuity. When there is separation of the retinal layers
through breakdown of the blood–retinal barrier or blood–RPE barrier, distorted vision is the consequence.
Through presentation of lines with artificial distortions of different intensities on the PHP, the presence of a
real distortion in the patient’s central visual field can be detected as the brain ignores the smaller deviation
when a larger one is introduced.
In a PHP test, the macula is scanned with a succession of stimuli, each stimulus consisting of a series of
dots arranged along a vertical or horizontal axis. In each stimulus, a small number of dots are misaligned,
thereby creating an artificial distortion (bump or wave). The examinee’s task is to perceive these artificial
distortions and mark their locations on the visual field. When a stimulus is projected on a healthy portion
of the retina, the examinee identifies the artificial distortion and is likely to mark a correct location. If the
stimulus is projected on a damaged region of the retina, a pathological distortion may be perceived instead
of the artificial distortion, especially if the pathological distortion is more prominent than the artificial
distortion. The examinee may then mark a location that is distant from the artificial distortion, indicating
that a pathological distortion may have been perceived. By manipulating the amplitude of artificial
distortions, the amplitude of the pathology in the area of interest can be quantified. At the end of the test,
comparison of the set of erroneous responses against a normative data base is used to determine if
test results are within normal limits.
Microperimetry
One conventional measure of vision is subjective visibility thresholds of small, short-duration stimuli as
performed by conventional automated static perimetry. In conventional perimetry, retinal localisation of a
stimulus is implied indirectly from the assumed retinal location of fixation. This approach can work well
when fixation is stable and foveal. However, loss of fixation stability or foveal vision, such as occurs
commonly in nAMD, complicates the measurement of macular function with conventional perimetry.
Accurate correspondence between retinal structures and visual function requires simultaneous imaging of
the fundus. Microperimetry includes real-time automated tracking of the fundus and appropriate
compensation of the location of stimulus presentation at predefined retinal loci.
Care pathway
See Diagnosis of neovascular age-related macular degeneration and care pathway, above.
Currently, patients with suspected nAMD seen by optometrists or other health professionals will be
referred to secondary care where ophthalmologists with expertise on AMD will perform the following tests:
VA measurement, SLB and, if the diagnosis of nAMD remains a possibility, FFA and OCT. The FFA and
OCT imaging tests are used to confirm the diagnosis and they also provide a baseline reference for future
comparisons during the follow-up of the patient. Alternative technologies are used at presentation in some
units (e.g. FAF imaging), to evaluate the status of the RPE which may have prognostic implications.
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Chapter 2 Definition of the decision problem
Decision problem
New treatments for nAMD have been approved by NICE for use in the NHS. These treatments often
require repeated injections of antiVEGF over a period of years, with frequent monitoring greatly increasing
the demand on secondary care AMD services.
Fundus fluorescein angiography, an invasive test, is the reference standard recommended for
detecting nAMD at initial presentation and also for detecting recurrent activity at some monitoring visits
(e.g. quarterly, or according to clinician criteria). OCT is a non-invasive test now widely used for detecting
nAMD both at initial presentation and for detecting recurrent activity during monitoring visits. Two OCT
systems are in use. The more recently introduced SD-OCT incorporates a number of improvements over the
earlier TD-OCT. Depending on the performance of OCT, in some situations its use could possibly replace
that of FFA. Also, as the interpretation of OCT images is more straightforward than that of FFA, it could
potentially be interpreted by other health professionals (e.g. medical photographers, nurses).
However, the value of OCT has not been well-defined and given the burden of monthly lifelong
monitoring by ophthalmologists, involving multiple tests, an assessment of the role of OCT in the
diagnosis, monitoring and guiding of treatment for nAMD is needed.
Index test(s)
The index test considered was OCT, either alone or in combination with alternative tests as described
below. Both TD-OCT and SD-OCT were considered.
Population
The population considered was people with newly suspected nAMD or those previously diagnosed with
the disease and under surveillance monitoring.
The setting considered was secondary care.
Relevant comparators
The alternative tests considered included the following examinations:
l clinical evaluation (with SLB, with or without use of diagnostic contact lens and evaluation of
patients’ symptoms)
l VA (for monitoring)
l Amsler grid
l colour fundus photographs
l infrared reflectance (IR)
l RFs or blue reflectance
l FAF imaging
l ICGA, dynamic high-speed or digital subtraction indocyanine green angiography (DS-ICGA)
l PHP
l microperimetry.
Reference standard
The reference standard considered was ophthalmologist-interpreted FFA. FFA is generally acknowledged
as being the recognised reference standard for detecting nAMD. The RCO states in its guidelines for
management of AMD that FFA is currently the reference standard for diagnosing exudative disease.1
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However, as few studies reported individual ophthalmologist-interpreted FFA (rather than reading
centre-interpreted FFA), studies using FFA as the reference standard but with unclear information about
which type of health-care professionals interpreted the images were also considered.
Outcomes
The following outcomes were considered for the use of OCT at presentation and during follow-up of
patients with nAMD:
l diagnostic accuracy [e.g. sensitivity, specificity, likelihood ratios (LRs), diagnostic odds ratio (DOR)]
l clinical effectiveness (e.g. VA, anatomical control of the disease, patient-reported outcomes)
l interpretability of the test – to be defined as in included studies, considering the ability to acquire a
quality image that can be interpreted or analysed
l acceptability of the test – to be defined as in included studies, considering users and health-care
providers’ perspective
l proportion of participants not able to receive the diagnostic test [due to an eye condition (e.g. lens or
other media opacity), or personal circumstances (e.g. wheelchair bound)].
The evidence for the use of OCT was considered separately for the purposes of diagnosis and monitoring.
Key issues
The key issues to be addressed are:
l How good a test is OCT, when used either alone or in combination with alternative tests, in the
diagnosis of people newly presenting with a suspicion of nAMD?
l How good a test is OCT, when used either alone or in combination with alternative tests, in detecting
recurrent nAMD activity during surveillance monitoring of people previously diagnosed with
the disease?
l Is SD-OCT a better test than TD-OCT?
l Could OCT images be interpreted by other health professionals in addition to ophthalmologists?
l Could OCT replace FFA in some situations in the diagnostic and/or monitoring pathways?
l How cost-effective are strategies involving OCT, both in the diagnostic and monitoring pathways?
Overall aims and objectives of assessment
The overall aim of the review was to determine the optimal role of OCT in (i) the diagnosis of people
newly presenting with suspected nAMD and (ii) monitoring those previously diagnosed with the disease.
Specific research objectives were:
l to determine the diagnostic performance of OCT, alone or in combination with alternative tests, in
detecting nAMD, including accuracy, interpretability and acceptability
l to determine the performance of OCT and/or other alternative tests in the monitoring of the disease
post diagnosis, specifically in detecting activity of the disease and the need for further treatment
l to determine the performance of other health professionals (e.g. medical photographers, nurses)
compared with ophthalmologists in interpreting OCT findings
l to model the effects of using OCT and/or other alternative tests in the diagnosis and management of
the disease and estimate the relative cost-effectiveness of alternative diagnostic and monitoring
strategies, including determination of an optimal cut-off point for sensitivity and specificity for use in
practice, and the alternative timing between tests during monitoring
l to identify future research needs.
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Chapter 3 Methods for reviewing test
performance
Methods were in accordance with the protocol.
Identification of studies
Published, unpublished and ongoing studies were identified from literature searches of electronic databases
(from 1995 onwards) and appropriate websites. The search strategies were designed to be highly sensitive,
including appropriate subject headings and text word terms that reflected both the clinical condition and
diagnostic tests under review. There were no language restrictions. Databases searched included MEDLINE,
MEDLINE In-Process & Other Non-Indexed Citations, EMBASE, Bioscience Information Services and Science
Citation Index for all reviews. The Cochrane Central Register of Controlled Trials was searched for additional
reports of RCTs for the effectiveness review and PsycINFO and Applied Social Sciences Index and Abstracts
for patient acceptability data. The Cochrane Database of Systematic Reviews, Database of Abstracts of
Reviews of Effects, Medion and Health Technology Assessment (HTA) database were searched for relevant
systematic reviews and HTA reports. Abstracts and presentations from recent conferences (2009 onwards)
of the American Academy of Ophthalmology, the Association for Research in Vision and Ophthalmology
(ARVO) and the European Association for Vision and Eye Research (EVER) were also searched. The World
Health Organization International Clinical Trials Registry Platform, ClinicalTrials.gov and European Union
Clinical Trials Registry were searched for ongoing studies. Websites of professional organisations and
manufacturers of OCT equipment were also consulted. Reference lists of all included studies were scanned
and experts contacted for details of additional potentially relevant reports. The date of the final searches
was March 2013. Full details of the search strategies used are provided in Appendix 1.
Inclusion and exclusion criteria
Types of studies
The following types of studies were considered.
i. Diagnostic studies:
l Direct (head-to head) comparisons in which the index test and comparator test(s) are evaluated in
the same study population. These could be fully paired [all study participants receive the index test,
comparator test(s) and the reference standard] or not fully paired (participants receive only a subset
of the tests, e.g. a randomised direct comparison in which study participants are randomly allocated
to receive the index test or the comparator and all receive the reference standard.
l Indirect comparisons in which estimates of the accuracy of the respective tests are obtained in
different study groups, for example two-gate or ‘case–control’ type studies where different sets of
criteria are used for those with and without the target condition. Indirect comparisons were to be
considered if there was insufficient evidence from direct comparisons.
ii. Studies reporting clinical effectiveness:
l RCTs evaluating outcomes when treatment was based on OCT compared with FFA findings.
iii. Qualitative studies evaluating patients’ and/or clinicians’/health-care professionals’ acceptability and/or
interpretability of the OCT tests.
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Types of participants
The types of participants considered were people with newly suspected nAMD or those previously
diagnosed with the disease and under surveillance monitoring.
The setting considered was secondary care.
Index tests
The index test considered was OCT, either alone or in combination with alternative tests as described
below. Both TD-OCT and SD-OCT were considered.
Comparator tests
The alternative tests considered included the following examinations:
l clinical evaluation (with SLB, with or without use of diagnostic contact lens and evaluation of
patients’ symptoms)
l VA (for monitoring)
l Amsler grid
l colour fundus photographs
l IR
l RFs or blue reflectance
l FAF imaging
l ICGA, dynamic high-speed or DS-ICGA
l PHP
l microperimetry.
Reference standard
The reference standard considered was ophthalmologist-interpreted FFA. FFA is generally acknowledged
as being the recognised reference standard for detecting nAMD. The RCO states in its guidelines for
management of AMD that FFA is currently the reference standard for diagnosing exudative (neovascular)
AMD.1 However, as few studies reported individual ophthalmologist-interpreted FFA (rather than reading
centre interpreted FFA), studies using FFA as the reference standard but with unclear information about
which type of health-care professionals interpreted the images were also considered.
Types of outcomes
The following outcomes were considered for the use of OCT at presentation and during follow-up of
patients with nAMD:
l diagnostic accuracy (e.g. sensitivity, specificity, LRs, DOR)
l clinical effectiveness (e.g. VA, anatomical control of the disease, patient-reported outcomes)
l interpretability of the test – defined as in the included studies, considering the ability to acquire a
quality image that can be interpreted or analysed
l acceptability of the test – defined as in the included studies, considering users and healthcare
providers’ perspective;
l proportion of participants not able to receive the diagnostic test [due to an eye condition (e.g. lens or
other media opacity), or personal circumstances (e.g. wheelchair bound)].
The evidence for the use of OCT was considered separately for the purposes of diagnosis and monitoring.
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Data extraction strategy
Two reviewers (MC plus GM or AAB) screened the titles (and abstracts if available) of all reports identified
by the search strategy. Full-text copies of all studies deemed to be potentially relevant were obtained and
two reviewers (MC plus GM or AAB) independently assessed them for inclusion. Disagreements were
resolved by consensus or arbitration by a third reviewer.
A data extraction form was developed and piloted. One reviewer (MC) extracted details of study design,
participants, index, comparator and reference standard tests and outcome data, and a second reviewer
(AAB or GM) checked the data extraction. Disagreements were resolved by consensus or arbitration by a
third reviewer.
Critical appraisal strategy
Two reviewers (MC plus GM or AAB) independently assessed the risk of bias and applicability concerns
of all included full-text diagnostic and monitoring studies using the updated quality assessment of
diagnostic accuracy studies, version 2 (QUADAS-2) checklist.17 Any disagreements were resolved by
consensus or arbitration by a third party. The original QUADAS checklist was developed for use in
systematic reviews of diagnostic studies through a formal consensus method and was based on empirical
evidence. Following anecdotal reports and feedback which suggested problems with QUADAS, the
QUADAS-2 tool was developed. QUADAS-2 consists of four key domains covering (1) patient selection,
(2) index test, (3) reference standard, and (4) flow of patients through the study, and timing of the index
test(s) and reference standard. Each domain is assessed in terms of the risk of bias. The first three domains
are also assessed for concerns regarding their applicability in terms of whether (i) the participants and
setting, (ii) the index test, its conduct or interpretation, and (iii) the target condition, as defined by the
reference standard, match the question being addressed by the review. Within each domain signalling
questions are included to assist in making a judgement about the risk of bias, with the standard tool
containing 11 such questions across the four domains.
Both the original and updated checklists were designed to be adapted to be more applicable to a specific
review topic. For this review, QUADAS-2 was modified by adding an additional signalling question to
domain 1 (patient selection) to assess whether or not participant pre-selection had been avoided. Domains
2 (index test), 3 (reference standard) and 4 (flow and timing) were retained in their entirety. Therefore the
modified tool contained 12 signalling questions, with each worded so that a rating of ‘Yes’ was always
optimal in terms of methodological quality. If any signalling questions within a domain were rated ‘No’
then that domain was judged to be at high risk of bias. With regard to question 9 in the modified tool
(appropriateness of the time interval between the index test and the reference standard), it was agreed
that to be considered appropriate, the time interval between the index test and reference standard should
be no longer than 1 week. An example of the QUADAS-2 checklist used in this review is shown at the end
of the protocol (www.nets.nihr.ac.uk/__data/assets/pdf_file/0010/81685/PRO-10-57-22.pdf).
We planned to assess the methodological quality of any RCTs reporting effectiveness outcomes that met
our inclusion criteria using the Cochrane risk of bias tool.18 This tool addresses six specific domains relating
to methodological quality (sequence generation, allocation concealment, blinding, incomplete outcome
data, selective outcome reporting and ‘other issues’). However, no RCTs reporting effectiveness outcomes
were identified that met our inclusion criteria.
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Methods of data synthesis
The results of the individual diagnostic studies were tabulated and, where data allowed, sensitivity,
specificity, predictive values, LRs and DORs were calculated.
Summary receiver operating characteristic (SROC) curves were produced for each test where two or more
diagnostic studies reported sufficient data. In the event of studies reporting 2 × 2 data [true positives (TPs),
false positives (FPs), false negatives (FNs), true negatives (TNs)] for a number of different cut-off values we
planned to select the most frequently used cut-off value across studies. However, this situation did not
arise. Meta-analysis models were fitted using the hierarchical summary receiver operating characteristic
(HSROC) model19 in SAS version 9.1 (SAS Institute Inc., Cary, NC, USA). A symmetric SROC model was
used, which takes proper account of the diseased and non-diseased sample sizes in each study, and allows
estimation of random effects for the threshold and accuracy effects. The SROC curves from the HSROC
models were produced on the corresponding SROC plots. Summary sensitivity, specificity, positive and
negative LRs and DORs for each model were reported as point estimate and 95% confidence interval (CI).
If numerical difficulties were encountered with the HSROC model and there was no evidence of a
threshold effect then we planned to pool sensitivity and specificity using the weighted average method.20
Pooled LRs and DOR were to be calculated using the DerSimonian and Laird random-effects method.21
These analyses were to be carried out using Metadisc software (version 1.4, Unit of Clinical Biostatistics
team of the Ramón y Cajal Hospital, Madrid), with heterogeneity assessed using the I2 statistic, which
describes the percentage of the variability in effect estimates that is due to heterogeneity rather than
sampling error.22
For relevant clinical outcomes reported based on use of the tests, where appropriate, we planned to use
meta-analysis to estimate a summary measure of effect. Dichotomous outcome data were to be combined
using the Mantel–Haenszel relative risk method and continuous outcomes were to be combined using the
inverse-variance weighted mean difference method. For the estimates of relative risk and weighted mean
difference, 95% CIs and p-values were to be calculated. Chi-squared tests and I2 statistics were to be
used to explore statistical heterogeneity across studies, with possible reasons for heterogeneity being
investigated using sensitivity analysis. Heterogeneity is to be expected in diagnostic test accuracy studies,
and random-effects models were to be used to describe the variability across studies. However, no studies
reporting clinical outcomes based on use of the tests were identified that met our inclusion criteria.
Where a quantitative synthesis was considered inappropriate (e.g. studies reporting acceptability of tests),
or not feasible, a narrative synthesis of results was provided.
METHODS FOR REVIEWING TEST PERFORMANCE
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Chapter 4 Assessment of diagnostic and
monitoring studies
This chapter is structured as follows: Quantity of research available describes the quantity of researchavailable for both diagnostic and monitoring studies together; Assessment of diagnostic studies and
Assessment of monitoring studies report the results for the diagnostic and monitoring studies, respectively;
and Summary of the reviews of diagnostic and monitoring studies provides a summary of the chapter.
Within each of the sections on diagnostic and monitoring studies there are subsections on the
characteristics of the included studies, their risk of bias, diagnostic accuracy results (single tests; studies
directly comparing tests; studies reporting combinations of tests) and other outcomes of interest.
Quantity of research available
Number and type of studies included
Appendix 2 lists the 29 studies, published in 31 reports, that met the inclusion criteria for the review of
diagnostic and monitoring studies.23–53 There were two reports of the studies by Cachulo et al.25,47 and
Torron et al.50,51 Figure 3 shows a flow diagram outlining the screening process, with reasons for exclusion
of full-text papers.
Number of records screened
(n = 4682)
Excluded
(n = 4503)
Number of full-text articles assessed for eligibility
(n = 179)
Reports excluded (n = 148)
•  Invalid study design, n = 32
•  No nAMD participants, n = 6
•  Invalid reference standard, n = 14
•  Required outcomes not reported, n = 65
•  Retained for background, n = 31
Number of records identified
through database
searching
(n = 6774)
Number of additional records
identified through
other sources
(n = 323)
Number of records after duplicates removed
(n = 4682)
Number of studies included in qualitative synthesis
31 reports of 29 studies
Number of studies included in meta-analyses
8 reports of 8 studies
FIGURE 3 Flow diagram outlining the screening process.
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Twenty-seven studies (29 reports in total as two studies each had two associated reports) were full-text
papers and two studies were only available as abstracts.34,42 Four studies (five reports) were non-English
language, with one each in Japanese,29 Chinese,26 German37 and Spanish.50,51 Of the 29 included studies,
22 (24 reports)24–27,29,31,33–42,44–51 were diagnostic studies involving people with suspected nAMD and
eight23,28,30,32,43,45,52,53 were monitoring studies involving people previously diagnosed with nAMD and under
follow-up surveillance. One study, by Salinas-Alaman et al.,45 reported results for both diagnosis
and monitoring.
Number and type of studies excluded
A list of full-text papers that were excluded along with the reasons for their exclusion is given in Appendix 3.
These reports were excluded because they failed to meet one or more of the inclusion criteria in terms of the
type of study, participants, test, reference standard or outcomes reported.
Assessment of diagnostic studies
Characteristics of the included diagnostic studies
Appendix 4 (see Table 42) provides details of the individual study characteristics for the 22 diagnostic
studies. Table 4 provides summary information for these studies. Of the 22 studies, nine were
prospective24,25,27,33,39–41,45,46 and seven were retrospective.34–36,38,39,49,51 Seven studies did not provide this
information.26,29,31,37,42,44,48 (The study by Loewenstein et al.39 reported both a prospective and retrospective
component.) In 10 studies, participant recruitment was consecutive.33,34,38,39,42,44–46,48,49 The studies enrolled
more than 2000 participants. Twenty-one studies reported eye as the unit of analysis (1754 eyes), whereas
one42 reported patient as the unit of analysis (155 patients).
TABLE 4 Summary of the characteristics of the included diagnostic studies
Characteristic Number Number of studies
Participants enrolleda 2124 22
Analysed (eyes) 1754 21
Analysed (patients) 155 1
Age: median (range) of means/medians 76.0 (51.4–84.6) 15
Gender: male : female, n (%) 742 (45.4) : 891 (54.6) 14
Median (range) prevalence of nAMDb 80.0% (17.2–100.0%) 13
Tests reported (number enrolled)
OCT 1335 13
TD-OCT 1316 12
SD-OCT 19 1
ICGA 458 8
PHP 491 3
Colour fundus photography 185 1
Amsler grid 98 1
FAF 62 1
a The study by Kozak et al.36 enrolled 654 participants (1272 eyes analysed) with a diagnosis of suspected or confirmed
macular oedema of various aetiologies, but did not specify how many were nAMD. Of these, 541 eyes with a diagnosis
of suspected or confirmed nAMD were included in the analysis and this number has been included in the above table as
an approximation of the number of nAMD participants enrolled by this study.
b The median (range) prevalence of nAMD was derived from 13 studies where this information was available at participant
level. Studies reporting eye as the unit of analysis where it was not possible to ascertain the number of participants with
nAMD, or studies reporting results only at phenotype level were not included in these calculations.
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Seven studies were undertaken in the USA,27,34,36,38,40,41,44 three in the UK,33,46,49 two each in Japan,29,31
Austria37,48 and Spain,45,51 and one each in Portugal,25 Italy (involving eight centres),42 the Republic of
Korea35 and China.26 The remaining two studies were international, taking place in (a) seven centres in the
USA, Germany, Israel, Austria and Portugal24 and (b) 15 centres in Israel and the USA.39 Of the three
UK-based studies, two took place at the Royal Victoria Infirmary, Newcastle upon Tyne,46,49 while the third
took place at King’s College Hospital, London.33 One of the UK-based studies, by Talks et al., involved a
nurse-led, fast-track screening clinic.49
The largest study was by Kozak et al.,36 which reported TD-OCT, was set in the USA and analysed
541 eyes, whereas the smallest was by Sulzbacher et al.,48 reporting ICGA and included only 13 eyes.
Across 15 studies reporting the mean or median age of the participants,24–27,29,31,35–37,39,40,45,46,49,51 the median
(range) of these values was 76 years (51.4–84.6 years). Fourteen studies involving 1633 participants
provided information on gender, in which 742 (45.4%) participants were men and 891 (54.6%) were
women.24,25,27,29,31,35,36,39–41,45,46,49,51 The median (range) prevalence of nAMD across 13 studies where this
information was available at participant level was 80.0% (17.2–100.0%).24,25,27,33,35,38–41,44,45,49,51
In three studies, by Cachulo et al.,25 Do et al.27 and Padnick-Silver et al.,40 the inclusion criteria specified
that participants were required to have previously diagnosed nAMD in the non-study eye.
Thirteen studies reported OCT (12 TD-OCT;25,27,33–38,40,45,46,49 one SD-OCT).41 The study by Kozak et al.,36
reporting TD-OCT, included a subset of patients who underwent additional examination with SD-OCT.36
Of the other tests reported, three studies reported PHP,24,27,39 one reported colour fundus photography,24
one Amsler grid,27 one FAF imaging25 and eight ICGA.25,26,29,31,42,44,48,51 Of the studies reporting more than
one test, Cachulo et al.25 reported TD-OCT, ICGA and FAF, Do et al.27 TD-OCT, Amsler grid and PHP, and
Alster et al.24 reported PHP and colour fundus photography. Two studies reported combinations of tests:
Alster et al.24 reported colour fundus photography plus VA, whereas Sandhu and Talks46 reported TD-OCT
plus colour fundus photography.
The 13 studies reporting OCT analysed 1262 eyes; in eight studies one eye per patient was analysed
(n= 479 eyes) (all TD-OCT).25,27,33–35,38,40,49 Eight studies reported detection of nAMD phenotypes
(predominantly classic, minimally classic, occult CNV).25,33,34,37,38,41,46,49 Four of these studies also reported
detection of RAP.25,34,37,38
Of the eight studies reporting ICGA, seven used the eye as the unit of analysis (number of eyes
analysed= 291).25,26,29,31,44,48,51 In three of these studies, one eye per patient was analysed (n= 109
eyes).25,31,44 Three studies only reported detection of nAMD phenotypes: IPCV;31 occult CNV;26 and type 2
CNV without an occult component.48 The study by Parravano et al.,42 with patient as the unit of analysis
(n= 155 patients), also only reported detection of an nAMD phenotype – RAP.
The three studies reporting PHP analysed one eye per patient (n= 302 eyes),24,27,39 as did the studies
reporting colour fundus photography (n= 120 eyes),24 Amsler grid (n= 46 eyes)27 and FAF (n= 50 eyes).25
Risk of bias of the included diagnostic studies
All 20 full-text papers were assessed using a modified version of the QUADAS-2 tool containing 12 items.
QUADAS-2 consists of four key domains covering (1) patient selection, (2) index test, (3) reference
standard, and (4) flow of patients through the study and timing of the index test(s) and reference
standard. Each domain is assessed in terms of the risk of bias and the first three domains are also assessed
for concerns regarding their applicability in terms of whether or not they match the question being
addressed by the review. Figure 4 presents a summary of the results for the QUADAS-2 risk of bias and
applicability domains across the full-text diagnostic papers. Appendix 5 (see Table 44) presents the results
of the risk of bias and applicability concerns for the individual studies.
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No study was judged to have a low risk of bias across all domains; in three studies the risk of bias was
judged to be unclear across all domains.29,35,48 The domains in which the greatest number of studies
were judged to be at high risk of bias were the patient selection domain (n= 11, 55%) and flow and
timing domain (n= 8, 40%).
In the patient selection domain, only one study36 was judged to be at low risk of bias, whereas
the majority were considered to have either a high (n= 11, 55%)24,27,31,37–41,44,45,49 or unclear
(n= 8, 40%)25,26,29,33,35,46,48,51 risk of bias. Reasons for studies being judged to be at high risk of bias
included not enrolling a consecutive sample of participants,27,37 not avoiding inappropriate
exclusions24,31,38–41,44 and not avoiding pre-selection of participants.24,27,31,39,40,44,45,49
In the index/comparator test domain, eight studies (40%) were judged to be at low risk of bias,24,27,33,37,38,41,46,49
two (10%) were considered high risk of bias44,51 and in half (n= 10, 50%) the risk of bias was considered to
be unclear.25,26,29,31,35,36,39,40,45,48 The reasons for the two studies being judged to be at high risk of bias were
that the test (ICGA in both cases) was interpreted with knowledge of the results of the reference standard.
In the reference standard domain, five studies (25%) were judged to be at low risk of bias,24,27,33,37,46
three (15%) were considered high risk of bias44,49,51 and in the majority (n= 12, 60%) the risk of bias was
considered to be unclear.25,26,29,31,35,36,38–41,45,48 The reasons for the three studies being judged to be at high
risk of bias were that the reference standard test was interpreted with knowledge of the results of the
index test (TD-OCT)49 or comparator test (ICGA).44,51
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FIGURE 4 Summary of risk of bias and applicability domains (diagnostic studies).
ASSESSMENT OF DIAGNOSTIC AND MONITORING STUDIES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
22
In the flow and timing domain, six studies (30%) were judged to be at low risk of bias,26,31,37,38,41,44
and the majority were considered to have either a high (n= 8, 40%)24,25,27,36,39,40,46,49 or unclear
(n= 6, 30%)29,33,35,45,48,51 risk of bias. Reasons for studies being judged to be at high risk of bias included an
interval of more than 1 week between the index/comparator test and reference standard,24,39 not all patients
receiving the reference standard test,39 or not all patients being included in the analysis.24,25,27,36,37,40,46,49
All 20 diagnostic studies were judged to have low concerns for applicability regarding the patient
selection, index/comparator test and reference standard domains, in that the participants and setting,
index/comparator test and target condition as defined by the reference standard were considered to match
the question being addressed by the review.
Results: diagnostic accuracy
Individual study results are presented in Appendix 6 (see Table 46).
Single tests
Optical coherence test
Thirteen studies, analysing 1262 eyes, reported the diagnostic accuracy of OCT in detecting nAMD
(12 TD-OCT;25,27,33–38,40,45,46,49 one SD-OCT41). In eight studies, one eye per patient was analysed (n= 479
eyes) (all TD-OCT).25,27,33–35,38,40,49 Eight studies reported detection of nAMD phenotypes.25,33,34,37,38,41,46,49
The median (range) prevalence of nAMD across nine OCT studies where this information was available at
participant level was 100.0% (17.2–100.0%).25,27,33,35,38,40,41,45,49
Figure 5 shows a forest plot of the sensitivity and specificity of the individual studies (excluding three where
information was only available at phenotype level).34,37,38 Across these 10 studies, the median (range) sensitivity
and specificity values reported were 94.5% (36.0–100.0%) and 73.5% (66.0–94.0%) respectively. Only four
studies (all TD-OCT) reported specificity. For TD-OCT, across the studies, the median (range) sensitivity values
reported were 92.0% (36.0–100.0%) whereas the only SD-OCT study reported sensitivity of 100%.
The studies shown in Figure 5 demonstrate heterogeneity across the sensitivities reported. The lowest
sensitivity reported was by Hughes et al.33 (36%) and Do et al.27 (40%). In the study by Hughes et al.,33
set in the UK, 22 individuals were classed as nAMD by FFA, seven with classic and 15 with occult CNV.
TD-OCT detected six of the seven classic CNVs but only 2 of the 15 occult CNVs, hence the low overall
sensitivity. The overall prevalence of nAMD in this study was 100%. Do et al.,27 using TD-OCT in a study
set in the USA, reported two separate sets of results, one for when the reference standard was FFA graded
as positive by the reading centre irrespective of treatment decision (sensitivity 40.0%, specificity 70.8%),
and one for when the reference standard was FFA graded as positive by the reading centre and the
clinician recommended treatment (sensitivity 69.2%, specificity 66.2%) (see also Appendix 6, Table 46).
The former reference standard was considered closer to the one used in this review and therefore it was
these results that were taken to represent the study. Of 87 eyes analysed by Do et al.,27 15 were classed as
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FIGURE 5 Individual study results for all OCT diagnostic studies reporting sensitivity and/or specificity.
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nAMD by FFA, with 13 of the 15 CNVs described as occult with no classic. The overall prevalence of nAMD in
this study was low at 17.2%. In theory, prevalence should not affect sensitivity, but if the low prevalence
contained more people with phenotypes that were difficult to diagnose compared with studies with a higher
prevalence of disease, then this might reduce the sensitivity of the test.
By far, the largest study was that by Kozak et al.36 This retrospective study was set in the USA and involved
the analysis of 1272 eyes of 654 participants with a diagnosis of confirmed or suspected macular oedema
of various aetiologies; in 541 eyes (number of participants not reported) the aetiology was nAMD. In this
study, no data were presented for TNs for the nAMD group and the total number of suspected nAMD
classed by FFA as without disease was not reported; as such it was not possible to calculate specificity.
The study stated that TD-OCT had detected nAMD in 13 eyes that had not been detected by FFA. As the
reference standard of FFA, for the purposes of this review, was considered to have perfect sensitivity and
specificity, these 13 cases were classed as TD-OCT FP (although not shown in Figure 5 in order to prevent
a spurious specificity value of 0% being calculated based on 13 FPs and zero TNs).
Pigment epithelial detachments can be classified as serous (non-specific) or vascularised. The latter are
characteristic of nAMD. A serous PED can occur as a result of retinal conditions other than nAMD, such as
central serous chorioretinopathy, angioid streaks or others. The study by Sandhu and Talks,46 considered a
serous PED to constitute presence of nAMD and on this basis reported sensitivity of 96.4% and specificity
of 66.0%. However, as a serous PED did not fall within our definition of nAMD for diagnostic studies,
cases with serous PED were classed as non-nAMD and the data from the study were recalculated
accordingly, resulting in alternative values for sensitivity of 77.8% and specificity of 76.0% and it was
these values that were taken to represent this study.
Four studies, all TD-OCT,27,40,46,49 reported both sensitivity and specificity, providing sufficient data for
inclusion in a meta-analysis. One of the studies, by Talks et al.49 was a retrospective audit on new patients
referred with nAMD to a nurse-led, fast-track screening clinic. Figure 6 shows a forest plot of the sensitivity
0.0 0.2 0.4 0.6 0.8 1 0.0 0.2 0.4 0.6 0.8 1
Do 201227 (TD-OCT)
Padnick-Silver 201140 (TD-OCT)
Sandhu 200546 (TD-OCT)
Talks 200449 (TD-OCT)
6
12
63
73
21
4
12
13
9
3
18
0
51
58
38
25
0.40 (0.16 to 0.68)
0.80 (0.52 to 0.96)
0.78 (0.67 to 0.86)
1.00 (0.95 to 1.00)
0.71 (0.59 to 0.81)
0.94 (0.84 to 0.98)
0.76 (0.62 to 0.87)
0.66 (0.49 to 0.80)
Study TP FP FN TN Sensitivity (95% Cl) Specificity (95% Cl) Sensitivity (95% Cl) Specificity (95% Cl)
(a)
1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
(b)
0.8
0.9
1
0.9 0.8 0.7 0.6 0.5
Specificity
0.4 0.3 0.2 0.1 0
Se
n
si
ti
vi
ty
FIGURE 6 All OCT diagnostic studies reporting sensitivity and specificity. (a) Individual study results; and
(b) SROC curve.
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and specificity of the individual studies and a SROC curve for the four OCT studies. Table 5 shows the
pooled estimates for the OCT studies. For all OCT studies, the pooled sensitivity and specificity (95% CI)
was 88% (46% to 98%) and 78% (64% to 88%) respectively.
A LR describes how many times a person with disease is more likely to receive a positive (LR+) or negative
(LR–) test result than a person without disease. It has been suggested that LR+s > 10 or LR−s < 0.1 can
provide convincing diagnostic evidence, whereas those > 5 and < 0.2 demonstrate strong diagnostic
evidence.54 The LR+ did not exceed 5 for OCT.
The DOR is a single summary of diagnostic performance and describes the ratio of the odds of a positive
test result in an individual with disease compared with someone without disease. It has been suggested
that a DOR of 25 could provide strong diagnostic evidence and that a DOR of 100 could provide
convincing diagnostic evidence.20
The risk of bias assessment of the four OCT studies included in the meta-analysis is shown in Table 6. The
domains in which most studies were judged to be at high risk of bias were the patient selection domain,
for reasons such as not enrolling a consecutive sample of participants,27 not avoiding inappropriate
exclusions40 and not avoiding pre-selection of participants,27,40,49 and the flow and timing domain, due to
all patients not being included in the analysis (all four studies).
Eight studies25,33,34,37,38,41,46,49 reported the sensitivity of OCT in the detection of nAMD phenotypes (Table 7).
The studies by Cachulo et al.25 and Khondkaryan et al.,34 and Talks et al.,49 using TD-OCT, and Park et al.41
using SD-OCT showed equally high sensitivity for the detection of classic CNV compared with occult CNV.
On the other hand, the studies by Hughes et al.33 (TD-OCT), Krebs et al.37 (TD-OCT), Liakopoulos et al.38
(TD-OCT), and Sandhu and Talks46 (TD-OCT) reported higher sensitivity for OCT in the detection of classic
CNV compared with occult CNV.
TABLE 5 Pooled estimates for the OCT diagnostic studies
Test
Number of
studies
Number of
eyes analysed
Pooled estimates (95% CI)
Sensitivity, % Specificity, % LR+ LR– DOR
All
OCT
4 406 88
(46 to 98)
78
(64 to 88)
4.08
(2.37 to 7.04)
0.15
(0.02 to 0.98)
26.86
(3.36 to 214.81)
TABLE 6 Risk of bias of the four OCT studies included in the meta-analysis
Study
Risk of bias domain
Patient selection Index/comparator test Reference standard Flow and timing
Do 201227 High Low Low High
Padnick-Silver 201240 High Unclear Unclear High
Sandhu 200546 Unclear Low Low High
Talks 200749 High Low High High
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TABLE 7 Sensitivity of OCT in detecting nAMD phenotypes
Study ID Test Unit of analysis nAMD phenotype
Number
by FFA
OCT
sensitivity, %
Cachulo 201125 TD-OCT Eye Predominantly classic 2 100.0
Minimally classic 4 100.0
Occult 6 100.0
RAP 5 100.0
Hughes 200533 TD-OCT Eye Classic 7 85.7
Occult 15 13.3
Khondkaryan 200934 TD-OCT Eye Classic Not
reported
80.9
Occult 81.1
RAP 57.1
Krebs 200737 TD-OCT Eye Primarily classic 5 100.0
RAP 11 72.7
Liakopoulos 200838 TD-OCT Eye Subretinal fluid
Predominantly classic 11 100.0
Minimally classic 23 91.3
Occult with no classic 24 79.2
RAP stage III 8 50.0
Cystoid oedema
Predominantly classic 11 81.8
Minimally classic 23 73.9
Occult with no classic 24 58.3
RAP stage III 8 100.0
Park 201041 SD-OCT Eye Classic 7 100.0
Minimally classic 3 100.0
Occult 11 100.0
Sandhu 200546 TD-OCT Eye Classic 56 78.6
Occult 25 20.0
TD-OCT+
fundus photo
Eye Classic 56 82.1
Occult 25 12.0
Talks 200749 TD-OCT Eye Predominantly classic 22 100.0
Minimally classic 6 100.0
Occult 45 100.0
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Amsler grid
One study, by Do et al.,27 in an analysis of 46 eyes of 46 patients, reported sensitivity of 41.7% for the
Amsler grid in detecting nAMD (specificity not reported and insufficient information to calculate prevalence
of nAMD in this group). As this study also reported OCT, information on risk of bias is presented in
that section.27
Fundus autofluorescence imaging
One study, by Cachulo et al.,25 in an analysis of 50 eyes of 50 patients, reported sensitivity of 93.3% and
specificity of 37.1% for FAF in detecting nAMD. The prevalence of nAMD in this group was 30.0%.
As this study also reported ICGA, information on risk of bias is presented in that section.25
Colour fundus photography
One study, by Alster et al.,24 in an analysis of 120 eyes of 120 patients, reported sensitivity of 70.0%
and specificity of 95.0% for colour fundus photography in detecting nAMD. The prevalence of nAMD
in this study was 53.3%. As this study also reported PHP, information on risk of bias is presented in
that section.24
Preferential hyperacuity perimetry
Three studies analysing 302 eyes of 302 patients reported the diagnostic accuracy of the PHP test in
detecting nAMD.24,27,39 Figure 7 shows a forest plot with the individual study results for sensitivity and
specificity. The studies by Alster et al.24 and Loewenstein et al.39 reported similarly high sensitivity and
specificity. However, it was not possible to calculate pooled estimates using HSROC methodology due to
insufficient data. The study by Do et al.27 reported lower sensitivity and did not report specificity. Across
the studies the median (range) of sensitivity values reported was 82% (50–85%). The specificity values
reported by Alster et al.24 and Loewenstein et al.39 were 88% and 85% respectively.
Across the three studies, the median (range) prevalence of nAMD was 50.4% (17.2–53.3%).
The risk of bias assessment of the three PHP studies is shown in Table 8. The domains in which most
studies were judged to be at high risk of bias were the patient selection domain, for reasons such as
inappropriate exclusions24,39 and pre-selection of participants,24,27,39 and the flow and timing domain, for
reasons such as an interval of more than 1 week between the index test and reference standard,24,39 not all
patients receiving the reference standard test39 and not all patients included in the analysis.24,39
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FIGURE 7 Preferential hyperacuity perimetry studies: individual study results for sensitivity and specificity.
TABLE 8 Risk of bias of the PHP studies
Study
Risk of bias domain
Patient selection Index/comparator test Reference standard Flow and timing
Alster 200524 High Low Low High
Do 201227 High Low Low High
Loewenstein 201039 High Unclear Unclear High
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Loewenstein et al.39 also reported the ability of PHP in detecting nAMD phenotypes, with 90% (18/20)
sensitivity for minimally or predominantly classic CNV and 82.6% (38/46) sensitivity for occult CNV.
Indocyanine green angiography
Eight studies reported the diagnostic accuracy of ICGA in detecting nAMD, of which seven25,26,29,31,44,48,51
reported the eye as the unit of analysis and one42 reported the patient as the unit of analysis. Four of these
studies only reported detection of nAMD phenotypes: IPCV;31 occult CNV;26 type 2 CNV without an occult
component;48 and RAP.42
The median (range) prevalence of nAMD across three studies where this information was available at
participant level (and excluding studies reporting results only at phenotype level) was
80.0% (32.7–100.0%).25,44,51
Figure 8 shows a forest plot of the sensitivity and specificity of the individual studies (excluding the four
that only reported detection of phenotypes). Across the studies, the median (range) sensitivity reported
was high at 93% (85–100%). Only the study by Fujii et al.29 reported specificity, which was low at 37%.
In the study by Reichel et al.,44 all participants were deemed to have nAMD (therefore there could be no
TNs and it was not possible to calculate specificity). Only participants who were suspected to have a CNV
obscured by haemorrhage were included in this study. The authors stated that ICGA had detected nAMD
in four eyes that had not been detected by FFA. As the reference standard of FFA, for the purposes of this
review, was considered to have perfect sensitivity and specificity, these four cases were classed as ICGA FPs
(although not shown in Figure 8 in order to prevent a spurious specificity value of 0% being calculated
based on four FPs and zero TNs).
The risk of bias assessment of the four ICGA studies is shown in Table 9. The domains in which most
studies were judged to be at high risk of bias were the index/comparator test domain, due to the ICGA
test being interpreted with knowledge of the FFA results, and the reference standard domain, due to FFA
being interpreted with knowledge of the ICGA results.44,51
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FIGURE 8 Indocyanine green angiography sensitivity and specificity: individual study results.
TABLE 9 Risk of bias of the four ICGA studies included in the forest plot
Study
Risk of bias domain
Patient selection Index/comparator test Reference standard Flow and timing
Cachulo 201125 Unclear Unclear Unclear High
Fujii 199629 Unclear Unclear Unclear Unclear
Reichel 199544 High High High Low
Torron 200251 Unclear High High Unclear
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Four studies26,31,42,48 reported the sensitivity of ICGA in the detection of nAMD phenotypes, with each study
reporting detection of a different phenotype (Table 10). Sensitivity was 100% for detection of IPCV31 and
type 2 CNV without an occult component,48 high (85.1%) for detection of RAP42 but lower (62.9%) for
detection of occult CNV.26
Studies directly comparing tests
Preferential hyperacuity perimetry versus colour fundus photography
versus colour fundus photography plus visual acuity
One study, by Alster et al.,24 analysing one eye per patient, reported PHP (n= 122 eyes) compared with
colour fundus photography (n= 120 eyes) and colour fundus photography plus VA (n= 66 eyes). Sensitivity
was highest for PHP (81.5%), followed by colour fundus photography (70.0%) and lowest for colour
fundus photography plus VA (53.0%). Specificity was similarly high for colour fundus photography (95.0%)
and colour fundus photography plus VA (94.0%), followed by PHP (87.7%).
Time domain optical coherence tomography versus indocyanine green
angiography versus fundus autofluorescence imaging
One study, by Cachulo et al.,25 analysing one eye per patient, reported TD-OCT (n= 52 eyes) compared
with ICGA (n= 52 eyes) and FAF (n= 50 eyes). Sensitivity was high for all three tests (TD-OCT 100.0%,
ICGA 94.1%, FAF 93.3%). Specificity was only reported for FAF, which was low at 37.1%.
Time domain optical coherence tomography versus Amsler grid versus
preferential hyperacuity perimetry
One study, by Do et al.,27 analysing one eye per patient, reported TD-OCT (n= 87 eyes) compared with
Amsler grid (n= 46 eyes) and PHP (n= 49 eyes). Based on the set of results for CNV defined as positive by
FFA irrespective of the treatment decision, the sensitivity for all three tests was fairly low (PHP 50.0%,
Amsler grid 41.7%, TD-OCT 40.0%). Specificity was only reported for TD-OCT, which was moderate at
70.8%. As previously stated, the overall prevalence of nAMD in this study was low at 17.2%, the majority
of which were occult CNV, which might at least partly explain the low sensitivity reported by this study
for TD-OCT.
Time domain optical coherence tomography versus time domain optical
coherence tomography plus stereo colour fundus photography
One study, by Sandhu and Talks,46 reported TD-OCT compared with TD-OCT plus stereo colour fundus
photography (both n= 131 eyes of 118 participants). As previously stated, serous PED did not fall within
this review’s definition of nAMD for diagnostic studies and the study data were recalculated accordingly.
Based on the recalculated data, sensitivity was similar and moderately high for both tests (TD-OCT 77.8%,
TD-OCT plus stereo colour fundus photography 74.1%), whereas specificity was higher for the
combination (92.0%) than for TD-OCT alone (76.0%).
TABLE 10 Sensitivity of ICGA in detecting nAMD phenotypes
Study Test Unit of analysis nAMD phenotype Number by FFA
ICGA
sensitivity, %
Chen 200326 ICGA Eye Occult CNV 35 62.9
Gomi 200731 ICGA Eye IPCV 37 100.0
Sulzbacher 201148 ICGA Eye Type 2 CNV without
an occult component
13 100.0
Parravano 201242 ICGA Patient RAP 155 85.1
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Studies reporting combinations of tests
Two studies reported combinations of tests. Sandhu and Talks46 reported TD-OCT combined with stereo
colour fundus photography. Alster et al.24 reported colour fundus photography combined with VA. As both
studies also reported other tests, the results for the test combinations are included in the preceding section
on studies directly comparing tests.
Assessment of other outcomes of interest
Clinical effectiveness
No studies were identified that met our inclusion criteria of providing information on clinical effectiveness
outcomes (e.g. VA) when treatment was based on OCT compared with FFA findings.
Interpretability of the tests
Six diagnostic studies24,25,27,36,39,46 provided information relating to the interpretability of the tests, in as
much as they reported on the numbers excluded from analysis due to poor image quality (Table 11).
In the TD-OCT study by Do et al.,27 166 individuals were screened and 98 were enrolled; in 6 of the 68
individuals screened but not enrolled, the reason given was poor image quality. However, it was unclear
whether the excluded images related to OCT, colour fundus photography or FFA. In the TD-OCT study by
Sandhu and Talks,46 10/128 individuals (7.8%) were excluded from the analysis due to poor image quality.
It was also unclear in this study whether the excluded images related to OCT or FFA.
Acceptability of the tests
No studies were identified meeting our inclusion criteria that reported the acceptability of the tests, either
to those providing the tests or to those receiving them.
TABLE 11 Studies reporting numbers excluded from analysis due to poor image quality
Study Test
Excluded from analysis,
n (%) Reason
Alster 200524 PHP 11/185 (5.9)
individuals/eyes
Results judged to be unreliable
Colour fundus
photography
17/185 (9.2)
individuals/eyes
Inadequate or poor-quality photographs
Cachulo 201125 FAF 2/52 (3.8) individuals/eyes Pattern of autofluorescence could not
be determined
Do 201227 TD-OCT, PHP,
Amsler grid, colour
fundus photography
6/104 (5.8)
individuals/eyesa
Poor image quality that was insufficient to
permit successful participation
Kozak 200836 TD-OCT 35/1307 (2.7) eyesb Poor quality or image decentration
Loewenstein 201039 PHP, colour fundus
photography
40/208 (19.2)
individuals/eyesc
Geographic atrophy, early AMD, pattern
dystrophy, no or poor-quality photographs
Sandhu 200546 TD-OCT 10/128 (7.8) individuals Poor quality of the images
a In the study by Do et al.,27 166 individuals were screened for study participation, of whom 98 were enrolled. Of the 68
individuals screened but not enrolled, the reason for this, in 6 of them, was poor image quality. Our calculation of 5.8%
excluded from the analysis was based on 6 as a percentage of 104 (98+ 6), on the assumption that these six individuals
would have been enrolled had their images been of sufficient quality.
b In the study by Kozak et al.,36 of 1272 eyes analysed, 541 were nAMD with the remainder macular oedema due to other
aetiologies. Thirty-five eyes were excluded prior to analysis due to poor quality or image decentration, but it was not
reported how many of these specifically related to nAMD.
c In the study by Loewenstein et al.,39 the specific number of individuals excluded solely due to poor-quality photographs
was not reported.
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Proportion of participants unable to receive the diagnostic test
Ten studies reported exclusion criteria relating to eye conditions (see Appendix 7, Table 48).24,25,27,31,39–41,44,48,49
The studies detailed various eye-related exclusion criteria, for example evidence of macular disease other than
AMD, previous surgical or laser treatment within the macular area, presence of any significant media opacity
that precluded a clear view of the fundus, subretinal or subpigment epithelial haemorrhages that obscured
lesions, and recent ocular surgery in the study eye.
A few non-ophthalmic exclusion criteria were reported, including current or past history of a medical
condition that would preclude scheduled study visits or completion of the study,25 allergy to fluorescein
dye27 and allergy to iodine-based dye.44 In the PHP study by Loewenstein et al.,39 individuals with no
experience of using a computer mouse were taught how to use the mouse and participation in the study
was conditional on passing an in-house computer mouse tutorial. The authors reported that 15 people did
not pass the tutorial and were excluded from the study.
Other health professionals compared with ophthalmologists interpreting
optical coherence tomography findings
No studies were identified meeting our inclusion criteria that reported the performance of other health
professionals compared with ophthalmologists in interpreting OCT findings. The setting for the TD-OCT
study by Talks et al.49 was a nurse-led, fast-track screening clinic in the UK for new nAMD referrals, but did
not involve a comparison with other health professionals in interpreting OCT findings. Trained nurses and
an ophthalmic photographer, who consulted an ophthalmologist when in doubt, conducted the screening
visit. If the VA was ≥ 6/60 an OCT was performed. If dry AMD or other retinal pathology was seen, the
patient was referred for management appropriate to their condition but no further imaging was performed.
The remaining patients underwent simultaneous FFA and ICGA. The images were taken, using standard
protocols, by an ophthalmic photographer. The ophthalmologist reviewed the images the following day.49
Assessment of monitoring studies
Characteristics of the included monitoring studies
Appendix 4 (see Table 43) provides details of the individual study characteristics for the eight monitoring
studies.23,28,30,32,43,45,52,53 Table 12 provides summary information for the studies. Of the eight monitoring
studies, four were prospective,32,43,45,53 three were retrospective,23,28,30 and in the study by van de
Moere et al.52 this information was not reported. In five studies, the participants were a consecutive
sample.28,30,43,45,53 The eight studies enrolled 463 participants.
Five studies used the eye as the unit of analysis (363 eyes),23,28,30,52,53 whereas three used test examination
as the unit of analysis (61 pairs of OCT and FFA examinations,32 176 pairs of OCT and FFA examinations45
and 54 pairs of ICGA and FFA examinations).43
Two studies were undertaken in the USA23,43 and one each in Italy,30 Germany,32 the Netherlands,53 Spain45
and the UK (Royal Victoria Infirmary, Newcastle upon Tyne).52 One study was international, taking place in
two centres in the USA and Germany.28
The largest study was by van de Moere et al.,52 which reported TD-OCT, was set in the UK and analysed
121 eyes, while the smallest was by van Velthoven et al.,53 reporting TD-OCT and analysing 30 eyes.
Across seven studies23,28,30,43,45,52,53 reporting the mean or median age of the participants, the median
(range) of these values was 76.5 years (73.9–78.1 years). Six studies involving 378 participants provided
information on gender,28,30,43,45,52,53 in which 177 (46.8%) participants were men and 201 (53.2%) women.
The median (range) prevalence of active nAMD across five studies where this information was available at
participant level was 57.9% (49.2–83.3%).23,28,30,52,53
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Seven studies reported OCT (six TD-OCT;23,28,32,45,52,53 and two SD-OCT).23,30 (The study by Khurana et al.23
reported both TD-OCT and SD-OCT.) One study, by Regillo et al.,43 reported ICGA.
Of the seven studies reporting OCT, five used the eye as the unit of analysis (number of eyes
analysed= 363).23,28,30,52,53 In four of these studies, one eye per patient was analysed (n= 304 eyes).28,30,52,53
Two studies reported examination as the unit of analysis (both TD-OCT).32,45 Two studies reported
detection of nAMD phenotype activity: classic and occult CNV;30 and PED and cystoid macular oedema.52
The studies by Henschel et al.32 and van de Moere et al.52 also reported the performance of OCT in
detecting intraretinal and subretinal fluid.
In two OCT monitoring studies,23,30 the participants had received antiVEGF therapy and in five28,32,45,52,53
the treatment was photodynamic therapy (PDT). In the study reporting ICGA,43 the participants had
received laser photocoagulation treatment.
Risk of bias of the included monitoring studies
Figure 9 presents a summary of the results for the QUADAS-2 risk of bias and applicability domains across
the eight full-text monitoring papers. Appendix 5 (see Table 45) presents the results of the risk of bias and
applicability concerns for the individual studies.
No study was judged to have a low risk of bias across all domains. More studies in the patient selection
domain (n= 2, 25%) and the flow and timing domain (n= 2, 25%) were judged to be at high risk of bias
than in the index/comparator test domain (n= 1, 12.5%) and reference standard domain (n= 1, 12.5%).
TABLE 12 Summary of the characteristics of the included monitoring studies
Characteristic Number Number of studies
Participants enrolled 463 8
Analysed (eyes) 363 5
Analysed (examinations, pairs) 291 3
Age: median (range) of means/medians 76.5 (73.9–78.1) 7
Gender: male : female, n (%) 177 (46.8) : 201 (53.2) 6
Median (range) prevalence of active nAMDa 57.9% (49.2–83.3%) 5
Tests reported (number enrolled)b
OCT 442 7
TD-OCT 349 6
SD-OCT 152 2
ICGA 21 1
Type of treatment received
AntiVEGF 149 2
PDT 293 5
Laser photocoagulation 21 1
PDT, photodynamic therapy
a The median (range) prevalence of active nAMD was derived from five studies where this information was available at
participant level. Three studies reporting examination as the unit of analysis, where it was not possible to ascertain the
number of participants with nAMD, were not included in these calculations.32,43,45
b One study reported both TD-OCT and SD-OCT.23
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In the patient selection domain, three studies43,52,53 (37.5%) were judged to be at low risk of bias, two30,45
(25%) were considered to have a high risk of bias and in three23,28,32 (37.5%) the risk of bias was unclear.
The study by Giani et al.30 was judged to be at high risk of bias due to not avoiding inappropriate
exclusions and pre-selection of participants, whereas the study by Salinas-Alaman et al.45 was judged to be
at high risk of bias due to not avoiding pre-selection of participants.
In the index/comparator test domain, three studies (37.5%) were judged to be at low risk of bias,28,30,32
one (12.5%) was considered high risk of bias43 and in the remaining four (50%) the risk of bias was
considered to be unclear.23,45,52,53 The reasons for the study by Regillo et al.43 being judged to be at
high risk of bias was that the test (ICGA) was interpreted with knowledge of the results of the
reference standard.
In the reference standard domain, four studies (50%) were judged to be at low risk of bias,28,30,32,53 one
(12.5%) was considered high risk of bias43 and in the remaining three (37.5%) the risk of bias was
considered to be unclear.23,45,52 The Regillo et al.43 study was judged to be at high risk of bias as the
reference standard test was interpreted with knowledge of the results of the comparator test (ICGA).
In the flow and timing domain, two studies (25%) were judged to be at low risk of bias,23,43 two45,52 (25%)
were considered to have a high risk of bias and in the remaining four28,30,32,53 (50%) the risk of bias was
considered to be unclear. The studies by Khurana et al.23 and Regillo et al.43 were judged to be at high risk
of bias as not all patients were included in the analysis.
All eight studies were judged to have low concerns for applicability on the patient selection,
index/comparator test and reference standard domains.
Patient selection
Index test
Reference standard
Flow and timing
0 20 40 60 80 100
Proportion of studies with low, high or unclear
risk of bias (%)
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FIGURE 9 Summary of risk of bias and applicability domains (monitoring studies).
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Results: detection of active neovascular age-related macular degeneration
Individual study results are presented in Appendix 6 (see Table 47).
Single tests
Optical coherence tomography
Seven studies reported the accuracy of OCT in detecting active nAMD, of which five reported
TD-OCT,28,32,45,52,53 one reported SD-OCT30 and one reported both TD-OCT and SD-OCT.23 In five studies
the unit of analysis was the eye23,28,30,52,53 and in two the unit of analysis was pairs of OCT and
FFA examinations.32,45
The median (range) prevalence of active nAMD across five studies where this information was available at
participant level was 57.9% (49.2–83.3%).23,28,30,52,53
Three TD-OCT studies23,28,53 and two SD-OCT studies,23,30 with eye as the unit of analysis, reported both
sensitivity and specificity, providing sufficient data for inclusion in a meta-analysis. Figure 10 shows forest
plots of the sensitivity and specificity of the individual studies and SROC curves for (a) all of the OCT studies,
0.0 0.2 0.4 0.6 0.8 1 0.0 0.2 0.4 0.6 0.8 1
Eter 200528 (TD-OCT)
van Velthoven 200653 (TD-OCT)
Giani 201130 (SD-OCT)
Khurana 201023 (SD-OCT)
40
15
49
26
2
4
30
16
10
8
3
3
8
3
11
14
0.80 (0.66 to 0.90)
0.65 (0.43 to 0.84)
0.94 (0.84 to 0.99)
0.90 (0.73 to 0.98)
0.80 (0.44 to 0.97)
0.43 (0.10 to 0.82)
0.27 (0.14 to 0.43)
0.47 (0.28 to 0.66)
Study TP FP FN TN Sensitivity (95% Cl) Specificity (95% Cl) Sensitivity (95% Cl) Specificity (95% Cl)
(a)
Eter 200528 (TD-OCT) 
Khurana 201023 (TD-OCT)
van Velthoven 200653 (TD-OCT)
40
17
15
2
11
4
10
12
8
8
19
3
0.80 (0.66 to 0.90)
0.59 (0.39 to 0.76)
0.65 (0.43 to 0.84)
0.80 (0.44 to 0.97)
0.63 (0.44 to 0.80)
0.43 (0.10 to 0.82)
Study TP FP FN TN Sensitivity (95% Cl) Specificity (95% Cl) Sensitivity (95% Cl) Specificity (95% Cl)
0.0 0.2 0.4 0.6 0.8 1 0.0 0.2 0.4 0.6 0.8 1
(b)
Specificity (95% Cl)
Giani 201130 (SD-OCT)
Khurana 201023 (SD-OCT)
49
26
30
16
3
3
11
14
0.94 (0.84 to 0.99)
0.90 (0.73 to 0.98)
0.27 (0.14 to 0.43)
0.47 (0.28 to 0.66)
Study TP FP FN TN Sensitivity (95% Cl) Sensitivity (95% Cl) Specificity (95% Cl)
0.0 0.2 0.4 0.6 0.8 1 0.0 0.2 0.4 0.6 0.8 1
(c)
FIGURE 10 Optical coherence tomography monitoring studies reporting sensitivity and specificity for detection of
nAMD activity: individual study results and SROC curves. (a) Sensitivity and specificity – individual study results – all
OCT; (b) sensitivity and specificity – individual study results – TD-OCT; (c) sensitivity and specificity – individual study
results – SD-OCT; (d) SROC curve – all OCT; (e) SROC curve – TD-OCT; and (f) SROC curve – SD-OCT. (continued )
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FIGURE 10 Optical coherence tomography monitoring studies reporting sensitivity and specificity for detection of
nAMD activity: individual study results and SROC curves. (a) Sensitivity and specificity – individual study results – all
OCT; (b) sensitivity and specificity – individual study results – TD-OCT; (c) sensitivity and specificity – individual study
results – SD-OCT; (d) SROC curve – all OCT; (e) SROC curve – TD-OCT; and (f) SROC curve – SD-OCT.
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(b) the three TD-OCT studies and (c) the two SD-OCT studies respectively. Table 13 shows the pooled
estimates for these studies. As the study by Khurana et al.23 reported both TD-OCT and SD-OCT for the
same 59 eyes, we chose to display only the data for SD-OCT from this study in the forest plot of all OCT
studies and to include only the SD-OCT data from this study in the pooled estimates for all OCT studies, in
order to avoid double counting and on the basis that the SD-OCT data were the more appropriate to
include in the pooled estimates for all OCT. The TD-OCT data from Khurana et al.23 are included in the
forest plot and SROC curve for TD-OCT in Figure 10 and were included in the pooled estimates for
TD-OCT shown in Table 13. For all OCT studies, the pooled sensitivity and specificity (95% CI) was 85%
(72% to 93%) and 48% (30% to 67%) respectively. For TD-OCT, the pooled sensitivity and specificity
(95% CI) was 70% (56% to 80%) and 65% (48% to 79%) respectively. For both TD-OCT and the group
of all four OCT studies, the LR and DOR values reported were below the level suggestive of strong
diagnostic evidence.
It was not possible to calculate pooled estimates using HSROC methodology for the two SD-OCT studies
due to insufficient data. These studies reported sensitivities of 94%30 and 90%23 and specificities of 27%30
and 47%,23 which suggests that SD-OCT has higher sensitivity than TD-OCT but lower specificity.
The risk of bias assessment of the four OCT studies included in the meta-analysis is shown in Table 14.
The only judgement of high risk of bias was for the study by Giani et al.30 for the patient selection domain
(inappropriate exclusions and pre-selection of participants).
TABLE 13 Pooled estimates for the OCT monitoring studies
Test
Number
of studies
Number
of eyes
analysed
Pooled estimates (95% CI)
Sensitivity, % Specificity, % LR+ LR– DOR
All OCTa 4 242 85 (72 to 93) 48 (30 to 67) 1.64
(1.19 to 2.26)
0.31
(0.18 to 0.54)
5.33
(2.57 to 11.06)
TD-OCT 3 149 70 (56 to 80) 65 (48 to 79) 2.00
(1.19 to 3.36)
0.47
(0.28 to 0.78)
4.27
(1.58 to 11.53)
SD-OCT 2 152 Not calculable using HSROC methodology
a Khurana et al.23 reported both TD-OCT and SD-OCT for the same 59 eyes of 56 patients analysed; only the SD-OCT data
were included in the pooled estimates for ‘All OCT’ in order to avoid double counting.
TABLE 14 Risk of bias of the four OCT studies included in the meta-analysis
Study
Risk of bias domain
Patient selection Index/comparator test Reference standard Flow and timing
Eter 200528 Unclear Low Low Unclear
Giani 201130 High Low Low Unclear
Khurana 201023 Unclear Unclear Unclear Low
van Velthoven 200653 Low Unclear Low Unclear
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Two studies used examination as the unit of analysis. Henschel et al.,32 in an analysis of 61 pairs of
TD-OCT and FFA examinations from 14 patients, reported sensitivity of 96.8% and specificity of 36.7%
for CNV based on detection of intraretinal and/or subretinal fluid. Salinas-Alaman et al.,45 in an analysis of
176 pairs of TD-OCT and FFA examinations (number of patients not stated), reported sensitivity of 95.7%
and specificity of 59.0% based on detection of intraretinal or subretinal fluid.
Four studies23,30,32,52 reported the sensitivity of OCT in detecting active nAMD phenotypes or active nAMD
based on detection of intraretinal/subretinal fluid (Table 15). The study by Giani et al.30 reported high
sensitivity for the detection by SD-OCT of both classic and occult CNV activity (90.9% and 100%
respectively). In the studies by Henschel et al.32 (unit of analysis: examination) and van de Moere et al.52
(unit of analysis: eye) sensitivity was higher for nAMD activity based on detection of intraretinal fluid
(90.3% and 82.9% respectively) compared with subretinal fluid (71.0% and 47.1% respectively).
van de Moere et al.52 also reported sensitivity of TD-OCT for detection of cystoid macular oedema and
PED, both low at 22.9% and 5.7% respectively. In the study by Khurana et al.,23 the sensitivity of SD-OCT
was higher than that of TD-OCT for nAMD activity based on the detection of intraretinal fluid, retinal
cystoid abnormalities or subretinal fluid.
Indocyanine green angiography
One study, by Regillo et al.,43 in an analysis of 54 pairs of ICG angiograms compared with fluorescein
angiograms, obtained from 24 eyes of 21 patients, reported sensitivity of 75.9% and specificity of 88.0%
in detecting nAMD activity. It was not possible to ascertain (at participant-level) the prevalence of nAMD.
This study was judged as high risk of bias for the index/comparator test and reference standard domains,
due to the ICGA–FFA pairs being analysed directly from the computer monitor (ICGA test results
interpreted with knowledge of the FFA results, and vice versa) and low risk of bias for the other domains.
TABLE 15 Sensitivity of OCT in detecting nAMD phenotype activity
Study
Unit of
analysis Detection of
Number
by FFA
OCT
sensitivity, %
Giani 201130 (SD-OCT) Eye Classic CNV 57 90.9
Occult CNV 36 100.0
Khurana 201023 (TD-OCT) Eye Intraretinal fluid 29 37.9
Retinal cystoid abnormalities 29 34.5
Subretinal fluid 29 48.3
Khurana 201023 (SD-OCT) Eye Intraretinal fluid 29 65.5
Retinal cystoid abnormalities 29 58.6
Subretinal fluid 29 69.0
van de Moere 200652 (TD-OCT) Eye Intraretinal fluid Not reported 82.9
Subretinal fluid Not reported 47.1
CMO Not reported 22.9
PED Not reported 5.7
Henschel 200932 (TD-OCT) Exam Intraretinal fluid 31 90.3
Subretinal fluid 31 71.0
CMO, cystoid macular oedema.
DOI: 10.3310/hta18690 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 69
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Mowatt et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
37
Studies directly comparing tests
Time domain optical coherence tomography versus spectral domain optical
coherence tomography
One study, by Khurana et al.,23 compared TD-OCT with SD-OCT in an analysis of 59 eyes of 56
participants. Although sensitivity was considerably higher for SD-OCT than for TD-OCT (89.7% vs. 58.6%),
specificity was lower (46.7% vs. 63.3%).
Assessment of other outcomes of interest
Clinical effectiveness
No studies were identified that met our inclusion criteria providing information on clinical effectiveness
outcomes (e.g. VA) when treatment was based on OCT compared with FFA findings.
Interpretability of the tests
Only one monitoring study, by van de Moere et al.,52 reported information relating to the interpretability of
the tests. This TD-OCT study reported that, of 136 participants enrolled, 17 (12.5%) were excluded from
the analysis due to the poor quality of the OCT or FFA images. The study did not specify how many of
these poor quality images were OCT images and how many were FFA.
Acceptability of the tests
No studies were identified that met our inclusion criteria reporting the acceptability of the tests, either to
those providing the tests or to those receiving them.
Proportion of participants unable to receive the monitoring test
Two studies reported exclusion criteria relating to eye conditions (see Appendix 7, see Table 49).23,30
The study by Giani et al.30 contained the following exclusion criteria: any previous laser treatment,
PDT or vitreoretinal surgery on the study eye; significant macular haemorrhage that obscured the lesion;
and a spherical refractive error > 6 diopters. The study by Khurana et al.23 excluded patients with CNV
resulting from causes other than AMD.
Other health professionals compared with ophthalmologists interpreting
optical coherence tomography findings
No studies were identified meeting our inclusion criteria that reported the performance of other health
professionals compared with ophthalmologists in interpreting OCT findings.
Summary of the reviews of diagnostic and monitoring studies
Diagnostic studies
Twenty-two diagnostic studies were included (20 full-text papers, two abstracts).24–27,29,31,33–42,44–46,48,49,51
The full-text papers were assessed for risk of bias using the QUADAS-2 checklist. The domains in which the
greatest number were judged to be at high risk of bias were the patient selection domain (55%, 11/20),
for reasons such as inappropriate exclusions and pre-selection of participants, and flow and timing domain
(40%, 8/20), for reasons such as the length of time between the index test and the reference standard,
and not all participants being included in the analysis. The risk of bias in the index/comparator test and
reference standard domains was judged to be unclear in 50% (10/20) and 60% (12/20) of studies
respectively. All of the studies were judged to have low concerns in terms of their applicability to the
question being addressed by the review.
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A descriptive summary of the results of the diagnostic studies with eye as the unit of analysis is shown in
Table 16 (excluding studies that only reported detection at phenotype level). Across the studies the median
(range) sensitivity was high for OCT (94.5%, range 36.0–100.0%; 10 studies25,27,33,35,36,40,41,45,46,49). Sensitivity
was also high for ICGA (93.2%, range 84.6%–100.0%; four studies25,29,44,51) and FAF (93.3%; one study25),
followed by PHP (81.5%, range 50.0–84.8%; three studies24,27,29), colour fundus photography (70.0%; one
study24) and lowest for Amsler grid (41.7%; one study27). The median (range) specificity for OCT was
moderate (73.5%, range 66.0–94.0%; four studies27,40,46,49). Specificity was highest for colour fundus
photography (95%; one study24), followed by PHP (84.6% and 87.7%; two studies24,39), and was low for
FAF (37.1%; one study25) and ICGA (36.8%; one study29).
Two studies reported the diagnostic accuracy of combinations of tests. Sensitivity and specificity for
TD-OCT plus colour fundus photography46 was 74.1% and 92.0%, respectively, whereas for colour fundus
photography plus VA,24 sensitivity was lower at 53.0% but with similarly high specificity at 94.0%.
Four OCT diagnostic studies (all TD-OCT) provided sufficient data for inclusion in a meta-analysis
(Table 17).27,40,46,49 The pooled sensitivity and specificity (95% CI) for all four OCT studies was 88%
(46% to 98%) and 78% (64% to 88%) respectively.
Eight diagnostic studies reported the sensitivity of OCT in the detection of specific nAMD
phenotypes.25,33,34,37,38,41,46,49 Four showed equally high sensitivity for the detection of classic CNV compared
with occult CNV.25,34,41,49 In four others, sensitivity for OCT was higher in the detection of classic CNV (range
79–100%) compared with occult CNV (range 13–79%).33,37,38,46 Four studies reported the sensitivity of ICGA
in the detection of specific nAMD phenotypes.25,29,44,51 Each study reported detection of a different phenotype,
with 100% sensitivity for detection of IPCV and type 2 CNV without an occult component, high sensitivity
(85.1%) for detection of RAP but lower sensitivity (62.9%) for detection of occult CNV.25,29,44,51
TABLE 16 Descriptive summary of sensitivity and specificity of diagnostic studies
Test
Number
of studies
Number of
eyes analysed
Median (range)
sensitivity, %
Median (range)
specificity, %
All OCT 10 1117 94.5 (36.0–100.0) 73.5 (66.0–94.0)
TD-OCT 9 1096 92.3 (36.0–100.0) 73.5 (66.0–94.0)
SD-OCT 1 21 100.0 Not reported
Amsler grid 1 46 41.7 Not reported
PHP 3 302 81.5 (50.0–84.8) (84.6, 87.7)a
Colour fundus photography 1 120 70.0 95.0
FAF 1 50 93.3 37.1
ICGA 4 167 93.2 (84.6–100.0) 36.8
TD-OCT + colour
fundus photography
1 131 74.1 92.0
Colour fundus photography + VA 1 66 53.0 94.0
a Only two studies reported specificity. Therefore no median is reported and values given are those reported in the
two studies.
TABLE 17 Pooled estimates for the OCT diagnostic studies
Test Number of studies Number of eyes analysed
Pooled estimates (95% CI)
Sensitivity, % Specificity, %
All OCT 4 406 88 (46 to 98) 78 (64 to 88)
DOI: 10.3310/hta18690 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 69
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Mowatt et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
39
Monitoring studies
Eight monitoring studies were included (all full-text papers).23,28,30,32,43,45,52,53 Seven reported
OCT,23,28,30,32,45,52,53 five with eye as the unit of analysis23,28,30,52,53 (one of which only reported detection at
phenotype level30) and two with test examination as the unit of analysis.32,45 One study reported ICGA.43
As with the diagnostic studies, the QUADAS-2 domains in which the greatest number of monitoring
studies were judged to be at high risk of bias were the patient selection domain (25%, 2/8),30,45 for
reasons such as inappropriate exclusions and pre-selection of participants, and flow and timing domain
(25%, 2/8),30,45 for reasons such as the length of time between the index test and the reference standard,
and not all participants being included in the analysis. The risk of bias in the index/comparator test and
reference standard domains was judged to be unclear in 50% (4/8)23,45,52,53 and 37.5% (3/8)23,45,52 of
studies respectively. All of the monitoring studies were judged to have low concerns in terms of their
applicability to the question being addressed by the review.
Four OCT monitoring studies, with eye as the unit of analysis, provided sufficient data for inclusion in a
meta-analysis (Table 18). The pooled sensitivity and specificity (95% CI) for all four OCT studies was 85%
(72% to 93%) and 48% (30% to 67%) respectively. For TD-OCT, the pooled sensitivity and specificity was
70% (56% to 80%) and 65% (48% to 79%). It was not possible to calculate pooled estimates using
HSROC methodology for the two SD-OCT studies due to insufficient data. These two studies reported
sensitivities of 94% and 90% and specificities of 27% and 47%, which suggests that SD-OCT has higher
sensitivity than TD-OCT but lower specificity.
Two OCT monitoring studies used test examination as the unit of analysis. The first, in an analysis of
61 pairs of TD-OCT and FFA examinations from 14 patients, reported high sensitivity of 96.8% but low
specificity of 36.7%, for CNV based on detection of intraretinal and/or subretinal fluid. The second, in an
analysis of 176 pairs of TD-OCT and FFA examinations (number of patients not stated), reported similarly
high sensitivity of 95.7% and moderate specificity of 59.0% based on detection of intraretinal or
subretinal fluid.
One ICGA monitoring study used test examination as the unit of analysis. In an analysis of 54 pairs of
ICGAs compared with fluorescein angiograms, obtained from 24 eyes of 21 patients, sensitivity of 75.9%
and specificity of 88.0% was reported for detecting nAMD activity.
Three studies reported OCT sensitivity in detecting activity of specific nAMD phenotypes or nAMD activity
based on detection of intraretinal/subretinal fluid. SD-OCT sensitivity was high for the detection of both
classic and occult CNV activity (90.9% and 100% respectively) (one study).30 Sensitivity of TD-OCT for
detection of cystoid macular oedema and PED was low (22.9% and 5.7% respectively) (one study).52 In
two studies, sensitivity was higher for detection of nAMD activity based on intraretinal fluid (90.3% and
82.9% respectively) compared with subretinal fluid (71.0% and 47.1% respectively).32,52
TABLE 18 Pooled estimates for the OCT monitoring studies
Test Number of studies Number of eyes analysed
Pooled estimates (95% CI)
Sensitivity, % Specificity, %
All OCTa 4 242 85 (72 to 93) 48 (30 to 67)
TD-OCT 3 149 70 (56 to 80) 65 (48 to 79)
SD-OCT 2 152 Not calculable using HSROC methods
a Three studies reported TD-OCT and two studies reported SD-OCT, with one study reporting both TD-OCT and SD-OCT.
Only the data for SD-OCT from this study were included in the pooled estimates for all OCT to avoid double counting.
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Chapter 5 Assessment of cost-effectiveness
The health economic component of this study explored the evidence for the cost-effectiveness of usingOCT for diagnosis and/or monitoring of individuals with nAMD. For this, a two-step approach was
used, with (1) a systematic review of economic evaluations to retrieve any readily available evidence on
cost-effectiveness, followed by (2) a de novo decision-analytic model to synthesise the available evidence
on effectiveness, health-care resources used and costs. Systematic review of economic evaluations reports
the systematic review of cost-effectiveness studies and Economic evaluation modelling exercise focuses on
the economic model exercise.
Systematic review of economic evaluations
The aim of this review was to retrieve evidence, from the perspective of the UK NHS, on the
cost-effectiveness of the use of OCT in the diagnosis and/or monitoring of individuals with nAMD.
This was attempted by systematically identifying and quality assessing all economic evaluations comparing
strategies that included OCT for diagnosing and/or monitoring of individuals with nAMD.
Inclusion and exclusion criteria
Inclusion criteria required the studies to be full economic evaluations,55 that is, to consider cost and effects for
more than one strategy, in order to be included in the review. No restrictions were imposed in the way cost
and/or effects were calculated. In addition, at least one of the compared strategies for diagnosis or monitoring
of nAMD had to include OCT. Finally, the studies were required to be performed in adults with nAMD.
Search strategy
Studies that reported both costs and outcomes in diagnosing nAMD using OCT were sought from a
systematic review of the literature. No language restrictions or limitations to searches were imposed.
Databases searched were MEDLINE (1996–November Week 2 2012), EMBASE (1980–Week 45 2012),
MEDLINE In-Process & Other Non-Indexed Citations (14 November 2012), NHS Economic Evaluation
Database (inception to October 2012), HTA database (inception to October 2012), Health Management
Information Consortium (1979–September 2012), Research Papers in Economics (September 2012) and
ARVO meeting abstracts from April 2009. In addition, reference lists of all included studies were scanned
to identify additional potentially relevant studies. Full details of the search strategies used are documented
in Appendix 1.
Results
From the database searches, 473 hits (titles and abstracts) were retrieved; from these 44 studies were
selected for full-text assessment. No studies fulfilled the inclusion criteria as none of these were diagnosis
or monitoring interventions for individuals with nAMD.
Economic evaluation modelling exercise
The aim of the economic model was to determine the relative efficiency of strategies for diagnosis and
monitoring of individuals with nAMD. Care pathways were developed within the project management
group and the project advisory group meetings. The groups initially considered all possible tests
(see Chapter 1) and several combinations of these. After subsequent discussions, a number of these
options were excluded. For instance, FFA only was originally considered as one of the (monthly) monitoring
pathways. However, this option was deemed unfeasible (i.e. FFA is an invasive test) and consequently
dropped. Three different strategies were finally selected for the nAMD diagnosis and monitoring stages,
respectively, giving a total of nine diagnosis–monitoring combinations.
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Diagnosis strategies
(a) (Stereoscopic) FFA interpreted by an ophthalmologist. If positive, treat and monitor; if
negative, discharge.
(b) OCT alone interpreted by an ophthalmologist. If positive, treat and monitor; if negative, discharge.
(c) VA, OCT and SLB in all. If positive or unclear, then arrange for stereoscopic FFA. If negative, discharge.
This is the strategy for diagnosis that best reflects standard practice.
Monitoring strategies
(a) OCT alone (interpreted by an ophthalmologist). If positive, treat; if negative or unclear, review in
1 month’s time.
(b) VA, SLB and OCT interpreted together by an ophthalmologist. If positive, treat; if negative, review in
1 month’s time. If unclear, then the ophthalmologist will arrange for a stereoscopic FFA. This is the
monitoring strategy that best reflects standard practice.
(c) VA and OCT interpreted by a technician or nurse. If negative, review in 1 month’s time. If positive or
unclear, refer for ophthalmologist assessment (e.g. SLB and ophthalmologist’s own interpretation of VA
and OCT test results). The ophthalmologist will make a decision: if positive, treat; if negative, review in
1 month’s time; if unclear, arrange for stereoscopic FFA.
Monitoring strategy c has been included in the monitoring stage in order to explore the cost-effectiveness
of the option, for example, of virtual clinics involving other health-care professionals (e.g. nurses,
technicians). Virtual clinics are increasingly used in NHS services for monitoring patients with nAMD.56
Table 19 shows the final nine combined strategies incorporated into the decision model. All strategies
considered monitoring on a monthly basis with a decision to treat when the disease was deemed active
(i.e. retinal fluid on OCT). All monitoring strategies that relied on stereoscopic FFA as a final assessment
step (e.g. monitoring strategies b and c) would treat if FFA positive, or review in a month’s time if
FFA negative. Treatment consisted of one injection only (i.e. 0.5mg ranibizumab) with review in
1 month’s time.
TABLE 19 Strategies for the economic evaluation model
Strategy Strategy label Diagnostic pathway Monitoring pathway Treatment
1 FFA & OCT FFA interpreted by an
ophthalmologist. If positive,
treat and monitor; if
negative, discharge
OCT alone (interpreted by an
ophthalmologist). If positive,
treat. If negative or unclear
review in 1 month
One monthly
injection if disease
deemed active
2 FFA &
Ophthalmologist
FFA interpreted by an
ophthalmologist. If positive,
treat and monitor; if
negative, discharge
VA, SLB and OCT interpreted
together by an ophthalmologist. If
positive, treat; if negative, review
in a month’s time. If unclear, then
the ophthalmologist will arrange
for stereoscopic FFA
One monthly
injection if disease
deemed active
3 FFA & Nurse FFA interpreted by an
ophthalmologist. If positive,
treat and monitor; if
negative, discharge
VA and OCT interpreted by a
technician or nurse. If negative,
review in a month. If positive or
unclear, referral for an
ophthalmologist assessment
(e.g. SLB and own interpretation
of VA and OCT test results).
If assessment positive, treat;
if negative, review in a month
time; if unclear, arrange for
stereoscopic FFA
One monthly
injection if disease
deemed active
ASSESSMENT OF COST-EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
42
TABLE 19 Strategies for the economic evaluation model (continued )
Strategy Strategy label Diagnostic pathway Monitoring pathway Treatment
4 OCT & OCT OCT alone interpreted by an
ophthalmologist. If positive,
treat and monitor; if
negative, discharge
OCT alone (interpreted by an
ophthalmologists). If positive,
treat. If negative or unclear
review in 1 month
One monthly
injection if disease
deemed active
5 OCT &
Ophthalmologist
OCT alone interpreted by an
ophthalmologist. If positive,
treat and monitor; if
negative, discharge
VA, SLB and OCT interpreted
together by an ophthalmologist.
If positive, treat; if negative,
review in a month’s time.
If unclear, then the
ophthalmologist will arrange
for stereoscopic FFA
One monthly
injection if disease
deemed active
6 OCT & Nurse OCT alone interpreted by an
ophthalmologist. If positive,
treat and monitor; if
negative, discharge
VA and OCT interpreted by a
technician or nurse. If negative,
review in a month. If positive or
unclear, referral for an
ophthalmologist assessment
(e.g. SLB and own interpretation
of VA and OCT test results).
If assessment positive, treat; if
negative, review in a month’s
time; if unclear, arrange
for stereoscopic FFA
One monthly
injection if disease
deemed active
7 Ophthalmologist &
OCT
VA, OCT and SLB in all
interpreted by an
ophthalmologist. If negative,
discharge. If positive or
unclear, then arrange for
stereoscopic FFA. If FFA
positive, treat and monitor;
if negative, discharge
OCT alone (interpreted by an
ophthalmologist). If positive,
treat. If negative or unclear
review in 1 month
One monthly
injection if disease
deemed active
8 Ophthalmologist &
Ophthalmologist
VA, OCT and SLB in all
interpreted by an
ophthalmologist. If negative,
discharge. If positive or
unclear, then arrange for
stereoscopic FFA. If FFA
positive, treat and monitor;
if negative, discharge
VA, SLB and OCT interpreted
together by an ophthalmologist.
If positive, treat; if negative,
review in a month’s time.
If unclear, then the
ophthalmologist will arrange
for stereoscopic FFA
One monthly
injection if disease
deemed active
9 Ophthalmologist &
Nurse
VA, OCT and SLB in all
interpreted by an
ophthalmologist. If negative,
discharge. If positive or
unclear, then arrange for
stereoscopic FFA. If FFA
positive, treat and monitor;
if negative, discharge
VA and OCT interpreted by a
technician or nurse. If negative,
review in a month. If positive
or unclear, referral for an
ophthalmologist assessment
(e.g. SLB and own interpretation
of VA and OCT test results).
If assessment positive, treat;
if negative, review in 1 month;
if unclear, arrange for
stereoscopic FFA
One monthly
injection if disease
deemed active
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The economic model
A Markov model approach was selected for the decision-analytic model exercise.57–60 Markov models have
Markov states where individuals spend a period of time, named a ‘cycle’. At the end of each cycle the
individuals can remain in their current Markov state or move to another state. The probabilities of moving to
other Markov states or remaining in the current state are named ‘transition probabilities’. Individuals in the
model would accrue costs and benefits (e.g. ‘life-years’) depending on the time spent in each Markov state and
the interventions and/or events modelled within each Markov state. Markov models are particularly suitable to
model recurrent issues and chronic diseases. They allow incorporating health states to reflect the movement of
the patients during diagnosis and monitoring. In the current study, model states reflect the underlying
condition (e.g. nAMD active or inactive) together with the decision on treatment (e.g. treated or untreated
nAMD) and VA states of the individuals (Table 20). In all these models, an absorbing state is included where all
individuals would end up if the model was run for a sufficiently long period of time (e.g. death state).
The present model incorporates a first diagnosis stage combined with a recurrent (monthly) monitoring phase.
The Markov models
This section presents a stepwise introduction to the Markov models used to compare the alternative
strategies. Individuals’ VA status is set aside for the moment to focus on the other two issues and
assumptions underpinning the movement of individuals throughout the model: (1) the underlying disease
condition (e.g. if the disease is present or not and, if present, its active or inactive status) as well as (2) the
diagnosis or monitoring test results on which the treatment decision will depend (i.e. a positive result will
trigger a decision to treat and a negative results will trigger a decision not to treat). Figure 11 shows the
schematic diagram of the final model used for the economic evaluation for this study.
TABLE 20 Visual acuity states
Visual health states (Snellen fractions) Visual health status
1 > 6/12 Normal VA
2 ≤ 6/12 to > 6/24 Mild VA loss
3 ≤ 6/24 to > 6/60 Moderate VA loss
4 ≤ 6/60 to > 3/60 Severe VA loss
5 ≤ 3/60 Profound visual loss/blindness
Positive result
(disease present)
Negative result
(disease not present)
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test(s)
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Active/treated
Monitoring test positive
Monitoring test positive
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Monitoring test negative
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FIGURE 11 Markov model schematic diagram assuming imperfect information at diagnosis and monitoring stages.
‘Inactive’=underlying condition regarded as inactive nAMD when the disease was actually not present.
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This section presents three schematic diagrams for this model. The figures differ in the assumptions made
with respect to the information retrieved from the diagnosis and/or monitoring test or assessments.
Namely, if perfect information from the tests or assessments is assumed, then there would be no FP or
FN results (i.e. equivalent to assuming that sensitivity and specificity are equal to 1). That is, the underlying
condition is detected with certainty. When this assumption is relaxed, then the possibility of incorrect
assessments appears.
Perfect information from diagnosis and monitoring tests
Figure 12 assumes perfect information at diagnosis and monitoring stages in the model. The whole
modelled cohort starts at the black arrow on the left hand side of the figure (corresponding to an initial
Markov model stage). The assumption of perfect information means that, at diagnosis stage, all individuals
with the disease will have a positive result while all those without the disease will obtain a negative result.
Individuals with a positive result will go to a monitoring scheme while those with a negative result will be
discharged. Those individuals with the disease and positive results will start within a Markov model state
with an ‘active disease and under treatment’ (e.g. ‘active/treated’ state). Note that ‘active’ refers to the
underlying condition while ‘treated’ or not depends on the test or assessment result.
Assuming monthly monitoring visits and assessments, a positive result at a monitoring visit means the
individual’s disease is active (assuming, again, perfect information and no possibility of FP or FN results)
and will therefore mean that the person remains in the ‘active/treated’ Markov state. If a negative result
from the monitoring assessment is obtained, then it would mean that the individual’s disease has become
inactive and the decision not to administer treatment will follow. In this case, the individual will move to
the ‘inactive/untreated’ Markov state. At each Markov cycle (monthly) individuals can become active or
inactive; this status would be detected at the next monitoring visit with a positive or negative result, and
the individual will either move from or stay in the corresponding Markov model state with a consistent
treatment decision.
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Monitoring test positive Monitoring test negative
Monitoring test
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Inactive/untreated
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Disease (active)
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FIGURE 12 Markov model schematic diagram assuming perfect information at diagnosis and monitoring stages.
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Individuals without the disease at the moment of first diagnosis could develop the disease in the
future (i.e. incident cases among the population). In the model (see Figures 11–13), it was assumed that
these individuals would be correctly diagnosed within a second visit and eventually moved to be monitored
within the ‘active/treated’ state. Finally, the ‘dead’ state is the absorbing state in this model (i.e. a state
that individuals cannot move out of); individuals can move from any other Markov state into the ‘dead’
absorbing state.
Imperfect information from diagnosis test combined with perfect information
from monitoring tests
Figure 13 shows a similar schematic diagram but in this case there is imperfect information at the moment
of first diagnosis. After this initial diagnostic intervention, further diagnosis and/or monitoring assessments
will be done with certainty (e.g. assuming perfect information). This opens the possibility of obtaining TP,
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False
(no disease)
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Active/treated
TP TP
TN
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FIGURE 13 Markov model schematic diagram assuming imperfect information at diagnosis and perfect information
at monitoring stage. ’Inactive’ =underlying condition regarded as inactive nAMD when the disease was actually
not present.
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TN as well as FP and FN results from the initial diagnosis test/s. Individuals with positive results, therefore,
might not have nAMD whereas individuals with negative diagnostic test results might actually have the
disease. This situation will have an effect on the Markov states the individuals will start at after diagnosis.
Those with a TP result will start with their active disease being treated and eventually move to an inactive
state (e.g. ‘inactive/untreated’) depending on the treatment effect. Individuals with a FP result will not have
nAMD but will be treated and monitored. However, this treatment cannot be effective as these people
did not have the disease. As this schematic diagram assumes perfect information at the monitoring
phase, these individuals would be correctly assessed in their subsequent monitoring visits, moving to the
‘inactive/untreated’ state.
In addition, if the person has a negative result at diagnosis, this could be a TN or a FN result. In either case
the individual would be discharged under the belief that nAMD was not present. If TN, meaning that the
disease was not present, the individual will start at the ‘no disease’ state and will remain at that stage
unless they develop nAMD. If FN (patients with the disease and negative test), the person will start within
the ‘disease (active)’ state.
Finally, an identical assumption of using FFA for diagnosis for those presenting for a second time
(rediagnosis) is followed for those with FN results at first diagnosis. These people will start to be monitored
and moved to the ‘active/treated’ state after second presentation for diagnosis. A further assumption is
used for this subgroup: based on expert opinion, these nAMD individuals that have been missed at first
diagnosis will present for rediagnosis within 3 months. The rationale behind this was the natural history of
the disease and the belief that nAMD would advance with VA deterioration making the individual return
for a further eye check.
Imperfect information from diagnosis and monitoring tests
Figure 11 shows the schematic diagram for the actual Markov model used. In this case, imperfect
information at diagnosis as well as monitoring phases was assumed. The cases for those with first
diagnosis negative results are identical to those in Figure 13 (lower part of Figure 11). However,
the diagram for those with positive results at first diagnosis will differ.
Individuals with TP results at first diagnosis will start as before within the ‘active/treated’ state. After this,
depending on the underlying condition (e.g. active or inactive) and the monitoring assessment result
(e.g. positive or negative, with a positive result reflecting the presence of disease activity), individuals
will move to alternative Markov states (e.g. ‘inactive/untreated’; ‘inactive/treated’; ‘active/untreated’).
The arrows in the figure show the direction in which individuals can move due to their underlying
condition and assessment while the arrow labels refer to the result of the assessment (e.g. TN, TP, FN, FP).
A further assumption in the model is that those individuals under monitoring who do not have nAMD
(i.e. ‘Inactive’ states) that subsequently become nAMD would be detected by the monitoring strategy test/s.
This monitoring strategy could include FFA (perfect information test) or other non-perfect information test
(e.g. OCT alone). Therefore, these individuals that now have nAMD could move to ‘active/treated’ or
‘active/untreated’ depending on positive or negative monitoring assessment respectively.
Markov model states and health status valuation link
The former diagrams show how individuals can move in the model according to their underlying condition
and the result of the test/s or assessments. However, it is not possible to attach utility weights to these
Markov states. In essence, individuals can experience alternative active or inactive disease but no difference
in their reported health status. The economic model attaches utility weights according to, mainly, VA.
Therefore, the effect on health status will come through the deterioration in VA, whereas VA deterioration
will result from the fact of individuals being misdiagnosed (e.g. no nAMD when actually the disease was
present) or misclassified as inactive when their true condition was active nAMD.
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In terms of the presented diagrams, the number of Markov states is multiplied by the number of VA
ranges considered by the model. Therefore, there is a trade-off between the number of VA ranges in order
to reflect differences in VA – and patient-reported health status – and the model complexity. Utility
differences between the alternative model strategies result from the different periods of time individuals
are misclassified within each strategy. It was considered that five VA states (see Table 20) would give
sufficient refinement for utility differences to be reflected. This approach has been used in other models in
this area of health care.61 Therefore, each strategy (i.e. each Markov model) has 32 Markov model states
[e.g. four VA states multiplied by six monitoring states, plus four VA states multiplied by one nAMD
undiagnosed state, plus profound visual loss/blindness, a ‘no disease’ state (normal VA only), the absorbing
state ‘dead’, and an initial state for first diagnosis].
Figure 14 shows a Markov model schematic diagram for the VA states considered in the model. Arrows in
the figure show the possible movements in the model in one cycle (e.g. 1 month). Individuals’ VA can
remain the same, improve or deteriorate in one particular cycle. Individuals can have their VA improved
and move one level up at the end of a cycle; however, their VA can deteriorate and move one or two
levels down from their current VA state. Finally, the model considered that a VA deterioration of ≤ 3/60
(i.e. profound visual loss/blindness) was not reversible and the individual was referred to supportive care.
Parameter estimates used in the economic model
The parameter estimates required to populate the economic model were obtained from the systematic
review of diagnostic and monitoring studies (see Chapter 4) as well as structured and focused literature
searches. When no suitable data resulted from these searches, expert opinion was sought. The next
section gives details of the probabilities, unit costs and utility weights used in the model. The section also
provides details of the probability distributions used for the probabilistic sensitivity analysis.62 Probabilistic
sensitivity analysis involves attaching probability distributions to model parameters and conducting a
number of Monte Carlo simulations (e.g. 1000). In each of these simulations a set of parameter values will
be drawn from the attached distributions, the model is run and results calculated. It is possible then to
obtain a distribution of the model cost-effectiveness results that reflects the overall parameter uncertainty
in the economic evaluation model.63,64
> 6/12 ≤ 6/12 to ≤ 6/24 ≤ 6/24 to ≤ 6/60 ≤ 6/60 to ≤ 3/60 ≤ 3/60
Dead
FIGURE 14 Markov model schematic diagram for VA states.
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Probabilities
Table 21 shows data on nAMD prevalence, incidence and VA at the start of the model run. Colquitt et al.61
reviewed studies assessing the prevalence and incidence of AMD and nAMD. The setting for this economic
evaluation was secondary care; therefore, the prevalence rate to inform the model should be that
corresponding to the group of individuals referred to hospital eye services with a suspected nAMD
diagnosis. The prevalence rate used was obtained from the literature retrieved by the systematic review of
test accuracy and agreed within the project management and advisory groups. An overall incidence of 1%
per year was used based on Mitchell et al.65 These incidence figures, presented for Australia, were similar
to the results by van Leeuwen et al.66 for the Rotterdam study but were reported in a form that could be
readily incorporated into the economic model. Mortality data were obtained from Interim Life Tables for
England and Wales (2009–11).16 No difference in mortality rates were found when comparing age-specific
mortality rates form the Interim Life Tables and those from the Comparison of Age-Related Macular
Degeneration Treatments Trials (CATT)8 and the Inhibit VEGF in Age-related choroidal Neovascularisation
(IVAN)9 studies. Therefore, no excess mortality was included due to nAMD.67,68 However, excess mortality
risk was incorporated for the last disease VA stage (profound visual loss/blindness – VA ≤ 3/60).
Table 21 also shows probability distributions defined for the probabilistic sensitivity analysis. Uninformative
uniform distributions were used for nAMD prevalence and profound visual loss/blindness excess mortality.
Ranges for defining these were assumptions based on data from the literature if available (e.g. from the
review of test accuracy). A gamma distribution was defined for nAMD incidence based on mean and
standard deviation (e.g. 1/10 of the mean) using the tool provided by TreeAge (TreeAge Software, Inc.,
Williamstown, MA, 2013).
TABLE 21 Prevalence, incidence and VA at start
Variable Value
Probability
distribution Source
Epidemiological data
Prevalence for nAMD 70% Uniform (0.6; 0.8) Expert opinion and articles from SR test accuracy
Incidence rate of nAMD
(monthly)
0.084% Gamma (1; 1190) Mitchell et al.65
Mortality Various Interim Life Tables, England and Wales
(2009–11)16
Profound visual loss/blindness
excess mortality
17% Uniform (0.1; 0.5) Assumption
Cohort details at start
Age (years) 65 n/a n/a Assumption based on expert opinion
Mean VA
Individuals with nAMD
≤ 6/12 to > 6/24 state 100% n/a n/a Assumption based on expert opinion and CATT
and IVAN RCTs mean VA at start
Individuals without nAMD
> 6/12 100% n/a n/a Assumption based on expert opinion
n/a, not applicable.
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The cohort start age was set at 65 years as this is the age where particular changes are observed
in the retina and macula (Dr Noemi Lois and Project Advisory Group, NHS Grampian, 2012, personal
communication). In addition, mean VA at the start was set at between ≤ 6/12 to > 6/24 for those
individuals with nAMD. This was agreed to be the most common VA at presentation by experts and also
the mean VA at baseline in the CATT and IVAN studies.8,9
Table 22 presents diagnostic test performance data. As mentioned above, three strategies were defined for
diagnosis within the economic model. For each of these strategies, sensitivity and specificity data were
needed, specifically for FFA, OCT, and ophthalmologist assessment (i.e. with VA test, SLB, and the results
from the OCT). FFA interpreted by an ophthalmologist was stated as the reference standard for the
diagnosis of nAMD; therefore, perfect information was assumed from this test, with sensitivity and
specificity equal to 1. OCT sensitivity and specificity were obtained from the systematic review of
diagnostic studies. These data correspond to OCT pooled estimates (four studies, number of eyes
406).27,40,46,49 No studies were identified on the ophthalmologist assessment diagnostic performance.
Hence, sensitivity and specificity estimates were derived from expert opinion.
Sensitivity and specificity data are bounded between 0 and 1. Therefore, beta distributions were defined
for probabilistic sensitivity analysis. For OCT, these were obtained using mean values and standard
deviation in order to obtain values within the 95% CI provided by the systematic review of diagnostic
studies (see Chapter 4, Table 17). Probability distributions for ophthalmologist diagnosis assessment were
obtained using the approximation tool provided by TreeAge, based on mean and standard deviation
(e.g. 1/10 of mean).
TABLE 22 Test performance parameters: diagnosis of nAMD
Variable Value Range
Probability
distribution Source
FFA
Sensitivity 1 n/a n/a Assumption
Specificity 1 n/a n/a Assumption
OCT
Sensitivity 0.88 0.46–0.98 Beta(36.3; 4.9) Systematic review of diagnostic studies
Specificity 0.78 0.64–0.88 Beta(82.9; 23.4) Systematic review of diagnostic studies
Ophthalmologist assessment (with VA, OCT and SLB)
Sensitivity 0.99 Beta(0.22; 0.002) Assumption based on expert opinion, using the
systematic review results as a starting point
Specificity 0.9 Beta(9.1; 1) Assumption based on expert opinion, using the
systematic review results as a starting point
Unclear 0.1 0.0–0.5 Beta(89.9; 809.1) Assumption based on expert opinion
n/a, not applicable.
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Table 23 shows similar data to Table 22 but for monitoring of individuals with nAMD. FFA was also stated
as the reference standard to detect disease activity; therefore, perfect information was assumed, with
sensitivity and specificity defined as equal to 1. OCT monitoring sensitivity and specificity data were
obtained from the systematic review of test performance (see Chapter 4). Pooled estimates (e.g. four
studies, n= 242), were used.23,28,30,53 No studies were identified reporting the diagnostic performance of
nurse or technician assessment, or for ophthalmologist assessment. Therefore, estimates for the sensitivity
and specificity of these strategies were derived from expert opinion.
A similar approach to the one used for the sensitivity and specificity of diagnostic tests was used for this
information for monitoring tests. Beta probability distributions were approximated and defined using mean
and standard deviation (e.g. 1/10 of the mean) values. The range of values of OCT used in the model did
not exceed the 95% CI values obtained from the systematic review of monitoring studies (i.e. OCT range
data in Table 23).
Disease progression in the model was defined in terms of VA changes. Gaining or losing three lines in
the Snellen chart (approximately 15 letters in the ETDRS chart) was assumed to make individuals move
from their current Markov model state to the next level (see Table 20 and Figure 14). Data for this were
obtained from Rosenfeld et al.69 [i.e. the Minimally Classic/Occult Trial of the Anti-VEGF Antibody
Ranibizumab in the Treatment of Neovascular Age-Related Macular Degeneration (MARINA) study].
This study was based in the USA, involved 716 participants and compared monthly treatment with
ranibizumab (0.3 mg, n= 238 or 0.5mg, n= 240) against sham injection (n= 238). Data from treatment
(0.5 mg) and control groups were used to calculate monthly progression probabilities for active treated
and non-treated individuals respectively. No VA progression was assumed for nAMD inactive individuals
as well as non-AMD individuals.
TABLE 23 Test performance data: monitoring of nAMD
Variable Value Range
Probability
distribution Source
FFA
Sensitivity 1 n/a n/a Assumption
Specificity 1 n/a n/a Assumption
OCT
Sensitivity 0.85 0.72–0.93 Beta(105; 18.5) Systematic review of monitoring studies
Specificity 0.48 0.30–0.67 Beta(32.8; 35.5) Systematic review of monitoring studies
Technician/nurse assessment (VA and OCT)
Sensitivity 0.9 Beta(108.9; 12.1) Assumption based on expert opinion, using the
systematic review results as a starting point
Specificity 0.6 Beta(72.6; 48.4) Assumption based on expert opinion, using the
systematic review results as a starting point
Unclear 0.1 Beta(89.9; 809.1) Assumption based on expert opinion
Ophthalmologist assessment (VA, OCT and SLB)
Sensitivity 0.97 Beta(2.51; 0.08) Assumption based on expert opinion, using the
systematic review results as a starting point
Specificity 0.8 Beta(19.2; 4.8) Assumption based on expert opinion, using the
systematic review results as a starting point
Unclear 0.1 Beta(89.9; 809.1) Assumption based on expert opinion
n/a, not applicable.
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Beta distributions were attached to VA progression data for probabilistic sensitivity analysis (Table 24).
Unfortunately, there were no data available to construct CIs around mean values used in the model.
As such, probability distributions parameter values were developed using mean values and assuming
1/10 of mean values for standard errors.
Additional data were required on disease status, namely the probability of becoming active when the
individual’s disease was inactive and under no treatment, as well as the probability of becoming inactive when
the individual’s disease was active and under treatment. First year data for these were developed using data
from the IVAN study (Dr Chris Rogers, University of Bristol, 12 June 2013, personal communication). The IVAN
study was a 2 × 2 factorial design and adults with untreated nAMD were randomised into four groups:
ranibizumab or bevacizumab, given either every month (continuous) or as needed (discontinuous).
All individuals were reviewed on a monthly basis. Survival data for participants’ first treatment failure
(e.g. subretinal fluid, increasing intraretinal fluid, or fresh blood) for the discontinuous arm (n= 302) were
used to develop mean probability values. All individuals were active at baseline and 95% of these did not fail
the retreatment criteria (i.e. did not need to be treated) at 3 months. This rate was used to obtain the monthly
probability of becoming inactive when active and under treatment.62 At month 6, 54% of individuals were still
inactive. The difference between the proportion of inactive individuals at months 3 and 6 was used to develop
the probability of becoming active when inactive and under no treatment (Table 25). Probability distributions
were developed using the 95% CI from the IVAN study survivor function using Crystal Ball software (release
11.1.2.0.00, 2010, Oracle Corporation, Redwood Shores, CA, USA) (see Table 25).
TABLE 25 Disease progression data: active and inactive nAMD
Variable Value Probability distribution Source
Probability of becoming
Inactive when active and under treatment
Year 1 0.616 Beta(176.6; 110) Based on data from IVAN study9
Year 2 onwards 0.365 Beta(63.1; 110) Based on data from CATT study8
Active when inactive and under no treatment
Year 1 0.306 Beta(148; 335) Based on data from IVAN study9
Year 2 onwards 0.097 Gamma(100; 1029) Based on Horster et al.70
Active when inactive and under treatment 0.5 × active when inactive and under no treatment
TABLE 24 Disease progression data: VA
Variable
Year 1 Year 2 onwards
Value Probability distribution Value Probability distribution
Treatment
Gain at least three lines 0.0338 Beta(96.6; 2761.9) 0.0167 Beta(98.3; 5777)
Gain or lose less than three lines Default Default
Lose between three and six lines 0.0036 Beta(99.6; 27817) 0.0032 Beta(99.7; 30634)
Lose six lines or more 0.0010 Beta(99.9; 99252) 0.0011 Beta(99.9; 94640)
No treatment
Gain at least three lines 0.0043 Beta(99.6; 23244) 0.0016 Beta(99.8; 61799)
Gain or lose less than three lines Default Default
Lose between three and six lines 0.0221 Beta(97.8; 4331) 0.0116 Beta(98.8; 8431)
Lose six lines or more 0.0128 Beta(98.7; 7627) 0.0107 Beta(98.9; 9171)
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Second year data for the probability of becoming inactive were developed using data from the CATT
study. The inclusion criteria and the treatment group for the CATT study were similar to that of the IVAN
study. However, within the IVAN study three monthly injections were administered when participants failed
the disease inactive criteria. The CATT study administered one injection only and reviewed participants in
1 month’s time before making a further treatment decision. A monthly probability was sought in order to
obtain the CATT study mean number of injections within the as needed arm at 2 years. A beta distribution
was attached based on mean value and 1/10 of the mean value as standard error (TreeAge software).
Second year data for the probability of becoming active when participants were inactive and under no
treatment was developed using data reported by Horster et al.70 The authors reviewed data on all patients
receiving intravitreal ranibizumab injections for nAMD at the University of Cologne, Germany. Eyes with
at least two recurrences (i.e. reappearance of intraretinal or subretinal fluid on OCT, and/or leakage on
angiography) were selected. The mean follow-up time (months) and number of recurrences were 28.8 and
2.8 respectively.
A number of individuals that were inactive at 3 months within the monthly treatment group in the IVAN
study9 failed the no retreatment criteria (e.g. subretinal fluid, increasing intraretinal fluid, or fresh blood) in
subsequent months. This means that, even under monthly treatment, inactive individuals could become
active again. Based on this, half the probability of becoming active when inactive and under no treatment
was assumed for the probability of becoming active when inactive and under treatment.
Diagnosis or monitoring strategies could result in over- or undertreatment; therefore, it was believed
important to include adverse events as a result of treatment. Two recent studies8,9 report systemic and
ocular adverse event rates. It was not clear from inspection of these data that systemic adverse events
could be due to treatment of nAMD. Therefore, only ocular adverse events were included in the model.
Table 26 shows monthly estimates for the proportion of individuals that were under treatment that
experienced cataract, endophthalmitis, glaucoma, retinal detachment and uveitis.
Costs
Table 27 shows cost estimates used in the model. Prices are expressed in 2011–12 pounds sterling (£).
Strategy assessment costs were a combination of the cost of a visit (e.g. ophthalmologist, nurse or
technician) and the cost of a particular test used for the assessment (e.g. FFA or OCT). For instance, the
diagnosis cost for strategies where diagnosis was conducted using FFA only was calculated adding up the
cost of an ophthalmologist visit and the cost for an FFA (e.g. £79.74+ £117.26= £197.00). NHS reference
costs were used for all but the ranibizumab unit costs in Table 27, for which British National Formulary
(BNF) data were used (£742.17).12 The unit cost for face-to-face consultant-led follow-up attendance
that resulted in non-admission for the ophthalmology service was used for the cost of a diagnosis or
monitoring visit to the ophthalmologist (£79.74). Likewise, non-consultant led was used for the cost of a
nurse or technician monitoring visit (£58.53). Minor vitreous retinal procedures cost category [Healthcare
Resource Group (HRG) BZ23Z code] was used to cost FFA (£117.26). Finally, after consultation with clinical
TABLE 26 Adverse events
Variable Value (monthly %) Source
Cataract 0.34 The CATT research group8
Endophthalmitis 0.40 The CATT research group8
Glaucoma 0.05 The CATT research group8
Retinal detachment 0.03 The CATT research group8
Uveitis 0.03 The CATT research group8
DOI: 10.3310/hta18690 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 69
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Mowatt et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
53
experts, an ultrasound scan (HRG RA23Z Ultrasound scan, less than 20 minutes) was deemed more likely
to reflect the cost of an OCT test (£51.27).
Gamma probability distributions were defined for unit cost data for probabilistic sensitivity analysis as these
are defined non-negative and provide a possibility of a right tail that could account for few very high unit
cost cases. Ranges for reference cost based data are also reported in Table 27; these are lower and upper
quartiles. These were used to tailor cost probability distributions.
The cost of profound visual loss/blindness from the NHS and Personal Social Services perspective was
calculated following Colquitt et al.61 The authors used proportion for service utilisation developed by
Meads and Hyde71 (Table 28). The unit costs reported by Colquitt et al.61 were updated using Hospital and
Community Health Service specific price inflation index (base 2005= 100) for March 2012 (e.g. £121.85).
Using an alternative weekly cost figure of £497 for residential care (the item in the list with higher unit
cost) reported by Curtis,72 results in an annual cost of £556 and £537 for the first and subsequent years,
respectively, and these were used as the basis for deterministic sensitivity analysis.
TABLE 27 Unit costs
Variable £ (2011–12) Range
Probability
distribution Source
Ophthalmologist
visit
79.74 68–86 Gamma(309.9; 3.9) NHS Reference Costs 2011–12 (consultant led:
follow-up attendance non-admitted face to face.
130: ophthalmology)11
Nurse/technician
visit
58.53 42–71 Gamma(34.3; 0.59) NHS Reference Costs 2011–12 (non-consultant led:
follow-up attendance non-admitted face to face.
130: ophthalmology)11
FFA 117.26 Gamma(25; 0.21) NHS Reference Costs 2011–12 (HRG BZ23Z minor
vitreous retinal procedures)11
OCT 51.27 32–62 Gamma(48.8; 0.95) NHS Reference Costs 2011–12 (HRG RA23Z
Ultrasound scan, less than 20 minutes)11
Treatment
Medication
ranibizumab
742.17 Gamma(4; 0.01) BNF12
TABLE 28 Cost of profound visual loss/blindness
Variable Requiring (%) Cost (£, 2005) Cost (£, 2012) Annual cost (£) Monthly cost (£)
Severe sight impairment
registration
95 115 140 133 11.09
Low-vision aids 33 150 183 60 5.03
Low-vision rehabilitation 11 259 316 35 2.89
Community care 6 6552 7984 479 39.92
Residential care 30 13,577 16,544 4963 413.59
Depression 39 431 525 205 17.07
Hip replacement 5 5379 6554 328 27.31
Total year 1 6203 517.00
Total year 2+ 5975 498.00
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Utility weights
Guidelines for economic evaluation of health-care technologies in the UK advocate the use of a
preference-based measure of utility.73 We conducted a focused search for these data for AMD individuals.
It was confirmed that one group had the majority of studies in this area74,75 and data from Brown et al.74
were included in the economic model. The study by Brown et al.75 used the time trade-off approach on
72 consecutive patients seen at the Retina Vascular Unit at Wills Eye Hospital, Philadelphia, USA, to obtain
utility weights for alternative VA scores. Table 29 presents utility weights used in the economic model
according to the Markov model health state. CIs were also obtained from Brown et al.74 Mean utility
weights and CIs were used to define beta distributions (see Table 29) for probabilistic sensitivity analysis.
Utility decrements due to adverse events were retrieved from Brown et al.75 The authors derived utility
values from 233 patients with AMD and decrement values were obtained from individuals who
experienced alternative adverse events. Table 29 shows the (monthly) utility decrements used within the
model. These were applied to the proportion of individuals who experienced an adverse event from within
those that were under treatment (see Table 26). Searches were conducted to retrieve information on the
effect of treatment injections on the quality of life of patients with nAMD; however, no evidence was
found. Moreover, from discussions within the project advisory group and clinical experts, anxiety seemed
to be associated with the uncertainty of the disease condition (i.e. active or inactive) rather than the
treatment itself. Adding a utility decrement for each monthly monitoring visit for all strategies would
have had no effect on the final results. As such, no utility adjustments were conducted due to
treatment injections.
Base-case and sensitivity analyses
The UK NICE guidelines of methods for technology appraisals were followed.73 The model base-case
analysis was run for a cohort of 65-year-old men for a time horizon of 35 years (lifetime). A 1-month cycle
length was defined. The analysis was conducted from the NHS and Personal Social Services perspective.
Costs were expressed in 2011–12 pounds sterling and effectiveness in quality-adjusted life-years (QALYs).
Costs and QALYs were discounted at 3.5%.73 Cost-effectiveness analysis results are reported using
incremental cost-effectiveness ratios (ICERs).55 ICERs are calculated as the ratio between the difference
in average cost between two alternative strategies and the difference in average QALYs. This ratio
measures the additional cost that would have to be paid in order to obtain an extra unit of effectiveness
(i.e. an extra QALY). Probabilistic analysis results are reported using cost-effectiveness acceptability
curves (CEACs).76,77 CEACs show the probability of a particular strategy to be cost-effective at alternative
values of willingness to pay for an extra QALY.
TABLE 29 Utility weights
Health state Mean 95% CI Probability distribution Source
> 6/12 0.89 0.82 to 0.96 Beta(12.7; 1.6) Colquitt et al.61 based on Brown et al.74
≤ 6/12 to > 6/24 0.81 0.73 to 0.89 Beta(18.7; 4.4)
≤ 6/24 to > 6/60 0.57 0.47 to 0.67 Beta(42.4; 32)
≤ 6/60 to > 3/60 0.52 0.38 to 0.66 Beta(51.4; 47.4)
≤ 3/60 0.4 0.29 to 0.50 Beta(59.6; 89.4)
Utility decrements (monthly) due to adverse events
Cataract 0.012 Brown et al.75
Endophthalmitis 0.025
Retinal detachment 0.023
Uveitis 0.025 Assumed equal to endophthalmitis
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Sensitivity analysis
Uncertainty in the economic model was explored conducting one-way sensitivity analysis, scenario analysis
and probabilistic sensitivity analysis. As mentioned above, the base-case analysis was run for a male cohort.
Gender-specific data were not available and the only different data for men and women were mortality
rates. Female mortality data show longer life expectancy. These could result in longer time for benefits, but
also costs. A further analysis was conducted using mortality data for women to observe the effect of
longer life expectancy in the model results.
One-way sensitivity analyses were conducted on test diagnosis sensitivity and specificity, the probability of
ophthalmologist diagnosis or monitoring results being unclear, tests and assessment monitoring sensitivity
and specificity, probability of the nurse or technician assessment being unclear, and unit costs for OCT,
FFA and ranibizumab.
Further deterministic sensitivity analyses were conducted using alternative discount rates for costs and
QALYs, as well as prevalence rates for nAMD. In addition, population utility weights were retrieved from
Czoski-Murray et al.78 The authors elicited time trade-off-based utility values from 108 healthy individuals
for AMD states simulated using contact lenses.
Given base-case and sensitivity analyses results, three scenario analyses were tested. All of these
incorporated data that favoured OCT (Table 30). Scenario 1 used the upper limit for the 95% CI for OCT
sensitivity and specificity for diagnosis and monitoring obtained from the systematic review of diagnostic
and monitoring studies, together with £20.90 and £139 unit costs for OCT and FFA respectively. Scenario
2 used the same data as for scenario 1 but assuming a cost per treatment injection of £50 instead of
£742. Finally, scenario 3 assumed the same input data as for scenario 1 but monitoring pathways that
based their decisions on OCT only considered the unit cost of the OCT test for the monitoring visit as that
of the OCT test for an optometry community service (£20.90).80 The cost of an ophthalmologist visit was
not considered in every monitoring visit but added only if the patient needed to be treated. This scenario
explored the effect of monitoring patients within the community and only referred them to secondary care
for treatment.
Base-case and selected sensitivity analyses are presented in the next section. Full sensitivity analysis results
are reported in Appendix 8.
TABLE 30 Input data for scenario analyses
Variable Diagnosis Monitoring Source
FFA
Sensitivity 0.99 0.99 Assumption
Specificity 0.99 0.99 Assumption
OCT
Sensitivity 0.98 0.93 Systematic review of diagnostic and monitoring studies
Specificity 0.88 0.67 Systematic review of diagnostic and monitoring studies
Unit costs (£, 2011–12)
FFA 139 NHS Reference Costs 2011–12 (HRG BZ23Z minor vitreous
retinal procedures)11
OCT 20.9 General Ophthalmic Services: Increases to NHS Sight Test Fee79
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Results
Table 31 reports base-case analysis results for men for the nine compared strategies. Model strategies are
ordered in terms of average cost in an ascending order. Diagnosis with FFA combined with the nurse or
technician-led monitoring strategy (e.g. nurse or technician as first monitoring contact conducting a VA
examination and interpreting OCT test results; if negative, discharge, if positive or unclear, refer to an
ophthalmologist for further assessment) was the strategy with the lowest average total cost. The next
non-dominated strategy (i.e. dominated strategy meaning a strategy with higher expected costs and lower
expected QALYs) is diagnosis based on FFA only, followed by ophthalmologist-led monitoring. This strategy
has higher total expected cost but also produces higher total expected QALYs. However, the incremental
cost for an extra QALY (i.e. ICER) to adopt this strategy is above the often accepted cost-effectiveness
threshold (i.e. £30,000).73 All other strategies are dominated by either of the strategies that based
diagnosis in FFA only followed by nurse-led or ophthalmologist-led monitoring. Diagnosis based only on
OCT appears in third place combined with nurse-led monitoring. In terms of costs, the strategies’ order is
driven mainly by the monitoring pathway, with the lowest average total costs coming from the nurse-led
monitoring pathway (first to third places), then the ophthalmologist-led (fourth to sixth) and OCT
only-based (seventh to ninth) monitoring pathways respectively. It should be noted, then, that the three
model strategies that used OCT only as the basis for monitoring criteria were the strategies with higher
average costs (see Table 31). This is due to the cost of treatment, that represents 76% of the total average
cost within these strategies, the highest proportion for all compared strategies (e.g. average 65% and
minimum 55%).
Figure 15 shows the cost-effectiveness plane for the base-case analysis and the nine diagnosis–monitoring
combination strategies. For easier interpretation, data marker shapes relate to the diagnosis strategy and
marker filling/colour relates to the monitoring strategy. Namely, square, circle and triangle shapes are used
for FFA only, OCT only, and ophthalmologist stepwise diagnosis respectively. In addition, blue, green and
none marker fillings correspond to ophthalmologist-led, nurse- or technician-led and OCT only-based
monitoring respectively.
Three clusters can be seen in Figure 15 according to the monitoring strategy. As such, the
ophthalmologist-led monitoring strategy cluster seems to produce higher expected QALYs and slightly
higher expected costs than the nurse- or technician-led monitoring strategy. The OCT only monitoring
strategy cluster results in a higher expected cost and lower expected QALYs than the other two
monitoring strategies.
TABLE 31 Base-case cost-effectiveness results: men
Strategy Cost (£)
Incremental
cost (£) QALYs
Incremental
QALYs ICER (£)a
(3) FFA & Nurse 39,769 – 10.473 0.000 0
(9) Ophthalmologist & Nurse 39,790 21 10.472 –0.001 –33,237
(6) OCT & Nurse 41,607 1838 10.465 –0.008 –224,403
(2) FFA & Ophthalmologist 44,649 4880 10.575 0.102 47,768
(8) Ophthalmologist & Ophthalmologist 44,669 20 10.574 –0.001 –31,094
(5) OCT & Ophthalmologist 47,131 2482 10.567 –0.008 –293,938
(1) FFA & OCT 62,759 18,110 10.449 –0.126 –144,229
(7) Ophthalmologist & OCT 62,778 18,129 10.449 –0.126 –143,662
(4) OCT & OCT 67,421 22,772 10.442 –0.133 –170,859
a The ICERs are calculated against the next cheapest non-dominated strategy.
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Within each of these clusters, the FFA diagnosis strategy dominates OCT only as well as the
ophthalmologist stepwise diagnosis strategy (e.g. VA, OCT and SLB in all, followed by FFA if positive or
unclear results). Also, to note is that the ophthalmologist diagnostic and FFA diagnostic pathways have very
similar expected cost and QALYs within each cluster and, as such, data markers seem to overlap. This is due
to the close values assumed for diagnosis sensitivity and specificity in these two diagnostic pathways.
Table 32 and Figure 16 show probabilistic sensitivity analysis for the base case. Diagnosing with FFA only
followed by nurse- or technician-led monitoring has the highest probability of being cost-effective for up to
£40,000 willingness to pay for an extra QALY. At higher threshold values (e.g. £50,000) diagnosing with
FFA only followed by ophthalmologist-based monitoring has a higher probability of being cost-effective.
Overall, diagnosis with FFA with either nurse- or ophthalmologist-led monitoring has more than a
70% chance of being cost-effective at willingness-to-pay values for an extra QALY of between
£10,000 and £50,000. These strategies lose some ground against ophthalmologist-based diagnosis
(e.g. ‘Ophthalmologist & Ophthalmologist’ and ‘Ophthalmologist & Nurse’) at high levels of willingness to
pay for extra QALY threshold values (see Table 32 and Figure 16). At £30,000 willingness to pay for a
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FIGURE 15 Base-case cost-effectiveness results: men.
TABLE 32 Probabilistic sensitivity analysis: base case – men
Strategy
Probability of strategy being cost-effective at alternative threshold
values for society’s willingness to pay for a QALY (%)
£10,000 £20,000 £30,000 £40,000 £50,000
(1) FFA & OCT 0.6 0.9 1.2 1.2 1.7
(2) FFA & Ophthalmologist 12.2 21.8 31.3 36.7 42.6
(3) FFA & Nurse 67.7 57.4 46.4 39.0 29.9
(4) OCT & OCT 0.0 0.0 0.0 0.0 0.0
(5) OCT & Ophthalmologist 0.0 0.0 0.0 0.0 0.0
(6) OCT & Nurse 0.0 0.0 0.0 0.0 0.0
(7) Ophthalmologist & OCT 0.0 0.1 0.1 0.3 0.5
(8) Ophthalmologist & Ophthalmologist 1.5 3.3 7.2 10.3 13.8
(9) Ophthalmologist & Nurse 18.0 16.5 13.8 12.5 11.5
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QALY threshold value and regardless of the diagnosis pathways (e.g. FFA only, OCT only or
ophthalmologist), nurse- or technician-led monitoring has a 61% probability of being cost-effective.
Figure 16 shows that when expanding this range up to £100,000, diagnosing with FFA only followed by
the ophthalmologist-based monitoring strategy will have more than a 50% chance of being cost-effective.
In addition, FFA only-based diagnosis strategies lose some ground against ophthalmologist-based diagnosis
strategies (i.e. ‘Ophthalmologist & Ophthalmologist’ and ‘Ophthalmologist & Nurse’) at high levels of
willingness to pay threshold values (see Table 32 and Figure 16).
Sensitivity analysis
Using mortality rate data for women
Table 33 and Figure 17 present cost-effectiveness results for women. As expected, all strategies produce
more QALYs, incurring higher average costs. This is because of the longer life expectancy for women.
This affects all of the model strategies in a similar manner. As such, there are no differences in the
(average cost) order of the strategies or the general results compared with those for the base-case analysis
for men (see Table 31). Diagnosing with FFA followed by nurse- or technician-led monitoring is still the
strategy with the lowest average cost and dominates all other compared strategies, apart from diagnosis
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FIGURE 16 Base case cost-effectiveness acceptability curves: men.
TABLE 33 Cost-effectiveness results: women
Strategy Cost (£)
Incremental
cost (£) QALYs
Incremental
QALYs ICER (£)
(3) FFA & Nurse 44,099 0 11.604 0.000 0
(9) Ophthalmologist & Nurse 44,119 21 11.603 –0.001 –30,521
(6) OCT & Nurse 46,125 2026 11.595 –0.009 –226,433
(2) FFA & Ophthalmologist 49,527 5428 11.725 0.121 44,959
(8) Ophthalmologist & Ophthalmologist 49,547 20 11.724 –0.001 –28,491
(5) OCT & Ophthalmologist 52,262 2735 11.715 –0.009 –296,276
(1) FFA & OCT 69,712 20,185 11.576 –0.148 –136,016
(7) Ophthalmologist & OCT 69,731 20,204 11.576 –0.149 –135,517
(4) OCT & OCT 74,847 25,321 11.568 –0.157 –161,433
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with FFA followed by ophthalmologist-led monitoring. However, the ICER for moving to the latter strategy
is above the usually accepted cost-effectiveness threshold (i.e. £30,000).73
Similar clusters can be observed in the cost-effectiveness results for men (see Figure 15) and women
(see Figure 17), with the three clusters depending on the monitoring care pathway (i.e. OCT only,
nurse-, technician-, or ophthalmologist-led monitoring). As was the case with Figure 15, the ophthalmologist
diagnostic and FFA diagnostic pathways have very similar expected cost and QALYs within each cluster and, as
such, data markers seem to overlap. The Table 33 and Figure 17 results indicate that no dramatic differences
can be expected for the women and men model run results. Therefore, further sensitivity analyses were
conducted only for the male cohort.
One-way sensitivity analyses
Extensive one-way sensitivity analyses were undertaken. This section reports a selected number of these,
with full results presented in Appendix 8. All one-way sensitivity analyses show results moving in the
expected direction (i.e. lower sensitivity or specificity for OCT would result in OCT-based strategies being
less cost-effective). Tables 34–38 show one-way sensitivity analysis for OCT diagnostic sensitivity and
specificity, OCT monitoring sensitivity and specificity and OCT unit cost respectively. The base-case analysis
results seem robust. In all reported sensitivity analyses, diagnosis with FFA combined with nurse- or
technician-led monitoring (based on VA and OCT with a referral to the ophthalmologist if positive or
unclear) has the lowest total expected costs and dominates all others, apart from FFA for diagnosis with
ophthalmologist-led monitoring. In a limited number of model runs, alternative strategies stop being
dominated by diagnosis with FFA followed by nurse- or technician-led monitoring. However, in many of
these cases the variable values used to run the analysis were extreme (see Tables 34 and 36 for OCT
diagnostic and monitoring sensitivities equal to 1 respectively). Results are sensitive to the value of
monitoring specificity for OCT. Table 37 suggests that OCT monitoring specificity above 80% could make
diagnosis with FFA combined with monitoring with OCT only, a cost-effective strategy. However, this is to
almost double the specificity values reported for monitoring in Chapter 4.
Scenario analysis
Scenario analysis favouring the OCT test was conducted to explore conditions under which OCT
only-based strategies could become cost-effective. The scenarios are described in Base-case and sensitivity
analyses and the input data used reported in Table 30. Best possible OCT test sensitivity and specificity were
incorporated into the model. In addition, the lowest possible unit cost for OCT and a higher assumed unit cost
value for FFA were used. Scenario 2 differs in the unit cost assumed for each treatment injection (£50) and
scenario 3 explores community monitoring (e.g. unit cost for OCT as for community optometrist and an
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FIGURE 17 Cost-effectiveness results: women.
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TABLE 34 One-way sensitivity analysis: OCT diagnostic sensitivity
OCT diagnostic
sensitivity Strategy Cost QALYs
Incremental
cost
Incremental
QALYs ICER
0.8 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist &
Nurse
39,790 10.472 21 –0.001 –33,237
(6) OCT & Nurse 41,594 10.459 1824 –0.014 –133,258
(2) FFA &
Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094
(5) OCT &
Ophthalmologist
47,114 10.561 2465 –0.014 –173,407
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229
(7) Ophthalmologist &
OCT
62,778 10.449 18,129 –0.126 –143,662
(4) OCT & OCT 67,394 10.436 22,745 –0.139 –163,795
0.9 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist &
Nurse
39,790 10.472 21 –0.001 –33,237
(6) OCT & Nurse 41,611 10.466 1841 –0.007 –270,172
(2) FFA &
Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094
(5) OCT &
Ophthalmologist
47,135 10.568 2486 –0.007 –355,119
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229
(7) Ophthalmologist &
OCT
62,778 10.449 18,129 –0.126 –143,662
(4) OCT & OCT 67,428 10.443 22,779 –0.132 –172,719
1.0 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist &
Nurse
39,790 10.472 21 –0.001 –33,237
(6) OCT & Nurse 41,628 10.473 1859 0.000 31,635,704
(2) FFA &
Ophthalmologist
44,649 10.575 3021 0.102 29,593
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094
(5) OCT &
Ophthalmologist
47,157 10.575 2507 0.000 11,797,675
(1) FFA & OCT 62,759 10.449 15,602 –0.126 –124,050
(7) Ophthalmologist &
OCT
62,778 10.449 15,621 –0.126 –123,584
(4) OCT & OCT 67,462 10.450 20,306 –0.125 –162,290
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TABLE 35 One-way sensitivity analysis: OCT diagnostic specificity
OCT
diagnostic
sensitivity Strategy Cost QALYs
Incremental
cost
Incremental
QALYs ICER
0.55 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist & Nurse 39,790 10.472 21 –0.001 –33,237
(6) OCT & Nurse 43,619 10.465 3850 –0.008 –473,564
(2) FFA & Ophthalmologist 44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094
(5) OCT & Ophthalmologist 49,821 10.567 5172 –0.008 –629,095
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229
(7) Ophthalmologist & OCT 62,778 10.449 18,129 –0.126 –143,662
(4) OCT & OCT 72,407 10.442 27,758 –0.133 –209,343
0.60 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist & Nurse 39,790 10.472 21 –0.001 –33,237
(6) OCT & Nurse 43,182 10.465 3412 –0.008 –419,079
(2) FFA & Ophthalmologist 44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094
(5) OCT & Ophthalmologist 49,236 10.567 4587 –0.008 –554,702
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229
(7) Ophthalmologist & OCT 62,778 10.449 18,129 –0.126 –143,662
(4) OCT & OCT 71,324 10.442 26,674 –0.133 –200,943
0.65 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist & Nurse 39,790 10.472 21 –0.001 –33,237
(6) OCT & Nurse 42,744 10.465 2975 –0.008 –364,772
(2) FFA & Ophthalmologist 44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094
(5) OCT & Ophthalmologist 48,651 10.567 4002 –0.008 –481,174
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229
(7) Ophthalmologist & OCT 62,778 10.449 18,129 –0.126 –143,662
(4) OCT & OCT 70,240 10.442 25,590 –0.133 –192,562
0.70 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist &
Nurse
39,790 10.472 21 –0.001 –33,237
(6) OCT & Nurse 42,307 10.465 2538 –0.008 –310,643
(2) FFA & Ophthalmologist 44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094
(5) OCT & Ophthalmologist 48,067 10.567 3418 –0.008 –408,495
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TABLE 35 One-way sensitivity analysis: OCT diagnostic specificity (continued )
OCT
diagnostic
sensitivity Strategy Cost QALYs
Incremental
cost
Incremental
QALYs ICER
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229
(7) Ophthalmologist & OCT 62,778 10.449 18,129 –0.126 –143,662
(4) OCT & OCT 69,156 10.442 24,507 –0.133 –184,200
0.75 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist & Nurse 39,790 10.472 21 –0.001 –33,237
(6) OCT & Nurse 41,870 10.465 2100 –0.008 –256,690
(2) FFA & Ophthalmologist 44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094
(5) OCT & Ophthalmologist 47,482 10.567 2833 –0.008 –336,651
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229
(7) Ophthalmologist & OCT 62,778 10.449 18,129 –0.126 –143,662
(4) OCT & OCT 68,072 10.442 23,423 –0.133 –175,856
0.80 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist & Nurse 39,790 10.472 21 –0.001 –33,237
(6) OCT & Nurse 41,432 10.465 1663 –0.008 –202,914
(2) FFA & Ophthalmologist 44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094
(5) OCT & Ophthalmologist 46,897 10.567 2248 –0.008 –265,626
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229
(7) Ophthalmologist & OCT 62,778 10.449 18,129 –0.126 –143,662
(4) OCT & OCT 66,988 10.442 22,339 –0.133 –167,531
0.85 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist & Nurse 39,790 10.472 21 –0.001 –33,237
(6) OCT & Nurse 40,995 10.465 1226 –0.008 –149,312
(2) FFA & Ophthalmologist 44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094
(5) OCT & Ophthalmologist 46,312 10.567 1663 –0.009 –195,408
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229
(7) Ophthalmologist & OCT 62,778 10.449 18,129 –0.126 –143,662
(4) OCT & OCT 65,904 10.442 21,255 –0.133 –159,225
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TABLE 35 One-way sensitivity analysis: OCT diagnostic specificity (continued )
OCT
diagnostic
sensitivity Strategy Cost QALYs
Incremental
cost
Incremental
QALYs ICER
0.90 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist & Nurse 39,790 10.472 21 –0.001 –33,237
(6) OCT & Nurse 40,558 10.465 788 –0.008 –95,884
(2) FFA & Ophthalmologist 44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094
(5) OCT & Ophthalmologist 45,727 10.566 1078 –0.009 –125,982
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229
(7) Ophthalmologist & OCT 62,778 10.449 18,129 –0.126 –143,662
(4) OCT & OCT 64,820 10.441 20,171 –0.134 –150,937
0.95 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist & Nurse 39,790 10.472 21 –0.001 –33,237
(6) OCT & Nurse 40,120 10.465 351 –0.008 –42,629
(2) FFA & Ophthalmologist 44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094
(5) OCT & Ophthalmologist 45,143 10.566 494 –0.009 –57,335
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229
(7) Ophthalmologist & OCT 62,778 10.449 18,129 –0.126 –143,662
(4) OCT & OCT 63,736 10.441 19,087 –0.134 –142,667
1.0 (6) OCT & Nurse 39,683 10.465
(3) FFA & Nurse 39,769 10.473 86 0.008 10,453
(9) Ophthalmologist & Nurse 39,790 10.472 21 –0.001 –33,237
(5) OCT & Ophthalmologist 44,558 10.566 4789 0.094 51,214
(2) FFA & Ophthalmologist 44,649 10.575 91 0.009 10,545
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094
4) OCT & OCT 62,652 10.441 18,003 –0.134 –134,416
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229
(7) Ophthalmologist & OCT 62,778 10.449 18,129 –0.126 –143,662
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TABLE 36 One-way sensitivity analysis: OCT monitoring sensitivity
Monitoring
sensitivity OCT Strategy Cost QALYs
Incremental
cost
Incremental
QALYs ICER
0.9 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist & Nurse 39,790 10.472 21 –0.001 –33,237
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403
(2) FFA & Ophthalmologist 44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094
(5) OCT & Ophthalmologist 47,131 10.567 2482 –0.008 –293,938
(1) FFA & OCT 63,312 10.503 18,663 –0.072 –260,619
(7) Ophthalmologist & OCT 63,331 10.503 18,682 –0.072 –258,561
(4) OCT & OCT 67,974 10.495 23,325 –0.080 –293,337
1.0 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist &
Nurse
39,790 10.472 21 –0.001 –33,237
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403
(2) FFA & Ophthalmologist 44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094
(5) OCT & Ophthalmologist 47,131 10.567 2482 –0.008 –293,938
(1) FFA & OCT 64,277 10.600 19,628 0.025 788,482
(7) Ophthalmologist & OCT 64,296 10.599 19 –0.001 –28,229
(4) OCT & OCT 68,939 10.592 4662 –0.008 –565,643
TABLE 37 One-way sensitivity analysis: OCT monitoring specificity
Monitoring
specificity OCT Strategy Cost QALYs
Incremental
cost
Incremental
effectiveness ICER
0.3 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist & Nurse 39,790 10.472 21 –0.001 –33,237
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403
(2) FFA & Ophthalmologist 44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094
(5) OCT & Ophthalmologist 47,131 10.567 2482 –0.008 –293,938
(1) FFA & OCT 74,212 10.459 29,563 –0.116 –255,643
(7) Ophthalmologist & OCT 74,230 10.459 29,581 –0.116 –254,397
(4) OCT & OCT 80,083 10.452 35,434 –0.123 –287,514
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TABLE 37 One-way sensitivity analysis: OCT monitoring specificity (continued )
Monitoring
specificity OCT Strategy Cost QALYs
Incremental
cost
Incremental
effectiveness ICER
0.4 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist & Nurse 39,790 10.472 21 –0.001 –33,237
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403
(2) FFA & Ophthalmologist 44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094
(5) OCT & Ophthalmologist 47,131 10.567 2482 –0.008 –293,938
(1) FFA & OCT 67,780 10.454 23,130 –0.121 –190,790
(7) Ophthalmologist & OCT 67,798 10.453 23,149 –0.122 –189,953
(4) OCT & OCT 72,979 10.446 28,330 –0.129 –219,784
0.5 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist & Nurse 39,790 10.472 21 –0.001 –33,237
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403
(2) FFA & Ophthalmologist 44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094
(5) OCT & Ophthalmologist 47,131 10.567 2482 –0.008 –293,938
(1) FFA & OCT 61,521 10.448 16,872 –0.127 –133,240
(7) Ophthalmologist & OCT 61,540 10.448 16,891 –0.127 –132,734
(4) OCT & OCT 66,049 10.441 21,400 –0.134 –159,275
0.6 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist & Nurse 39,790 10.472 21 –0.001 –33,237
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403
(2) FFA & Ophthalmologist 44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094
(5) OCT & Ophthalmologist 47,131 10.567 2482 –0.008 –293,938
(1) FFA & OCT 55,429 10.443 10,780 –0.132 –81,774
(7) Ophthalmologist & OCT 55,449 10.443 10,800 –0.132 –81,537
(4) OCT & OCT 59,286 10.435 14,636 –0.140 –104,824
0.7 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist & Nurse 39,790 10.472 21 –0.001 –33,237
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403
(2) FFA & Ophthalmologist 44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094
(5) OCT & Ophthalmologist 47,131 10.567 2482 –0.008 –293,938
(1) FFA & OCT 49,498 10.438 4849 –0.137 –35,432
(7) Ophthalmologist & OCT 49,518 10.438 4869 –0.137 –35,418
(4) OCT & OCT 52,683 10.430 8033 –0.145 –55,508
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TABLE 37 One-way sensitivity analysis: OCT monitoring specificity (continued )
Monitoring
specificity OCT Strategy Cost QALYs
Incremental
cost
Incremental
effectiveness ICER
0.8 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist & Nurse 39,790 10.472 21 –0.001 –33,237
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403
(1) FFA & OCT 43,721 10.433 3952 –0.040 –99,944
(7) Ophthalmologist & OCT 43,742 10.433 3973 –0.040 –98,928
(2) FFA & Ophthalmologist 44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094
(4) OCT & OCT 46,234 10.425 1585 –0.150 –10,589
(5) OCT & Ophthalmologist 47,131 10.567 2482 –0.008 –293,938
0.9 (1) FFA & OCT 38,093 10.429
(7) Ophthalmologist & OCT 38,114 10.428 21 –0.001 –34,221
(3) FFA & Nurse 39,769 10.473 1676 0.044 37,884
(9) Ophthalmologist & Nurse 39,790 10.472 21 –0.001 –33,237
(4) OCT & OCT 39,934 10.421 164 –0.052 –3,146
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403
(2) FFA & Ophthalmologist 44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094
(5) OCT & Ophthalmologist 47,131 10.567 2482 –0.008 –293,938
1.0 (1) FFA & OCT 32,608 10.424
(7) Ophthalmologist & OCT 32,629 10.423 21 –0.001 –35,125
(4) OCT & OCT 33,776 10.416 1168 –0.008 –144,031
(3) FFA & Nurse 39,769 10.473 7161 0.049 146,783
(9) Ophthalmologist & Nurse 39,790 10.472 21 –0.001 –33,237
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403
(2) FFA & Ophthalmologist 44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094
(5) OCT & Ophthalmologist 47,131 10.567 2482 –0.008 –293,938
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TABLE 38 One-way sensitivity analysis: OCT unit cost
Unit Cost OCT Strategy Cost QALYs
Incremental
cost
Incremental
QALYs ICER
30 (9) Ophthalmologist & Nurse 37,446 10.472
(3) FFA & Nurse 37,446 10.473 1 0.001 835
(6) OCT & Nurse 39,071 10.465 1625 –0.008 –198,353
(8) Ophthalmologist &
Ophthalmologist
42,317 10.574 4870 0.102 47,980
(2) FFA & Ophthalmologist 42,318 10.575 1 0.001 1398
(5) OCT & Ophthalmologist 44,586 10.567 2268 –0.008 –268,648
(7) Ophthalmologist & OCT 60,434 10.449 18,116 –0.126 –143,560
(1) FFA & OCT 60,436 10.449 18,118 –0.126 –144,295
(4) OCT & OCT 64,885 10.442 22,567 –0.133 –169,320
40 (3) FFA & Nurse 38,538 10.473
(9) Ophthalmologist & Nurse 38,548 10.472 9 –0.001 –15,184
(6) OCT & Nurse 40,263 10.465 1725 –0.008 –210,601
(2) FFA & Ophthalmologist 43,414 10.575 4875 0.102 47,723
(8) Ophthalmologist &
Ophthalmologist
43,423 10.574 9 –0.001 –13,878
(5) OCT & Ophthalmologist 45,783 10.567 2369 –0.008 –280,538
(1) FFA & OCT 61,528 10.449 18,114 –0.126 –144,264
(7) Ophthalmologist & OCT 61,536 10.449 18,122 –0.126 –143,608
(4) OCT & OCT 66,078 10.442 22,664 –0.133 –170,044
50 (3) FFA & Nurse 39,630 10.473
(9) Ophthalmologist & Nurse 39,650 10.472 19 –0.001 –31,202
(6) OCT & Nurse 41,456 10.465 1825 –0.008 –222,848
(2) FFA & Ophthalmologist 44,510 10.575 4879 0.102 47,763
(8) Ophthalmologist &
Ophthalmologist
44,529 10.574 19 –0.001 –29,154
(5) OCT & Ophthalmologist 46,979 10.567 2469 –0.008 –292,428
(1) FFA & OCT 62,620 10.449 18,110 –0.126 –144,233
(7) Ophthalmologist & OCT 62,638 10.449 18,128 –0.126 –143,656
(4) OCT & OCT 67,270 10.442 22,760 –0.133 –170,767
60 (3) FFA & Nurse 40,722 10.473
(9) Ophthalmologist & Nurse 40,752 10.472 29 –0.001 –47,221
(6) OCT & Nurse 42,648 10.465 1926 –0.008 –235,095
(2) FFA & Ophthalmologist 45,606 10.575 4884 0.102 47,803
(8) Ophthalmologist &
Ophthalmologist
45,635 10.574 29 –0.001 –44,429
(5) OCT & Ophthalmologist 48,176 10.567 2569 –0.008 –304,319
(1) FFA & OCT 63,712 10.449 18,106 –0.126 –144,201
(7) Ophthalmologist & OCT 63,740 10.449 18,134 –0.126 –143,703
(4) OCT & OCT 68,462 10.442 22,856 –0.133 –171,491
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ophthalmologist visit cost added only when treatment was needed). Tables 39–41 show the scenario analysis
results. For scenario 1 (see Table 39) and scenario 3 (see Table 41) strategies that based their diagnosis or
monitoring decisions on OCT test results only are dominated (i.e. have higher expected costs and lower
expected QALYs). It should be noted that, due to the lower unit cost for the OCT test, the strategy with the
lower expected cost is diagnosis by an ophthalmologist combined with nurse- or technician-led monitoring.
Table 40 shows results for scenario 2 (i.e. the same input data as for scenario 1 but assuming cost of
treatment of £50 per injection). The pathway strategy with the lowest cost is the ophthalmologist stepwise
diagnosis followed by monitoring decisions based on OCT only. The next costly strategy is the one that
based the diagnosis decision on FFA only and the monitoring treatment decision on OCT test results only.
However, this strategy is dominated by the former. The next non-dominated strategy was diagnosis by an
ophthalmologist followed by ophthalmologist-led monitoring (e.g. ‘Ophthalmologist & Ophthalmologist’)
with an ICERs of £19,917. This is within the usual £30,00073 threshold and potentially worthwhile to
adopt. The results in Table 40 indicate that OCT strategies could become cost-effective if the cost of
treatment was lower. In terms of the economic model, this would be a lower penalisation for those
strategies that treat individuals who do not need to be treated (i.e. those tests or strategies that result in
lower specificity and therefore a higher number of FP results).
TABLE 38 One-way sensitivity analysis: OCT unit cost (continued )
Unit Cost OCT Strategy Cost QALYs
Incremental
cost
Incremental
QALYs ICER
70 (3) FFA & Nurse 41,814 10.473
(9) Ophthalmologist & Nurse 41,854 10.472 39 –0.001 –63,240
(6) OCT & Nurse 43,840 10.465 2026 –0.008 –247,342
(2) FFA & Ophthalmologist 46,702 10.575 4888 0.102 47,842
(8) Ophthalmologist &
Ophthalmologist
46,741 10.574 39 –0.001 –59,705
(5) OCT & Ophthalmologist 49,372 10.567 2670 –0.008 –316,209
(1) FFA & OCT 64,805 10.449 18,102 –0.126 –144,170
(7) Ophthalmologist & OCT 64,842 10.449 18,140 –0.126 –143,751
(4) OCT & OCT 69,655 10.442 22,953 –0.133 –172,214
TABLE 39 Scenario analysis 1
Strategy
Cost
(£)
Incremental
cost (£) QALYs
Incremental
QALYs ICER (£)
(9) Ophthalmologist & Nurse 36,320 – 10.478
(3) FFA & Nurse 36,707 387 10.471 –0.007 –54,280
(6) OCT & Nurse 37,417 1097 10.470 –0.008 –140,873
(8) Ophthalmologist &
Ophthalmologist
41,284 4964 10.579 0.101 49,012
(2) FFA & Ophthalmologist 41,740 456 10.573 –0.006 –73,232
(5) OCT & Ophthalmologist 42,781 1497 10.573 –0.007 –218,869
(7) Ophthalmologist & OCT 48,24 6957 10.536 –0.043 –161,687
(1) FFA & OCT 48,791 7507 10.530 –0.050 –151,253
(4) OCT & OCT 50,273 8989 10.529 –0.050 –179,277
–, there is no incremental cost on this option.
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Summary and discussion
This chapter reported on a systematic review of economic evaluations and a model-based economic
evaluation of alternative strategies for the diagnosis and monitoring of individuals with nAMD.
No studies identified in the literature met the inclusion criteria for the systematic review.
Nine strategies (combinations of three different diagnostic and monitoring pathways) were considered
within the economic model. The strategies used OCT for diagnosis and/or monitoring of nAMD individuals
to a different extent. Extensive deterministic and probabilistic sensitivity analyses were conducted.
The strategy that based its diagnosis decision on the results of FFA only, combined with VA and
OCT interpreted together by a nurse or technician as the first monitoring step, with a referral to an
ophthalmologist if the first monitoring assessment was positive or unclear (‘FFA & Nurse’), had the lowest
expected total cost. This strategy dominated (i.e. lower expected costs and higher expected QALYs)
all others apart from one: diagnosis with FFA only, combined with monitoring by an ophthalmologist
(‘FFA & Ophthalmologist’). The ‘FFA & Nurse’ and ‘FFA & Ophthalmologist’ strategies had, respectively,
a 46.5% and 29.8% probability of being cost-effective at the £30,000 threshold value of willingness to
TABLE 40 Scenario analysis 2
Strategy
Cost
(£)
Incremental
cost (£) QALYs
Incremental
QALYs ICER (£)
(7) Ophthalmologist & OCT 13,983 – 10.536
(1) FFA & OCT 14,158 175 10.530 –0.007 –26,423
(4) OCT & OCT 14,583 600 10.529 –0.007 –84,256
(8) Ophthalmologist &
Ophthalmologist
14,840 857 10.579 0.043 19,917
(2) FFA & Ophthalmologist 15,024 184 10.573 –0.006 –29,567
(5) OCT & Ophthalmologist 15,477 636 10.573 –0.007 –93,000
(9) Ophthalmologist & Nurse 15,601 761 10.478 –0.101 –7,511
(3) FFA & Nurse 15,790 949 10.471 –0.108 –8,757
(6) OCT & Nurse 16,218 1377 10.470 –0.109 –12,627
–, there is no incremental cost in this option.
TABLE 41 Scenario analysis 3
Strategy
Cost
(£)
Incremental
cost (£) QALYs
Incremental
QALYs ICER (£)
(9) Ophthalmologist & Nurse 36,320 – 10.478 0.000 0
(3) FFA & Nurse 36,707 387 10.471 –0.007 –54,280
(6) OCT & Nurse 37,417 1097 10.470 –0.008 –140,873
(8) Ophthalmologist &
Ophthalmologist
41,284 4964 10.579 0.101 49,012
(2) FFA & Ophthalmologist 41,740 456 10.573 –0.006 –73,232
(5) OCT & Ophthalmologist 42,781 1497 10.573 –0.007 –218,869
(7) Ophthalmologist & OCT 43,527 2243 10.536 –0.043 –52,132
(1) FFA & OCT 44,018 2734 10.530 –0.050 –55,084
(4) OCT & OCT 45,257 3974 10.529 –0.050 –79,247
–, there is no incremental cost in this option.
pay for an extra QALY. In addition, the ‘FFA & Nurse’ strategy dominated all others in the great majority of
sensitivity analyses.
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The strategies that used OCT only for their monitoring decisions were in almost every model run ordered
last in terms of total expected cost and were often dominated by others. The strategy that used OCT only
for both diagnosis and monitoring decisions was in almost every model run, the most costly strategy.
Scenario analysis was conducted in order to explore the conditions under which an OCT only strategy
would become cost-effective. Three scenarios were developed using the best test performance data for
OCT combined with a lower cost for OCT (£20.90) and a higher cost for FFA (£137). Scenario 2 added to
this a lower unit cost for treatment (e.g. equivalent to the cost of bevacizumab, £50, instead of the £742
cost of ranibizumab considered for the base-case analysis). This scenario showed the ophthalmologist
stepwise pathway for diagnosis combined with OCT only for monitoring, to be, on average, the least costly
strategy. Alternative strategies were either dominated (i.e. more costly and produced fewer QALYs) or the
resulted ICER was well above the usual threshold accepted for policy decisions.73 This was an expected
result. The low OCT specificity for monitoring in these scenarios and in the base case (0.61 and 0.44,
respectively) meant that a high number of positive results would actually be FPs. The lower cost of treating
individuals who do not need to be treated reduced the model penalisation for the OCT only-based
strategies and therefore improved their cost-effectiveness.
Best practice guidelines were followed for this model-based economic evaluation exercise.73,81 In spite of
this, these results should be interpreted with caution. A considerable effort was made to retrieve the best
available test or assessment performance data by conducting a systematic review of the literature.
Other data were obtained from focused but reproducible searches. Nevertheless, there is an inherent
problem with model-based economic evaluations that incorporate evidence from several sources, even
when these data have been obtained systematically. The limitations of the SD-OCT performance data
incorporated into the economic model have been mentioned in Chapter 4, with no SD-OCT studies
contributing to the diagnosis performance data and only two SD-OCT studies23,30 contributing to the
monitoring performance data. Moreover, although OCT diagnosis and monitoring performance data were
retrieved from a systematic review of the literature, no such data were available for the strategies involving
diagnosis or monitoring assessment by an ophthalmologist or monitoring assessment by a nurse or
technician. Therefore, these data for the model were obtained from expert opinion. This constitutes a
major caveat of the analysis and further research in this area is needed.
This economic model needed to consider individuals’ disease status (i.e. active or inactive nAMD) as well as
test results on a monthly basis. In addition, these had to be combined with alternative VA states in order
to incorporate utility weights into the model. It was felt that considering the effect of a fellow eye status
(VA and nAMD status) would add major complexity to the model without a great deal of benefit from
such incorporation. This is the most common approach used among economic models in this health area
but constitutes a limitation of the current study. Utility weights used were obtained from nAMD individuals
and grouped according to VA in the better-seeing eye. It is believed that this would better reflect
individuals’ health status. However, the clear limitation of ‘one eye models’ is the underestimation of
resources used. A proportion of monitored nAMD individuals will have this condition in both eyes instead
of one, and, had the disease been active, would be receiving treatment injections in each eye. Intuitively,
this would increase the treatment cost for those strategies with a higher number of TP and FP results
(i.e. higher sensitivity and lower specificity) and hence would be unlikely to modify the overall conclusions
of this economic evaluation.
The model did not consider effects on utility due to treatment injections. Anxiety in nAMD individuals was
believed to occur at each monitoring visit mainly due to the uncertainty of the underlying condition
(i.e. whether or not nAMD was active) and not the effects of the treatment injections. No evidence was
obtained on this issue in spite of focused searches. Further research in this area is needed. Utility weight
decrements from treatment adverse effects were included and this might partially overcome the
above-mentioned potential limitation.
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Limited evidence was available on the probability of nAMD active individuals becoming inactive when
under treatment or inactive nAMD individuals becoming active. Data were retrieved from the literature and
also from a UK-based RCT.9 Survival data were received from the IVAN study (Dr Chris Rogers, personal
communication) on first retreatment failure criteria (i.e. inactive individuals who needed to be retreated).
These were used to develop model parameter values for the first year of the model run. There were no
such data available for further failures and we had to rely on the available limited data from the literature70
or on expert opinion for year 2 onwards. In addition, progression data on VA were based on the 2-year
follow-up MARINA study.69 All of these were relatively short-term follow-up studies (around 2 years) but
used to inform model parameters for a lifetime time horizon. These are clear limitations of the model and
therefore its results should be interpreted with caution. Further research investigating individuals’ nAMD
active/inactive status (e.g. probability of disease changing from inactive to active) would be desirable.
Conclusions
A strategy that based its diagnostic decision on the results of FFA only, combined with VA and OCT
interpreted together by a nurse or technician as a first monitoring step, with a referral to an
ophthalmologist if this first monitoring assessment was positive or unclear, had the lowest expected total
cost. This strategy had a 46.5% probability of being cost-effective at a £30,000 threshold value of
willingness to pay for an extra QALY. In addition, this strategy dominated all others apart from one
(i.e. diagnosis with FFA combined with ophthalmologist-led monitoring) in the great majority of sensitivity
analyses. Strategies that used OCT test results alone to make diagnosis or monitoring treatment decisions
were unlikely to be a cost-effective use of resources. This result seemed to be driven by the OCT low
specificity that resulted in a high number of FP results. The present analysis indicated that a further
refinement of monitoring (i.e. a further monitoring step other than OCT alone) seemed desirable.
These results should be interpreted with caution. The economic model would benefit from further
research to better inform a number of model parameter values. Studies that investigate the likelihood of
nAMD individuals becoming active or inactive after subsequent treatments are desirable. In addition,
a preference-based health status and process of care valuation study to explore the effects of treatment
injections on individuals’ utility weights is needed. Finally, a comparative study to establish the
performance of the ophthalmologist-based strategy compared with the nurse- or technician-based strategy
for monitoring individuals with nAMD is required to inform future economic models in this area.
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Chapter 6 Assessment of factors relevant to the
NHS and other parties
The introduction of OCT and other diagnostic technologies for the diagnosis and monitoring of patientswith nAMD has a range of implications for the NHS, patients and other parties. There has already been
a shift in the diagnostic pathway for this group of patients caused by the adoption of OCT, rather than the
previously used FFA, as a method of establishing the diagnosis and of evaluating disease activity. There are
consequential effects not only on patient outcomes but also on service delivery, health-care professionals
and wider society of this change in preferred diagnostic technologies used.
Factors relevant to the NHS
Estimating the numbers of patients with neovascular age-related
macular degeneration
A summary of the epidemiology of nAMD has been described in this study. In brief, the prevalence and
incidence of nAMD and the consequent burden to the NHS will increase over the next few decades
because of the ageing population. By 2060, mean life expectancy will grow by 8.5 years for men
(to 84.5 years) and 6.9 years for women (to 89.0 years).82
Implications for service provision
The clinical workload associated with the frequent follow-up required for patients with nAMD is
substantial. As more new patients are diagnosed and the population continues to age, the patient
population will continue to increase. It is thus vital that clinical services continue to adapt so that they can
provide a fast and efficient service for patients with nAMD.
There are still challenges and questions about whether or not ophthalmology departments have
sufficient capacity and the means to offer relevant testing and treatments within adequate time scales.
Local diagnostic pathways require updating and assessment to ensure compliance with national guidelines
(e.g. to detect recurrence of active disease in these subjects). Occasional local disruptions may occur if OCT
equipment suffers technical failures.
In 2012, Amoaku et al.56 published a document entitled ‘Action on AMD’ that was developed by eye
health-care professionals and patient representatives with the intention of highlighting the urgent and
continuing need for change within nAMD services. This document also provided examples of good practice
and service development, including the possibility of involving other health professionals and using OCT in
the community.
Considerations regarding the performance of optical coherence tomography
for diagnosis and monitoring
At the diagnostic stage, OCT is currently used in addition to FFA to provide a baseline that will be used for
comparisons during the monitoring stage.
For monitoring, OCT has virtually replaced FFA in most NHS units.83 During follow-up, monitoring also
includes VA testing. There is larger variability in the adoption of other tests and perceived need for FFA
during follow-up. The replacement of FFA is probably due to the convenience of OCT (e.g. non-invasive,
user friendly, quick, efficient). However, expert clinicians recognise the difficulty of interpreting FFA and
OCT in patients with previously treated nAMD who often develop atrophic changes. The low specificity
of OCT observed in this study would suggest that OCT alone should not be used for monitoring.
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Another consideration is the evolving technology. For example, theoretically an increased sensitivity and
specificity of new versions or novel technologies (SD-OCT) would lead to more patients being correctly
diagnosed with active nAMD, and fewer wrongly diagnosed as having no active disease. This review did
not find sufficient evidence on the performance of SD-OCT and it is unclear if it is superior to TD-OCT.
Regarding cost implications, there will be little cost implications for procuring and maintaining OCT
equipment because most centres already use this technology. Although many units will already have
access to the new SD-OCT equipment, other centres may have to upgrade the current TD-OCT
(e.g. purchase or lease new SD-OCT equipment).
There may be a need for training ophthalmology staff to ensure adequate technical skills to interpret the
OCT scans. There is a learning curve to interpreting OCT images, especially in relation to those patients
who are being monitored after treatment. Adequate quality control and quality assurance programmes
would be needed in order to maintain high standards of interpretation.
Factors relevant to patients and other parties
A highly specific test may reduce the number of patients undergoing unnecessarily treatment with
antiVEGF injections, avoiding the associated discomfort, side effects and possible complications. Using OCT
alone for diagnosis or monitoring would be associated with a number of FPs and unnecessary treatments.
From the efficiency point of view, a specificity of at least 80% would be required for a monitoring strategy
using OCT alone to be cost-effective.
From a patient preference point of view, if the diagnostic performance were adequate, it is likely that
patients would prefer OCT when compared with FFA because of the unpleasantness of the
latter procedure.
Monitoring in the community would be a positive development for patients and carers, who would have
less distance to travel to access OCT testing. This may be possible as OCT is becoming increasingly used by
community optometrists but would need to be associated with another test (e.g. VA). Local arrangements
and financial support would need to be put in place as community optometrists would need to be trained
and reimbursed for their services. Community optometrists should also be able to communicate their
findings in a timely and efficient way to clinicians in secondary care. However, inequalities in access may
arise as people from disadvantaged socioeconomic backgrounds may be reluctant to attend private
community optometrists.
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Chapter 7 Discussion
Diagnostic accuracy
Statement of principal findings
Diagnostic studies
Twenty-two diagnostic studies were included (20 full-text papers,24–27,29,31,33,35–41,44–51 two abstracts34,42) involving
over 2000 participants. The studies reported the performance of OCT (13 studies25,27,33–38,40,41,45,46,49),
ICGA (eight studies25,26,29,31,42,44,48,51), PHP (three studies24,27,39), colour fundus photography, Amsler grid27 and
FAF25 (one study each) in the detection of nAMD. Studies that reported true and false positive and true
and false negative or provided information that allowed these data to be calculated were considered for
inclusion in pooled estimates (meta-analyses), which were performed with eye as the unit of analysis.
Full-text papers were assessed for risk of bias using the QUADAS-2 tool. The domains with the greatest
number of studies judged to be at high risk of bias were the patient selection domain (55%, 11/20),
for reasons such as inappropriate exclusions and pre-selection of participants, and the flow and timing
domain (40%, 8/20), for reasons such as the length of time between the index test and the reference
standard being longer than 1 week, and not all participants being included in the analysis. In the
index/comparator test domain and reference standard domain, the risk of bias was judged to be unclear
in around half of the studies [50% (10/20) and 60% (12/20) respectively]. However, all of the studies were
judged to be of low concern in terms of their applicability to the review question.
Only four OCT diagnostic studies (all TD-OCT)27,40,46,49 provided sufficient data for inclusion in a
meta-analysis. The pooled sensitivity and specificity (95% CI) for all OCT was moderately high at 88%
(46% to 98%) and 78% (64% to 88%) respectively.
Of the other tests of interest, median sensitivity (range) was similarly high for ICGA [93.2% (84.6–100%);
four studies25,29,44,51] and FAF (93.3%; one study25), followed by PHP [81.5% (50.0–84.8%); three
studies24,27,39] and colour fundus photography (70.0%; one study24) and was lowest for Amsler grid
(41.7%; one study27). Specificity was highest for colour fundus photography (95%; one study24), followed
by PHP (84.6% and 87.7%; two studies24,39), and was similarly low for FAF (37.1%; one study25) and ICGA
(36.8%; one study29).
Two studies reported test combinations. For OCT plus colour fundus photography,46 sensitivity was
moderate at 74.1%, with specificity high at 92.0%. For colour fundus photography plus VA,24
sensitivity was low at 53.0% but again specificity was high at 94.0%.
Monitoring studies
Eight monitoring studies23,28,30,32,43,45,52,53 were included (all full-text) involving over 400 participants.
Seven reported the performance of OCT (five TD-OCT,28,32,45,52,53 one SD-OCT,30 one both types23) and one
the performance of ICGA in the detection of nAMD activity.43 As with the diagnostic studies, the
QUADAS-2 domains with the greatest number of monitoring studies judged to be at high risk of bias were
the patient selection domain (25%, 2/8)30,45 and flow and timing domain (25%, 2/8),45,52 for similar reasons
to those reported above. In the index/comparator test domain and reference standard domain the risk of
bias was judged to be unclear in 50% (4/8)23,45,52,53 and 37.5% (3/8)23,45,52 of studies respectively. Similar to
the diagnostic studies, all of the monitoring studies were judged to be of low concern in terms of their
applicability to the review question.
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Four of the OCT studies provided sufficient data for inclusion in a meta-analysis.23,28,30,53 The pooled
sensitivity (95% CI) for all OCT was moderately high at 85% (72% to 93%) but with low specificity at
48% (30% to 67%). For TD-OCT,23,28,53 the pooled sensitivity and specificity was moderate at 70%
(56% to 80%) and 65% (48% to 79%) respectively. It was not possible to calculate pooled estimates for
the two SD-OCT studies23,30 using HSROC methodology due to insufficient data. These studies reported
sensitivities of 94%30 and 90%23 and specificities of 27%30 and 47%.23 These results suggest that SD-OCT
has higher sensitivity but lower specificity than TD-OCT. In particular, the specificity of the SD-OCT
monitoring studies was quite low.
Other than OCT, one study reported ICGA,43 with sensitivity of 75.9% and specificity of 88.0% for the
detection of active nAMD.
Strengths and limitations of the assessment
In terms of strengths, a comprehensive literature search was undertaken and non-English-language studies
were included. Risk of bias was assessed using a modified QUADAS-2 questionnaire, tailored to the needs
of this review. A HSROC model was used for the analysis, which takes account of the trade-off between
TPs/FPs and models between-study heterogeneity.84 The evidence for diagnosis and monitoring was
considered separately. In addition to the pooled estimates for all OCT, separate pooled estimates were
undertaken for TD-OCT (monitoring studies). It was not possible to undertake separate pooled estimates
for SD-OCT as no SD-OCT studies were included in the diagnosis meta-analysis, and, in the monitoring
meta-analysis, there were insufficient data from the two SD-OCT studies to use HSROC methods.
There was a very limited amount of evidence available for evaluating the performance of SD-OCT, both for
diagnosis (one study) and for surveillance monitoring of those previous diagnosed with nAMD. There was
also limited evidence for the performance of TD-OCT for surveillance monitoring. Although this review
considered a number of alternative tests, only a few of these were reported by studies that met our
inclusion criteria. There was insufficient information to address the questions of (1) the clinical effectiveness
of OCT compared with FFA; (2) the acceptability of the tests; and (3) the performance of other health
professionals compared with ophthalmologists in interpreting OCT findings.
Uncertainties
Reference standard
Fundus fluorescein angiography interpreted by an ophthalmologist was our reference standard test and as
such was assumed to have perfect sensitivity and specificity for the detection of active nAMD. Therefore,
it was not possible to address the question of whether or not OCT might actually have better sensitivity or
specificity than FFA; the optimal judgement that could have been made about OCT was that it had equally
high sensitivity and specificity as FFA. In fact, although OCT did have very high sensitivity, the specificity for
diagnosis and monitoring was suboptimal.
Glasziou et al.85 considered the question of when a new test should replace the existing reference
standard. They suggested that this might be determined by a ‘fair umpire’ test applied to the cases where
the new test and reference standard differed. This third test, although potentially less accurate than
either the new test or reference standard, could be considered a fair umpire, if its errors were considered
to be independent of the other tests, although it was acknowledged that this would usually be difficult to
demonstrate. Possible umpires suggested included causal exposures, concurrent testing, prognosis, or
response to treatment. Glasziou et al.85 argued that using this approach, the umpire test might be able
to distinguish which test was the better reference standard. An example given was that of a new test
for tuberculosis, with the tuberculin skin test as the reference standard, interferon-γ enzyme-linked
immunospot (ELISpot) assays as the new test and tuberculosis exposure as the fair umpire.85 However,
none of the studies included in our review provided a sufficient level of information to allow such a
‘fair umpire’ approach to be applied.
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False positives
Excluding studies where information was only available for detection of phenotypes,34,37,38,52 specificity for OCT
was reported by six23,28,30,32,45,53 of seven monitoring studies, but only 427,40,46,49 of 10 diagnostic studies.
As already reported, specificity for OCT for diagnosis was only moderate and for monitoring was lower,
with a large number of FP results. A few studies provided some additional information on their FP results,
with suggested reasons for these including the presence of a disciform scar with persistent cystic cavities,45
an increase in the central subfield measurement,27 drusen/atrophy,46,49 cystoid abnormalities,23 subretinal
fluid being detected before FFA leakage was observed,40 and the detection of remnants of intraretinal fluid
that had not yet been resorbed even though the underlying CNV was no longer actively leaking fluid.32
Do et al.27 suggested that SD-OCT may have lower specificity for the detection of CNV than TD-OCT
because it is more likely to detect structural changes in the retina, which may be a normal anatomic
variant and not necessarily representative of secondary changes in the retina owing to CNV.
Sandhu and Talks46 noted that the OCT FP rate was reduced with the addition of stereo colour images
(separate test). In current practice OCT is typically associated with VA data which may improve the
specificity of the test.
In two of the monitoring studies,23,30 participants had been treated with antiVEGF therapy and in
five28,32,45,52,53 they were treated with PDT. For all OCT, median sensitivity was similar across the antiVEGF
(90%) and PDT (88%) groups of studies, whereas median specificity was slightly higher across the PDT
studies (51%) compared with the antiVEGF studies (43%). It is possible that following treatment with
PDT there is less likelihood of having fluid in the retina than following therapy with antiVEGF, as fluid is a
common feature in eyes treated with antiVEGF, even after many sessions of treatment. Currently PDT is
rarely used for nAMD, but the reviewed literature reflects this older modality of treatment. OCT (especially
the newer version with the highest resolution, SD-OCT) may detect fluid, even when only a small amount
is present and it does not necessarily relate to CNV activity (e.g. fluid may be present if there is RPE
dysfunction/damage as a result of the disease or its treatment, as in normal circumstances RPE pumps fluid
out of the retina). Therefore, it is possible that there might be more OCT FPs resulting in lower specificity
for detecting active nAMD following antiVEGF compared with PDT treatment.
In two diagnostic studies, by Kozak et al.36 and Reichel et al.,44 some patients were classed as having
nAMD who were negative on FFA but positive on one of the other tests being assessed (13/541 eyes
by TD-OCT in the Kozak et al. study36 and 4/20 participants by ICGA in the Reichel et al.44 study).
For the purposes of this review, these cases were considered to be test FPs (as the reference standard of
FFA was considered to have perfect sensitivity and specificity). However, in some cases (e.g. with retinal
haemorrhage), it is possible that ICGA may be better than FFA in detecting nAMD.
Heterogeneity across the studies
Other than the fact that one group of studies was concerned with initial diagnosis of nAMD and another
with monitoring of those previously diagnosed, there were a number of other differences across the
studies. In terms of differences across the participant groups, the prevalence of nAMD in the diagnostic
studies ranged from 17.2% to 100% (median 80.0%) and of active nAMD in the monitoring studies
from 49.2% to 83.3% (median 57.9%). The proportion of participants classed as having specific
nAMD phenotpyes (e.g. classic CNV, occult CNV) varied across the studies. In eight diagnostic
studies24,27,31,39,40,44,45,49 and one monitoring study30 participants were judged to have been pre-selected.
Detection of phenotypes
Twelve studies (eight diagnostic,25,33,34,37,38,41,46,49 four monitoring23,30,32,52) reported the sensitivity of OCT in
the detection of nAMD phenotypes (predominantly classic, minimally classic, occult or RAP). None of the
studies reported detection of IPCV. Results were mixed and overall there was insufficient evidence to
understand whether or not the performance of OCT differs among the different phenotypes.
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The monitoring study by Giani et al.30 (SD-OCT) reported high sensitivity for the detection of both classic
and occult CNV activity (90.9% and 100% respectively).
Across four (TD-OCT) diagnostic studies25,34,37,38 reporting detection of RAP the median (range) sensitivity
was 65% (50–100%). Of the monitoring studies, Khurana et al.23 reported higher sensitivity for SD-OCT
(59%) compared with TD-OCT (35%) for detecting retinal cystoid abnormalities, whereas van de Moere
et al.52 reported poor sensitivity for TD-OCT for detecting cystoid macular oedema (23%) and PED (6%).
Unit of analysis issues
Twelve OCT studies used one eye per patient in the analysis.25,27,28,30,33–35,38,40,49,52,53 In three of these
studies25,27,40 the inclusion criteria stipulation for the fellow eye meant that only one (study) eye per subject
was eligible for analysis. In the remaining studies, the inclusion criteria were such that both eyes of some
subjects might have been potentially eligible.23,36,37,41,45,46 Of these, however, only the study by van de
Moere et al.52 reported the method used for selecting the study eye in the event of such a situation,
stating that if both eyes were eligible one eye was randomly chosen for analysis. It was unclear from the
other studies whether only one eye per subject had met the inclusion criteria or whether for some subjects
both eyes were eligible but only one was selected.
In six OCT studies, both eyes of some participants met the inclusion criteria and were included in the
analysis;23,36,37,41,45,46 however, none of these studies mentioned the issue of the possible influence that
the non-independence of the fellow eye might have on the analysis.
All studies included in the meta-analyses used one eye per subject, apart from the study by Sandhu and
Talks46 (meta-analysis of diagnostic studies) and the study by Khurana et al.23 (meta-analysis of monitoring
studies). In the study by Sandhu and Talks,46 131 eyes of 118 patients were included in the analysis,
as 13 patients had bilateral activity. In the study by Khurana et al.,23 59 eyes of 56 patients were included
in the analysis, as three patients had received antiVEGF treatment for nAMD in both eyes. These studies
did not report whether or not any adjustment had been made to take account of the non-independence
of the fellow eye and contained an insufficient level of detail to allow for an exploration of this issue.
However, the potential impact of fellow eye non-independence would probably be minor, at most, given
the small number of subjects in the two studies for whom both eyes were included in the analysis.
Other relevant factors
Ongoing studies
No ongoing studies were identified of OCT or alternative tests of interest compared with a reference
standard of FFA for the diagnosis, monitoring and guiding of treatment for nAMD.
Comparison of our results with other systematic reviews/health
technology assessments
Our searches identified four HTA reports that included an assessment of OCT in the detection of
nAMD.14,86–88 The German HTA report by Stürzlinger et al.87 (report summary in English, full text in
German), published in 2007, considered head-to-head comparisons between OCT and FFA for newly
presenting patients. Eight studies were included, of which three were included in our review.33,35,46
The other five studies did not meet our inclusion criteria (assessment of RPE tear,89 retinal PED,90 drusen,91
geographic atrophy,92 and no diagnostic outcomes reported).93 The report’s conclusions were that
although OCT yielded diagnostic findings in addition to FFA results, OCT could not replace FFA during the
primary diagnostic procedure.
The Belgian Health Care Knowledge Centre report by Van den Bruel et al.,88 published in 2008,
considered five ophthalmic tests in clinical practice, including OCT. The assessment identified the German
HTA report and included an additional three studies,28,37,45 all three of which were included in our review.
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The review considered FFA as the reference standard for neovascular AMD, and, similar to our review,
reported high sensitivity (96–97%) and moderate specificity (66%) of OCT in detecting CNV.
In the Australian Medical Services Advisory Committee (MSAC) report,86 published in 2009, OCT was
compared (a) with FFA or clinical observation in the diagnosis of macular diseases; (b) in addition
to FFA and clinical examination in the monitoring of patients with macular diseases; (c) in addition to
computerised perimetry and clinical examination in the diagnosis of glaucoma; and (d) in addition
to computerised perimetry and clinical examination in the monitoring of patients with glaucoma.
Regarding the diagnostic accuracy of OCT for AMD, the MSAC report concluded that due to the absence
of a valid reference standard, the diagnostic accuracy of OCT for the detection of macular abnormalities
could not be assessed. This approach contradicted our study, the German and Belgian HTA reports and
also current practice in the UK where FFA is considered the reference standard for the diagnosis of nAMD.
In the evidence-based analysis by the Medical Advisory Secretariat, Ontario, Canada,14 published in 2009,
OCT was compared with the reference standard of FFA for AMD and diabetic macular oedema.
The evaluation summarised the German HTA report and the study by Sandhu and Talks46 that was also
included in our review. This report also questioned the validity of FFA as a reference standard and
presented conclusions that were based on expert consultations.
Aflibercept
In May 2013, NICE published final draft guidance recommending aflibercept solution for injection as an
option for treating nAMD (www.nice.org.uk/guidance/ta294). Full guidance was published in July 2013
(www.nice.org.uk/guidance/ta294/resources/guidance-aflibercept-solution-for-injection-for-treating-wet-
agerelated-macular-degeneration-pdf). The treatment and monitoring schedule for this drug differs from
that of ranibizumab. According to the summary of product characteristics for aflibercept, treatment should
be given monthly for three consecutive 2-mg doses, followed by one injection every 2 months, with no
need for monitoring between injections. After the first 12 months of treatment, the treatment interval may
be extended based on visual and anatomic outcomes, with the schedule for monitoring determined by the
treating doctor. In terms of the economic model, extending the length of time between monitoring visits
would reduce the cost associated with monitoring as well as the number of treatment courses needed.
However, this would be expected to affect all model strategies in a similar manner and therefore would be
unlikely to modify the general conclusions from the economic analysis. This might nevertheless reduce the
cost associated with treatment and monitoring of nAMD patients for the NHS.
Future technological developments
It is likely that future technological developments in OCT will be introduced. Most OCT devices create
cross-sectional images of the retina. En-face OCT technology is an emerging imaging technique derived
from SD-OCT that creates images of frontal sections of retinal layers that are compatible with conventional
fundus images.
Another emerging technique is OCT angiography, which uses high-speed Fourier-domain OCT for
non-invasive three-dimensional imaging of the vasculature and blood flow at the posterior part of the eye.
Cost-effectiveness
Statement of principal findings
No studies met the inclusion criteria for the systematic review of economic evaluations as none compared
diagnostic or monitoring strategies for individuals with nAMD.
Nine strategies that used to a different extent OCT for diagnosis and/or monitoring of nAMD individuals
were considered within the Markov cohort economic evaluation model. The strategy that based its
diagnosis decision on the results of FFA only, combined with VA and OCT interpreted together by a nurse
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or technician as the first monitoring step, with a referral to an ophthalmologist if the first monitoring
assessment was positive or unclear (‘FFA & Nurse’), had the lowest expected total cost. This strategy
dominated (i.e. lower expected costs and higher expected QALYs) all others apart from one: diagnosis with
FFA only, combined with monitoring by an ophthalmologist (‘FFA & Ophthalmologist’). The ‘FFA & Nurse’
and ‘FFA & Ophthalmologist’ strategies had, respectively, a 46.5% and 29.8% probability of being
cost-effective at the £30,000 threshold value of willingness to pay for an extra QALY. In addition, the
‘FFA & Nurse’ strategy dominated all others in the great majority of sensitivity analyses.
The strategies that used OCT only for their monitoring decisions were, in almost every model run, ordered
last in terms of ascending total expected cost and were often dominated by others. The strategy that used
OCT as its only criteria for diagnosis and monitoring decisions was in almost every model run the most
costly strategy.
Results were sensitive to the unit cost of treatment injections. A scenario with a lower unit cost for
treatment (e.g. £50, equivalent to the cost of bevacizumab, instead of £742 considered for the base-case
analysis) resulted in the FFA only for diagnosis combined with OCT only for monitoring strategy having
the lowest total expected cost. Alternative strategies were either dominated or had an ICER well above the
usual threshold stated for cost-effectiveness (i.e. £30,000).
Strengths and limitations of the economic assessment
The major strength of the economic evaluation is that it attempted to use the best available evidence with
the compared strategies developed from extensive discussions within the project team and advisory
group. Best practice guidelines were followed for this economic evaluation exercise.73 For instance,
test performance data were obtained from the systematic review of the literature with other data retrieved
from focused but reproducible searches. There is, however, an inherent problem with model-based
economic evaluations that incorporate evidence from several sources, even when these data have been
retrieved systematically.
The economic model needed to consider individuals’ disease status (i.e. active or inactive nAMD) as well as
test results on a monthly basis. In addition, these had to be combined with alternative VA states in order
to incorporate utility weights into the model. It was felt that considering the effect of fellow eye status
(VA and nAMD status) would add major complexity to the model without much benefit from this
incorporation. A clear limitation of the so-called ‘one eye models’ is the underestimation of resources used.
A proportion of nAMD individuals will have this condition in both eyes instead of one eye and would
need treatment injections in each eye should the disease be active. In the current model this would
increase the cost for those strategies with higher numbers of FPs (i.e. lower specificity) and therefore
would be unlikely to modify the general conclusions of this study. A ‘one eye model’ has also been
adopted by other teams involved in economic evaluations in this health area.61
The model did not consider effects on utility due to treatment injections. Anxiety in nAMD individuals was
believed to occur at each monitoring visit mainly due to the uncertainty of the underlying condition
(i.e. active or inactive nAMD) and not the effects of the treatment injections. No evidence was obtained on
this from the utility weight searches. However, utility weight decrements from adverse effects as a result of
the treatment were included and this might partially overcome the above-mentioned potential limitation.
The model did not consider factors relating to patient experience of alternative monitoring schemes.
As such, there was no consideration of the process of care on patient preferences and only the effect of
VA and the adverse effects of treatment on individual utility were incorporated into the model.
Limited evidence was available on the probability of nAMD active individuals becoming inactive when
under treatment or inactive nAMD individuals becoming active. Data were retrieved from the literature,
from a UK-based RCT (Dr Chris Rogers, personal communication) and expert opinion. In addition,
progression data on VA were based on the 2-year follow-up MARINA study.69 All these data were based
on short follow-up but in a number of cases extrapolated to a lifetime time horizon. These clear limitations
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of the analysis indicate that its results should be interpreted with caution. Further research looking at the
individual’s nAMD active/inactive status is desirable. A conditional or a retrospective analysis of existing
data sets would be helpful in order to obtain data to inform future economic models.
The analysis was conducted from the NHS and Personal Social Services perspective, incorporating cost
of visual impairment that considered, for instance, cost for community care and residential care. The
model, however, did not take into account the cost for patients or their carers. For instance, as this is likely
to be an elderly population, someone might accompany the patient for their monitoring visits. These costs
have not been considered in the model.
Uncertainties of the economic analysis
Undoubtedly, the limitations of the data together with the assembly of key data of varied quality are
of most concern. No SD-OCT studies contributed to the diagnosis performance data and only two SD-OCT
studies23,30 contributed to the monitoring performance data in the economic model. Moreover, although
OCT diagnosis and monitoring sensitivity and specificity data were retrieved from a systematic review
of the literature, no such data were available for other tests proposed in alternative diagnosis or
monitoring pathways (e.g. examination by the ophthalmologist or the monitoring assessment by a nurse
or technician). Therefore, data for the model were obtained from expert opinion. These constitute major
limitations of the analysis and further research in these areas is needed.
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Chapter 8 Conclusions
Implications for service provision
In terms of OCT test performance, the evidence, which was limited in quantity, especially for monitoring
studies, and variable in quality, suggests that:
l For diagnosis of newly suspected nAMD, OCT has high sensitivity (88%) and moderate specificity
(78%) (meta-analysis)
l For monitoring of those previously diagnosed with nAMD, OCT has relatively high sensitivity (85%) but
low specificity (48%) (meta-analysis)
l SD-OCT had higher sensitivity than TD-OCT but lower specificity (monitoring studies).
The strategy that based its diagnostic decision on the results of FFA only, combined with a nurse- or
technician-led stepwise approach for monitoring, had the lowest expected total cost and a 47%
probability of being cost-effective at a £30,000 threshold value of willingness to pay for an extra QALY.
In addition, this strategy dominated all others apart from one (i.e. diagnosis with FFA combined with
stepwise ophthalmologist-led monitoring) in the great majority of sensitivity analyses. The economic
evaluation results suggest that strategies that used OCT test results alone to make diagnosis or monitoring
treatment decisions were unlikely to be a cost-effective use of resources. This seems to be driven by the
OCT low specificity inducing a high number of individuals with FP test results being treated.
There has already been a shift in the diagnostic and monitoring pathways for nAMD caused by the
adoption of OCT. At the diagnostic stage, OCT is currently used in addition to FFA (reference standard),
whereas for monitoring it has largely replaced FFA, which is only used in selected circumstances.
The evidence suggests that using OCT as the only test for monitoring patients with nAMD and detecting
activity would, potentially, result in a substantial proportion of patients receiving treatment unnecessarily
with intraocular injections of antiVEGF.
The continuing rise in the ageing population, with increasing numbers of people being diagnosed with
nAMD and moving on to monitoring for renewed disease activity, will continue to present challenges for
ophthalmology departments to have sufficient capacity to provide timely testing, and treatment.
Suggested research priorities
l Regarding monitoring of nAMD, in current practice OCT is routinely used and FFA is used only in
particular scenarios. There is a substantial disagreement between OCT and FFA. There is a need to
research if OCT (without FFA) is an acceptable way of detecting active nAMD and guiding treatment.
As there is the theoretical possibility of OCT being better in some cases than the current reference
standard, such studies might be designed to include a ‘fair umpire’ test, if available,
to examine differences between OCT and FFA, or should be designed to incorporate a period of
follow-up to assess the consequences of the tests in terms of clinical effectiveness outcomes (e.g. VA).
Currently used SD-OCT models should be evaluated, rather than TD-OCT.
l Regarding diagnosis of nAMD, current practice consists of FFA (as reference standard) associated
with OCT. Further research should be considered to establish the added value of OCT, and whether or
not OCT (associated with SLB and VA) can fully replace FFA. As above, such studies might be designed
to include a ‘fair umpire’ test, or the evaluation of the consequences of the diagnostic intervention.
Currently used SD-OCT models should be evaluated, rather than TD-OCT.
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l Regarding the different phenotypes of nAMD, further evidence on the natural history, efficacy of
treatment and diagnostic performance of OCT according to phenotype of nAMD is required.
l For both diagnosis and monitoring of nAMD, prospective studies are required to assess the diagnostic
accuracy and clinical effectiveness of strategies involving possible different combinations and sequences
of tests (e.g. VA, SLB, FAF imaging, OCT), including a comparison of their interpretation by
ophthalmologists compared with other health professionals.
l To strengthen the evidence base used to develop the economic model, it would be important to
explore the likelihood of active and inactive nAMD individuals becoming inactive or active respectively.
In addition, a preference-based study to assess utility weights (e.g. decrements) associated with
treatment and frequent monitoring is needed.
l Further research is needed to evaluate health status (utilities) in patients with nAMD, taking into
consideration the visual function and spectrum of disease in both eyes and exploring the value added
by inclusion of fellow eye information.
CONCLUSIONS
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Appendix 1 Search strategies
Clinical effectiveness and diagnostic accuracy of optical
coherence tomography for age-related macular degeneration
EMBASE, Ovid MEDLINE(R) and Ovid MEDLINE(R) In-Process &
Other Non-Indexed Citations
Searched: 1988 to 2013 Week 12 (EMBASE), 1946 to March Week 2 2013 [Ovid MEDLINE(R)]
and 25 March 2013 [Ovid MEDLINE(R)] (In-Process & Other Non-Indexed Citations).
Ovid multifile search. URL: https://shibboleth.ovid.com/.
Date of search: 25 March 2013.
Search strategy
1. ( *macular degeneration/ or wet macular degeneration/) use mesz
2. macular edema/ not (diabetic or diabetes).hw.
3. ( *retina macula age related degeneration/ or exudative macular degeneration/) use emed
4. retinal hemorrhage/ use mesz or choroid hemorrhage/ use mesz
5. retina haemorrhage/ use emed or choroid haemorrhage/ use emed
6. choroidal neovascularization/ use mesz
7. subretinal neovascularization/ use emed
8. retinal neovascularization/ use mesz not (diabetes or diabetic).hw.
9. retina neovascularization/ use emed not (diabetes or diabetic).hw.
10. ((exudative or wet or neovascular) and amd).tw.
11. ((exudative or wet or neovascular) adj3 age related).tw.
12. ((exudative or wet or neovascular) adj3 degenerat$).tw.
13. ((exudative or wet or neovascular) adj3 macula$).tw.
14. or/1-13
15. Tomography, Optical Coherence/ use mesz
16. optical coherence tomography/ use emed
17. oct.tw.
18. (stratus or cirrus or spectralis or rtvue or soct).tw.
19. or/15-18
20. autofluorescence.tw.
21. autofluorescence/ use emed
22. (fund$ adj3 (photograph$ or imag$)).tw.
23. photography/ use mesz
24. eye photography/ use emed
25. (microperimetry or micro perimetry).tw.
26. (visual acuity adj3 (test$ or assess$ or measure$ or value$ or exam$)).tw.
27. (dva or nva or bcva).tw
28. icga.tw.
29. indocyanine green angiograph$.tw
30. (dynamic adj3 angiograph$).tw
31. digital subtraction angiograph$.tw
32. preferential hyperacuity perimet$.tw
33. amsler$.tw.
34. clinical exam$.tw.
35. (ophthalmol$ adj1 (exam$ or assess$ or evaluat$)).tw.
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36. or/20-35
37. 14 and (19 or 36)
38. nonhuman/ not human/
39. animals/ not humans/
40. 37 not (38 or 39)
41. 40 not (letter or editorial or comment).pt.
42. 41 not case report/
43. ("2008" or “2007”).yr. and conference abstract.pt.
44. 42 not 43 (4803)
45. remove duplicates from 44
46. limit 45 to yr=“1995 –Current”
Science Citation Index and Bioscience Information Services
Searched: 1995–22 March 2013 (Science Citation Index) and 1995–22 March 2013
(Bioscience Information Services).
ISI Web of Knowledge. URL: http://wok.mimas.ac.uk/.
Date of search: 22 March 2013.
Search strategy
#1 ((TS=(AMD and (exudative or wet or neovascular*))))
#2 ((TS=((exudative or wet or neovascular) NEAR/3 “age related”)))
#3 (((TS=((exudative or wet or neovascular) NEAR/3 degenerat*))
#4 (((TS=((exudative or wet or neovascular) NEAR/3 macula*))))
#5 ((TS=(choroid* NEAR/1 neovascular*)))
#6 (TS= (macular NEAR/1 (edema or oedema))
#7 (((TS=(retina* NEAR/1 neovascular*))))
#8 #1 or #2 or #3 or #4 or #5 or #6 or #7
#9 (((TS=optical coherence tomography)))
#10 (((TS=(stratus or cirrus or spectralis or rtvue or soct))))
#11 ((TS=autofluorescence)))
#12 (((TS=(fundus NEAR/3 (photograph* or imag*)))))
#13 (((TS=(microperimetry or “micro perimetry”))))
#14 TS=(dva or nva or bcva)
#15 TS=icga
#16 TS= indocyanine green angiograph*
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#17 TS=(dynamic NEAR/3 angiograph*)
#18 TS= digital subtraction angiograph*
#19 TS= preferential hyperacuity perimet*
#20 TS=amsler*
#21 TS=clinical exam*
#22 TS=(ophthalmol* NEAR/1 (exam* or assess* or evaluat*))
#23 #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22
#24 #8 and #23
The Cochrane Library
Searched: Cochrane Database of Systematic Reviews Issue 2 2013; Cochrane Central Register of
Controlled Trials Issue 1 2013.
URL: www3.interscience.wiley.com/.
Date of search: 22 March 2013.
Search strategy
#1 MeSH descriptor Macular Degeneration, this term only
#2 MeSH descriptor Macular Edema, this term only
#3 MeSH descriptor Wet Macular Degeneration explode all trees
#4 MeSH descriptor Retinal Hemorrhage, this term only
#5 MeSH descriptor Choroid Hemorrhage, this term only
#6 MeSH descriptor Choroidal Neovascularization, this term only
#7 MeSH descriptor Retinal Neovascularization, this term only
#8 (exudative or wet or neovascular) and amd:ti,ab,kw or (exudative or wet or neovascular) NEAR/3 age
related:ti,ab,kw and (exudative or wet or neovascular) NEAR/3 degenerat*:ti,ab,kw and (exudative or wet
or neovascular) NEAR/3 macula*:ti,ab,kw
#9 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8)
#10 MeSH descriptor Tomography, Optical Coherence, this term only
#11 (stratus or cirrus or spectralis or rtvue or soct or oct):ti,ab,kw
#12 (#10 OR #11)
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#13 (autofluorescence):ti,ab,kw or (fund* NEAR/3 (photograph* or imag*)):ti,ab,kw or (microperimetry
or micro perimetry):ti,ab,kw or (visual acuity NEAR/3 (test* or assess* or measure* or value* or
exam*)):ti,ab,kw or (dva or nva or bcva):ti,ab,kw
#14 (clinical exam*):ti,ab,kw or (ophthalmol* NEAR/1 (exam* or assess* or evaluat*)).:ti,ab,kw
#15 (#13 OR #14)
#16 (#9 AND #12)
#17 (#9 AND #15)
#18 (#16 OR #17)
#19 (diabetes):ti,ab,kw or (diabetic):ti,ab,kw
#20 (#18 AND NOT #19)
#21 (#20), from 1995 to 2012
Health Technology Assessment database/Database of Abstracts of Reviews
of Effects
Searched: inception until March 2013.
Centre for Reviews and Dissemination. URL: www.york.ac.uk/inst/crd/index.htm.
Date of search: March 2013.
Search strategy
#1 MeSH macular degeneration EXPLODE 1
#2 Amd or macular degeneration
#3 MeSH Tomography, Optical Coherence EXPLODE 1
#4 # 1 or #2 or #3
Medion
Searched: inception until March 2013.
URL: www.mediondatabase.nl/.
Date of search: March 2013.
Search strategy
Textword=Macular degeneration
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ClinicalTrials.gov
Searched: inception until March 2013.
URL: http://clinicaltrials.gov/ct/gui/c/r.
Date of search: October 2014.
Search strategy
Condition=macular degeneration AND tomograph*
International Clinical Trials Registry Platform
Searched: inception until March 2013.
World Health Organization. URL: www.who.int/ictrp/en/.
Date of search: October 2012.
Search strategy
Condition=macular degeneration AND Intervention=tomography
Conference proceedings
Association for Research In Vision and Ophthalmology
Searched: 2009–12.
URL: www.iovs.org/search?arvomtgsearch=true.
Date of search: March 2013.
Search strategy
macular degeneration (as phrase) in title and wet exudative neovascular (any words) in title or abstract,
from January 2009 through January 2012.
American Association of Ophthalmology
Searched: 2009–12.
URL: http://aao.scientificposters.com/.
Date of search: October 2012.
Search strategy
Macular degeneration and tomography
European Association for Vision and Eye Research
Searched: 2009–12.
URL: www.ever.be/.
Date of search: October 2012.
EVER 2009, September 30–3 October 2009 Portoroz, Slovenia.
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EVER 2010, October 6–9, Crete, Greece.
EVER 2011, October 5–8, Crete, Greece.
EVER 2012, October 10–13, Nice, France.
Search strategy
Manufacturers’ websites
Date of search: March 2013
Carl Zeiss Meditec: www.meditec.zeiss.com/.
Optovue: www.optovue.com/.
Heidelberg Engineering: http://www.heidelbergengineering.co.uk/.
Topcon: www.topconmedical.com/categories/imaging.htm.
Patient acceptability of optical coherence tomography
EMBASE Ovid MEDLINE(R), Ovid MEDLINE(R) and In-Process &
Other Non-Indexed Citations
Searched: 1988 to 2013 Week 12 [EMBASED Ovid MEDLINE(R)], 1946 to March Week 2 2013
[Ovid MEDLINE(R)] and 25 March 2013 (In-Process & Other Non-Indexed Citations).
Ovid multifile search. URL: https://shibboleth.ovid.com/.
Date of search: 25 March 2013.
Search strategy
1. *macular degeneration/ or wet macular degeneration/ use mesz
2. macular edema/
3. *retina macula age related degeneration/ or exudative macular degeneration/ use emed
4. retinal hemorrhage/ use mesz or choroid hemorrhage/ use mesz
5. retina haemorrhage/ use emed or choroid haemorrhage/ use emed
6. choroidal neovascularization/ use mesz
7. subretinal neovascularization/ use emed
8. retinal neovascularization/ use mesz
9. retina neovascularization/ use emed
10. ((exudative or wet or neovascular) and amd).tw.
11. ((exudative or wet or neovascular) adj3 age related).tw.
12. ((exudative or wet or neovascular) adj3 degenerat$).tw.
13. ((exudative or wet or neovascular) adj3 macula$).tw.
14. or/1-13
15. Tomography, Optical Coherence/ use mesz
16. optical coherence tomography/ use emed
17. oct.tw.
18. (stratus or cirrus or spectralis or rtvue or soct).tw.
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
98
19. or/15-18
20. 14 and 19
21. exp patient acceptance of health care/ use mesz
22. exp patient attitude/ use emed
23. consumer satisfaction/ use mesz
24. patient dropouts/ use mesz
25. attitude of health personnel/ use mesz
26. health personnel attitude/ use emed
27. (patient? adj3 (compliance or participat$ or accept$ or refus$)).tw.
28. ((patient? or ophthalmolog$ or optometr$ or clinician?) adj3 (attitide? or prefer$ or perception?
or satisfaction)).tw.
29. qualitative research/
30. questionnaires/
31. (qualitative or interview$ or focus group? or questionnaire$ or survey$).tw.
32. (ethno$ or grounded or thematic or interpretive or narrative).tw.
33. or/21-32
34. 20 and 33
35. exp eye diseases/
36. *Tomography, Optical Coherence/ use mesz
37. *optical coherence tomography/ use emed
38. oct.ti.
39. (stratus or cirrus or spectralis or rtvue or soct).ti.
40. 35 and (36 or 37 or 38 or 39)
41. 33 and 40 (124)
42. 34 or 41 (212)
43. remove duplicates from 42
44. limit 43 to yr=“1995 -Current”
Applied Social Science Index and Abstracts (1995–23 March 2013)
Searched: 1995–23 March 2013.
ProQuest. URL: http://search.proquest.com/assia/.
Date of search: 23 March 2013.
Search strategy
KW=(OCT or optical coherence tomograph*)
PsycINFO
Searched: 1995–26 March 2013.
EBSCOhost. URL: http://web.ebscohost.com/ehost/.
Date of search: 26 March 2013.
Search strategy
Optical coherence tomograph* AND macular degeneration (ALL TEXT)
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Cost-effectiveness for coherence tomography for age-related
macular degeneration
EMBASE, Ovid MEDLINE(R) and Ovid MEDLINE(R) In-Process &
Other Non-Indexed Citations
Searched: 1980–2012 week 45 (EMBASE), 1996–November week 2 2012 [Ovid MEDLINE(R)] and
14 November 2012 (Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations)
Ovid Multifile Search URL: https://shibboleth.ovid.com/
Date searched: November 2012.
Search strategy
1. *macular degeneration/ or wet macular degeneration/ use mesz
2. macular edema/
3. *retina macula age related degeneration/ or exudative macular degeneration/ use emez
4. retinal hemorrhage/ use mesz or choroid hemorrhage/ use mesz
5. retina haemorrhage/ use emez or choroid haemorrhage/ use emez
6. choroidal neovascularization/ use mesz
7. subretinal neovascularization/ use emez
8. retinal neovascularization/ use mesz
9. [retina neovascularization/ use emez
10. ((exudative or wet or neovascular) and amd).tw.
11. ((exudative or wet or neovascular) adj3 age related).tw.
12. ((exudative or wet or neovascular) adj3 degenerat$).tw.
13. ((exudative or wet or neovascular) adj3 macula$).tw.
14. or/1-13
15. Tomography, Optical Coherence/ use mesz
16. optical coherence tomography/ use emed
17. (stratus or cirrus or spectralis or rtvue or soct).tw.
18. or/14-18
19. exp "costs and cost analysis"/ use mesz
20. exp economic evaluation/ use emez
21. economics/
22. health economics/ use emez
23. exp economics,hospital/ use mesz
24. exp economics,medical/ use mesz
25. economics,pharmaceutical/ use mesz
26. exp budgets/
27. exp models, economic/ use mesz
28. exp decision theory/
29. monte carlo method/
30. markov chains/
31. exp technology assessment, biomedical/
32. cost$.ti.
33. (cost$ adj2 (effective$ or utilit$ or benefit$ or minimis$)).ab.
34. economics model$.tw
35. (economic$ or pharmacoeconomic$).tw.
36. (price or prices or pricing).tw.
37. (value adj1 money).tw.
38. markov$.tw
39. monte carlo.tw.
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40. (decision$ adj2 (tree? or analy$ or model$)).tw.
41. or/15-36
42. 14 and 37
43. remove duplicates from 38
44. 39 not (letter or editorial or comment).pt.
Health Technology Assessment/NHS Economic Evaluation Databases
Searched: inception until October 2012.
Centre for Reviews & Dissemination. URL: http://nhscrd.york.ac.uk/welcome.htm
Date searched: October 2012.
Search strategy
#1 MeSH macular degeneration EXPLODE 1
#2 Amd or macular degeneration
#3 MeSH Tomography, Optical Coherence EXPLODE 1
#4 # 1 or #2 or #3
Health Management Information Consortium
Searched: 1979 September 2012.
Ovid URL: https://shibboleth.ovid.com/
Date of search: November 2012.
Search strategy
1. macular degeneration/
2. retinal diseases/
3. ((exudative or wet or neovascular) and amd).tw.
4. ((exudative or wet or neovascular) adj3 age related).tw.
5. ((exudative or wet or neovascular) adj3 degenerat$).tw.
6. ((exudative or wet or neovascular) adj3 macula$).tw.
7. or/1-6
Research Papers in Economics
Searched: inception until September 2012.
URL: http://repec.org/
Date of search: September 2012.
Search strategy
macula or macular
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Association for Research In Vision and Ophthalmology
Searched: January 2009 to January 2012.
URL: www.iovs.org/search?arvomtgsearch=true.
Date searched: January 2012.
Search strategy
macular degeneration (as phrase) in title and wet exudative neovascular (any words) in title or abstract.
Quality of life and neovascular age-related
macular degeneration
EMBASE, Ovid MEDLINE(R) and Ovid MEDLINE(R) In-Process & Other
Non-Indexed Citations
Searched: 1980–2012 week 45 (Embase), 1946–November week 2 2012 [Ovid MEDLINE(R)],
14 November 2012 [Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations].
Ovid Multifile Search URL: https://shibboleth.ovid.com/
Date searched: November 2012.
Search strategy
1. *macular degeneration/ or wet macular degeneration/
2. macular edema/ not (diabetic or diabetes).hw
3. *retina macula age related degeneration/ or exudative macular degeneration/
4. retinal hemorrhage/ use mesz or choroid hemorrhage/
5. retina haemorrhage/ use emez or choroid haemorrhage/
6. choroidal neovascularization/
7. subretinal neovascularization/
8. retinal neovascularization/ use mesz not (diabetes or diabetic).hw.
9. retina neovascularization/ use emed not (diabetes or diabetic).hw.
10. ((exudative or wet or neovascular) and amd).tw.
11. ((exudative or wet or neovascular) adj3 age related).tw.
12. ((exudative or wet or neovascular) adj3 degenerat$).tw.
13. ((exudative or wet or neovascular) adj3 macula$).tw.
14. or/1-13
15. quality of life/
16. quality adjusted life year/
17. "Value of Life"/ use mesz
18. health status indicators/ use mesz
19. health status/ use emez
20. sickness impact profile/ use mesz
21. disability evaluation/ use mesz
22. disability/ use emez
23. activities of daily living/ use mesz
24. exp daily life activity/ use emez
25. cost utility analysis/ use emez
26. rating scale/
27. questionnaires
28. (quality adj1 life).tw.
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29. quality adjusted life.tw.
30. disability adjusted life.tw.
31. (qaly? or qald? or qale? or qtime? or daly?).tw
32. (euroqol or euro qol or eq5d or eq 5d).tw.
33. (hql or hqol or h qol or hrqol or hr qol).tw.
34. (hye or hyes).tw.
35. health$ year$ equivalent$.tw.
36. (hui or hui1 or hui2 or hui3).tw
37. (health adj3 (utilit$ or disutili$)).tw.
38. (health adj3 (state or status)).tw.
39. (sf36 or sf 36 or short form 36 or shortform 36).tw.
40. (sf6 or sf 6 or short form 6 or shortform 6).tw.
41. (sf12 or sf 12 or short form 12 or shortform 12).tw.
42. (sf16 or sf 16 or short form 16 or shortform 16).tw.
43. (sf20 or sf 20 or short form 20 or shortform 20).tw.
44. willingness to pay.tw.
45. standard gamble.tw
46. trade off.tw.
47. conjoint analys?s.tw.
48. discrete choice.tw.
49. (case report or editorial or letter).pt.
50. case report/
51. (VQOL or NEI-VFQ-25 or MACDQOL or ADVS or VF-14 or SIPV).tw.
52. or/15-48,51
53. 14 and 52
54. 53 not (49 or 50)
55. remove duplicates from 54
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Appendix 2 List of included studies
Diagnostic studies
Alster 2005
Alster Y, Bressler NM, Bressler SB, Brimacombe JA, Crompton RM, Duh YJ, et al. Preferential
hyperacuity perimeter (PreView PHP) for detecting choroidal neovascularization study. Ophthalmology
2005;112:1758–65.
Cachulo 2011
Cachulo L, Silva R, Fonseca P, Pires I, Carvajal-Gonzalez S, Bernardes R, et al. Early markers of choroidal
neovascularization in the fellow eye of patients with unilateral exudative age-related macular degeneration.
Ophthalmologica 2011;225:144–9.
Silva R, Cachulo ML, Fonseca P, Bernardes R, Nunes S, Vilhena N, et al. Age-related macular degeneration
and risk factors for the development of choroidal neovascularisation in the fellow eye: a 3-year follow-up
study. Ophthalmologica 2011;226:110–18. (Secondary to Cachulo 2011.)
Chen 2003
Chen S, Han M, Wang L. Indocyanine green angiography of exudative age-related macular degeneration.
Chin Ophthalmol Res 2003;21:428–30.
Do 2012
Do DV, Gower EW, Cassard SD, Boyer D, Bressler NM, Bressler SB, et al. Detection of new-onset choroidal
neovascularization using optical coherence tomography: the AMD DOC Study. Ophthalmology
2012;119:771–8.
Fujii 1996
Fujii C, Inobe K, Sugimoto Y, Sugimoto A, Takahashi Y, Akagi Y. Indocyanine green angiographic findings
in eyes with age-related macular degeneration. Folia Ophthalmol Jpn 1996;47:300–5.
Gomi 2007
Gomi F, Sawa M, Mitarai K, Tsujikawa M, Tano Y. Angiographic lesion of polypoidal choroidal
vasculopathy on indocyanine green and fluorescein angiography. Graefes Arch Clin Exp Ophthalmol
2007;245:1421–7.
Hughes 2005
Hughes EH, Khan J, Patel N, Kashani S, Chong NV. In vivo demonstration of the anatomic differences
between classic and occult choroidal neovascularization using optical coherence tomography.
Am J Ophthalmol 2005;139:344–6.
Khondkaryan 2009
Khondkaryan A, Keane PA, Liakopoulos S, Walsh AC, Sadda SR. Comparison of optical coherence
tomography and fluorescein angiography for the classification of neovascular age-related macular
degeneration. Invest Ophthalmol Vis Sci 2009;50:E-abstract 5259.
Kim 2003
Kim SG, Lee SC, Seong YS, Kim SW, Kwon OW. Choroidal neovascularization characteristics and its size in
optical coherence tomography. Yonsei Med J 2003;44:821–7.
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Kozak 2008
Kozak I, Morrison VL, Clark TM, Bartsch DU, Lee BR, Falkenstein I, et al. Discrepancy between fluorescein
angiography and optical coherence tomography in detection of macular disease. Retina 2008;28:538–44.
Krebs 2007
Krebs I, Binder S, Stolba U, Krepler K, Zeiler F, Glittenberg C. The value of optical coherence tomography in
diagnosis and therapy of age-related macular degeneration. Spektrum der Augenheilkunde 2007;21:33–8.
Liakopoulos 2008
Liakopoulos S, Ongchin S, Bansal A, Msutta S, Walsh AC, Updike PG, et al. Quantitative optical
coherence tomography findings in various subtypes of neovascular age-related macular degeneration.
Invest Ophthalmol Vis Sci 2008;49:5048–54.
Loewenstein 2010
Loewenstein A, Ferencz JR, Lang Y, Yeshurun I, Pollack A, Siegal R, et al. Toward earlier detection of
choroidal neovascularization secondary to age-related macular degeneration: multicenter evaluation of a
preferential hyperacuity perimeter designed as a home device. Retina 2010;30:1058–64.
Padnick-Silver 2012
Padnick-Silver L, Weinberg AB, Lafranco FP, MacSai MS. Pilot study for the detection of early exudative
age-related macular degeneration with optical coherence tomography. Retina 2012;32:1045–56.
Park 2010
Park SS, Truong SN, Zawadzki RJ, Alam S, Choi SS, Telander DG, et al. High-resolution Fourier-domain
optical coherence tomography of choroidal neovascular membranes associated with age-related macular
degeneration. Invest Ophthalmol Vis Sci 2010;51:4200–6.
Parravano 2012
Parravano M, Varano M, Virgili G. Integrated imaging approach in RAP diagnosis. Acta Ophthalmol
2012;90:abstract 4426.
Reichel 1995
Reichel E, Duker JS, Puliafito CA. Indocyanine green angiography and choroidal neovascularization
obscured by hemorrhage. Ophthalmology 1995;102:1871–6.
Salinas-Alaman 2005
Salinas-Alaman A, Garcia-Layana A, Maldonado MJ, Sainz-Gomez C, Alvarez-Vidal A. Using optical
coherence tomography to monitor photodynamic therapy in age related macular degeneration.
Am J Ophthalmol 2005;140:23–8.
Sandhu 2005
Sandhu SS, Talks SJ. Correlation of optical coherence tomography, with or without additional colour
fundus photography, with stereo fundus fluorescein angiography in diagnosing choroidal neovascular
membranes. Br J Ophthalmol 2005;89:967–70.
Sulzbacher 2011
Sulzbacher F, Kiss C, Munk M, Deak G, Sacu S, Schmidt-Erfurth U. Diagnostic evaluation of type 2 (classic)
choroidal neovascularization: optical coherence tomography, indocyanine green angiography,
and fluorescein angiography. Am J Ophthalmol 2011;152:799–806e1.
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Talks 2007
Talks J, Koshy Z, Chatzinikolas K. Use of optical coherence tomography, fluorescein angiography and
indocyanine green angiography in a screening clinic for wet age-related macular degeneration.
Br J Ophthalmol 2007;91:600–1.
Torron 2002
Torron FB, Perez O, Melcon SF, Ferrer N, Ruiz-Moreno O, Honrubia L. Dynamic angiography in age related
macular degeneration. Arch Soc Esp Oftalmol 2002;77:353–9.
Torron FB, Melcon SF, Ferrer N, Ruiz M, Honrubia L. Indocyanine green angiography and subretinal
neovascularization. Patterns in age related macular degeneration. Archiv Soc Esp Oftalmol 2001;76:221–8.
(Secondary to Torron 2002.)
Monitoring studies
Eter 2005
Eter N, Spaide RF. Comparison of fluorescein angiography and optical coherence tomography for patients
with choroidal neovascularization after photodynamic therapy. Retina 2005;25:691–6.
Giani 2011
Giani A, Luiselli C, Esmaili DD, Salvetti P, Cigada M, Miller JW, et al. Spectral-domain optical coherence
tomography as an indicator of fluorescein angiography leakage from choroidal neovascularization.
Invest Ophthalmol Vis Sci 2011;52:5579–86.
Henschel 2009
Henschel A, Spital G, Lommatzsch A, Pauleikhoff D. Optical coherence tomography in neovascular
age related macular degeneration compared to fluorescein angiography and visual acuity.
Eur J Ophthalmol 2009;19:831–5.
Khurana 2010
Khurana RN, Dupas B, Bressler NM. Agreement of time-domain and spectral-domain optical coherence
tomography with fluorescein leakage from choroidal neovascularization. Ophthalmology 2010;117:1376–80.
Regillo 1998
Regillo CD, Blade KA, Custis PH, O’Connell SR. Evaluating persistent and recurrent choroidal
neovascularization. The role of indocyanine green angiography. Ophthalmology 1998;105:1821–6.
Salinas-Alaman 2005
Salinas-Alaman A, Garcia-Layana A, Maldonado MJ, Sainz-Gomez C, Alvarez-Vidal A. Using optical
coherence tomography to monitor photodynamic therapy in age related macular degeneration.
Am J Ophthalmol 2005;140:23–8.
van de Moere 2006
van de Moere A, Sandhu SS, Talks SJ. Correlation of optical coherence tomography and fundus
fluorescein angiography following photodynamic therapy for choroidal neovascular membranes.
Br J Ophthalmol 2006;90:304–6.
van Velthoven 2006
van Velthoven ME, de Smet MD, Schlingemann RO, Magnani M, Verbraak FD. Added value of OCT in
evaluating the presence of leakage in patients with age-related macular degeneration treated with PDT.
Graefes Arch Clin Exp Ophthalmol 2006;244:1119–23.
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Appendix 3 List of excluded studies
Study design (n= 30)
Arias L, Garcia-Arumi J, Ramon JM, Badia M, Rubio M, Pujol O. Optical coherence tomography analysis of
a randomized study combining photodynamic therapy with intravitreal triamcinolone. Graefes Arch Clin
Exp Ophthalmol 2008;246:245–54.
Baranano AE, Keane PA, Ruiz-Garcia H, Walsh AC, Sadda SR. Impact of scanning density on spectral
domain optical coherence tomography assessments in neovascular age-related macular degeneration.
Acta Opthalmol 2012;90:e274–80.
Bojke L, Claxton K, Sculpher MJ, Palmer S. Identifying research priorities: the value of information associated
with repeat screening for age-related macular degeneration. Med Decis Making 2008;28:33–43.
Cruess AF, Zlateva G, Pleil AM, Wirostko B. Photodynamic therapy with verteporfin in age-related macular
degeneration: a systematic review of efficacy, safety, treatment modifications and pharmacoeconomic
properties. Acta Ophthalmol 2009;87:118–32.
Dunavoelgyi R, Sacu S, Simader C, Pruente C, Schmidt-Erfurth U. Changes in macular sensitivity
after reduced fluence photodynamic therapy combined with intravitreal triamcinolone. Acta Opthalmol
2011;89:166–71.
Elsner H, Barbazetto I, Schmidt-Erfurth U. Natural course of events in subfoveal choroidal
neovascularisation by age-linked macular degeneration. Ophthalmologe 2001;98:665–70.
Freund KB, Ho IV, Barbazetto IA, Koizumi H, Laud K, Ferrara D, et al. Type 3 neovascularization –
the expanded spectrum of retinal angiomatous proliferation. Retina 2008;28:201–11.
Gupta B, Adewoyin T, Patel SK, Sivaprasad S. Comparison of two intravitreal ranibizumab treatment
schedules for neovascular age-related macular degeneration. Br J Ophthalmol 2011;95:386–90.
Heimes B, Lommatzsch A, Zeimer M, Gutfleisch M, Spital G, Dietzel M, et al. Long-term visual course after
anti-VEGF therapy for exudative AMD in clinical practice evaluation of the German reinjection scheme.
Graefes Arch Clin Exp Ophthalmol 2011;249:639–44.
Hernandez-Pastor LJ, Ortega A, Garcia-Layana A, Giraldez J. Cost-effectiveness of ranibizumab compared
with pegaptanib in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol
2010;248:467–76.
Holz FG, Jorzik J, Schutt F, Flach U, Unnebrink K. Agreement among ophthalmologists in evaluating
fluorescein angiograms in patients with neovascular age-related macular degeneration for photodynamic
therapy eligibility (FLAP-Study). Ophthalmology 2003;110:400–5.
Horster R, Ristau T, Sadda SR, Liakopoulos S. Individual recurrence intervals after anti-VEGF therapy for
age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2011;249:645–52.
Javier Hernandez-Pastor Lle, Ortega A, Garcia-Layana A, Giraldez J. Cost-effectiveness of ranibizumab
compared with photodynamic treatment of neovascular age-related macular degeneration. Clin Ther
2008;30:2436–51.
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Kaiser RS, Berger JW, Williams GA, Tolentino MJ, Maguire AM, Alexander J, et al. Variability in fluorescein
angiography interpretation for photodynamic therapy in age-related macular degeneration. Retina
2002;22:683–90.
Katz G, Giavedoni L, Muni R, Evans T, Pezda M, Wong D, et al. Effectiveness at 1 year of monthly versus
variable-dosing intravitreal ranibizumab in the treatment of choroidal neovascularization secondary to
age-related macular degeneration. Retina 2012;32:293–8.
Kubicka-Trzaska A. The differential diagnosis of exudative age-related macular degeneration with posterior
pole choroidal tumours. Klinika Oczna 2005;107:147–55.
Loewenstein A. Use of home device for early detection of neovascular age-related macular degeneration.
Ophthalmic Res 2012;48(Suppl. 1):11–15.
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Treatment of Occult and Classic CNV in Exsudative AMD.] Klin Monatsbl Augenheilkd 2011;228:161–7.
Mekjavic PJ, Kraut A, Urbancic M, Lenassi E, Hawlina M. Efficacy of 12-month treatment of neovascular
age-related macular degeneration with intravitreal bevacizumab based on individually determined injection
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Mookhtiar M, Downey L. Combined OCT and colour fundus photography in virtual clinic assessments of
wet AMD patients. Eye 2012;26:619.
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for the treatment of neovascular age-related macular degeneration in Germany: model analysis from the
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Acta Opthalmol 2011;89:e344–9.
Patel PJ, Browning AC, Chen FK, Da C, Tufail A. Interobserver agreement for the detection of optical
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disease. Ophthalmology 2011;118:1619–25.
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vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology
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Scholl HP, Peto T, Dandekar S, Bunce C, Xing W, Jenkins S, et al. Inter- and intra-observer variability
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fractionated external beam radiation for neovascular age-related macular degeneration. Retina
2011;31:1303–15.
van Zeeburg EJ, Cereda MG, van der Schoot J, Pertile G, van Meurs JC. Early perfusion of a free
RPE-choroid graft in patients with exudative macular degeneration can be imaged with spectral
domain-OCT. Invest Ophthalmol Vi Sci 2011;52:5881–6.
Not age-related macular degeneration (n= 6)
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Spraul CW, Lang GE, Lang GK. Optical coherence tomography of age-related macular degeneration.
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Appendix 4 Characteristics of the included studies
TABLE 42 Diagnostic studies
Study Participants Tests Outcomes reported
Alster 200524
Full text: Yes
Study type:
Comparative,
concurrent,
non-randomised
Prospective: Yes
Multicentre: Yes
(seven centres)
Country: USA
Study start/end dates:
15 October 2003/
23 August 2004
Duration of study:
10 months, 1 week
Enrolled: 185
Analysed: 122 patients
(65 CNV; 57 intermediate
AMD)
Consecutive: Yes
Age (years) median: 77
Gender M : F: 26 : 39
Baseline BCVA: 20/63
(Snellen equivalent)
Inclusion criteria: Age
≥ 50 years, BCVA 220/160 or
better, newly diagnosed
(≤ 60 days) non-treated
neovascular lesion from AMD,
mental and physical ability
to perform PHP test, ability
to tolerate intravenous
fluorescein angiography,
subject able and willing to
sign consent form and
participate in study
Exclusion criteria: Evidence of
macular disease other than
AMD, previous surgical or
laser treatment within the
macular area, presence of
any significant media opacity
that precludes a clear view
of the macular area as
identified by biomicroscopy,
fundus photography, or
fluorescein angiography, any
non-macular-related ocular
surgery performed within
3 months before the study
Index test(s): N/R
Definition of positive test
result: n/a
Interpreted by: N/R
Comparator test(s): PHP
Definition of positive test
result: N/R
Interpreted by: N/R
Reference standard:
Stereoscopic FFA
Interpreted by: Experienced
photograph reading centre
Unit of analysis (n): Patient
(one eye per patient)
If both eyes per subject
eligible, how was study eye
selected: The enrolling
ophthalmologist and the
participant made a joint
decision regarding which eye
would be the study eye
Diagnostic accuracy: Yes
Sensitivity:
PHP 82% (95% CI 70%
to 90%)
Colour fundus photography
70%
Colour fundus photography
+VA 53% (95% CI 30%
to 76%)
Specificity:
PHP 88% (95% CI 76%
to 95%)
Colour fundus photography
95%
Colour fundus photography
+VA 94% (95% CI 83%
to 99%)
Clinical effectiveness: N/R
Interpretability of the test:
11 patients (5.9%) were
excluded from analysis as PHP
results were judged to be
unreliable
Acceptability of the test: N/R
Proportion of participants not
able to receive the test due to
an eye condition/personal
circumstances: N/R
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TABLE 42 Diagnostic studies (continued )
Study Participants Tests Outcomes reported
Cachulo 201125
(Silva 2011 – 3 years
secondary report to
Cachulo 2011)47
Full text: Yes
Study type:
Observational,
longitudinal 2 years
plus 1-year extension
study
Prospective: Yes
Multicentre: No
Country: Portugal
Study start/end dates:
N/R
Duration of study:
3 years
Enrolled: 62 patients
Analysed: 52 patients
Consecutive: Unclear
Age (years) mean (range/SD):
76 (56–92/6)
Gender M : F: 26 : 26
Baseline BCVA: N/R
Inclusion criteria: Patients
aged ≥ 50 years, any race and
either sex, early age-related
maculopathy in the study eye
(at least ≥ 5 intermediate
drusen, ≥ 1 large soft drusen
or confluent drusen within
3000 µm of the foveal centre;
with or without pigmentary
changes), nAMD in the fellow
eye, signed inform consent,
able to returned to the
required visits
Exclusion criteria: Other
fundus disease (e.g. vascular
retinopathy, central serous
chorioretinopathy,
inflammation or non-AMD
CNV), current or past history
of intraocular surgery within
60 days prior to enrolling in
the study, evidence of past or
present CNV in the study eye
Index test: TD-OCT (Stratus
OCT™, Carl Zeiss Meditec,
Dublin, CA)
Definition of positive test
result: N/R
Interpreted by: N/R
Comparator test(s):
ICGA, FAF
Definition of positive test
result: N/R
Interpreted by: N/R
Reference standard:
Non-stereoscopic FFA
Interpreted by: N/R
(assumed interpreted
by ophthalmologist)
Unit of analysis (n):
Eye (one eye per patient)
If both eyes per subject
eligible, how was study eye
selected: n/a
Diagnostic accuracy: Yes
Sensitivity – Cachulo 2011:25
TD-OCT 100%
ICGA 94.1%
FAF 93.3%
Sensitivity – Silva 2011:47 100%
Specificity – Cachulo 2011:25
TD-OCTN/R
ICGAN/R
FAF 37%
Specificity – Silva 201147 N/R
Clinical effectiveness:N/R
Interpretability of the test:N/R
Acceptability of the test:N/R
Proportion of participants not
able to receive the test due to
an eye condition/personal
circumstances:N/R
Chen 200326
Full text: Yes
Study type: Direct
head-to-head
comparison
Prospective/
retrospective: N/R
Multicentre: Unclear
Country: China
Study start/end dates:
November 1999/
December 2000
Duration of study:
1 year
Enrolled: 52 patients
Analysed: 52 patients
Consecutive: Unclear
Age (years) mean (range/SD):
64.12 (51–80/8.59)
Gender M : F: N/R
Baseline BCVA: ≈0.7
(index/30 cm)
Inclusion criteria: Patients with
diagnosis of exudative AMD
following the diagnostic criteria
in Chinese ophthalmology
diagnosing guidance
Exclusion criteria: N/R
Index test: N/R
Definition of positive test
result: N/R
Interpreted by: N/R
Comparator test: ICGA
Definition of positive test
result: N/R
Interpreted by: N/R
Reference standard: FFA
(unclear if stereoscopic or not)a
Interpreted by: N/R
Unit of analysis (n):
Eye (one eye per patient,
except in 13 patients with
both eyes assessed)
Was adjustment made for
non-independence of fellow
eyes for cases where both
eyes per subject included: N/R
Diagnostic accuracy: Yes
Sensitivity: 62.90%
Specificity: N/R
Clinical effectiveness: N/R
Interpretability of the test: N/R
Acceptability of the test: N/R
Proportion of participants not
able to receive the test due to
an eye condition/personal
circumstances: N/R
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TABLE 42 Diagnostic studies (continued )
Study Participants Tests Outcomes reported
Do 201227
Full text: Yes
Study type: Direct
head-to-head
observational
Prospective: Yes
Multicentre: Yes
(four centres)
Country: USA
Study start/end dates:
N/R
Duration of study:
2 years
Enrolled: 98 patients
Analysed: 87 patients
Consecutive: No
Age (years) median (range):
79 (58–91)
Gender M : F: 31 : 56
Baseline BCVA: Median 20/25
(Snellen equivalent), range
(66–95)
Inclusion criteria: Minimum
age 50 years, nAMD in the
non-study eye, BCVA (ETDRS)
of ≥ 65 (Snellen of
approximately 20/50), no
evidence of CNV or foveal
geographic atrophy in the
fellow eye (candidate study
eye), ≥ 1 large druse
(> 125 μm) and focal RPE
hyperpigmentation within
3600 µm of the macula
centre, visible on colour or
red-free fundus photographs
or FFA
Exclusion criteria: Allergy to
fluorescein dye, advanced
AMD with CNV in both eyes
confirmed on FFA, geographic
atrophy extending through
the centre of the macula in
the candidate study eye,
positive OCT for the
candidate eye, evidence of
macular disease other than
AMD in the candidate study
eye, prior surgical or laser
treatment to the macula in
the study eye
Index test: TD-OCT
(Stratus OCT™)
Definition of positive test
result: 10% increase in the
central subfield thickness
measurement relative to
baseline, subretinal fluid
questioned or graded as
definitely present,
intraretinal cystoid
abnormalities questioned or
graded as definitely present
Interpreted by: trained
masked graders at the
reading centre
Comparator test(s): Amsler
grid (supervised) PHP
Definition of positive test
result: Any defect perceived
by the subject
Interpreted by: N/R
Reference standard:
Stereoscopic FFA
Interpreted by: two trained
masked graders at the
reading centre
Unit of analysis (n):
Eye (one eye per patient)
If both eyes per subject
eligible, how was study eye
selected: n/a
Diagnostic accuracy: Yes
Sensitivity: CNV defined by
the reading centre only
Irrespective of treatment
decision
TD-OCT 40% (95% CI
16% to 68%)
Amsler grid 41.7% (95% CI
15% to 72%)
PHP 50%
Specificity:
TD-OCT 70.8%
Amsler grid N/R
PHP N/R
Clinical effectiveness: N/R
Interpretability of the test:
6/68 (8.8%) screened but not
enrolled as ineligible and
excluded cases due to poor
image quality that was
insufficient to permit
successful study participation
Acceptability of the test: n/a
Proportion of participants not
able to receive the test due to
an eye condition/personal
circumstances: N/R
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TABLE 42 Diagnostic studies (continued )
Study Participants Tests Outcomes reported
Fujii 199629
Full text: Yes
Study type: Direct
head-to-head
[all participants receive
index and comparator
test(s) and reference
standard]
Prospective/
retrospective: Unclear
Multicentre: No
Country: Japan
Study start/end dates:N/R
Duration of study:N/R
Enrolled: 24 patients (32 eyes)
Analysed: 24 patients
(32 eyes)
Consecutive: Unclear
Age (years) mean (range):
68.6 (61–86)
Gender M : F: 17 : 7
Baseline BCVA: N/R
Inclusion criteria: Patients with
diagnosis of AMD with CNV
not detected by FFA, or
unlikely to be the subject of
photocoagulation (e.g. CNV
located in the fovea)
Exclusion criteria: N/R
Index test: N/R
Definition of positive test
result: N/R
Interpreted by: N/R
Comparator test: ICGA
Definition of positive test
result: Four stages: stage I
neovascularisation of RPE
without injury of palisade
tissue; stage II bleeding
(leakage) – subretinal
haemorrhage injury of RPE,
exudates subretinal space;
stage III subretinal fibrosis
and membranes proliferation
plus stage II; and stage IV
scar tissue
Interpreted by: N/R
Reference standard:
Non-stereoscopic FFA
interpreted by
ophthalmologist
Interpreted by: N/R
Unit of analysis (n): Eye
Was adjustment made for
non-independence of fellow
eyes for cases where both
eyes per subject included: N/R
Diagnostic accuracy: Yes
Sensitivity: 84.61%
Specificity: 36.84%
Clinical effectiveness: N/R
Interpretability of the test: N/R
Acceptability of the test: N/R
Proportion of participants not
able to receive the test due to
an eye condition/personal
circumstances: N/R
Gomi 200731
Full text: Yes
Study type: Direct
head-to-head
comparison
Prospective/
retrospective: Unclear
Multicentre: No
Country: Japan
Study start/end dates:
July 2005/January 2006
Duration of study:
6 months
Enrolled: 37 patients
Analysed: 37 patients
Consecutive: Unclear
Age (years) mean (range):
71.6 (54–83)
Gender M : F: 27 : 10
Baseline BCVA: N/R
Inclusion criteria: Patients
diagnosed with PCV in the
macular region; informed
consent provided
Exclusion criteria: Eyes with
subretinal or subpigment
epithelial haemorrhages that
obscured lesions; eyes with a
history of any previous
treatment and any other
macular pathologies such as
CNV or central serous
chorioretinopathy
Index test: N/R
Definition of positive test
result: N/R
Interpreted by: N/R
Comparator test: ICGA
Definition of positive test
result: N/R
Interpreted by: N/R
Reference standard:
Non-stereoscopic FFA
Interpreted by: Images were
traced by two readers.
When no agreement was
reached by the readers on
the location of the lesion
borders, another
author arbitrated
Unit of analysis (n):
Eye (one eye per patient)
If both eyes per subject
eligible, how was study eye
selected: N/R
Diagnostic accuracy: Yes
Sensitivity: 100%
Specificity: N/R
Clinical effectiveness: N/R
Interpretability of the test: N/R
Acceptability of the test: N/R
Proportion of participants not
able to receive the test due to
an eye condition/personal
circumstances: N/R
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TABLE 42 Diagnostic studies (continued )
Study Participants Tests Outcomes reported
Hughes 200533
Full text: Yes
Study type: Direct
head-to-head
comparison
Prospective: Yes
Multicentre: No
Country: UK
Study start/end dates:
N/R
Duration of study: N/R
Enrolled: 22 patients
Analysed: 22 patients
Consecutive: Yes
Age (years) mean/median
(range/SD): N/R
Gender M : F: N/R
Baseline BCVA: N/R
Inclusion criteria: Patients with
acute CNV
Exclusion criteria: N/R
Index test(s): TD-OCT
(OCT 3000™, Carl Zeiss
Ophthalmic Systems Inc.,
Dublin, CA)
Definition of positive test
result: Presence of a discreet
subretinal lesion indicating a
CNV membrane
Interpreted by: N/R
Comparator test(s): N/R
Definition of positive test
result: N/R
Interpreted by: N/R
Reference standard: FFA
(unclear if stereoscopic
or not)a
Interpreted by: N/R
Unit of analysis (n):
Eye (one eye per patient)
If both eyes per subject
eligible, how was study eye
selected: N/R
Diagnostic accuracy: Yes
Sensitivity: 36.36%
Specificity: n/a
Clinical effectiveness: N/R
Interpretability of the test: N/R
Acceptability of the test: N/R
Proportion of participants not
able to receive the test due to
an eye condition/personal
circumstances: N/R
Khondkaryan 200934
Abstract: Yes
Study type: Direct
head-to-head [all
participants receive
index and comparator
test(s) and reference
standard]
Retrospective: Yes
Multicentre: N/R
Country: USA
Study start/end dates:
N/R
Duration of study: N/R
Enrolled: 51 patients (51 eyes)
Analysed: 51 patients
(51 eyes)
Consecutive: Yes
Age (years) mean/median
(range/SD): N/R
Gender M : F: N/R
Baseline BCVA: N/R
Inclusion criteria: Newly
diagnosed patients with
nAMD who underwent
stratus OCT imaging and FFA
at the time of diagnosis
Exclusion criteria: N/R
Index test: TD-OCT
(Stratus OCT™)
Definition of positive test
result: N/R
Interpreted by: N/R
Comparator test(s): N/R
Definition of positive test
result: N/R
Interpreted by: N/R
Reference standard: FFA
(not specified whether
stereoscopic or not)a
Interpreted by: N/R
Unit of analysis (n):
Eye (one eye per patient)
If both eyes per subject
eligible, how was study eye
selected: N/R
Diagnostic accuracy: Yes
Sensitivity:
Classic CNV 80.90%
RAP 57.10%
Occult CNV 81.10%
Specificity:
Classic CNV 56.70%
RAP 81.80%
Occult CNV 42.90%
Clinical effectiveness: N/R
Interpretability of the test: N/R
Acceptability of the test: N/R
Proportion of participants not
able to receive the test due to
an eye condition/personal
circumstances: N/R
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TABLE 42 Diagnostic studies (continued )
Study Participants Tests Outcomes reported
Kim 200335
Full text: Yes
Study type: Direct
head-to-head
comparison
Retrospective: Yes
Multicentre: No
Country: the Republic
of Korea
Study start/end dates:
N/R
Duration of study: N/R
Enrolled: 32 patients (32 eyes)
Analysed: 13 eyes
Consecutive: Unclear
Age (years) mean (SD):
51.38 (20.68)
Gender M : F: 16 : 16
Baseline BCVA: N/R
Inclusion criteria: Patients with
diagnosis of CNV
Exclusion criteria: N/R
Index test: TD-OCT
(manufacturer N/R)
Definition of positive test
result: Lesion classed as well
defined, poorly defined,
fibrovascular PED,
haemorrhagic PED and
serous PED (not considered
as this is a diagnostic study)
Interpreted by: N/R
Comparator test: ICGA
Definition of positive test
result: Hyperfluorescent
lesion by ICGA was confined
as the leaking on late phase,
and measured relative to the
diameter of the optic disc
Interpreted by: N/R
Reference standard: FFA
(not specified whether or
not stereoscopic)
Interpreted by: N/R
Unit of analysis (n): Eye
If both eyes per subject
eligible, how was study eye
selected: N/R
Diagnostic accuracy: Yes
Sensitivity: 92.30%
Specificity: N/R
Clinical effectiveness: No
Interpretability of the test: N/R
Acceptability of the test: N/R
Proportion of participants not
able to receive the test due to
an eye condition/personal
circumstances: N/R
Kozak 200836
Full text: Yes
Study type: Direct
head-to-head
comparison
Retrospective: Yes
Multicentre: No
Country: USA
Study start/end dates:
1 October 2005/
1 October 2006
Duration of study:
12 months
Enrolled: Unclear (541 eyes)
Analysed: 541 eyes
Consecutive: Yes
Age (years) mean/median
(range/SD): 54± 12.1 years
Gender M : F: N/R
Baseline BCVA: N/R
Inclusion criteria: Patients with
diagnosis of macular oedema
(confirmed or suspected)
Exclusion criteria: N/R
Index test(s): TD-OCT
(Stratus OCT™) although a
subset of patients received
SD-OCT (SLO, OTI
Ophthalmic Technologies,
Inc., Toronto, ON, Canada)
Definition of positive test
result: Macular oedema
defined as loss of central
contour, intraretinal cysts,
subretinal fluid, retinal
thickening > 250 μm (foveal
and perifoveal)
Interpreted by:
Ophthalmologists
Comparator test(s): Colour
fundus photograph (TRC-50
VT, Topcon, Tokyo, Japan)
Definition of positive test
result: N/R
Interpreted by: N/R
Reference standard:
Stereoscopic FFA
Interpreted by:
Ophthalmologists
(retina specialists)
Unit of analysis (n): Eye
Was adjustment made for
non-independence of fellow
eyes for cases where both
eyes per subject included: N/R
Diagnostic accuracy: Yes
Sensitivity: 97.3%
Specificity: n/a
Clinical effectiveness: N/R
Interpretability of the test:
35 eyes (6.5%) were excluded
from the analysis due to poor
quality or image decentration
Acceptability of the test: N/R
Proportion of participants not
able to receive the test due to
an eye condition/personal
circumstances: N/R
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TABLE 42 Diagnostic studies (continued )
Study Participants Tests Outcomes reported
Krebs 200737
Full text: Yes
Study type: Direct
head-to-head
comparison
Retrospective: Yes
Multicentre: No
Country: Austria
Study start/end dates:
N/R
Duration of study: N/R
Enrolled: 50 patients
Analysed: 50 patients
Consecutive: No
Age (years) mean/median
(range/SD): 77.8± 6.4 years
Gender M : F: N/R
Baseline BCVA: N/R
Inclusion criteria: N/R
Exclusion criteria: N/R
Index test(s): TD-OCT
(OCT 3000™)
Definition of positive test
result: Increase retinal
thickness compared with
healthy retina of the study
eye or fellow eye,
neurosensory detachment,
PED
Interpreted by: N/R
Comparator test(s): N/R
Definition of positive test
result: N/R
Interpreted by: N/R
Reference standard: FFA
(not specified whether or
not stereoscopic)a
Interpreted by: N/R
Unit of analysis (n): Eye
Was adjustment made for
non-independence of fellow
eyes for cases where both
eyes per subject included: N/R
Diagnostic accuracy: Yes
Sensitivity:
CNV primarily classic 100%
RAP 72.7%
Specificity: 100% for dry
AMD (as negative diagnosis)
Clinical effectiveness: N/R
Interpretability of the test: N/R
Acceptability of the test: N/R
Proportion of participants not
able to receive the test due to
an eye condition/personal
circumstances: N/R
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TABLE 42 Diagnostic studies (continued )
Study Participants Tests Outcomes reported
Liakopoulos 200838
Full text: Yes
Study type: Direct
head-to-head
comparison
Retrospective: Yes
Multicentre: No
Country: USA
Studystart/end dates:
N/R
Duration of study: N/R
Enrolled: 66 patients (eyes)
Analysed: 66 patients (eyes)
Consecutive: Y/N
Age (years) mean/median
(range/SD): N/R
Gender M : F: N/R
Baseline BCVA: N/R
Inclusion criteria: Previously
untreated, active subfoveal
CNV due to AMD, stratus
OCT and FFA imaging
performed on the same date,
the entire CNV lesion had to
fall within a 6mm-diameter
circle centred on the fovea
Exclusion criteria: N/R
Index test(s): TD-OCT
(Stratus OCT™)
Definition of positive test
result: Active CNV defined
as the presence of
haemorrhage or evidence of
lesion growth within the
prior 3 months
Interpreted by: Certified
graders
Comparator test(s): Colour
fundus photographs
(TOPCON 50 I X, Topcon,
Tokyo, Japan)
Definition of positive test
result: N/R
Interpreted by: N/R
Reference standard:
Stereoscopic FFA
Interpreted by:
Ophthalmologists
(certified graders)
Unit of analysis (n):
Eye (one eye per patient)
If both eyes per subject
eligible, how was study eye
selected: N/R
Diagnostic accuracy: Yes
Sensitivity based on subretinal
fluid:
Occult with no classic 79.2%
Minimally classic 91.3%
Predominantly classic 100%
RAP stage III 50%
All subtypes 83.3%
Specificity: n/a
Sensitivity based on cystoid
oedema:
Occult with no classic 79.2%
Minimally classic 91.3%
Predominantly classic 81.8%
RAP stage III 100%
All subtypes 72.7%
Clinical effectiveness: N/R
Interpretability of the test: N/R
Acceptability of the test: N/R
Proportion of participants not
able to receive the test due to
an eye condition/personal
circumstances: N/R
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TABLE 42 Diagnostic studies (continued )
Study Participants Tests Outcomes reported
Loewenstein 201039
Full text: Yes
Study type: Prospective
and retrospective
Prospective/
retrospective: Yes
Multicentre: Yes
Country: Israel, USA (for
the prospective part
only)
Study start/end dates:
Retrospective part:
January–September
2007
Prospective part:
April–September 2008
Duration of study:
Retrospective part:
8 months
Prospective part:
5 months
Enrolled:
Retrospective: 109 patients
Prospective: 99 patients
Analysed:
Retrospective part: 77 patients
Prospective part: 54 patients
Consecutive:
Retrospective part: Unclear
Prospective part: Yes
Age (years) mean/median
(range/SD):
Retrospective part: 76 years
Prospective part: 78 years
Gender M : F:
Retrospective part: 41 : 35
(one unknown)
Prospective part: 17 : 34
(three unknown)
Baseline BCVA:
Retrospective part: 20/33
(iAMD group); 20/63
(CNV group)
Prospective part: 20/30 (iAMD
group); 20/63 (CNV group)
Inclusion criteria:
Retrospective part: Passing an
in-house tutorial
Prospective part: Mouse
experience, willingness and
ability to sign a written
informed consent,
intermediate AMD (using the
definition from Age-Related
Eye Disease study), recent
onset CNV within 3000 μm of
the fovea in the study eye,
aged > 50 years, CVA
> 20/200 on Snellen charts
Index test(s): N/R
Definition of positive test
result: N/R
Interpreted by: N/R
Comparator test(s): PHP
Definition of positive test
result: N/R
Interpreted by: N/R
Reference standard: FFA
(not specified whether or
not stereoscopic)a
Interpreted by: N/R
Unit of analysis (n):
Eye (one eye per patient)
If both eyes per subject
eligible, how was study eye
selected: N/R
Diagnostic accuracy: Yes
Sensitivity:
Retrospective part: 85.3%
Prospective part: 84.4%
All: 84.8%
Specificity:
Prospective part: 83.7%
Retrospective part: 86.4%
All: 84.6%
Clinical effectiveness: N/R
Interpretability of the test:
40 patients (19.2%) were
excluded from the analysis due
to geographic atrophy, early
AMD, pattern dystrophy, no or
poor-quality photographs
Acceptability of the test: N/R
Proportion of participants not
able to receive the test due to
an eye condition/personal
circumstances: N/R
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TABLE 42 Diagnostic studies (continued )
Study Participants Tests Outcomes reported
Exclusion criteria: Macular
disease other than AMD,
geographic atrophy, media
opacity precluding a clear
view of the fundus, no or
poor-quality photographs that
prevented unambiguous
grading, ocular surgery in the
study eye within the previous
3 months
Padnick-Silver 201240
Full text: Yes
Study type:
Observational,
non-randomised
Prospective: Yes
Multicentre: No
Country: USA
Study start/end dates:
N/R
Duration of study: N/R
Enrolled: 79 patients
Analysed: 77 patients
Consecutive: Unclear
Age (years) mean/median
(range/SD): 79.7± 6.3 years
Gender M : F: 24 : 55
Baseline BCVA: 0.27± 0.21
(≈20/40) in the study eye,
1.42± 0.74 (< 20/400) in the
fellow eye
Inclusion criteria: Patients with
bilateral AMD who had
developed unilateral exudative
changes
Exclusion criteria: Presence of
other retinal disease in the
eye with non-exudative AMD,
for example, significant
diabetic retinopathy,
glaucomatous retinal atrophy,
retinal detachment
Index test(s): TD-OCT
(Stratus OCT™)
Definition of positive test
result: Subretinal pigment
epithelial or subretinal fluid
Interpreted by: Retinal
physician
Comparator test(s): N/R
Definition of positive test
result: n/a
Interpreted by: N/R
Reference standard: FFA
(not specified whether or
not stereoscopic)a
Interpreted by: N/R
Unit of analysis (n): Eye
(one eye per patient)
If both eyes per subject
eligible, how was study eye
selected: n/a
Diagnostic accuracy: Yes
Sensitivity: 80%
Specificity: 93.5%
Clinical effectiveness: N/R
Interpretability of the test: N/R
Acceptability of the test: N/R
Proportion of participants not
able to receive the test due to
an eye condition/personal
circumstances: N/R
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TABLE 42 Diagnostic studies (continued )
Study Participants Tests Outcomes reported
Park 201041
Full text: Yes
Study type: Direct
head-to-head
comparison
Prospective: Yes
Multicentre: No
Country: USA
Study start/end dates:
September 2005/June
2006
Duration of study:
9 months
Enrolled: 19 patients (21 eyes)
Analysed: 21 eyes
Consecutive: Unclear
Age (years) Mean/median
(range/SD): 78 (48–92) years
Gender M : F: 8 : 11
Baseline BCVA: N/R
Inclusion criteria: Patients
newly diagnosed with
exudative AMD
Exclusion criteria: Eyes
diagnosed with RAP or
concurrent macular
haemorrhage that may
obscure part of the CNM
on FFA
Index test(s): SD-OCT
(Fourier domain)
(constructed at the
University of California,
Davis Medical Centre)
Definition of positive test
result: CNVM images as a
highly reflective lesion in the
subretinal space, subretinal
pigment epithelial space or
both
Interpreted by:
Ophthalmologists
(retinal specialists)
Comparator test(s): N/R
Definition of positive test
result: N/R
Interpreted by: N/R
Reference standard: FFA
(not specified whether or
not stereoscopic)a
Interpreted by:
Ophthalmologists
(retinal specialists)
Unit of analysis (n): Eye
Was adjustment made for
non-independence of fellow
eyes for cases where both
eyes per subject included: N/R
Diagnostic accuracy: Yes
Sensitivity: 100%
Specificity: N/R
Clinical effectiveness: N/R
Interpretability of the test: N/R
Acceptability of the test: N/R
Proportion of participants not
able to receive the test due to
an eye condition/personal
circumstances: N/R
Parravano 201242
Abstract: Yes
Study type: Diagnostic
cross-sectional
Prospective: Yes
Multicentre: Yes
(eight centres)
Country: Italy
Study start/end dates:
N/R
Duration of study: N/R
Enrolled: 155 patients
(201 eyes)
Analysed: 155 patients
Consecutive: Yes
Age (years) mean/median
(range/SD): 76± 8 years
Gender M : F: N/R
Baseline BCVA: N/R
Inclusion criteria: Patients with
newly diagnosed neovascular
AMD
Exclusion criteria: N/R
Index test(s): N/R
Definition of positive test
result: N/R
Interpreted by: N/R
Comparator test(s): ICGA
Definition of positive test
result: N/R
Interpreted by: All images
were graded by two
observers from different
institutions
Reference standard: FFA
(not specified whether or
not stereoscopic)a
Interpreted by: All images
were graded by two
observers from
different institutions
Unit of analysis (n): Patient
Was adjustment made for
non-independence of fellow
eyes for cases where both
eyes per subject included: N/R
Diagnostic accuracy: Yes
Sensitivity: 85.1%
Specificity: N/R
Clinical effectiveness: N/R
Interpretability of the test: N/R
Acceptability of the test: N/R
Proportion of participants not
able to receive the test due to
an eye condition/personal
circumstances: N/R
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TABLE 42 Diagnostic studies (continued )
Study Participants Tests Outcomes reported
Reichel 199544
Full text: Yes
Study type: Direct
head-to-head
comparison
Prospective/
retrospective: N/R
Multicentre: No
Country: USA
Study start/end dates:
September 1991/
January 1993
Duration of study:
16 months
Enrolled: 200 patients
Analysed: 20 patients
Consecutive: Yes
Age (years) mean/median
(range/SD): N/R
Gender M : F: N/R
Baseline BCVA: N/R
Inclusion criteria: Patients with
central visual symptoms with
clinical suspicious for CNV
due to the presence of a
retinal PED, exudates,
subretinal fluid, macular
oedema and/or subretinal or
intraretinal haemorrhage,
patients suspected to have a
CNV obscured by
haemorrhage
Exclusion criteria: Patients
with small amounts of
intraretinal or subretinal
haemorrhage (no significant
thickening on slit lamp
biomicroscopy), known allergy
to iodine-base dye, previous
laser photocoagulation in the
study eye
Index test(s): N/R
Definition of positive test
result: N/R
Interpreted by: N/R
Comparator test(s): ICGA
Definition of positive test
result: N/R
Interpreted by: N/R
Reference standard: FFA (not
specified whether or not
stereoscopic)a
Interpreted by: N/R
Unit of analysis (n):
Eye (one eye per patient)
If both eyes per subject
eligible, how was study eye
selected: N/R
Diagnostic accuracy: Yes
Sensitivity: 100%
Specificity: N/R
Clinical effectiveness: N/R
Interpretability of the test: N/R
Acceptability of the test: N/R
Proportion of participants not
able to receive the test due to
an eye condition/personal
circumstances: N/R
Salinas-Alaman 200545
Full text: Yes
Study type: Direct
head-to-head
comparison,
observational
Prospective: Yes
Multicentre: No
Country: Spain
Study start/end dates:
N/R
Duration of study: N/R
Enrolled: 53 patients
Analysed: 62 eyes
(53 patients)
Consecutive: Yes
Age (years) mean/median
(range/SD): 76.50± 7.5 years
Gender M : F: 26 : 27
Baseline BCVA: 20/80
Inclusion criteria: Patients
presenting with signs of
exudative AMD with
predominantly classic CNV
Exclusion criteria: N/R
Index test(s): TD-OCT
(OCT 2000™, Humphrey
Instruments, San Leonardo,
CA)
Definition of positive test
result: Presence of subretinal
or intraretinal fluid
Interpreted by: Unclear
(independent observers)
Comparator test(s): N/R
Definition of positive test
result: N/R
Interpreted by: N/R
Reference standard: FFA
(not specified whether or
not stereoscopic)a
Interpreted by: Unclear
(independent observers)
Unit of analysis (n): Eye
Was adjustment made for
non-independence of fellow
eyes for cases where both
eyes per subject included: N/R
Diagnostic accuracy: Yes
Sensitivity: 96.8%
Specificity: n/a
Clinical effectiveness: N/R
Interpretability of the test:
20 cases (9.6%) were
excluded from the analysis as
OCT tests were performed by
a less experienced technician
Acceptability of the test: N/R
Proportion of participants not
able to receive the test due to
an eye condition/personal
circumstances: N/R
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TABLE 42 Diagnostic studies (continued )
Study Participants Tests Outcomes reported
Sandhu 200546
Full text: Yes
Study type: Direct
head-to-head
comparison
Prospective: Yes
Multicentre: No
Country: UK
Study start/end dates:
N/R
Duration of study:
6 months
Enrolled: 128 patients
Analysed: 118 patients
(131 eyes)
Consecutive: Yes
Age (years) mean/median
(range/SD): 73.2± 13.7
(30–97) years
Gender M : F: 42.4% : 57.6%
Baseline BCVA: N/R
Inclusion criteria: First time
presentation of suspected
CNV with potentially treatable
lesion; predominantly classic
CNV with no PED
Exclusion criteria: N/R
Index test(s): TD-OCT
(OCT 3™, Zeiss, Dublin, CA)
Definition of positive test
result: (a) classic CNV –
subretinal band (RPE) with
choriocapilaris thickened and
disrupted-fusiform shape
with/without intraretinal or
subretinal fluid; (b) occult
CNV – less well-defined
band than ‘(a)’ but more
subRPE with more
disorganisation of the retina
and intraretinal fluid
(cystoid)/subretinal fluid;
(c) serous PED – dome shape
elevation of the reflective
band (RPE) with area of low
reflectivity underneath
Interpreted by:
Ophthalmologists
Comparator test(s):
SD-OCT+ stereo colour
fundus photography
Definition of positive test
result: N/R
Interpreted by: N/R
Reference standard:
Stereoscopic FFA
Interpreted by:
Ophthalmologists
Unit of analysis (n): Eye
Was adjustment made for
non-independence of fellow
eyes for cases where both
eyes per subject included: N/R
Diagnostic accuracy: Yes
Sensitivity:
SD-OCT: 77.8%
SD-OCT+ stereo colour
fundus photograph: 74.1%
Specificity:
SD-OCT: 76%
SD-OCT+ stereo colour
fundus photograph): 92.0%
Clinical effectiveness: N/R
Interpretability of the test:
10 patients (7.8%) were
excluded from the analysis
due to poor quality of images
Acceptability of the test: N/R
Proportion of participants not
able to receive the test due to
an eye condition/personal
circumstances: N/R
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TABLE 42 Diagnostic studies (continued )
Study Participants Tests Outcomes reported
Sulzbacher 201148
Full text: Yes
Study type: Direct
head-to-head
comparison
Prospective/
retrospective: Unclear
Multicentre: No
Country: Austria
(Vienna)
Study start/end dates:
July 2008/August 2009
Duration of study:
12 months
Enrolled: 13 eyes
Analysed: 13 eyes
Consecutive: Yes
Age (years) mean/median
(range/SD): N/R
Gender M : F: N/R
Baseline BCVA: N/R
Inclusion criteria: CNV type 2
treatment-naive eyes without
an occult component
Exclusion criteria: Occult
component (CNV),
neovascular maculopathy
from pathologic myopia,
angioid streaks, infectious
inflammatory chorioretinal
disease, tumours, hereditary
disorders or trauma
Index test(s): SD-OCT
(Spectralis™, Heidelberg
Engineering, Heidelberg,
Germany)
Definition of positive test
result: N/R
Interpreted by: Certified
reader at the Vienna reading
centre (non-ophthalmologist
technician, optometrist,
nurse, or other)
Comparator test(s): ICGA
Definition of positive test
result: Detection of type 2
CNV (without an occult
component): area of
choroidal hyperfluorescence
with well-demarcated
boundaries, with progressive
leakage beyond the initial
boundaries of the CNV and
an area of hypercyanescence
without marked leakage
activity on ICGA (early phase –
neovascular complex; late
phase – retinal leakage)
Interpreted by: Certified
reader at the Vienna reading
centre (non-ophthalmologist
technician, optometrist,
nurse, or other)
Reference standard: FFA
(not specified whether or not
stereoscopic)a
Interpreted by:
Ophthalmologists
(experienced readers)
Unit of analysis (n): Eye
Was adjustment made for
non-independence of fellow
eyes for cases where both
eyes per subject included: N/R
Diagnostic accuracy: Yes
Sensitivity: 100%
Specificity: N/R
Clinical effectiveness: N/R
Interpretability of the test: N/R
Acceptability of the test: N/R
Proportion of participants not
able to receive the test due to
an eye condition/personal
circumstances: N/R
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TABLE 42 Diagnostic studies (continued )
Study Participants Tests Outcomes reported
Talks 200749
Full text: Yes
Study type:
Retrospective audit
Retrospective: Yes
Multicentre: No
Country: UK
Study start/end dates:
N/R
Duration of study: N/R
Enrolled: 134 patients
Analysed: 111 patients
Consecutive: Yes
Age (years) mean/median
(range/SD): 84.6 (58–97) years
Gender M : F: 53:81
Baseline BCVA: N/R
Inclusion criteria: Patients
referred with suspected wet
AMD
Exclusion criteria: N/R
Index test(s): TD-OCT
(OCT 3™, Zeiss)
Definition of positive test
result: N/R
Interpreted by: N/R
Comparator test(s): ICGA
Definition of positive test
result: N/R
Interpreted by:
Ophthalmologists
Reference standard:
Stereoscopic FFA
Interpreted by:
Ophthalmologists
Unit of analysis (n): Eye
(one eye per patient)
If both eyes per subject
eligible, how was study eye
selected: N/R
Diagnostic accuracy: Yes
Sensitivity: 100%
Specificity: 65.8%
Clinical effectiveness: N/R
Interpretability of the test: N/R
Acceptability of the test: N/R
Proportion of participants not
able to receive the test due to
an eye condition/personal
circumstances: N/R
Torron 200251 (and
2-year interim study –
Torron 2001)50
Full text: Yes
Study type: Direct
head-to-head
comparison
Retrospective: Yes
Multicentre: No
Country: Spain
Study start/end dates:
April 1998/April 2001
Duration of study:
3 years
Enrolled:
Torron 200251 – 95 patients
(102 eyes)
Torron 200150 – 55 patients
(56 eyes)
Analysed:
Torron 200251 – 102 eyes
Torron 200150 – 56 eyes
Consecutive: Unclear
Age (years) mean/median
(range/SD): 75.3 (60–85) years
Gender M : F: 44 : 51
Baseline BCVA: ≤ 0.1
(42 eyes), 0.1–0.3 (28 eyes),
> 0.3 (30 eyes)
Inclusion criteria: N/R
Exclusion criteria: N/R
Index test(s): N/R
Definition of positive test
result: N/R
Interpreted by: N/R
Comparator test(s): ICGA
(SLO 101, Rodenstock,
Germany)
Definition of positive test
result: N/R
Interpreted by: N/R
Reference standard: FFA
(not specified whether or
not stereoscopic)a
Interpreted by: N/R
Unit of analysis (n): Eye
Was adjustment made for
non-independence of fellow
eyes for cases where both
eyes per subject included: N/R
Diagnostic accuracy: Yes
Sensitivity:
Torron 2002:51 92.2%
Torron 2001:50 89.3%
Specificity:
Torron 200251/2001:50 N/R
Clinical effectiveness: N/R
Interpretability of the test: N/R
Acceptability of the test: N/R
Proportion of participants not
able to receive the test due to
an eye condition/personal
circumstances: N/R
BCVA, best corrected visual acuity; CNM, choroidal neovascular membrane; F, female; iAMD, intermediate age-related
macular degeneration; M, male; n/a, not applicable; N/R, not reported; PCV, polpoidal choroidal vasculopathy;
SD, standard deviation.
a Agreement by the research group on studies with no information on FFA. It was assumed that in these studies,
non-stereoscopic FFA-interpreted by ophthalmologists has been performed.
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TABLE 43 Monitoring studies
Study Participants Tests Outcomes reported
Eter 200528
Full text: Yes
Study type: Direct
head-to head
comparison
Retrospective: Yes
Multicentre: Yes
(two centres)
Country: Germany
Study start/end dates:
N/R
Duration of study: N/R
Enrolled: 60 patients
(60 eyes)
Analysed: 60 patients
(60 eyes)
Consecutive: Yes
Age (years) median:
78 years
Gender M : F: 31 : 29
Baseline BCVA: 20/100
Inclusion criteria: Patients with
predominantly classic CNV
secondary to AMD treated
with PDT with verteporfin
Exclusion criteria: N/R
Index test(s): TD-OCT (Zeiss,
Humphrey Instruments)
Definition of positive test result:
Subretinal fluid or cystoid
spaces within the retina.
Subretinal fluid defined as
hyporeflective, black zone
between retinal pigment
epithelial layer and outer
neuro-sensory retinal surface.
Cystoid spaces defined as
hyporeflective black area of at
least 2 × 2 pixels within the
neuro-retina
Interpreted by: Ophthalmologists
Comparator test(s): N/R
Definition of positive test result:
N/R
Interpreted by: N/R
Reference standard:
FFA (unclear if stereoscopic
or not)a
Interpreted by: N/R
Unit of analysis (n): Eye
(one eye per patient)
If both eyes per subject
eligible, how was study eye
selected: N/R
Diagnostic accuracy: Yes
Sensitivity: 80%
Specificity: 80%
Clinical effectiveness: N/R
Interpretability of the test: N/R
Acceptability of the test: N/R
Proportion of participants not
able to receive the test due to
an eye condition/personal
circumstances: N/R
Giani 201130
Full text: Yes
Study type: Direct
head-to-head
comparison,
cross-sectional
Retrospective: Yes
Multicentre: No
Country: Italy (Milan)
Study start/end dates:
N/R
Duration of study: N/R
Enrolled: 93 patients
(93 eyes)
Analysed: 93 patients
(93 eyes)
Consecutive: Yes
Age (years) mean
(range/SD): 77 years
Gender M : F: 41 : 52
BCVA: Mean 0.40 (SD 0.25)
Inclusion criteria: Clinical
history of AMD, FFA diagnosis
of subfoveal CNV, previous
treatment with antiVEGF
agents for CNV
Exclusion criteria: Any previous
laser treatment, PDT, vitreo-
retinal surgery, macular
haemorrhage (significant) that
obscured the lesion, spherical
refractive error > 6 diopters
Index test(s): SD-OCT
(HRA+OCT Spectralis™)
Definition of positive test result:
At least one of the following
parameters: intraretinal cystic
spaces, without differentiation
in retinal layer localisation,
content, or number/density;
RPE detachment (PED), defined
as a localised elevation of RPE
due to fluid or fibrovascular
tissue; and neurosensory retinal
detachment, defined as a fluid
detachment of the retinal layers
from the RPE
Interpreted by: N/R
(two different examiners)
Comparator test(s): N/R
Definition of positive test result:
N/R
Interpreted by: N/R
Reference standard: Dynamic
video FFA (unclear if
stereoscopic or not)a
Interpreted by: N/R
Unit of analysis (n):
Eye (1 eye per patient)
If both eyes per subject
eligible, how was study eye
selected: N/R
Diagnostic accuracy: Yes
Sensitivity:
Overall: 94.2%
Classic: 90.9%
Occult: 100%
Specificity:
Overall: 26.8%
Classic: 37.5%
Occult: 11.8%
Clinical effectiveness: N/R
Interpretability of the test: N/R
Acceptability of the test: N/R
Proportion of participants not
able to receive the test due to
an eye condition/personal
circumstances: N/R
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TABLE 43 Monitoring studies (continued )
Study Participants Tests Outcomes reported
Henschel 200932
Full text: Yes
Study type: Direct
head-to-head
comparison
Prospective: Yes
Multicentre: No
Country: Germany
Study start/end dates:
N/R
Duration of study: N/R
Enrolled: 14 patients
(61 examinations)
Analysed: 61 pair of
examinations (OCT and FFA)
Consecutive: Unclear
Age (years) mean/median
(range/SD): N/R
Gender M : F: N/R
BCVA: 20/32 – 20/200 (range)
Inclusion criteria: Patients with
CNV for AMD (different types
as predominantly classic
and occult)
Exclusion criteria: N/R
Index test(s): TD-OCT
(Stratus OCT™)
Definition of positive test result:
Presence of intraretinal or
subretinal fluid present when
loculated hyporeflective cystoid
spaces were visible in one of
the acquired scans; subretinal
fluid was rated as present if a
hyporeflective space was
definable between the
outer retinal surface and
the hyporeflective
RPE/choriocapilary complex
in one of the OCT scans
Interpreted by: N/R
Comparator test(s): N/R
Definition of positive test result:
N/R
Interpreted by: N/R
Reference standard:
FFA (unclear if stereoscopic
or not)a
Interpreted by:
Ophthalmologists
Unit of analysis (n):
Examination
Diagnostic accuracy: Yes
Sensitivity:
CNV based in detection of
intraretinal fluid: 90.3%
CNV based on detection of
subretinal fluid: 71%
CNV based on detection of
intraretinal and/or subretinal
fluid: 96.8%
Specificity:
CNV based in detection of
intraretinal fluid: 40%
CNV based on detection of
subretinal fluid: 73.3%
CNV based on detection of
intraretinal and/or subretinal
fluid: 36.7%
Clinical effectiveness: N/R
Interpretability of the test: N/R
Acceptability of the test: N/R
Proportion of participants not
able to receive the test due to
an eye condition/personal
circumstances: N/R
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TABLE 43 Monitoring studies (continued )
Study Participants Tests Outcomes reported
Khurana 201023
Full text: Yes
Study type: Direct
head-to-head
comparison
Retrospective: Yes
Multicentre: No
Country: USA
Study start/end dates:
November 2007/
June 2008
Duration of study:
8 months
Enrolled: 56 patients
(59 eyes)
Analysed: 59 eyes
Consecutive: Yes
Age (years) mean/median
(range/SD): 78.1 (7.8)
Gender M : F: N/R
BCVA: 0.64± 0.35
(mean, log-MAR); Snellen
equivalent 20/80 (median)
Inclusion criteria: Age
≥ 50 years, CNV secondary to
AMD, FFA, TD-OCT and
SD-OCT performed at the
same visit
Exclusion criteria: Patients with
CNV resulting from
other causes
Index test(s): TD-OCT
(Stratus OCT™) and SD-OCT
(Cirrus™, Carl Zeiss Meditec,
Dublin, CA)
Definition of positive test result:
Presence of intersticial retinal
fluid, retinal cystoid
abnormalities, and subretinal
fluid (subretinal pigment
epithelial abnormalities were
not evaluated)
Interpreted by: Trained grader
(non-ophthalmologist
technician, optometrist, nurse,
or other)
Comparator test(s): N/R
Definition of positive test result:
N/R
Interpreted by: N/R
Reference standard:
Stereoscopic FFA
Interpreted by: Trained grader
(non-ophthalmologist
technician, optometrist,
nurse, or other)
Unit of analysis (n): Eye
Was adjustment made for
non-independence of fellow
eyes for cases where both eyes
per subject included: N/R
Diagnostic accuracy: Yes
Sensitivity:
TD-OCT: 58.6%
SD-OCT: 89.7%
Specificity:
TD-OCT: 63.3%
SD-OCT: 46.7%
Clinical effectiveness: N/R
Interpretability of the test: N/R
Acceptability of the test: N/R
Proportion of participants not
able to receive the test due to
an eye condition/personal
circumstances: N/R
Regillo 199843
Full text: Yes
Study type: Direct
head-to-head
comparison
Prospective: Yes
Multicentre: No
Country: USA
Study start/end dates:
April 1995/
December 1996
Duration of study:
20 months
Enrolled: 21 patients
(24 eyes)
Analysed: 54 examinations
Consecutive: Yes
Age (years) mean/median
(range/SD): 75 (59–91) years
Gender M : F: 11 : 10
BCVA: N/R
Inclusion criteria: patients with
eAMD that had conventional
laser treatment for CNV, first
post-treatment visit and all
subsequent follow-up
Exclusion criteria: N/R
Index test(s): N/R
Definition of positive test result:
N/R
Interpreted by: N/R
Comparator test(s): ICGA
(H1024, Topcon, Tokyo, Japan)
Definition of positive test result:
N/R
Interpreted by: N/R
Reference standard: Unclear if
FFA stereoscopic or not
[as macular stereoscopic colour
fundus photographs were
taken at the beginning of all
angiogram (or FFA) pairs]
Interpreted by:
Ophthalmologists
Unit of analysis (n):
Examination
Diagnostic accuracy: Yes
Sensitivity: 75.9%
Specificity: 88%
Clinical effectiveness: N/R
Interpretability of the test: N/R
Acceptability of the test: N/R
Proportion of participants not
able to receive the test due to
an eye condition/personal
circumstances: N/R
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TABLE 43 Monitoring studies (continued )
Study Participants Tests Outcomes reported
Salinas-Alaman 200545
Full text: Yes
Study type: Direct
head-to-head
comparison,
observational
Prospective: Yes
Multicentre: No
Country: Spain
Study start/end dates:
N/R
Duration of study: N/R
Enrolled: N/R
Analysed:
Follow-up at 6 months
62 eyes
Follow-up at 12 months
42 eyes
Consecutive: Yes
Age (years) mean/median
(range/SD): 76.5± 7.5 years at
6 months (N/R at 12 months)
Gender M : F: 26 : 27 at
6 months (N/R at 12 months)
BCVA: N/R
Improvement of BCVA
reported:
At 6 months: 40 eyes same
VA; 7 eyes improved VA;
15 eyes with worse VA
At 12 months: 25 eyes same
VA; 5 eyes improved VA;
12 eyes with worse VA
Inclusion criteria: Patients
presenting with signs of
exudative AMD with
predominantly classic CNV
Exclusion criteria: N/R
Index test(s): TD-OCT
(OCT 2000™, Humphrey
Instruments)
Definition of positive test result:
Presence of subretinal or
intraretinal fluid
Interpreted by: Unclear
(independent observers)
Comparator test(s): N/R
Definition of positive test result:
N/R
Interpreted by: N/R
Reference standard: FFA
(not specified whether or not
stereoscopic)a
Interpreted by: Unclear
(independent observers)
Unit of analysis (n): Remarks
(= examination)
Diagnostic accuracy: Yes
(CNV activity after PDT
treatment)
Sensitivity: 95.7%
Specificity: 59%
Clinical effectiveness: N/R
Interpretability of the test:
20 cases (9.6%) were excluded
from the analysis as OCT tests
were performed by a less
experienced technician
Acceptability of the test: N/R
Proportion of participants not
able to receive the test due to
an eye condition/personal
circumstances: N/R
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TABLE 43 Monitoring studies (continued )
Study Participants Tests Outcomes reported
van de Moere 200652
Full text: Yes
Study type: Direct
head-to-head
comparison
Retrospective: Yes
Multicentre: No
Country: UK
Study start/end dates:
July 2001/October
2004
Duration of study:
3 years, 3 months
Enrolled: 136 patients
Analysed: 121 eyes
(121 patients)
Consecutive: Yes
Age (years) mean/median
(range/SD): 73.9 (30–94) years
Gender M : F: 55 : 66
BCVA: N/R
Inclusion criteria: Patients who
had all received initial PDT with
verteporfin (Visudyne®,
Novartis AG) for a classic or
predominantly classic subfoveal
CNV secondary to AMD
Exclusion criteria: Poor quality
of the OCT or FFA images
Index test(s): TD-OCT
(OCT 3™, Zeiss)
Definition of positive test result:
PED (not specified if vascular
component present or not),
subretinal fluid, intraretinal fluid
(solitary foveal cyst, sponge-like
retinal thickening, intraretinal
cysts or cystoid macular
oedema), vitreomacular
tractions
Interpreted by: N/R
Comparator test(s): N/R
Definition of positive test result:
N/R
Interpreted by: N/R
Reference standard:
Stereoscopic FFA
Interpreted by:
Ophthalmologists
Unit of analysis (n):
Eye (one eye per patient)
If both eyes per subject
eligible, how was study eye
selected: If both eyes were
eligible, one eye was randomly
chosen for analysis
Diagnostic accuracy: Yes
Sensitivity:
PED: 5.7%
Subretinal fluid: 47.1%
Intraretinal fluid: 82.9%
Cystoid macular oedema: 98%
Specificity:
PED: 100%
Subretinal fluid: 84.3%
Intraretinal fluid: 52.9%
Cystoid macular oedema:
22.9%
Clinical effectiveness: N/R
Interpretability of the test:
17 cases (12.5%) were
excluded from analysis due to
poor quality of OCT or FFA
Acceptability of the test: N/R
Proportion of participants not
able to receive the test due to
an eye condition/personal
circumstances: N/R
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TABLE 43 Monitoring studies (continued )
Study Participants Tests Outcomes reported
van Velthoven 200653
Full text: Yes
Study type: Direct
head-to-head
comparison
Retrospective: Yes
Multicentre: No
Country: Netherlands
Study start/end dates:
July 2003/October 2003
Duration of study:
3 months
Enrolled: 30 patients
(30 eyes)
Analysed: 30 patients
(30 eyes)
Consecutive: Yes
Age (years) mean/median
(range/SD): 75.5± 9.0 years
Gender M : F: 13 : 17
BCVA: Mean 45± 14 (SD)
Inclusion criteria: Patients with
AMD and subfoveal CNV who
had received at least one prior
PDT treatment
Exclusion criteria: N/R
Index test(s): TD-OCT
(Stratus OCT™)
Definition of positive test result:
OCT activity score – positive if
any sign of leakage, that is
cystoid macular oedema and/or
subretinal fluid and/or retinal
thickening
Interpreted by: N/R
Comparator test(s): N/R
Definition of positive test
result: N/R
Interpreted by: N/R
Reference standard:
Stereoscopic FFA
Interpreted by: N/R
Unit of analysis (n):
Eye (one eye per patient)
If both eyes per subject
eligible, how was study eye
selected: N/R
Diagnostic accuracy: Yes
Sensitivity: 65.2%
Specificity: 42.9%
Clinical effectiveness: N/R
Interpretability of the test: N/R
Acceptability of the test: N/R
Proportion of participants not
able to receive the test due to
an eye condition/personal
circumstances: N/R
eAMD, exudative age-related macular degeneration; N/R, not reported; SD, standard deviation.
a Agreement by the research group on studies with no information on FFA. It was assumed that in these studies,
non-stereoscopic FFA-interpreted by ophthalmologists has been performed.
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Appendix 5 Results of the risk of bias and
applicability concerns for the individual
full-text studies
TABLE 44 Diagnostic studies (n= 20 studies, 22 reports)
Study
Risk of bias Applicability concerns
Patient
selection
Index
test
Reference
standard
Flow and
timing
Patient
selection
Index
test
Reference
standard
Alster 200524 – + + – + + +
Cachulo 201125 ? ? ? – + + +
Chen 200326 ? ? ? + + + +
Do 201227 – + + – + + +
Fujii 199629 ? ? ? ? + + +
Gomi 200731 – ? ? + + + +
Hughes 200533 ? + + ? + + +
Kim 200335 ? ? ? ? + + +
Kozak 200836 + ? ? – + + +
Krebs 200737 – + + + + + +
Liakopoulos 200838 – + ? + + + +
Loewenstein 201039 – ? ? – + + +
Padnick-Silver 201140 – ? ? – + + +
Park 201041 – + ? + + + +
Reichel 199544 – – – + + + +
Salinas-Alaman 200545 – ? ? ? + + +
Sandhu 200546 ? + + – + + +
Silva 201147 ? ? ? – + + +
Sulzbacher 201148 ? ? ? ? + + +
Talks 200749 – + – – + + +
Torron 200150 ? – – + + + +
Torron 200251 ? – – ? + + +
–, high risk; +, low risk; ?, unclear.
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TABLE 45 Monitoring studies (n= 8 studies, 8 reports)
Study
Risk of bias Applicability concerns
Patient
selection
Index
test
Reference
standard
Flow and
timing
Patient
selection
Index
test
Reference
standard
Eter 200528 ? + + ? + + +
Giani 201130 – + + ? – + +
Henschel 200932 ? + + ? + + +
Khurana 201023 ? ? ? + + + +
Regillo 199843 + – – + + + +
Salinas-Alaman 200545 – ? ? – + + +
van de Moere 200652 + ? ? – + + +
van Velthoven 200653 + ? + ? + + +
–, high risk; +, low risk; ?, unclear.
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Appendix 6 Individual study results
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Appendix 7 Studies reporting eye-related
exclusion criteria
TABLE 48 Diagnostic studies
Study Eye-related exclusion criteria
Alster 200524 l Presence of any significant media opacity that precludes a clear view of the fundus on
fundus photography and FFA
l Any non-macular-related ocular surgery performed within 3 months before the study
Cachulo 201125 l Current or past history of an ophthalmic disease in the study eye (other than AMD) that
would likely compromise the VA of the study eye
l Clinical signs of myopic retinopathy or refractive power > 8 diopters or fundoscopic
evidence of degenerative myopia
l Past history of intraocular surgery within 60 days prior to enrolling in the study
l Evidence of past or present CNV in the study eye
Do 201227 l Evidence of CNV or foveal geographic atrophy in the fellow (candidate study) eye
Gomi 200731 l Subretinal or subpigment epithelial haemorrhages that obscured lesions
l History of any previous treatment and any other macular pathologies such as CNV or
central serous chorioretinopathy
Loewenstein 201039 l Macular disease other than AMD
l Geographic atrophy
l Media opacity precluding a clear view of the fundus
l Ocular surgery in the study eye with in the previous 3 months
Padnick-Silver 201240 l Presence of other retinal disease in the eye with non-nAMD (e.g. significant diabetic
retinopathy, glaucomatous retinal atrophy, retinal detachment)
Park 201041 l RAP or concurrent macular haemorrhage that might obscure part of the CNVM on FFA
Reichel 199544 l Previous laser photocoagulation in the study eye
Sulzbacher 201148 l Neovascular maculopathy from pathologic myopia, angioid streaks, infectious inflammatory
chorioretinal disease, tumours, hereditary disorders, or trauma
Talks 200749 l Macular holes
l Central serous retinopathy
l Disciform scar
TABLE 49 Monitoring studies
Study Eye-related exclusion criteria
Giani 201130 l Any previous laser treatment, PDT, or vitreoretinal surgery on the study eye
l Significant macular haemorrhage that obscured the lesion
l Spherical refractive error > 6 diopters
Khurana 201023 l CNV resulting from other causes
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Appendix 8 Sensitivity analysis results
One-way sensitivity analysis
All analyses show results moving in the expected direction (e.g. lower sensitivity or specificity for OCT
would result in OCT-based strategies being less cost-effective). Briefly, base-case analysis results seem
robust. In a limited number of model runs, alternative OCT-based strategies stopped being dominated or
became cost-effective. However, in these cases the variable values used to run the analysis were extreme.
For instance, diagnosing with OCT combined with nurse-/technician-led monitoring seemed worthwhile
when OCT diagnosis sensitivity and specificity was equal to 1. It should be noted that it is unlikely that the
other strategies’ diagnostic assessment that were also based on OCT and other tests would result in a
lower sensitivity and specificity than using OCT only (interpreted by the same ophthalmologist)
(Tables 50–74).
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TABLE 50 One-way sensitivity analysis: OCT diagnosis sensitivity
Diagnosis
sensitivity
OCT Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
0.1 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist &
Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 41,474 10.411 1705 –0.062 –27,580 Dominated
(2) FFA & Ophthalmologist 44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT & Ophthalmologist 46,965 10.510 2316 –0.065 –35,789 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist & OCT 62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,155 10.387 22,506 –0.188 –119,903 Dominated
0.2 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist &
Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 41,491 10.418 1722 –0.055 –31,342 Dominated
(2) FFA & Ophthalmologist 44,649 10.575 4,880 0.102 47,768
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT & Ophthalmologist 46,986 10.518 2337 –0.057 –40,649 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist & OCT 62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,189 10.394 22,540 –0.181 –124,721 Dominated
0.3 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist &
Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 41,508 10.425 1739 –0.048 –36,180 Dominated
(2) FFA & Ophthalmologist 44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT & Ophthalmologist 47,008 10.525 2358 –0.050 –46,904 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist & OCT 62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,223 10.401 22,574 –0.174 –129,926 Dominated
0.4 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 41,525 10.432 1756 –0.041 –42,633 Dominated
(2) FFA & Ophthalmologist 44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
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TABLE 50 One-way sensitivity analysis: OCT diagnosis sensitivity (continued )
Diagnosis
sensitivity
OCT Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
(5) OCT & Ophthalmologist 47,029 10.532 2380 –0.043 –55,254 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist & OCT 62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,257 10.408 22,608 –0.167 –135,566 Dominated
0.5 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 41,542 10.439 1773 –0.034 –51,673 Dominated
(2) FFA & Ophthalmologist 44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT & Ophthalmologist 47,050 10.539 2401 –0.036 –66,965 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist & OCT 62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,292 10.415 22,642 –0.160 –141,699 Dominated
0.6 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 41,559 10.445 1790 –0.027 –65,241 Dominated
(2) FFA & Ophthalmologist 44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT & Ophthalmologist 47,071 10.546 2422 –0.029 –84,573 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist & OCT 62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,326 10.422 22,677 –0.153 –148,392 Dominated
0.7 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 41,576 10.452 1807 –0.021 –87,881 Dominated
(2) FFA & Ophthalmologist 44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT & Ophthalmologist 47,093 10.554 2444 –0.021 –114,038 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist & OCT 62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,360 10.429 22,711 –0.146 –155,725 Dominated
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TABLE 50 One-way sensitivity analysis: OCT diagnosis sensitivity (continued )
Diagnosis
sensitivity
OCT Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
0.8 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 41,594 10.459 1824 –0.014 –133,258 Dominated
(2) FFA & Ophthalmologist 44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT & Ophthalmologist 47,114 10.561 2465 –0.014 –173,407 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist & OCT 62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,394 10.436 22,745 –0.139 –163,795 Dominated
0.9 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 41,611 10.466 1841 –0.007 –270,172 Dominated
(2) FFA & Ophthalmologist 44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT & Ophthalmologist 47,135 10.568 2486 –0.007 –355,119 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist & OCT 62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,428 10.443 22,779 –0.132 –172,719 Dominated
1.0 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 41,628 10.473 1859 0.000 31,635,704
(2) FFA & Ophthalmologist 44,649 10.575 3021 0.102 29,593
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT & Ophthalmologist 47,157 10.575 2507 0.000 11,797,675
(1) FFA & OCT 62,759 10.449 15,602 –0.126 –124,050 Dominated
(7) Ophthalmologist & OCT 62,778 10.449 15,621 –0.126 –123,584 Dominated
(4) OCT & OCT 67,462 10.450 20,306 –0.125 –162,290 Dominated
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TABLE 51 One-way sensitivity analysis: OCT diagnosis specificity
Diagnosis
specificity
OCT Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
0.55 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 43,619 10.465 3850 –0.008 –473,564 Dominated
(2) FFA & Ophthalmologist 44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT & Ophthalmologist 49,821 10.567 5172 –0.008 –629,095 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist & OCT 62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 72,407 10.442 27,758 –0.133 –209,343 Dominated
0.60 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 43,182 10.465 3412 –0.008 –419,079 Dominated
(2) FFA & Ophthalmologist 44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT & Ophthalmologist 49,236 10.567 4587 –0.008 –554,702 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist & OCT 62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 71,324 10.442 26,674 –0.133 –200,943 Dominated
0.65 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 42,744 10.465 2975 –0.008 –364,772 Dominated
(2) FFA & Ophthalmologist 44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT & Ophthalmologist 48,651 10.567 4002 –0.008 –481,174 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist & OCT 62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 70,240 10.442 25,590 –0.133 –192,562 Dominated
0.70 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 42,307 10.465 2538 –0.008 –310,643 Dominated
(2) FFA & Ophthalmologist 44,649 10.575 4880 0.102 47,768
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TABLE 51 One-way sensitivity analysis: OCT diagnosis specificity (continued )
Diagnosis
specificity
OCT Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT & Ophthalmologist 48,067 10.567 3418 –0.008 –408,495 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist & OCT 62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 69,156 10.442 24,507 –0.133 –184,200 Dominated
0.75 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 41,870 10.465 2100 –0.008 –256,690 Dominated
(2) FFA & Ophthalmologist 44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT & Ophthalmologist 47,482 10.567 2833 –0.008 –336,651 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist & OCT 62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 68,072 10.442 23,423 –0.133 –175,856 Dominated
0.80 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 41,432 10.465 1663 –0.008 –202,914 Dominated
(2) FFA & Ophthalmologist 44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT & Ophthalmologist 46,897 10.567 2248 –0.008 –265,626 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist & OCT 62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 66,988 10.442 22,339 –0.133 –167,531 Dominated
0.85 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 40,995 10.465 1226 –0.008 –149,312 Dominated
(2) FFA & Ophthalmologist 44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT & Ophthalmologist 46,312 10.567 1663 –0.009 –195,408 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist & OCT 62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 65,904 10.442 21,255 –0.133 –159,225 Dominated
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TABLE 51 One-way sensitivity analysis: OCT diagnosis specificity (continued )
Diagnosis
specificity
OCT Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
0.90 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 40,558 10.465 788 –0.008 –95,884 Dominated
(2) FFA & Ophthalmologist 44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT & Ophthalmologist 45,727 10.566 1078 –0.009 –125,982 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist & OCT 62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 64,820 10.441 20,171 –0.134 –150,937 Dominated
0.95 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 40,120 10.465 351 –0.008 –42,629 Dominated
(2) FFA & Ophthalmologist 44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT & Ophthalmologist 45,143 10.566 494 –0.009 –57,335 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist & OCT 62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 63,736 10.441 19,087 –0.134 –142,667 Dominated
1.00 (6) OCT & Nurse 39,683 10.465
(3) FFA & Nurse 39,769 10.473 86 0.008 10,453
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(5) OCT & Ophthalmologist 44,558 10.566 4789 0.094 51,214
(2) FFA & Ophthalmologist 44,649 10.575 91 0.009 10,545
(8) Ophthalmologist &
Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(4) OCT & OCT 62,652 10.441 18,003 –0.134 –134,416 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist & OCT 62,778 10.449 18,129 –0.126 –143,662 Dominated
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TABLE 52 Two-way sensitivity analysis: OCT diagnosis sensitivity and specificity (NMB at £30,000)
OCT diagnosis
Strategy
Expected
Cost (£)
Expected
QALYs NMB (£)
Maximum
NMBSensitivity Specificity
0.60 0.55 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 72,312 10.4229 240,374
(5) OCT & Ophthalmologist 49,761 10.5466 266,636
(6) OCT & Nurse 43,571 10.4455 269,793
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.60 0.60 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA &
Ophthalmologist
44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 71,228 10.4227 241,454
(5) OCT &
Ophthalmologist
49,177 10.5465 267,220
(6) OCT & Nurse 43,134 10.4455 270,230
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.60 0.65 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA &
Ophthalmologist
44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 70,144 10.4226 242,533
(5) OCT & Ophthalmologist 48,592 10.5465 267,803
(6) OCT & Nurse 42,696 10.4454 270,667
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
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TABLE 52 Two-way sensitivity analysis: OCT diagnosis sensitivity and specificity (NMB at £30,000) (continued )
OCT diagnosis
Strategy
Expected
Cost (£)
Expected
QALYs NMB (£)
Maximum
NMBSensitivity Specificity
0.60 0.70 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 69,060 10.4224 243,613
(5) OCT & Ophthalmologist 48,007 10.5464 268,386
(6) OCT & Nurse 42,259 10.4454 271,104
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.60 0.75 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 67,976 10.4223 244,692
(5) OCT & Ophthalmologist 47,422 10.5464 268,970
(6) OCT & Nurse 41,822 10.4454 271,541
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.60 0.80 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 66,892 10.4221 245,772
(5) OCT & Ophthalmologist 46,837 10.5463 269,553
(6) OCT & Nurse 41,384 10.4454 271,978
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
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TABLE 52 Two-way sensitivity analysis: OCT diagnosis sensitivity and specificity (NMB at £30,000) (continued )
OCT diagnosis
Strategy
Expected
Cost (£)
Expected
QALYs NMB (£)
Maximum
NMBSensitivity Specificity
0.60 0.85 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 65,808 10.4220 246,851
(5) OCT & Ophthalmologist 46,253 10.5463 270,136
(6) OCT & Nurse 40,947 10.4454 272,415
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.60 0.90 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 64,724 10.4218 247,931
(5) OCT & Ophthalmologist 45,668 10.5462 270,720
(6) OCT & Nurse 40,510 10.4454 272,851
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.60 0.95 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 63,641 10.4217 249,010
(5) OCT & Ophthalmologist 45,083 10.5462 271,303
(6) OCT & Nurse 40,072 10.4454 273,288
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.60 1.00 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 62,557 10.4215 250,089
(5) OCT & Ophthalmologist 44,498 10.5462 271,886
(6) OCT & Nurse 39,635 10.4453 273,725
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
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TABLE 52 Two-way sensitivity analysis: OCT diagnosis sensitivity and specificity (NMB at £30,000) (continued )
OCT diagnosis
Strategy
Expected
Cost (£)
Expected
QALYs NMB (£)
Maximum
NMBSensitivity Specificity
0.70 0.55 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 72,346 10.4299 240,550
(5) OCT & Ophthalmologist 49,783 10.5538 266,831
(6) OCT & Nurse 43,588 10.4523 269,982
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.70 0.60 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 71,262 10.4297 241,629
(5) OCT & Ophthalmologist 49,198 10.5538 267,415
(6) OCT & Nurse 43,151 10.4523 270,419
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.70 0.65 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 70,178 10.4296 242,708
(5) OCT & Ophthalmologist 48,613 10.5537 267,998
(6) OCT & Nurse 42,714 10.4523 270,856
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
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TABLE 52 Two-way sensitivity analysis: OCT diagnosis sensitivity and specificity (NMB at £30,000) (continued )
OCT diagnosis
Strategy
Expected
Cost (£)
Expected
QALYs NMB (£)
Maximum
NMBSensitivity Specificity
0.70 0.70 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 69,094 10.4294 243,788
(5) OCT & Ophthalmologist 48,028 10.5537 268,581
(6) OCT & Nurse 42,276 10.4523 271,293
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.70 0.75 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 68,010 10.4293 244,867
(5) OCT & Ophthalmologist 47,444 10.5536 269,165
(6) OCT & Nurse 41,839 10.4523 271,730
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.70 0.80 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 66,926 10.4291 245,947
(5) OCT & Ophthalmologist 46,859 10.5536 269,748
(6) OCT & Nurse 41,402 10.4523 272,167
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
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TABLE 52 Two-way sensitivity analysis: OCT diagnosis sensitivity and specificity (NMB at £30,000) (continued )
OCT diagnosis
Strategy
Expected
Cost (£)
Expected
QALYs NMB (£)
Maximum
NMBSensitivity Specificity
0.70 0.85 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 65,842 10.4290 247,026
(5) OCT & Ophthalmologist 46,274 10.5535 270,331
(6) OCT & Nurse 40,964 10.4523 272,604
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.70 0.90 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 64,759 10.4288 248,106
(5) OCT & Ophthalmologist 45,689 10.5535 270,915
(6) OCT & Nurse 40,527 10.4522 273,041
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.70 0.95 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 63,675 10.4287 249,185
(5) OCT & Ophthalmologist 45,104 10.5534 271,498
(6) OCT & Nurse 40,090 10.4522 273,478
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
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TABLE 52 Two-way sensitivity analysis: OCT diagnosis sensitivity and specificity (NMB at £30,000) (continued )
OCT diagnosis
Strategy
Expected
Cost (£)
Expected
QALYs NMB (£)
Maximum
NMBSensitivity Specificity
0.70 1.00 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 62,591 10.4285 250,265
(5) OCT & Ophthalmologist 44,520 10.5534 272,081
(6) OCT & Nurse 39,652 10.4522 273,914
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.80 0.55 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 72,380 10.4368 240,725
(5) OCT & Ophthalmologist 49,804 10.5610 267,026
(6) OCT & Nurse 43,605 10.4592 270,171
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.80 0.60 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 71,296 10.4367 241,804
(5) OCT & Ophthalmologist 49,219 10.5610 267,610
(6) OCT & Nurse 43,168 10.4592 270,608
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
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TABLE 52 Two-way sensitivity analysis: OCT diagnosis sensitivity and specificity (NMB at £30,000) (continued )
OCT diagnosis
Strategy
Expected
Cost (£)
Expected
QALYs NMB (£)
Maximum
NMBSensitivity Specificity
0.80 0.65 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 70,212 10.4365 242,884
(5) OCT & Ophthalmologist 48,634 10.5609 268,193
(6) OCT & Nurse 42,731 10.4592 271,045
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.80 0.70 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 69,128 10.4364 243,963
(5) OCT & Ophthalmologist 48,050 10.5609 268,776
(6) OCT & Nurse 42,293 10.4592 271,482
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.80 0.75 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 68,044 10.4362 245,043
(5) OCT & Ophthalmologist 47,465 10.5608 269,360
(6) OCT & Nurse 41,856 10.4592 271,919
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
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TABLE 52 Two-way sensitivity analysis: OCT diagnosis sensitivity and specificity (NMB at £30,000) (continued )
OCT diagnosis
Strategy
Expected
Cost (£)
Expected
QALYs NMB (£)
Maximum
NMBSensitivity Specificity
0.80 0.80 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 66,961 10.4361 246,122
(5) OCT & Ophthalmologist 46,880 10.5608 269,943
(6) OCT & Nurse 41,419 10.4592 272,356
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.80 0.85 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 65,877 10.4359 247,201
(5) OCT & Ophthalmologist 46,295 10.5607 270,526
(6) OCT & Nurse 40,981 10.4591 272,793
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.80 0.90 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 64,793 10.4358 248,281
(5) OCT & Ophthalmologist 45,710 10.5607 271,110
(6) OCT & Nurse 40,544 10.4591 273,230
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
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TABLE 52 Two-way sensitivity analysis: OCT diagnosis sensitivity and specificity (NMB at £30,000) (continued )
OCT diagnosis
Strategy
Expected
Cost (£)
Expected
QALYs NMB (£)
Maximum
NMBSensitivity Specificity
0.80 0.95 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 63,709 10.4356 249,360
(5) OCT & Ophthalmologist 45,126 10.5606 271,693
(6) OCT & Nurse 40,107 10.4591 273,667
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.80 1.00 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 62,625 10.4355 250,440
(5) OCT & Ophthalmologist 44,541 10.5606 272,277
(6) OCT & Nurse 39,669 10.4591 274,104
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.90 0.55 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 72,414 10.4438 240,900
(5) OCT & Ophthalmologist 49,825 10.5682 267,222
(6) OCT & Nurse 43,622 10.4661 270,360
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
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TABLE 52 Two-way sensitivity analysis: OCT diagnosis sensitivity and specificity (NMB at £30,000) (continued )
OCT diagnosis
Strategy
Expected
Cost (£)
Expected
QALYs NMB (£)
Maximum
NMBSensitivity Specificity
0.90 0.60 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 71,330 10.4437 241,979
(5) OCT & Ophthalmologist 49,241 10.5682 267,805
(6) OCT & Nurse 43,185 10.4661 270,797
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.90 0.65 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 70,246 10.4435 243,059
(5) OCT & Ophthalmologist 48,656 10.5681 268,388
(6) OCT & Nurse 42,748 10.4661 271,234
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.90 0.70 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 69,163 10.4434 244,138
(5) OCT & Ophthalmologist 48,071 10.5681 268,972
(6) OCT & Nurse 42,310 10.4661 271,671
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
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TABLE 52 Two-way sensitivity analysis: OCT diagnosis sensitivity and specificity (NMB at £30,000) (continued )
OCT diagnosis
Strategy
Expected
Cost (£)
Expected
QALYs NMB (£)
Maximum
NMBSensitivity Specificity
0.90 0.75 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 68,079 10.4432 245,218
(5) OCT & Ophthalmologist 47,486 10.5680 269,555
(6) OCT & Nurse 41,873 10.4660 272,108
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.90 0.80 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 66,995 10.4431 246,297
(5) OCT & Ophthalmologist 46,901 10.5680 270,138
(6) OCT & Nurse 41,436 10.4660 272,545
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.90 0.85 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 65,911 10.4429 247,377
(5) OCT & Ophthalmologist 46,317 10.5679 270,722
(6) OCT & Nurse 40,998 10.4660 272,982
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
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TABLE 52 Two-way sensitivity analysis: OCT diagnosis sensitivity and specificity (NMB at £30,000) (continued )
OCT diagnosis
Strategy
Expected
Cost (£)
Expected
QALYs NMB (£)
Maximum
NMBSensitivity Specificity
0.90 0.90 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 64,827 10.4428 248,456
(5) OCT & Ophthalmologist 45,732 10.5679 271,305
(6) OCT & Nurse 40,561 10.4660 273,419
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.90 0.95 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 63,743 10.4426 249,535
(5) OCT & Ophthalmologist 45,147 10.5678 271,888
(6) OCT & Nurse 40,124 10.4660 273,856
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.90 1.00 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 62,659 10.4425 250,615
(5) OCT & Ophthalmologist 44,562 10.5678 272,472
(6) OCT & Nurse 39,686 10.4660 274,293
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
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TABLE 52 Two-way sensitivity analysis: OCT diagnosis sensitivity and specificity (NMB at £30,000) (continued )
OCT diagnosis
Strategy
Expected
Cost (£)
Expected
QALYs NMB (£)
Maximum
NMBSensitivity Specificity
1.00 0.55 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 72,448 10.4508 241,075
(5) OCT & Ophthalmologist 49,847 10.5754 267,417
(6) OCT & Nurse 43,639 10.4730 270,550
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
1.00 0.60 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 71,365 10.4506 242,154
(5) OCT & Ophthalmologist 49,262 10.5754 268,000
(6) OCT & Nurse 43,202 10.4730 270,986
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
1.00 0.65 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 70,281 10.4505 243,234
(5) OCT & Ophthalmologist 48,677 10.5753 268,583
(6) OCT & Nurse 42,765 10.4729 271,423
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
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TABLE 52 Two-way sensitivity analysis: OCT diagnosis sensitivity and specificity (NMB at £30,000) (continued )
OCT diagnosis
Strategy
Expected
Cost (£)
Expected
QALYs NMB (£)
Maximum
NMBSensitivity Specificity
1.00 0.70 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 69,197 10.4503 244,313
(5) OCT & Ophthalmologist 48,092 10.5753 269,167
(6) OCT & Nurse 42,327 10.4729 271,860
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
1.00 0.75 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 68,113 10.4502 245,393
(5) OCT & Ophthalmologist 47,507 10.5752 269,750
(6) OCT & Nurse 41,890 10.4729 272,297
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
1.00 0.80 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 67,029 10.4500 246,472
(5) OCT & Ophthalmologist 46,923 10.5752 270,333
(6) OCT & Nurse 41,453 10.4729 272,734
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
1.00 0.85 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 65,945 10.4499 247,552
(5) OCT & Ophthalmologist 46,338 10.5752 270,917
(6) OCT & Nurse 41,015 10.4729 273,171
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
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TABLE 52 Two-way sensitivity analysis: OCT diagnosis sensitivity and specificity (NMB at £30,000) (continued )
OCT diagnosis
Strategy
Expected
Cost (£)
Expected
QALYs NMB (£)
Maximum
NMBSensitivity Specificity
1.00 0.90 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 64,861 10.4497 248,631
(5) OCT & Ophthalmologist 45,753 10.5751 271,500
(6) OCT & Nurse 40,578 10.4729 273,608
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
1.00 0.95 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 63,777 10.4496 249,711
(5) OCT & Ophthalmologist 45,168 10.5751 272,083
(6) OCT & Nurse 40,141 10.4729 274,045
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
1.00 1.00 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416
(4) OCT & OCT 62,693 10.4494 250,790
(5) OCT & Ophthalmologist 44,583 10.5750 272,667
(6) OCT & Nurse 39,703 10.4728 274,482 ✓
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist &
Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
NMB, net monetary benefit.
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TABLE 53 One-way sensitivity analysis: ophthalmologist diagnosis sensitivity
Diagnosis
sensitivity
ophthalmologist
assessment Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
0.1 (9) Ophthalmologist
& Nurse
39,587 10.417
(3) FFA & Nurse 39,769 10.473 182 0.056 3267
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(8) Ophthalmologist
& Ophthalmologist
44,433 10.517 4664 0.044 106,648
(2) FFA &
Ophthalmologist
44,649 10.575 216 0.058 3696
(5) OCT &
Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(7) Ophthalmologist
& OCT
62,439 10.393 17,790 –0.182 –97,705 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
0.2 (9) Ophthalmologist
& Nurse
39,610 10.423
(3) FFA & Nurse 39,769 10.473 159 0.050 3215
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(8) Ophthalmologist
& Ophthalmologist
44,460 10.523 4691 0.050 93,392
(2) FFA
& Ophthalmologist
44,649 10.575 189 0.052 3647
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(7) Ophthalmologist
& OCT
62,477 10.399 17,828 –0.176 –101,411 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
0.3 (9) Ophthalmologist
& Nurse
39,633 10.430
(3) FFA & Nurse 39,769 10.473 136 0.043 3149
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(8) Ophthalmologist
& Ophthalmologist
44,486 10.530 4717 0.057 83,170
(2) FFA
& Ophthalmologist
44,649 10.575 163 0.045 3584
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(7) Ophthalmologist
& OCT
62,515 10.405 17,866 –0.170 –105,393 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
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TABLE 53 One-way sensitivity analysis: ophthalmologist diagnosis sensitivity (continued )
Diagnosis
sensitivity
ophthalmologist
assessment Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
0.4 (9) Ophthalmologist
& Nurse
39,656 10.436
(3) FFA & Nurse 39,769 10.473 114 0.037 3061
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(8) Ophthalmologist
& Ophthalmologist
44,513 10.536 4744 0.063 75,047
(2) FFA
& Ophthalmologist
44,649 10.575 136 0.039 3501
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(7) Ophthalmologist
& OCT
62,553 10.412 17,904 –0.163 –109,680 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
0.5 (9) Ophthalmologist
& Nurse
39,678 10.442
(3) FFA & Nurse 39,769 10.473 91 0.031 2938
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(8) Ophthalmologist
& Ophthalmologist
44,539 10.543 4770 0.070 68,438
(2) FFA
& Ophthalmologist
44,649 10.575 110 0.032 3383
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(7) Ophthalmologist
& OCT
62,591 10.418 17,942 –0.157 –114,311 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
0.6 (9) Ophthalmologist
& Nurse
39,701 10.448
(3) FFA & Nurse 39,769 10.473 68 0.025 2754
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(8) Ophthalmologist
& Ophthalmologist
44,566 10.549 4797 0.076 62,955
(2) FFA
& Ophthalmologist
44,649 10.575 83 0.026 3207
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(7) Ophthalmologist
& OCT
62,629 10.424 17,980 –0.151 –119,327 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
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TABLE 53 One-way sensitivity analysis: ophthalmologist diagnosis sensitivity (continued )
Diagnosis
sensitivity
ophthalmologist
assessment Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
0.7 (9) Ophthalmologist
& Nurse
39,724 10.454
(3) FFA & Nurse 39,769 10.473 45 0.019 2446
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(8) Ophthalmologist
& Ophthalmologist
44,592 10.556 4823 0.083 58,333
(2) FFA
& Ophthalmologist
44,649 10.575 57 0.019 2914
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(7) Ophthalmologist
& OCT
62,667 10.431 18,018 –0.144 –124,780 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
0.8 (9) Ophthalmologist
& Nurse
39,746 10.460
(3) FFA & Nurse 39,769 10.473 23 0.012 1831
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(8) Ophthalmologist
& Ophthalmologist
44,619 10.562 4850 0.089 54,384
(2) FFA
& Ophthalmologist
44,649 10.575 30 0.013 2328
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(7) Ophthalmologist
& OCT
62,706 10.437 18,056 –0.138 –130,729 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
0.9 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,769 10.467 0 –0.006 –15 Dominated
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(8) Ophthalmologist
& Ophthalmologist
44,645 10.569 4876 0.096 50,971
(2) FFA
& Ophthalmologist
44,649 10.575 4 0.006 569
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(7) Ophthalmologist
& OCT
62,744 10.443 18,095 –0.132 –137,244 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
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TABLE 53 One-way sensitivity analysis: ophthalmologist diagnosis sensitivity (continued )
Diagnosis
sensitivity
ophthalmologist
assessment Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
1.0 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,792 10.473 23 0.000 0 Dominated
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist
& Ophthalmologist
44,672 10.575 23 0.000 0 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,782 10.449 18,133 –0.126 –144,410 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
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TABLE 54 One-way sensitivity analysis: ophthalmologist diagnosis specificity
Diagnosis
sensitivity
ophthalmologist
assessment Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
0.1 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,815 10.472 46 –0.001 –74,082 Dominated
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist
& Ophthalmologist
44,695 10.574 45 –0.001 –70,022 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,803 10.449 18,154 –0.126 –143,862 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
0.2 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,812 10.472 43 –0.001 –68,977 Dominated
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist
& Ophthalmologist
44,691 10.574 42 –0.001 –65,156 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,800 10.449 18,151 –0.126 –143,837 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
0.3 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,809 10.472 40 –0.001 –63,871 Dominated
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist
& Ophthalmologist
44,688 10.574 39 –0.001 –60,290 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,797 10.449 18,148 –0.126 –143,812 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
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TABLE 54 One-way sensitivity analysis: ophthalmologist diagnosis specificity (continued )
Diagnosis
sensitivity
ophthalmologist
assessment Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
0.4 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,806 10.472 36 –0.001 –58,765 Dominated
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist
& Ophthalmologist
44,685 10.574 36 –0.001 –55,424 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,794 10.449 18,145 –0.126 –143,787 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
0.5 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,802 10.472 33 –0.001 –53,659 Dominated
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist
& Ophthalmologist
44,682 10.574 33 –0.001 –50,558 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,791 10.449 18,141 –0.126 –143,762 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
0.6 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,799 10.472 30 –0.001 –48,554 Dominated
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist
& Ophthalmologist
44,679 10.574 30 –0.001 –45,692 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2,482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,787 10.449 18,138 –0.126 –143,737 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
continued
DOI: 10.3310/hta18690 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 69
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Mowatt et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
179
TABLE 54 One-way sensitivity analysis: ophthalmologist diagnosis specificity (continued )
Diagnosis
sensitivity
ophthalmologist
assessment Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
0.7 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,796 10.472 27 –0.001 –43,448 Dominated
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist
& Ophthalmologist
44,676 10.574 27 –0.001 –40,826 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,784 10.449 18,135 –0.126 –143,712 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
0.8 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,793 10.472 24 –0.001 –38,342 Dominated
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist
& Ophthalmologist
44,673 10.574 23 –0.001 –35,960 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,781 10.449 18,132 –0.126 –143,687 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
0.9 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
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TABLE 54 One-way sensitivity analysis: ophthalmologist diagnosis specificity (continued )
Diagnosis
sensitivity
ophthalmologist
assessment Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
1.0 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,787 10.472 17 –0.001 –28,131 Dominated
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist
& Ophthalmologist
44,666 10.574 17 –0.001 –26,228 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,775 10.449 18,126 –0.126 –143,637 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
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TABLE 55 Two-way sensitivity analysis: ophthalmologist diagnosis sensitivity and specificity
(NMB at £30,000)
Ophthalmologist
diagnosis
Strategy
Expected
cost (£)
Expected
QALYs
NMB
(£)
Maximum
NMBSensitivity Specificity
0.8 0.5 (1) FFA & OCT 66,249 10.544 250,079
(2) FFA & Ophthalmologist 44,649 10.575 272,601
(3) FFA & Nurse 39,769 10.473 274,416 ✓
(4) OCT & OCT 72,821 10.544 243,493
(5) OCT & Ophthalmologist 47,971 10.574 269,244
(6) OCT & Nurse 42,237 10.472 271,910
(7) Ophthalmologist & OCT 66,204 10.531 249,730
(8) Ophthalmologist
& Ophthalmologist
44,632 10.562 272,229
(9) Ophthalmologist & Nurse 39,759 10.460 274,055
0.8 0.6 (1) FFA & OCT 66,249 10.544 250,079
(2) FFA & Ophthalmologist 44,649 10.575 272,601
(3) FFA & Nurse 39,769 10.473 274,416 ✓
(4) OCT & OCT 72,821 10.544 243,493
(5) OCT & Ophthalmologist 47,971 10.574 269,244
(6) OCT & Nurse 42,237 10.472 271,910
(7) Ophthalmologist & OCT 66,201 10.531 249,733
(8) Ophthalmologist
& Ophthalmologist
44,628 10.562 272,232
(9) Ophthalmologist & Nurse 39,756 10.460 274,058
0.8 0.7 (1) FFA & OCT 66,249 10.544 250,079
(2) FFA & Ophthalmologist 44,649 10.575 272,601
(3) FFA & Nurse 39,769 10.473 274,416 ✓
(4) OCT & OCT 72,821 10.544 243,493
(5) OCT & Ophthalmologist 47,971 10.574 269,244
(6) OCT & Nurse 42,237 10.472 271,910
(7) Ophthalmologist & OCT 66,197 10.531 249,736
(8) Ophthalmologist
& Ophthalmologist
44,625 10.562 272,235
(9) Ophthalmologist & Nurse 39,753 10.460 274,061
0.8 0.8 (1) FFA & OCT 66,249 10.544 250,079
(2) FFA & Ophthalmologist 44,649 10.575 272,601
(3) FFA & Nurse 39,769 10.473 274,416 ✓
(4) OCT & OCT 72,821 10.544 243,493
(5) OCT & Ophthalmologist 47,971 10.574 269,244
(6) OCT & Nurse 42,237 10.472 271,910
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TABLE 55 Two-way sensitivity analysis: ophthalmologist diagnosis sensitivity and specificity
(NMB at £30,000) (continued )
Ophthalmologist
diagnosis
Strategy
Expected
cost (£)
Expected
QALYs
NMB
(£)
Maximum
NMBSensitivity Specificity
(7) Ophthalmologist & OCT 66,194 10.531 249,739
(8) Ophthalmologist
& Ophthalmologist
44,622 10.562 272,239
(9) Ophthalmologist & Nurse 39,750 10.460 274,064
0.8 0.9 (1) FFA & OCT 66,249 10.544 250,079
(2) FFA & Ophthalmologist 44,649 10.575 272,601
(3) FFA & Nurse 39,769 10.473 274,416 ✓
(4) OCT & OCT 72,821 10.544 243,493
(5) OCT & Ophthalmologist 47,971 10.574 269,244
(6) OCT & Nurse 42,237 10.472 271,910
(7) Ophthalmologist & OCT 66,191 10.531 249,743
(8) Ophthalmologist
& Ophthalmologist
44,619 10.562 272,242
(9) Ophthalmologist & Nurse 39,746 10.460 274,068
0.8 1.0 (1) FFA & OCT 66,249 10.544 250,079
(2) FFA & Ophthalmologist 44,649 10.575 272,601
(3) FFA & Nurse 39,769 10.473 274,416 ✓
(4) OCT & OCT 72,821 10.544 243,493
(5) OCT & Ophthalmologist 47,971 10.574 269,244
(6) OCT & Nurse 42,237 10.472 271,910
(7) Ophthalmologist & OCT 66,188 10.531 249,746
(8) Ophthalmologist
& Ophthalmologist
44,616 10.562 272,245
(9) Ophthalmologist & Nurse 39,743 10.460 274,071
0.9 0.5 (1) FFA & OCT 66,249 10.544 250,079
(2) FFA & Ophthalmologist 44,649 10.575 272,601
(3) FFA & Nurse 39,769 10.473 274,416 ✓
(4) OCT & OCT 72,821 10.544 243,493
(5) OCT & Ophthalmologist 47,971 10.574 269,244
(6) OCT & Nurse 42,237 10.472 271,910
(7) Ophthalmologist & OCT 66,244 10.538 249,886
(8) Ophthalmologist
& Ophthalmologist
44,658 10.569 272,397
(9) Ophthalmologist & Nurse 39,782 10.467 274,218
0.9 0.6 (1) FFA & OCT 66,249 10.544 250,079
(2) FFA & Ophthalmologist 44,649 10.575 272,601
(3) FFA & Nurse 39,769 10.473 274,416 ✓
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TABLE 55 Two-way sensitivity analysis: ophthalmologist diagnosis sensitivity and specificity
(NMB at £30,000) (continued )
Ophthalmologist
diagnosis
Strategy
Expected
cost (£)
Expected
QALYs
NMB
(£)
Maximum
NMBSensitivity Specificity
(4) OCT & OCT 72,821 10.544 243,493
(5) OCT & Ophthalmologist 47,971 10.574 269,244
(6) OCT & Nurse 42,237 10.472 271,910
(7) Ophthalmologist & OCT 66,241 10.538 249,890
(8) Ophthalmologist
& Ophthalmologist
44,655 10.569 272,400
(9) Ophthalmologist & Nurse 39,779 10.467 274,221
0.9 0.7 (1) FFA & OCT 66,249 10.544 250,079
(2) FFA & Ophthalmologist 44,649 10.575 272,601
(3) FFA & Nurse 39,769 10.473 274,416 ✓
(4) OCT & OCT 72,821 10.544 243,493
(5) OCT & Ophthalmologist 47,971 10.574 269,244
(6) OCT & Nurse 42,237 10.472 271,910
(7) Ophthalmologist & OCT 66,238 10.538 249,893
(8) Ophthalmologist
& Ophthalmologist
44,652 10.569 272,404
(9) Ophthalmologist & Nurse 39,776 10.467 274,224
0.9 0.8 (1) FFA & OCT 66,249 10.544 250,079
(2) FFA & Ophthalmologist 44,649 10.575 272,601
(3) FFA & Nurse 39,769 10.473 274,416 ✓
(4) OCT & OCT 72,821 10.544 243,493
(5) OCT & Ophthalmologist 47,971 10.574 269,244
(6) OCT & Nurse 42,237 10.472 271,910
(7) Ophthalmologist & OCT 66,235 10.538 249,896
(8) Ophthalmologist
& Ophthalmologist
44,649 10.569 272,407
(9) Ophthalmologist & Nurse 39,772 10.467 274,227
0.9 0.9 (1) FFA & OCT 66,249 10.544 250,079
(2) FFA & Ophthalmologist 44,649 10.575 272,601
(3) FFA & Nurse 39,769 10.473 274,416 ✓
(4) OCT & OCT 72,821 10.544 243,493
(5) OCT & Ophthalmologist 47,971 10.574 269,244
(6) OCT & Nurse 42,237 10.472 271,910
(7) Ophthalmologist & OCT 66,232 10.538 249,899
(8) Ophthalmologist
& Ophthalmologist
44,645 10.569 272,410
(9) Ophthalmologist & Nurse 39,769 10.467 274,231
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TABLE 55 Two-way sensitivity analysis: ophthalmologist diagnosis sensitivity and specificity
(NMB at £30,000) (continued )
Ophthalmologist
diagnosis
Strategy
Expected
cost (£)
Expected
QALYs
NMB
(£)
Maximum
NMBSensitivity Specificity
0.9 1.0 (1) FFA & OCT 66,249 10.544 250,079
(2) FFA & Ophthalmologist 44,649 10.575 272,601
(3) FFA & Nurse 39,769 10.473 274,416 ✓
(4) OCT & OCT 72,821 10.544 243,493
(5) OCT & Ophthalmologist 47,971 10.574 269,244
(6) OCT & Nurse 42,237 10.472 271,910
(7) Ophthalmologist & OCT 66,228 10.538 249,902
(8) Ophthalmologist
& Ophthalmologist
44,642 10.569 272,413
(9) Ophthalmologist & Nurse 39,766 10.467 274,234
1.0 0.5 (1) FFA & OCT 66,249 10.544 250,079
(2) FFA & Ophthalmologist 44,649 10.575 272,601
(3) FFA & Nurse 39,769 10.473 274,416 ✓
(4) OCT & OCT 72,821 10.544 243,493
(5) OCT & Ophthalmologist 47,971 10.574 269,244
(6) OCT & Nurse 42,237 10.472 271,910
(7) Ophthalmologist & OCT 66,285 10.544 250,043
(8) Ophthalmologist
& Ophthalmologist
44,685 10.575 272,566
(9) Ophthalmologist & Nurse 39,805 10.473 274,381
1.0 0.6 (1) FFA & OCT 66,249 10.544 250,079
(2) FFA & Ophthalmologist 44,649 10.575 272,601
(3) FFA & Nurse 39,769 10.473 274,416 ✓
(4) OCT & OCT 72,821 10.544 243,493
(5) OCT & Ophthalmologist 47,971 10.574 269,244
(6) OCT & Nurse 42,237 10.472 271,910
(7) Ophthalmologist & OCT 66,281 10.544 250,046
(8) Ophthalmologist
& Ophthalmologist
44,681 10.575 272,569
(9) Ophthalmologist & Nurse 39,801 10.473 274,384
1.0 0.7 (1) FFA & OCT 66,249 10.544 250,079
(2) FFA & Ophthalmologist 44,649 10.575 272,601
(3) FFA & Nurse 39,769 10.473 274,416 ✓
(4) OCT & OCT 72,821 10.544 243,493
(5) OCT & Ophthalmologist 47,971 10.574 269,244
(6) OCT & Nurse 42,237 10.472 271,910
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TABLE 55 Two-way sensitivity analysis: ophthalmologist diagnosis sensitivity and specificity
(NMB at £30,000) (continued )
Ophthalmologist
diagnosis
Strategy
Expected
cost (£)
Expected
QALYs
NMB
(£)
Maximum
NMBSensitivity Specificity
(7) Ophthalmologist & OCT 66,278 10.544 250,049
(8) Ophthalmologist
& Ophthalmologist
44,678 10.575 272,572
(9) Ophthalmologist & Nurse 39,798 10.473 274,387
1.0 0.8 (1) FFA & OCT 66,249 10.544 250,079
(2) FFA & Ophthalmologist 44,649 10.575 272,601
(3) FFA & Nurse 39,769 10.473 274,416 ✓
(4) OCT & OCT 72,821 10.544 243,493
(5) OCT & Ophthalmologist 47,971 10.574 269,244
(6) OCT & Nurse 42,237 10.472 271,910
1.0 0.8 (7) Ophthalmologist & OCT 66,275 10.544 250,053
(8) Ophthalmologist
& Ophthalmologist
44,675 10.575 272,575
(9) Ophthalmologist & Nurse 39,795 10.473 274,390
1.0 0.9 (1) FFA & OCT 66,249 10.544 250,079
(2) FFA & Ophthalmologist 44,649 10.575 272,601
(3) FFA & Nurse 39,769 10.473 274,416 ✓
(4) OCT & OCT 72,821 10.544 243,493
(5) OCT & Ophthalmologist 47,971 10.574 269,244
(6) OCT & Nurse 42,237 10.472 271,910
(7) Ophthalmologist & OCT 66,272 10.544 250,056
(8) Ophthalmologist
& Ophthalmologist
44,672 10.575 272,578
(9) Ophthalmologist & Nurse 39,792 10.473 274,393
1.0 1.0 (1) FFA & OCT 66,249 10.544 250,079
(2) FFA & Ophthalmologist 44,649 10.575 272,601
(3) FFA & Nurse 39,769 10.473 274,416 ✓
(4) OCT & OCT 72,821 10.544 243,493
(5) OCT & Ophthalmologist 47,971 10.574 269,244
(6) OCT & Nurse 42,237 10.472 271,910
(7) Ophthalmologist & OCT 66,269 10.544 250,059
(8) Ophthalmologist
& Ophthalmologist
44,669 10.575 272,581
(9) Ophthalmologist & Nurse 39,789 10.473 274,397
NMB, net monetary benefit.
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TABLE 56 One-way sensitivity analysis: probability of ophthalmologist diagnosis unclear results
Ophthalmologist
diagnoses unclear
results (%) Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
0 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,786 10.472 17 –0.001 –24,950 Dominated
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist
& Ophthalmologist
44,666 10.574 17 –0.001 –23,196 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,774 10.449 18,125 –0.126 –143,554 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
0.1 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
0.2 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,793 10.472 24 –0.001 –43,595 Dominated
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist
& Ophthalmologist
44,673 10.574 24 –0.001 –40,966 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,782 10.449 18,132 –0.126 –143,770 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
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TABLE 56 One-way sensitivity analysis: probability of ophthalmologist diagnosis unclear results (continued )
Ophthalmologist
diagnoses unclear
results (%) Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
0.3 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,797 10.472 27 0.000 –56,912 Dominated
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist
& Ophthalmologist
44,676 10.575 27 –0.001 –53,658 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,785 10.449 18,136 –0.126 –143,878 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
0.4 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,800 10.472 31 0.000 –74,669 Dominated
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist
& Ophthalmologist
44,680 10.575 31 0.000 –70,581 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,789 10.449 18,140 –0.126 –143,986 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
0.5 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,803 10.473 34 0.000 –99,528 Dominated
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist
& Ophthalmologist
44,683 10.575 34 0.000 –94,274 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,792 10.449 18,143 –0.126 –144,094 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
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TABLE 57 One-way sensitivity analysis: OCT monitoring sensitivity
OCT
monitoring
sensitivity Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
0.4 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 54,070 9.686 9421 –0.889 –10,596 Dominated
(7) Ophthalmologist
& OCT
54,090 9.686 9441 –0.890 –10,614 Dominated
(4) OCT & OCT 58,742 9.681 14,093 –0.894 –15,761 Dominated
0.5 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 56,826 9.915 12,177 –0.661 –18,436 Dominated
(7) Ophthalmologist
& OCT
56,846 9.914 12,197 –0.661 –18,453 Dominated
(4) OCT & OCT 61,495 9.909 16,845 –0.666 –25,281 Dominated
0.6 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 59,000 10.103 14,351 –0.472 –30,377 Dominated
(7) Ophthalmologist
& OCT
59,019 10.102 14,370 –0.473 –30,384 Dominated
(4) OCT & OCT 63,666 10.096 19,017 –0.479 –39,707 Dominated
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TABLE 57 One-way sensitivity analysis: OCT monitoring sensitivity (continued )
OCT
monitoring
sensitivity Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
0.7 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 60,740 10.259 16,090 –0.316 –50,949 Dominated
(7) Ophthalmologist
& OCT
60,759 10.259 16,110 –0.316 –50,918 Dominated
(4) OCT & OCT 65,404 10.252 20,754 –0.323 –64,283 Dominated
0.8 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,151 10.391 17,502 –0.184 –95,174 Dominated
(7) Ophthalmologist
& OCT
62,170 10.391 17,521 –0.185 –94,962 Dominated
(4) OCT & OCT 66,814 10.384 22,165 –0.191 –115,799 Dominated
0.9 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 63,312 10.503 18,663 –0.072 –260,619 Dominated
(7) Ophthalmologist
& OCT
63,331 10.503 18,682 –0.072 –258,561 Dominated
(4) OCT & OCT 67,974 10.495 23,325 –0.080 –293,337 Dominated
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TABLE 57 One-way sensitivity analysis: OCT monitoring sensitivity (continued )
OCT
monitoring
sensitivity Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
1.0 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2,482 –0.008 –293,938 Dominated
(1) FFA & OCT 64,277 10.600 19,628 0.025 788,482
(7) Ophthalmologist
& OCT
64,296 10.599 19 –0.001 –28,229 Dominated
(4) OCT & OCT 68,939 10.592 4662 –0.008 –565,643 Dominated
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TABLE 58 One-way sensitivity analysis: OCT monitoring specificity
OCT
monitoring
specificity Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
0.3 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 74,212 10.459 29,563 –0.116 –255,643 Dominated
(7) Ophthalmologist
& OCT
74,230 10.459 29,581 –0.116 –254,397 Dominated
(4) OCT & OCT 80,083 10.452 35,434 –0.123 –287,514 Dominated
0.4 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 67,780 10.454 23,130 –0.121 –190,790 Dominated
(7) Ophthalmologist
& OCT
67,798 10.453 23,149 –0.122 –189,953 Dominated
(4) OCT & OCT 72,979 10.446 28,330 –0.129 –219,784 Dominated
0.5 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 61,521 10.448 16,872 –0.127 –133,240 Dominated
(7) Ophthalmologist
& OCT
61,540 10.448 16,891 –0.127 –132,734 Dominated
(4) OCT & OCT 66,049 10.441 21,400 –0.134 –159,275 Dominated
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TABLE 58 One-way sensitivity analysis: OCT monitoring specificity (continued )
OCT
monitoring
specificity Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
0.6 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 55,429 10.443 10,780 –0.132 –81,774 Dominated
(7) Ophthalmologist
& OCT
55,449 10.443 10,800 –0.132 –81,537 Dominated
(4) OCT & OCT 59,286 10.435 14,636 –0.140 –104,824 Dominated
0.7 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 49,498 10.438 4849 –0.137 –35,432 Dominated
(7) Ophthalmologist
& OCT
49,518 10.438 4869 –0.137 –35,418 Dominated
(4) OCT & OCT 52,683 10.430 8033 –0.145 –55,508 Dominated
0.8 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(1) FFA & OCT 43,721 10.433 3952 –0.040 –99,944 Dominated
(7) Ophthalmologist
& OCT
43,742 10.433 3973 –0.040 –98,928 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(4) OCT & OCT 46,234 10.425 1585 –0.150 –10,589 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
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TABLE 58 One-way sensitivity analysis: OCT monitoring specificity (continued )
OCT
monitoring
specificity Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
0.9 (1) FFA & OCT 38,093 10.429
(7) Ophthalmologist
& OCT
38,114 10.428 21 –0.001 –34,221 Dominated
(3) FFA & Nurse 39,769 10.473 1676 0.044 37,884
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(4) OCT & OCT 39,934 10.421 164 –0.052 –3,146 Dominated
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
1.0 (1) FFA & OCT 32,608 10.424
(7) Ophthalmologist
& OCT
32,629 10.423 21 –0.001 –35,125 Dominated
(4) OCT & OCT 33,776 10.416 1168 –0.008 –144,031 Dominated
(3) FFA & Nurse 39,769 10.473 7161 0.049 146,783
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
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TABLE 59 Two-way sensitivity analysis: OCT monitoring sensitivity and specificity (NMB at £30,000)
OCT monitoring
Strategy
Expected
cost (£)
Expected
QALYs
NMB
(£)
Maximum
NMBSensitivity Specificity
0.8 0.3 (1) FFA & OCT 73,512 10.4055 238,652
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 79,384 10.3981 232,558
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 41,607 10.4647 272,332
(7) Ophthalmologist & OCT 73,531 10.4048 238,615
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.8 0.4 (1) FFA & OCT 67,127 10.3974 244,794
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 72,327 10.3899 239,370
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 41,607 10.4647 272,332
(7) Ophthalmologist & OCT 67,146 10.3967 244,757
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.8 0.5 (1) FFA & OCT 60,925 10.3896 250,762
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 65,454 10.3821 246,008
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 41,607 10.4647 272,332
(7) Ophthalmologist & OCT 60,944 10.3890 250,725
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.8 0.6 (1) FFA & OCT 54,899 10.3821 256,564
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 58,756 10.3745 252,480
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 41,607 10.4647 272,332
(7) Ophthalmologist & OCT 54,918 10.3815 256,527
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TABLE 59 Two-way sensitivity analysis: OCT monitoring sensitivity and specificity (NMB at £30,000) (continued )
OCT monitoring
Strategy
Expected
cost (£)
Expected
QALYs
NMB
(£)
Maximum
NMBSensitivity Specificity
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.8 0.7 (1) FFA & OCT 49,041 10.3749 262,206
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 52,226 10.3672 258,791
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 41,607 10.4647 272,332
(7) Ophthalmologist & OCT 49,061 10.3743 262,168
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.8 0.8 (1) FFA & OCT 43,344 10.3680 267,695
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 45,858 10.3602 264,949
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 41,607 10.4647 272,332
(7) Ophthalmologist & OCT 43,365 10.3674 267,656
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.8 0.9 (1) FFA & OCT 37,803 10.3613 273,035
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 39,645 10.3535 270,960
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 41,607 10.4647 272,332
(7) Ophthalmologist & OCT 37,824 10.3607 272,997
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.8 1.0 (1) FFA & OCT 32,411 10.3548 278,234 ✓
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416
(4) OCT & OCT 33,581 10.3469 276,828
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 41,607 10.4647 272,332
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TABLE 59 Two-way sensitivity analysis: OCT monitoring sensitivity and specificity (NMB at £30,000) (continued )
OCT monitoring
Strategy
Expected
cost (£)
Expected
QALYs
NMB
(£)
Maximum
NMBSensitivity Specificity
(7) Ophthalmologist & OCT 32,432 10.3542 278,195
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.9 0.3 (1) FFA & OCT 74,844 10.5091 240,429
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 80,715 10.5013 234,324
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 41,607 10.4647 272,332
(7) Ophthalmologist & OCT 74,862 10.5084 240,391
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.9 0.4 (1) FFA & OCT 68,371 10.5059 246,806
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 73,570 10.4980 241,371
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 41,607 10.4647 272,332
(7) Ophthalmologist & OCT 68,389 10.5052 246,768
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.9 0.5 (1) FFA & OCT 62,063 10.5028 253,020
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 66,591 10.4949 248,255
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 41,607 10.4647 272,332
(7) Ophthalmologist & OCT 62,082 10.5021 252,982
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.9 0.6 (1) FFA & OCT 55,915 10.4998 259,078
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 59,770 10.4918 254,982
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TABLE 59 Two-way sensitivity analysis: OCT monitoring sensitivity and specificity (NMB at £30,000) (continued )
OCT monitoring
Strategy
Expected
cost (£)
Expected
QALYs
NMB
(£)
Maximum
NMBSensitivity Specificity
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 41,607 10.4647 272,332
(7) Ophthalmologist & OCT 55,934 10.4991 259,040
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.9 0.7 (1) FFA & OCT 49,920 10.4968 264,985
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 53,103 10.4887 261,559
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 41,607 10.4647 272,332
(7) Ophthalmologist & OCT 49,939 10.4962 264,946
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.9 0.8 (1) FFA & OCT 44,072 10.4940 270,747
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 46,584 10.4858 267,990
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 41,607 10.4647 272,332
(7) Ophthalmologist & OCT 44,093 10.4933 270,707
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.9 0.9 (1) FFA & OCT 38,367 10.4912 276,368 ✓
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416
(4) OCT & OCT 40,207 10.4829 274,282
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 41,607 10.4647 272,332
(7) Ophthalmologist & OCT 38,388 10.4906 276,329
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.9 1.0 (1) FFA & OCT 32,800 10.4885 281,854 ✓
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416
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TABLE 59 Two-way sensitivity analysis: OCT monitoring sensitivity and specificity (NMB at £30,000) (continued )
OCT monitoring
Strategy
Expected
cost (£)
Expected
QALYs
NMB
(£)
Maximum
NMBSensitivity Specificity
(4) OCT & OCT 33,967 10.4801 280,438
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 41,607 10.4647 272,332
(7) Ophthalmologist & OCT 32,821 10.4878 281,815
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
1.0 0.3 (1) FFA & OCT 75,937 10.5978 241,996
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 81,809 10.5897 235,882
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 41,607 10.4647 272,332
(7) Ophthalmologist & OCT 75,955 10.5971 241,958
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
1.0 0.4 (1) FFA & OCT 69,399 10.5990 248,571
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 74,598 10.5908 243,126
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 41,607 10.4647 272,332
(7) Ophthalmologist & OCT 69,417 10.5983 248,532
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
1.0 0.5 (1) FFA & OCT 63,011 10.6001 254,992
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 67,539 10.5919 250,217
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 41,607 10.4647 272,332
(7) Ophthalmologist & OCT 63,030 10.5994 254,953
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
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TABLE 59 Two-way sensitivity analysis: OCT monitoring sensitivity and specificity (NMB at £30,000) (continued )
OCT monitoring
Strategy
Expected
cost (£)
Expected
QALYs
NMB
(£)
Maximum
NMBSensitivity Specificity
1.0 0.6 (1) FFA & OCT 56,770 10.6011 261,265
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 60,625 10.5928 257,159
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 41,607 10.4647 272,332
(7) Ophthalmologist & OCT 56,789 10.6005 261,225
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
1.0 0.7 (1) FFA & OCT 50,669 10.6021 267,394
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 53,852 10.5937 263,958
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 41,607 10.4647 272,332
(7) Ophthalmologist & OCT 50,689 10.6014 267,354
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
1.0 0.8 (1) FFA & OCT 44,705 10.6030 273,384
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 47,215 10.5945 270,619
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 41,607 10.4647 272,332
(7) Ophthalmologist & OCT 44,725 10.6023 273,344
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
1.0 0.9 (1) FFA & OCT 38,872 10.6038 279,241 ✓
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416
(4) OCT & OCT 40,710 10.5952 277,145
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 41,607 10.4647 272,332
(7) Ophthalmologist & OCT 38,893 10.6031 279,201
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
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TABLE 59 Two-way sensitivity analysis: OCT monitoring sensitivity and specificity (NMB at £30,000) (continued )
OCT monitoring
Strategy
Expected
cost (£)
Expected
QALYs
NMB
(£)
Maximum
NMBSensitivity Specificity
1.0 1.0 (1) FFA & OCT 33,167 10.6045 284,968 ✓
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416
(4) OCT & OCT 34,331 10.5958 283,543
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 41,607 10.4647 272,332
(7) Ophthalmologist & OCT 33,188 10.6038 284,928
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
NMB, net monetary benefit.
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TABLE 60 One-way sensitivity analysis: ophthalmologist monitoring sensitivity
Ophthalmologist
monitoring
assessment
sensitivity Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
0.1 (3) FFA & Nurse 35,469 8.830
(9) Ophthalmologist
& Nurse
35,491 8.830 22 0.000 –121,961 Dominated
(2) FFA
& Ophthalmologist
35,931 8.920 462 0.089 5167
(8) Ophthalmologist
& Ophthalmologist
35,953 8.920 22 0.000 –108,940 Dominated
(6) OCT & Nurse 37,324 8.828 1392 –0.092 –15,092 Dominated
(5) OCT
& Ophthalmologist
38,432 8.917 2501 –0.003 –810,442 Dominated
(1) FFA & OCT 62,759 10.449 26,828 1.530 17,539
(7) Ophthalmologist
& OCT
62,778 10.449 19 –0.001 –30,303 Dominated
(4) OCT & OCT 67,421 10.442 4662 –0.008 –604,118 Dominated
0.2 (3) FFA & Nurse 36,017 9.133
(9) Ophthalmologist
& Nurse
36,039 9.133 22 0.000 –84,837 Dominated
(2) FFA
& Ophthalmologist
37,512 9.243 1495 0.109 13,708
(8) Ophthalmologist
& Ophthalmologist
37,534 9.242 22 0.000 –76,050 Dominated
(6) OCT & Nurse 37,869 9.130 358 –0.113 –3,169 Dominated
(5) OCT
& Ophthalmologist
40,010 9.238 2498 –0.004 –609,285 Dominated
(1) FFA & OCT 62,759 10.449 25,247 1.207 20,919
(7) Ophthalmologist
& OCT
62,778 10.449 19 –0.001 –30,303 Dominated
(4) OCT & OCT 67,421 10.442 4662 –0.008 –604,118 Dominated
0.3 (3) FFA & Nurse 36,593 9.397
(9) Ophthalmologist
& Nurse
36,615 9.397 22 0.000 –66,222 Dominated
(6) OCT & Nurse 38,444 9.392 1851 –0.005 –402,106 Dominated
(2) FFA
& Ophthalmologist
38,913 9.517 2320 0.120 19,394
(8) Ophthalmologist
& Ophthalmologist
38,934 9.516 21 0.000 –59,673 Dominated
(5) OCT
& Ophthalmologist
41,408 9.512 2495 –0.005 –499,702 Dominated
(1) FFA & OCT 62,759 10.449 23,846 0.933 25,560
(7) Ophthalmologist
& OCT
62,778 10.449 19 –0.001 –30,303 Dominated
(4) OCT & OCT 67,421 10.442 4662 –0.008 –604,118 Dominated
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TABLE 60 One-way sensitivity analysis: ophthalmologist monitoring sensitivity (continued )
Ophthalmologist
monitoring
assessment
sensitivity Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
0.4 (3) FFA & Nurse 37,161 9.625
(9) Ophthalmologist
& Nurse
37,183 9.625 21 0.000 –55,221 Dominated
(6) OCT & Nurse 39,010 9.620 1849 –0.005 –345,207 Dominated
(2) FFA
& Ophthalmologist
40,137 9.749 2976 0.124 24,018
(8) Ophthalmologist
& Ophthalmologist
40,159 9.749 21 0.000 –50,052 Dominated
(5) OCT
& Ophthalmologist
42,630 9.744 2492 –0.006 –432,284 Dominated
(1) FFA & OCT 62,759 10.449 22,621 0.700 32,314
(7) Ophthalmologist
& OCT
62,778 10.449 19 –0.001 –30,303 Dominated
(4) OCT & OCT 67,421 10.442 4662 –0.008 –604,118 Dominated
0.5 (3) FFA & Nurse 37,703 9.824
(9) Ophthalmologist
& Nurse
37,725 9.824 21 0.000 –48,047 Dominated
(6) OCT & Nurse 39,550 9.818 1847 –0.006 –306,735 Dominated
(2) FFA
& Ophthalmologist
41,202 9.948 3499 0.124 28,209
(8) Ophthalmologist
& Ophthalmologist
41,223 9.948 21 0.000 –43,812 Dominated
(5) OCT
& Ophthalmologist
43,692 9.942 2490 –0.006 –387,406 Dominated
(1) FFA & OCT 62,759 10.449 21,557 0.501 43,001
(7) Ophthalmologist
& OCT
62,778 10.449 19 –0.001 –30,303 Dominated
(4) OCT & OCT 67,421 10.442 4662 –0.008 –604,118 Dominated
0.6 (3) FFA & Nurse 38,211 9.997
(9) Ophthalmologist
& Nurse
38,232 9.997 21 0.000 –43,049 Dominated
(6) OCT & Nurse 40,055 9.991 1845 –0.007 –279,334 Dominated
(2) FFA
& Ophthalmologist
42,128 10.119 3917 0.121 32,250
(8) Ophthalmologist
& Ophthalmologist
42,148 10.118 21 –0.001 –39,488 Dominated
(5) OCT
& Ophthalmologist
44,615 10.112 2488 –0.007 –355,836 Dominated
(1) FFA & OCT 62,759 10.449 20,631 0.331 62,364
(7) Ophthalmologist
& OCT
62,778 10.449 19 –0.001 –30,303 Dominated
(4) OCT & OCT 67,421 10.442 4662 –0.008 –604,118 Dominated
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TABLE 60 One-way sensitivity analysis: ophthalmologist monitoring sensitivity (continued )
Ophthalmologist
monitoring
assessment
sensitivity Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
0.7 (3) FFA & Nurse 38,680 10.149
(9) Ophthalmologist
& Nurse
38,701 10.148 21 –0.001 –39,397 Dominated
(6) OCT & Nurse 40,523 10.141 1843 –0.007 –259,036 Dominated
(2) FFA
& Ophthalmologist
42,934 10.266 4254 0.117 36,287
(8) Ophthalmologist
& Ophthalmologist
42,955 10.265 21 –0.001 –36,346 Dominated
(5) OCT
& Ophthalmologist
45,420 10.258 2486 –0.007 –332,704 Dominated
(1) FFA & OCT 62,759 10.449 19,825 0.184 107,925
(7) Ophthalmologist
& OCT
62,778 10.449 19 –0.001 –30,303 Dominated
(4) OCT & OCT 67,421 10.442 4662 –0.008 –604,118 Dominated
0.8 (3) FFA & Nurse 39,113 10.281
(9) Ophthalmologist
& Nurse
39,134 10.281 21 –0.001 –36,631 Dominated
(6) OCT & Nurse 40,954 10.274 1841 –0.008 –243,534 Dominated
(2) FFA
& Ophthalmologist
43,639 10.394 4526 0.112 40,409
(1) FFA & OCT 62,759 10.449 19,119 0.056 341,760
(8) Ophthalmologist
& Ophthalmologist
43,660 10.393 20 –0.001 –33,978 Dominated
(5) OCT
& Ophthalmologist
46,124 10.386 2484 –0.008 –315,219 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 19 –0.001 –30,303 Dominated
(4) OCT & OCT 67,421 10.442 4662 –0.008 –604,118 Dominated
0.9 (3) FFA & Nurse 39,511 10.399
(9) Ophthalmologist
& Nurse
39,531 10.398 21 –0.001 –34,477 Dominated
(6) OCT & Nurse 41,350 10.391 1839 –0.008 –231,400 Dominated
(2) FFA
& Ophthalmologist
44,259 10.505 4749 0.106 44,674
(8) Ophthalmologist
& Ophthalmologist
44,280 10.504 20 –0.001 –32,144 Dominated
(5) OCT
& Ophthalmologist
46,742 10.497 2483 –0.008 –301,676 Dominated
(1) FFA & OCT 62,759 10.449 18,500 –0.056 –332,463 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 18,519 –0.056 –329,091 Dominated
(4) OCT & OCT 67,421 10.442 23,162 –0.063 –365,551 Dominated
APPENDIX 8
NIHR Journals Library www.journalslibrary.nihr.ac.uk
204
TABLE 60 One-way sensitivity analysis: ophthalmologist monitoring sensitivity (continued )
Ophthalmologist
monitoring
assessment
sensitivity Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
1.0 (3) FFA & Nurse 39,875 10.503
(9) Ophthalmologist
& Nurse
39,896 10.502 21 –0.001 –32,760 Dominated
(6) OCT & Nurse 41,713 10.494 1838 –0.008 –221,712 Dominated
(2) FFA
& Ophthalmologist
44,806 10.603 4931 0.100 49,125
(8) Ophthalmologist
& Ophthalmologist
44,827 10.602 20 –0.001 –30,691 Dominated
(5) OCT
& Ophthalmologist
47,288 10.595 2481 –0.009 –290,979 Dominated
(1) FFA & OCT 62,759 10.449 17,953 –0.154 –116,811 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 17,972 –0.154 –116,459 Dominated
(4) OCT & OCT 67,421 10.442 22,615 –0.161 –140,112 Dominated
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TABLE 61 One-way sensitivity analysis: ophthalmologist monitoring specificity
Ophthalmologist
monitoring
assessment
specificity Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
0.1 (3) FFA & Nurse 56,447 10.483
(9) Ophthalmologist
& Nurse
56,467 10.482 19 –0.001 –30,720 Dominated
(6) OCT & Nurse 60,233 10.475 3786 –0.008 –475,573 Dominated
(1) FFA & OCT 62,759 10.449 6312 –0.033 –189,611 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 6331 –0.034 –186,661 Dominated
(4) OCT & OCT 67,421 10.442 10,974 –0.041 –267,627 Dominated
(2) FFA
& Ophthalmologist
84,302 10.575 27,854 0.092 301,922
(8) Ophthalmologist
& Ophthalmologist
84,319 10.574 18 –0.001 –26,020 Dominated
(5) OCT
& Ophthalmologist
91,018 10.567 6716 –0.008 –845,509 Dominated
0.2 (3) FFA & Nurse 53,989 10.481
(9) Ophthalmologist
& Nurse
54,009 10.481 20 –0.001 –31,085 Dominated
(6) OCT & Nurse 57,497 10.473 3508 –0.008 –438,888 Dominated
(1) FFA & OCT 62,759 10.449 8770 –0.032 –275,574 Dominated
0.2 (7) Ophthalmologist
& OCT
62,778 10.449 8789 –0.032 –270,828 Dominated
(4) OCT & OCT 67,421 10.442 13,432 –0.040 –339,701 Dominated
(2) FFA
& Ophthalmologist
78,264 10.575 24,275 0.094 258,685
(8) Ophthalmologist
& Ophthalmologist
78,282 10.574 18 –0.001 –26,767 Dominated
(5) OCT
& Ophthalmologist
84,376 10.567 6112 –0.008 –763,048 Dominated
0.3 (3) FFA & Nurse 51,557 10.480
(9) Ophthalmologist
& Nurse
51,577 10.479 20 –0.001 –31,448 Dominated
(6) OCT & Nurse 54,787 10.472 3230 –0.008 –402,465 Dominated
(1) FFA & OCT 62,759 10.449 11,202 –0.030 –368,763 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 11,221 –0.031 –361,908 Dominated
(4) OCT & OCT 67,421 10.442 15,864 –0.038 –416,445 Dominated
(2) FFA
& Ophthalmologist
72,358 10.575 20,801 0.095 218,127
(8) Ophthalmologist
& Ophthalmologist
72,377 10.575 18 –0.001 –27,506 Dominated
(5) OCT
& Ophthalmologist
77,865 10.567 5507 –0.008 –681,762 Dominated
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TABLE 61 One-way sensitivity analysis: ophthalmologist monitoring specificity (continued )
Ophthalmologist
monitoring
assessment
specificity Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
0.4 (3) FFA & Nurse 49,150 10.478
(9) Ophthalmologist
& Nurse
49,170 10.478 20 –0.001 –31,809 Dominated
(6) OCT & Nurse 52,102 10.470 2951 –0.008 –366,309 Dominated
(1) FFA & OCT 62,759 10.449 13,609 –0.029 –470,106 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 13,628 –0.030 –460,768 Dominated
(2) FFA
& Ophthalmologist
66,579 10.575 17,428 0.097 179,997
(8) Ophthalmologist
& Ophthalmologist
66,597 10.575 19 –0.001 –28,239 Dominated
(4) OCT & OCT 67,421 10.442 843 –0.133 –6313 Dominated
(5) OCT
& Ophthalmologist
71,481 10.567 4902 –0.008 –601,684 Dominated
0.5 (3) FFA & Nurse 46,769 10.477
(9) Ophthalmologist
& Nurse
46,789 10.476 20 –0.001 –32,169 Dominated
(6) OCT & Nurse 49,442 10.469 2673 –0.008 –330,421 Dominated
(2) FFA
& Ophthalmologist
60,922 10.575 14,153 0.098 144,077
(8) Ophthalmologist
& Ophthalmologist
60,941 10.575 19 –0.001 –28,964 Dominated
(1) FFA & OCT 62,759 10.449 1837 –0.126 –14,607 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 1856 –0.126 –14,685 Dominated
(5) OCT
& Ophthalmologist
65,219 10.567 4297 –0.008 –522,843 Dominated
(4) OCT & OCT 67,421 10.442 6500 –0.133 –48,691 Dominated
0.6 (3) FFA & Nurse 44,411 10.476
(9) Ophthalmologist
& Nurse
44,432 10.475 20 –0.001 –32,527 Dominated
(6) OCT & Nurse 46,806 10.467 2395 –0.008 –294,806 Dominated
(2) FFA
& Ophthalmologist
55,384 10.575 10,972 0.100 110,175
(8) Ophthalmologist
& Ophthalmologist
55,403 10.575 19 –0.001 –29,681 Dominated
(5) OCT
& Ophthalmologist
59,076 10.567 3692 –0.008 –445,261 Dominated
(1) FFA & OCT 62,759 10.449 7375 –0.126 –58,658 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 7394 –0.126 –58,517 Dominated
(4) OCT & OCT 67,421 10.442 12,038 –0.133 –90,204 Dominated
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TABLE 61 One-way sensitivity analysis: ophthalmologist monitoring specificity (continued )
Ophthalmologist
monitoring
assessment
specificity Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
0.7 (3) FFA & Nurse 42,078 10.474
(9) Ophthalmologist
& Nurse
42,099 10.474 20 –0.001 –32,882 Dominated
(6) OCT & Nurse 44,195 10.466 2116 –0.008 –259,466 Dominated
(2) FFA
& Ophthalmologist
49,961 10.575 7882 0.101 78,122
(8) Ophthalmologist
& Ophthalmologist
49,981 10.574 20 –0.001 –30,391 Dominated
(5) OCT
& Ophthalmologist
53,048 10.567 3087 –0.008 –368,955 Dominated
(1) FFA & OCT 62,759 10.449 12,798 –0.126 –101,847 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 12,817 –0.126 –101,491 Dominated
(4) OCT & OCT 67,421 10.442 17,461 –0.133 –130,910 Dominated
0.8 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
0.9 (3) FFA & Nurse 37,483 10.472
(9) Ophthalmologist
& Nurse
37,504 10.471 21 –0.001 –33,589 Dominated
(6) OCT & Nurse 39,043 10.463 1560 –0.008 –189,620 Dominated
(2) FFA
& Ophthalmologist
39,446 10.575 1962 0.103 18,981
(8) Ophthalmologist
& Ophthalmologist
39,466 10.574 21 –0.001 –31,789 Dominated
(5) OCT
& Ophthalmologist
41,322 10.566 1877 –0.009 –220,218 Dominated
(1) FFA & OCT 62,759 10.449 23,313 –0.125 –185,856 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 23,332 –0.126 –185,082 Dominated
(4) OCT & OCT 67,421 10.442 27,976 –0.133 –210,099 Dominated
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TABLE 61 One-way sensitivity analysis: ophthalmologist monitoring specificity (continued )
Ophthalmologist
monitoring
assessment
specificity Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
1.0 (2) FFA
& Ophthalmologist
34,347 10.575
(8) Ophthalmologist
& Ophthalmologist
34,368 10.574 21 –0.001 –32,476 Dominated
(3) FFA & Nurse 35,221 10.470 874 –0.105 –8357 Dominated
(9) Ophthalmologist
& Nurse
35,242 10.470 895 –0.105 –8507 Dominated
(5) OCT
& Ophthalmologist
35,618 10.566 1271 –0.009 –147,799 Dominated
(6) OCT & Nurse 36,502 10.462 2155 –0.113 –19,102 Dominated
(1) FFA & OCT 62,759 10.449 28,412 –0.125 –226,777 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 28,431 –0.126 –225,797 Dominated
(4) OCT & OCT 67,421 10.442 33,074 –0.133 –248,673 Dominated
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TABLE 62 Two-way sensitivity analysis: ophthalmologist monitoring sensitivity and specificity
(NMB at £30,000)
Ophthalmologist
monitoring
Strategy
Expected
cost (£)
Expected
QALYs
NMB
(£)
Maximum
NMBSensitivity Specificity
0.8 0.5 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 59,393 10.4103 252,918
(3) FFA & Nurse 45,800 10.2925 262,976 ✓
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 63,691 10.4027 248,389
(6) OCT & Nurse 48,475 10.2850 260,076
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
59,412 10.4097 252,880
(9) Ophthalmologist & Nurse 45,820 10.2919 262,938
0.8 0.6 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 54,012 10.4045 258,125
(3) FFA & Nurse 43,544 10.2888 265,120 ✓
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 57,705 10.3968 254,199
(6) OCT & Nurse 45,941 10.2813 262,498
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
54,031 10.4039 258,087
(9) Ophthalmologist & Nurse 43,564 10.2882 265,082
0.8 0.7 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 48,762 10.3989 263,206
(3) FFA & Nurse 41,315 10.2851 267,238 ✓
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 51,851 10.3911 259,883
(6) OCT & Nurse 43,434 10.2776 264,893
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
48,782 10.3983 263,168
(9) Ophthalmologist & Nurse 41,336 10.2845 267,200
0.8 0.8 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 43,639 10.3935 268,166
(3) FFA & Nurse 39,113 10.2815 269,331 ✓
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 46,124 10.3856 265,445
(6) OCT & Nurse 40,954 10.2739 267,264
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
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TABLE 62 Two-way sensitivity analysis: ophthalmologist monitoring sensitivity and specificity
(NMB at £30,000) (continued )
Ophthalmologist
monitoring
Strategy
Expected
cost (£)
Expected
QALYs
NMB
(£)
Maximum
NMBSensitivity Specificity
(8) Ophthalmologist
& Ophthalmologist
43,660 10.3929 268,127
(9) Ophthalmologist & Nurse 39,134 10.2809 269,294
0.8 0.9 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 38,639 10.3882 273,008 ✓
(3) FFA & Nurse 36,938 10.2779 271,400
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 40,519 10.3803 270,890
(6) OCT & Nurse 38,500 10.2703 269,610
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
38,660 10.3876 272,969
(9) Ophthalmologist & Nurse 36,959 10.2774 271,362
0.8 1.0 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 33,758 10.3831 277,736 ✓
(3) FFA & Nurse 34,788 10.2744 273,445
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 35,032 10.3751 276,221
(6) OCT & Nurse 36,072 10.2668 271,932
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
33,779 10.3825 277,697
(9) Ophthalmologist & Nurse 34,809 10.2739 273,407
0.9 0.5 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 60,343 10.5119 255,013
(3) FFA & Nurse 46,394 10.4057 265,776 ✓
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 64,640 10.5039 250,476
(6) OCT & Nurse 49,068 10.3978 262,867
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
60,362 10.5112 254,975
(9) Ophthalmologist & Nurse 46,414 10.4051 265,738
0.9 0.6 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 54,861 10.5096 260,425
(3) FFA & Nurse 44,074 10.4034 268,026 ✓
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TABLE 62 Two-way sensitivity analysis: ophthalmologist monitoring sensitivity and specificity
(NMB at £30,000) (continued )
Ophthalmologist
monitoring
Strategy
Expected
cost (£)
Expected
QALYs
NMB
(£)
Maximum
NMBSensitivity Specificity
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 58,554 10.5015 256,490
(6) OCT & Nurse 46,470 10.3955 265,394
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
54,881 10.5089 260,387
(9) Ophthalmologist & Nurse 44,095 10.4028 267,988
0.9 0.7 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 49,502 10.5073 265,717
(3) FFA & Nurse 41,780 10.4011 270,252 ✓
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 52,589 10.4991 262,385
(6) OCT & Nurse 43,897 10.3931 267,897
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
49,522 10.5067 265,678
(9) Ophthalmologist & Nurse 41,800 10.4005 270,213
0.9 0.8 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,259 10.5051 270,893
(3) FFA & Nurse 39,511 10.3988 272,453 ✓
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 46,742 10.4969 268,164
(6) OCT & Nurse 41,350 10.3908 270,376
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,280 10.5045 270,854
(9) Ophthalmologist & Nurse 39,531 10.3982 272,415
0.9 0.9 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 39,130 10.5029 275,957 ✓
(3) FFA & Nurse 37,266 10.3966 274,631
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 41,008 10.4946 273,831
(6) OCT & Nurse 38,827 10.3886 272,831
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
39,151 10.5023 275,918
(9) Ophthalmologist & Nurse 37,287 10.3960 274,592
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TABLE 62 Two-way sensitivity analysis: ophthalmologist monitoring sensitivity and specificity
(NMB at £30,000) (continued )
Ophthalmologist
monitoring
Strategy
Expected
cost (£)
Expected
QALYs
NMB
(£)
Maximum
NMBSensitivity Specificity
0.9 1.0 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 34,111 10.5008 280,913 ✓
(3) FFA & Nurse 35,045 10.3944 276,786
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 35,384 10.4924 279,389
(6) OCT & Nurse 36,328 10.3863 275,263
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
34,132 10.5002 280,873
(9) Ophthalmologist & Nurse 35,066 10.3938 276,747
1.0 0.5 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 61,151 10.6006 256,868
(3) FFA & Nurse 46,920 10.5057 268,253 ✓
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 65,449 10.5923 252,322
(6) OCT & Nurse 49,592 10.4976 265,334
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
61,170 10.6000 256,829
(9) Ophthalmologist & Nurse 46,940 10.5051 268,214
1.0 0.6 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 55,592 10.6015 262,455
(3) FFA & Nurse 44,548 10.5047 270,594 ✓
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 59,284 10.5932 258,511
(6) OCT & Nurse 46,942 10.4965 267,953
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
55,611 10.6009 262,415
(9) Ophthalmologist & Nurse 44,568 10.5041 270,555
1.0 0.7 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 50,144 10.6024 267,927
(3) FFA & Nurse 42,200 10.5037 272,912 ✓
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 53,231 10.5939 264,586
(6) OCT & Nurse 44,316 10.4955 270,549
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TABLE 62 Two-way sensitivity analysis: ophthalmologist monitoring sensitivity and specificity
(NMB at £30,000) (continued )
Ophthalmologist
monitoring
Strategy
Expected
cost (£)
Expected
QALYs
NMB
(£)
Maximum
NMBSensitivity Specificity
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
50,164 10.6017 267,887
(9) Ophthalmologist & Nurse 42,220 10.5031 272,873
1.0 0.8 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,806 10.6031 273,288
(3) FFA & Nurse 39,875 10.5028 275,207 ✓
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 47,288 10.5946 270,550
(6) OCT & Nurse 41,713 10.4945 273,121
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,827 10.6025 273,248
(9) Ophthalmologist & Nurse 39,896 10.5021 275,168
1.0 0.9 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 39,574 10.6038 278,541 ✓
(3) FFA & Nurse 37,574 10.5018 277,480
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 41,450 10.5952 276,407
(6) OCT & Nurse 39,133 10.4935 275,671
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
39,595 10.6032 278,501
(9) Ophthalmologist & Nurse 37,594 10.5012 277,440
1.0 1.0 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 34,445 10.6045 283,690 ✓
(3) FFA & Nurse 35,295 10.5008 279,730
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 35,716 10.5958 282,159
(6) OCT & Nurse 36,576 10.4925 278,198
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
34,466 10.6038 283,650
(9) Ophthalmologist & Nurse 35,316 10.5002 279,690
NMB, net monetary benefit.
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TABLE 63 One-way sensitivity analysis: probability ophthalmologist monitoring assessment having unclear results
Ophthalmologist
monitoring
assessment
unclear
results (%) Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
0 (3) FFA & Nurse 39,548 10.470
(9) Ophthalmologist
& Nurse
39,569 10.469 21 –0.001 –33,315 Dominated
(6) OCT & Nurse 41,400 10.462 1852 –0.008 –226,583 Dominated
(2) FFA
& Ophthalmologist
44,524 10.572 4976 0.102 48,739
(8) Ophthalmologist
& Ophthalmologist
44,544 10.571 20 –0.001 –31,134 Dominated
(5) OCT
& Ophthalmologist
47,035 10.563 2511 –0.008 –298,363 Dominated
(1) FFA & OCT 62,759 10.449 18,235 –0.122 –148,955 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 18,254 –0.123 –148,350 Dominated
(4) OCT & OCT 67,421 10.442 22,897 –0.130 –175,949 Dominated
0.1 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
0.2 (3) FFA & Nurse 39,991 10.476
(9) Ophthalmologist
& Nurse
40,012 10.475 21 –0.001 –33,159 Dominated
(6) OCT & Nurse 41,815 10.468 1824 –0.008 –222,233 Dominated
(2) FFA
& Ophthalmologist
44,778 10.578 4787 0.102 46,820
(8) Ophthalmologist
& Ophthalmologist
44,798 10.578 20 –0.001 –31,053 Dominated
(5) OCT
& Ophthalmologist
47,231 10.570 2453 –0.008 –289,539 Dominated
(1) FFA & OCT 62,759 10.449 17,981 –0.129 –139,671 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 18,000 –0.129 –139,140 Dominated
(4) OCT & OCT 67,421 10.442 22,643 –0.136 –165,940 Dominated
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TABLE 63 One-way sensitivity analysis: probability ophthalmologist monitoring assessment having
unclear results (continued )
Ophthalmologist
monitoring
assessment
unclear
results (%) Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
0.3 (3) FFA & Nurse 40,214 10.479
(9) Ophthalmologist
& Nurse
40,234 10.478 21 –0.001 –33,081 Dominated
(6) OCT & Nurse 42,024 10.471 1811 –0.008 –220,072 Dominated
(2) FFA
& Ophthalmologist
44,911 10.581 4698 0.102 45,894
(8) Ophthalmologist
& Ophthalmologist
44,931 10.581 20 –0.001 –31,011 Dominated
(5) OCT
& Ophthalmologist
47,335 10.573 2423 –0.009 –285,164 Dominated
(1) FFA & OCT 62,759 10.449 17,848 –0.132 –135,275 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 17,867 –0.133 –134,778 Dominated
(4) OCT & OCT 67,421 10.442 22,510 –0.140 –161,186 Dominated
0.4 3) FFA & Nurse 40,437 10.482
9) Ophthalmologist
& Nurse
40,458 10.482 20 –0.001 –33,003 Dominated
6) OCT & Nurse 42,234 10.474 1797 –0.008 –217,921 Dominated
2) FFA
& Ophthalmologist
45,048 10.585 4611 0.102 44,991
8) Ophthalmologist
& Ophthalmologist
45,068 10.584 20 –0.001 –30,969 Dominated
5) OCT
& Ophthalmologist
47,443 10.576 2394 –0.009 –280,815 Dominated
(1) FFA & OCT 62,759 10.449 17,711 –0.135 –131,033 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 17,730 –0.136 –130,567 Dominated
(4) OCT & OCT 67,421 10.442 22,373 –0.143 –156,587 Dominated
0.5 (3) FFA & Nurse 40,661 10.485
(9) Ophthalmologist
& Nurse
40,682 10.485 20 –0.001 –32,926 Dominated
(6) OCT & Nurse 42,445 10.477 1784 –0.008 –215,780 Dominated
(2) FFA
& Ophthalmologist
45,189 10.588 4528 0.103 44,111
(8) Ophthalmologist
& Ophthalmologist
45,209 10.587 20 –0.001 –30,925 Dominated
(5) OCT
& Ophthalmologist
47,554 10.579 2365 –0.009 –276,491 Dominated
(1) FFA & OCT 62,759 10.449 17,570 –0.138 –126,936 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 17,589 –0.139 –126,500 Dominated
(4) OCT & OCT 67,421 10.442 22,233 –0.146 –152,138 Dominated
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TABLE 64 One-way sensitivity analysis: nurse/technician monitoring assessment sensitivity
Nurse
monitoring
assessment
sensitivity Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
0.1 (3) FFA & Nurse 32,207 8.877
(9) Ophthalmologist
& Nurse
32,229 8.877 22 0.000 –116,739 Dominated
(6) OCT & Nurse 34,065 8.874 1859 –0.003 –623,825 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 12,443 1.698 7329
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
0.2 (3) FFA & Nurse 33,490 9.193
(9) Ophthalmologist
& Nurse
33,512 9.193 22 0.000 –81,140 Dominated
(6) OCT & Nurse 35,346 9.189 1856 –0.004 –469,932 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 11,159 1.382 8077
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
0.3 (3) FFA & Nurse 34,692 9.465
(9) Ophthalmologist
& Nurse
34,714 9.465 22 0.000 –63,348 Dominated
(6) OCT & Nurse 36,545 9.460 1853 –0.005 –383,994 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 9957 1.110 8973
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
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TABLE 64 One-way sensitivity analysis: nurse/technician monitoring assessment sensitivity (continued )
Nurse
monitoring
assessment
sensitivity Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
0.4 (3) FFA & Nurse 35,788 9.699
(9) Ophthalmologist
& Nurse
35,809 9.699 22 0.000 –52,864 Dominated
(6) OCT & Nurse 37,638 9.693 1850 –0.006 –330,369 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 8862 0.876 10,115
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
0.5 (3) FFA & Nurse 36,773 9.900
(9) Ophthalmologist
& Nurse
36,794 9.900 21 0.000 –46,047 Dominated
(6) OCT & Nurse 38,620 9.894 1847 –0.006 –294,327 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 7876 0.675 11,672
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
0.6 (3) FFA & Nurse 37,654 10.074
(9) Ophthalmologist
& Nurse
37,675 10.074 21 –0.001 –41,312 Dominated
(6) OCT & Nurse 39,499 10.067 1845 –0.007 –268,779 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 6995 0.501 13,967
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
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TABLE 64 One-way sensitivity analysis: nurse/technician monitoring assessment sensitivity (continued )
Nurse
monitoring
assessment
sensitivity Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
0.7 (3) FFA & Nurse 38,440 10.225
(9) Ophthalmologist
& Nurse
38,461 10.225 21 –0.001 –37,863 Dominated
(6) OCT & Nurse 40,282 10.218 1842 –0.007 –249,932 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 6209 0.350 17,753
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
0.8 (3) FFA & Nurse 39,142 10.357
(9) Ophthalmologist
& Nurse
39,162 10.357 21 –0.001 –35,259 Dominated
(6) OCT & Nurse 40,982 10.349 1840 –0.008 –235,590 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 5507 0.218 25,280
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
0.9 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
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TABLE 64 One-way sensitivity analysis: nurse/technician monitoring assessment sensitivity (continued )
Nurse
monitoring
assessment
sensitivity Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
1.0 (3) FFA & Nurse 40,332 10.575
(9) Ophthalmologist
& Nurse
40,352 10.574 20 –0.001 –31,631 Dominated
(6) OCT & Nurse 42,168 10.566 1836 –0.009 –215,499 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4318 0.000 31,416,455
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
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TABLE 65 One-way sensitivity analysis: nurse/technician monitoring assessment specificity
Nurse
monitoring
assessment
specificity Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
0.1 (2) FFA
& Ophthalmologist
44,649 10.575
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(3) FFA & Nurse 47,769 10.476 3120 –0.099 –31,362 Dominated
(9) Ophthalmologist
& Nurse
47,789 10.475 3140 –0.100 –31,367 Dominated
(6) OCT & Nurse 50,523 10.467 5874 –0.108 –54,589 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
0.2 (2) FFA
& Ophthalmologist
44,649 10.575
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(3) FFA & Nurse 46,156 10.475 1507 –0.100 –15,067 Dominated
(9) Ophthalmologist
& Nurse
46,176 10.474 1527 –0.101 –15,174 Dominated
0.2 (5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(6) OCT & Nurse 48,727 10.467 4078 –0.108 –37,703 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
0.3 (3) FFA & Nurse 44,550 10.474
(9) Ophthalmologist
& Nurse
44,570 10.474 20 –0.001 –32,581 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 99 0.101 988
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(6) OCT & Nurse 46,938 10.466 2288 –0.109 –21,050 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
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TABLE 65 One-way sensitivity analysis: nurse/technician monitoring assessment specificity (continued )
Nurse
monitoring
assessment
specificity Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
0.4 (3) FFA & Nurse 42,950 10.474
(9) Ophthalmologist
& Nurse
42,970 10.473 20 –0.001 –32,800 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 1699 0.101 16,809
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(6) OCT & Nurse 45,154 10.466 505 –0.109 –4624 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
0.5 (3) FFA & Nurse 41,356 10.473
(9) Ophthalmologist
& Nurse
41,377 10.473 20 –0.001 –33,019 Dominated
(6) OCT & Nurse 43,378 10.465 2021 –0.008 –247,178 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 3293 0.102 32,401
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
0.6 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
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TABLE 65 One-way sensitivity analysis: nurse/technician monitoring assessment specificity (continued )
Nurse
monitoring
assessment
specificity Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
0.7 (3) FFA & Nurse 38,188 10.472
(9) Ophthalmologist
& Nurse
38,209 10.472 21 –0.001 –33,454 Dominated
(6) OCT & Nurse 39,843 10.464 1655 –0.008 –201,701 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 6461 0.103 62,917
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
0.8 (3) FFA & Nurse 36,614 10.472
(9) Ophthalmologist
& Nurse
36,635 10.471 21 –0.001 –33,672 Dominated
(6) OCT & Nurse 38,085 10.464 1472 –0.008 –179,071 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 8035 0.103 77,851
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
0.9 (3) FFA & Nurse 35,046 10.471
(9) Ophthalmologist
& Nurse
35,066 10.471 21 –0.001 –33,888 Dominated
(6) OCT & Nurse 36,334 10.463 1288 –0.008 –156,514 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 9604 0.104 92,575
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
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TABLE 65 One-way sensitivity analysis: nurse/technician monitoring assessment specificity (continued )
Nurse
monitoring
assessment
specificity Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
1.0 (3) FFA & Nurse 33,484 10.471
(9) Ophthalmologist
& Nurse
33,505 10.470 21 –0.001 –34,105 Dominated
(6) OCT & Nurse 34,589 10.463 1105 –0.008 –134,030 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 11,166 0.104 107,095
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
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TABLE 66 Two-way sensitivity analysis: nurse- or technician-led monitoring sensitivity and specificity
(NMB at £30,000)
Nurse monitoring
Strategy
Expected
cost (£)
Expected
QALYs
NMB
(£)
Maximum
NMBSensitivity Specificity
0.6 0.4 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601 ✓
(3) FFA & Nurse 40,503 10.0787 261,857
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 42,714 10.0718 259,441
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 40,524 10.0782 261,821
0.6 0.5 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601 ✓
(3) FFA & Nurse 39,074 10.0764 263,218
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 41,102 10.0696 260,985
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,095 10.0759 263,182
0.6 0.6 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601 ✓
(3) FFA & Nurse 37,654 10.0742 264,571
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 39,499 10.0673 262,521
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 37,675 10.0737 264,535
0.6 0.7 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601 ✓
(3) FFA & Nurse 36,242 10.0720 265,917
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 37,903 10.0651 264,049
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TABLE 66 Two-way sensitivity analysis: nurse- or technician-led monitoring sensitivity and specificity
(NMB at £30,000) (continued )
Nurse monitoring
Strategy
Expected
cost (£)
Expected
QALYs
NMB
(£)
Maximum
NMBSensitivity Specificity
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 36,263 10.0714 265,881
0.6 0.8 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601 ✓
(3) FFA & Nurse 34,837 10.0698 267,256
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 36,316 10.0629 265,571
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 34,858 10.0692 267,219
0.6 0.9 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601 ✓
(3) FFA & Nurse 33,440 10.0676 268,587
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 34,736 10.0607 267,084
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 33,462 10.0671 268,550
0.6 1.0 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601 ✓
(3) FFA & Nurse 32,051 10.0654 269,911
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 33,163 10.0585 268,591
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 32,073 10.0649 269,874
0.7 0.4 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601 ✓
(3) FFA & Nurse 41,424 10.2286 265,433
(4) OCT & OCT 67,421 10.4417 245,830
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TABLE 66 Two-way sensitivity analysis: nurse- or technician-led monitoring sensitivity and specificity
(NMB at £30,000) (continued )
Nurse monitoring
Strategy
Expected
cost (£)
Expected
QALYs
NMB
(£)
Maximum
NMBSensitivity Specificity
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 43,633 10.2212 263,004
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 41,445 10.2280 265,396
0.6 0.5 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601 ✓
(3) FFA & Nurse 39,928 10.2269 266,879
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 41,954 10.2196 264,633
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,949 10.2264 266,842
0.6 0.6 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601 ✓
(3) FFA & Nurse 38,440 10.2253 268,318
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 40,282 10.2179 266,255
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 38,461 10.2247 268,280
0.6 0.7 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601 ✓
(3) FFA & Nurse 36,959 10.2236 269,750
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 38,618 10.2163 267,869
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 36,980 10.2231 269,712
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TABLE 66 Two-way sensitivity analysis: nurse- or technician-led monitoring sensitivity and specificity
(NMB at £30,000) (continued )
Nurse monitoring
Strategy
Expected
cost (£)
Expected
QALYs
NMB
(£)
Maximum
NMBSensitivity Specificity
0.6 0.8 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601 ✓
(3) FFA & Nurse 35,485 10.2220 271,175
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 36,961 10.2146 269,477
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 35,507 10.2215 271,137
0.6 0.9 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601 ✓
(3) FFA & Nurse 34,019 10.2204 272,593
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 35,312 10.2130 271,078
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 34,040 10.2198 272,555
0.6 1.0 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 32,560 10.2188 274,004 ✓
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 33,669 10.2114 272,672
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 32,581 10.2182 273,966
0.8 0.4 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601 ✓
(3) FFA & Nurse 42,235 10.3593 268,545
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 44,441 10.3515 266,105
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
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TABLE 66 Two-way sensitivity analysis: nurse- or technician-led monitoring sensitivity and specificity
(NMB at £30,000) (continued )
Nurse monitoring
Strategy
Expected
cost (£)
Expected
QALYs
NMB
(£)
Maximum
NMBSensitivity Specificity
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 42,255 10.3587 268,506
0.8 0.5 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601 ✓
(3) FFA & Nurse 40,685 10.3582 270,062
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 42,708 10.3504 267,805
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 40,705 10.3576 270,024
0.8 0.6 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601 ✓
(3) FFA & Nurse 39,142 10.3571 271,573
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 40,982 10.3493 269,498
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,162 10.3566 271,534
0.8 0.7 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 37,606 10.3561 273,077 ✓
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 39,263 10.3483 271,185
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 37,626 10.3555 273,038
0.8 0.8 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 36,076 10.3550 274,574 ✓
(4) OCT & OCT 67,421 10.4417 245,830
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TABLE 66 Two-way sensitivity analysis: nurse- or technician-led monitoring sensitivity and specificity
(NMB at £30,000) (continued )
Nurse monitoring
Strategy
Expected
cost (£)
Expected
QALYs
NMB
(£)
Maximum
NMBSensitivity Specificity
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 37,550 10.3472 272,866
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 36,097 10.3544 274,536
0.8 0.9 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 34,554 10.3540 276,065 ✓
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 35,844 10.3461 274,539
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 34,575 10.3534 276,027
0.8 1.0 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 33,038 10.3529 277,550 ✓
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 34,145 10.3451 276,207
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 33,059 10.3523 277,511
0.9 0.4 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601 ✓
(3) FFA & Nurse 42,950 10.4739 271,267
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 45,154 10.4657 268,818
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 42,970 10.4733 271,229
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TABLE 66 Two-way sensitivity analysis: nurse- or technician-led monitoring sensitivity and specificity
(NMB at £30,000) (continued )
Nurse monitoring
Strategy
Expected
cost (£)
Expected
QALYs
NMB
(£)
Maximum
NMBSensitivity Specificity
0.9 0.5 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 41,356 10.4734 272,845 ✓
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 43,378 10.4652 270,578
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 41,377 10.4728 272,806
0.9 0.6 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 39,769 10.4728 274,416 ✓
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 41,607 10.4647 272,332
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 39,790 10.4722 274,377
0.9 0.7 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 38,188 10.4723 275,981 ✓
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 39,843 10.4641 274,080
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 38,209 10.4717 275,942
0.9 0.8 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 36,614 10.4718 277,540 ✓
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 38,085 10.4636 275,822
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TABLE 66 Two-way sensitivity analysis: nurse- or technician-led monitoring sensitivity and specificity
(NMB at £30,000) (continued )
Nurse monitoring
Strategy
Expected
cost (£)
Expected
QALYs
NMB
(£)
Maximum
NMBSensitivity Specificity
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 36,635 10.4712 277,501
0.9 0.9 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 35,046 10.4713 279,092 ✓
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 36,334 10.4630 277,557
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 35,066 10.4707 279,053
0.9 1.0 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 33,484 10.4707 280,639 ✓
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 34,589 10.4625 279,286
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 33,505 10.4701 280,599
1.0 0.4 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 43,584 10.5749 273,664 ✓
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 45,787 10.5664 271,206
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 43,604 10.5743 273,624
1.0. 0.5 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 41,955 10.5749 275,292 ✓
(4) OCT & OCT 67,421 10.4417 245,830
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TABLE 66 Two-way sensitivity analysis: nurse- or technician-led monitoring sensitivity and specificity
(NMB at £30,000) (continued )
Nurse monitoring
Strategy
Expected
cost (£)
Expected
QALYs
NMB
(£)
Maximum
NMBSensitivity Specificity
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 43,974 10.5664 273,017
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 41,975 10.5742 275,252
1.0 0.6 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 40,332 10.5749 276,914 ✓
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 42,168 10.5663 274,823
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 40,352 10.5742 276,875
1.0 0.7 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 38,714 10.5748 278,531 ✓
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 40,367 10.5663 276,622
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 38,735 10.5742 278,491
1.0 0.8 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 37,103 10.5748 280,141 ✓
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 38,573 10.5663 278,415
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 37,124 10.5742 280,101
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TABLE 66 Two-way sensitivity analysis: nurse- or technician-led monitoring sensitivity and specificity
(NMB at £30,000) (continued )
Nurse monitoring
Strategy
Expected
cost (£)
Expected
QALYs
NMB
(£)
Maximum
NMBSensitivity Specificity
1.0 0.9 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 35,498 10.5748 281,746 ✓
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 36,784 10.5662 280,203
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 35,518 10.5741 281,706
1.0 1.0 (1) FFA & OCT 62,759 10.4494 250,724
(2) FFA & Ophthalmologist 44,649 10.5750 272,601
(3) FFA & Nurse 33,898 10.5748 283,345 ✓
(4) OCT & OCT 67,421 10.4417 245,830
(5) OCT & Ophthalmologist 47,131 10.5666 269,866
(6) OCT & Nurse 35,001 10.5662 281,984
(7) Ophthalmologist & OCT 62,778 10.4488 250,686
(8) Ophthalmologist
& Ophthalmologist
44,669 10.5744 272,561
(9) Ophthalmologist & Nurse 33,919 10.5741 283,305
NMB, net monetary benefit.
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TABLE 67 One-way sensitivity analysis: probability nurse/technician monitoring assessment unclear
Nurse
monitoring
assessment
unclear (%) Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
0 (3) FFA & Nurse 39,518 10.460
(9) Ophthalmologist
& Nurse
39,539 10.460 21 –0.001 –33,469 Dominated
(6) OCT & Nurse 41,306 10.452 1788 –0.008 –219,099 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 5131 0.115 44,737
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,919 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
0.1 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
0.2 (3) FFA & Nurse 40,027 10.485
(9) Ophthalmologist
& Nurse
40,048 10.485 21 –0.001 –33,009 Dominated
(6) OCT & Nurse 41,915 10.477 1888 –0.008 –229,688 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4622 0.090 51,428
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,958 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
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TABLE 67 One-way sensitivity analysis: probability nurse/technician monitoring assessment unclear (continued )
Nurse
monitoring
assessment
unclear (%) Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
0.3 (3) FFA & Nurse 40,292 10.497
(9) Ophthalmologist
& Nurse
40,312 10.497 21 –0.001 –32,787 Dominated
(6) OCT & Nurse 42,230 10.489 1938 –0.008 –234,954 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4357 0.078 55,983
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,978 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
0.4 (3) FFA & Nurse 40,563 10.509
(9) Ophthalmologist
& Nurse
40,584 10.508 20 –0.001 –32,570 Dominated
(6) OCT & Nurse 42,552 10.501 1989 –0.008 –240,202 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4086 0.066 61,882
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,998 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
0.5 (3) FFA & Nurse 40,841 10.521
(9) Ophthalmologist
& Nurse
40,862 10.520 20 –0.001 –32,358 Dominated
(6) OCT & Nurse 42,880 10.512 2039 –0.008 –245,435 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 3808 0.054 69,925
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –294,018 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
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TABLE 68 One-way sensitivity analysis: OCT unit cost
OCT unit
cost (£) Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
30 (9) Ophthalmologist
& Nurse
37,446 10.472
(3) FFA & Nurse 37,446 10.473 1 0.001 835
(6) OCT & Nurse 39,071 10.465 1625 –0.008 –198,353 Dominated
(8) Ophthalmologist
& Ophthalmologist
42,317 10.574 4870 0.102 47,980
(2) FFA
& Ophthalmologist
42,318 10.575 1 0.001 1398
(5) OCT
& Ophthalmologist
44,586 10.567 2268 –0.008 –268,648 Dominated
(7) Ophthalmologist
& OCT
60,434 10.449 18,116 –0.126 –143,560 Dominated
(1) FFA & OCT 60,436 10.449 18,118 –0.126 –144,295 Dominated
(4) OCT & OCT 64,885 10.442 22,567 –0.133 –169,320 Dominated
40 (3) FFA & Nurse 38,538 10.473
(9) Ophthalmologist
& Nurse
38,548 10.472 9 –0.001 –15,184 Dominated
(6) OCT & Nurse 40,263 10.465 1725 –0.008 –210,601 Dominated
(2) FFA
& Ophthalmologist
43,414 10.575 4875 0.102 47,723
(8) Ophthalmologist
& Ophthalmologist
43,423 10.574 9 –0.001 –13,878 Dominated
(5) OCT
& Ophthalmologist
45,783 10.567 2369 –0.008 –280,538 Dominated
(1) FFA & OCT 61,528 10.449 18,114 –0.126 –144,264 Dominated
(7) Ophthalmologist
& OCT
61,536 10.449 18,122 –0.126 –143,608 Dominated
(4) OCT & OCT 66,078 10.442 22,664 –0.133 –170,044 Dominated
50 (3) FFA & Nurse 39,630 10.473
(9) Ophthalmologist
& Nurse
39,650 10.472 19 –0.001 –31,202 Dominated
(6) OCT & Nurse 41,456 10.465 1825 –0.008 –222,848 Dominated
(2) FFA
& Ophthalmologist
44,510 10.575 4879 0.102 47,763
(8) Ophthalmologist
& Ophthalmologist
44,529 10.574 19 –0.001 –29,154 Dominated
(5) OCT
& Ophthalmologist
46,979 10.567 2469 –0.008 –292,428 Dominated
(1) FFA & OCT 62,620 10.449 18,110 –0.126 –144,233 Dominated
(7) Ophthalmologist
& OCT
62,638 10.449 18,128 –0.126 –143,656 Dominated
(4) OCT & OCT 67,270 10.442 22,760 –0.133 –170,767 Dominated
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TABLE 68 One-way sensitivity analysis: OCT unit cost (continued )
OCT unit
cost (£) Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
60 (3) FFA & Nurse 40,722 10.473
(9) Ophthalmologist
& Nurse
40,752 10.472 29 –0.001 –47,221 Dominated
(6) OCT & Nurse 42,648 10.465 1926 –0.008 –235,095 Dominated
(2) FFA
& Ophthalmologist
45,606 10.575 4884 0.102 47,803
(8) Ophthalmologist
& Ophthalmologist
45,635 10.574 29 –0.001 –44,429 Dominated
(5) OCT
& Ophthalmologist
48,176 10.567 2569 –0.008 –304,319 Dominated
(1) FFA & OCT 63,712 10.449 18,106 –0.126 –144,201 Dominated
(7) Ophthalmologist
& OCT
63,740 10.449 18,134 –0.126 –143,703 Dominated
(4) OCT & OCT 68,462 10.442 22,856 –0.133 –171,491 Dominated
70 (3) FFA & Nurse 41,814 10.473
(9) Ophthalmologist
& Nurse
41,854 10.472 39 –0.001 –63,240 Dominated
(6) OCT & Nurse 43,840 10.465 2026 –0.008 –247,342 Dominated
(2) FFA
& Ophthalmologist
46,702 10.575 4888 0.102 47,842
(8) Ophthalmologist
& Ophthalmologist
46,741 10.574 39 –0.001 –59,705 Dominated
(5) OCT
& Ophthalmologist
49,372 10.567 2670 –0.008 –316,209 Dominated
(1) FFA & OCT 64,805 10.449 18,102 –0.126 –144,170 Dominated
(7) Ophthalmologist
& OCT
64,842 10.449 18,140 –0.126 –143,751 Dominated
(4) OCT & OCT 69,655 10.442 22,953 –0.133 –172,214 Dominated
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TABLE 69 One-way sensitivity analysis: FFA unit cost
FFA unit
cost (£) Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
80 (3) FFA & Nurse 39,503 10.473
(9) Ophthalmologist
& Nurse
39,533 10.472 30 –0.001 –47,802 Dominated
(6) OCT & Nurse 41,360 10.465 1857 –0.008 –226,713 Dominated
(2) FFA
& Ophthalmologist
44,207 10.575 4704 0.102 46,042
(8) Ophthalmologist
& Ophthalmologist
44,236 10.574 29 –0.001 –44,992 Dominated
(5) OCT
& Ophthalmologist
46,690 10.567 2483 –0.008 –294,041 Dominated
(1) FFA & OCT 62,721 10.449 18,514 –0.126 –147,446 Dominated
(7) Ophthalmologist
& OCT
62,749 10.449 18,542 –0.126 –146,934 Dominated
(4) OCT & OCT 67,417 10.442 23,210 –0.133 –174,147 Dominated
90 (3) FFA & Nurse 39,575 10.473
(9) Ophthalmologist
& Nurse
39,602 10.472 27 –0.001 –43,865 Dominated
(6) OCT & Nurse 41,427 10.465 1852 –0.008 –226,089 Dominated
(2) FFA
& Ophthalmologist
44,326 10.575 4751 0.102 46,509
(8) Ophthalmologist
& Ophthalmologist
44,353 10.574 27 –0.001 –41,236 Dominated
(5) OCT
& Ophthalmologist
46,809 10.567 2482 –0.008 –294,013 Dominated
(1) FFA & OCT 62,731 10.449 18,405 –0.126 –146,577 Dominated
(7) Ophthalmologist
& OCT
62,757 10.449 18,430 –0.126 –146,050 Dominated
(4) OCT & OCT 67,418 10.442 23,092 –0.133 –173,258 Dominated
100 (3) FFA & Nurse 39,647 10.473
(9) Ophthalmologist
& Nurse
39,672 10.472 25 –0.001 –39,929 Dominated
(6) OCT & Nurse 41,494 10.465 1847 –0.008 –225,465 Dominated
(2) FFA
& Ophthalmologist
44,446 10.575 4799 0.102 46,975
(8) Ophthalmologist
& Ophthalmologist
44,470 10.574 24 –0.001 –37,479 Dominated
(5) OCT
& Ophthalmologist
46,928 10.567 2482 –0.008 –293,985 Dominated
(1) FFA & OCT 62,741 10.449 18,295 –0.126 –145,707 Dominated
(7) Ophthalmologist
& OCT
62,765 10.449 18,319 –0.126 –145,165 Dominated
(4) OCT & OCT 67,420 10.442 22,974 –0.133 –172,370 Dominated
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TABLE 69 One-way sensitivity analysis: FFA unit cost (continued )
FFA unit
cost (£) Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
110 (3) FFA & Nurse 39,719 10.473
(9) Ophthalmologist
& Nurse
39,741 10.472 22 –0.001 –35,992 Dominated
(6) OCT & Nurse 41,560 10.465 1842 –0.008 –224,840 Dominated
(2) FFA
& Ophthalmologist
44,565 10.575 4847 0.102 47,442
(8) Ophthalmologist
& Ophthalmologist
44,587 10.574 22 –0.001 –33,723 Dominated
(5) OCT
& Ophthalmologist
47,047 10.567 2482 –0.008 –293,958 Dominated
(1) FFA & OCT 62,752 10.449 18,186 –0.126 –144,837 Dominated
(7) Ophthalmologist
& OCT
62,772 10.449 18,207 –0.126 –144,281 Dominated
(4) OCT & OCT 67,421 10.442 22,855 –0.133 –171,481 Dominated
120 (3) FFA & Nurse 39,791 10.473
(9) Ophthalmologist
& Nurse
39,811 10.472 20 –0.001 –32,056 Dominated
(6) OCT & Nurse 41,627 10.465 1837 –0.008 –224,216 Dominated
(2) FFA
& Ophthalmologist
44,685 10.575 4894 0.102 47,908
(8) Ophthalmologist
& Ophthalmologist
44,704 10.574 19 –0.001 –29,967 Dominated
(5) OCT
& Ophthalmologist
47,167 10.567 2482 –0.008 –293,930 Dominated
(1) FFA & OCT 62,762 10.449 18,077 –0.126 –143,968 Dominated
(7) Ophthalmologist
& OCT
62,780 10.449 18,095 –0.126 –143,396 Dominated
(4) OCT & OCT 67,422 10.442 22,737 –0.133 –170,593 Dominated
130 (3) FFA & Nurse 39,863 10.473
(9) Ophthalmologist
& Nurse
39,880 10.472 17 –0.001 –28,119 Dominated
(6) OCT & Nurse 41,694 10.465 1831 –0.008 –223,592 Dominated
(2) FFA
& Ophthalmologist
44,805 10.575 4942 0.102 48,374
(8) Ophthalmologist
& Ophthalmologist
44,822 10.574 17 –0.001 –26,211 Dominated
(5) OCT
& Ophthalmologist
47,286 10.567 2482 –0.008 –293,903 Dominated
(1) FFA & OCT 62,772 10.449 17,968 –0.126 –143,098 Dominated
(7) Ophthalmologist
& OCT
62,788 10.449 17,984 –0.126 –142,512 Dominated
(4) OCT & OCT 67,423 10.442 22,618 –0.133 –169,704 Dominated
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TABLE 69 One-way sensitivity analysis: FFA unit cost (continued )
FFA unit
cost (£) Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
140 (3) FFA & Nurse 39,934 10.473
(9) Ophthalmologist
& Nurse
39,949 10.472 15 –0.001 –24,182 Dominated
(6) OCT & Nurse 41,761 10.465 1826 –0.008 –222,967 Dominated
(2) FFA
& Ophthalmologist
44,924 10.575 4990 0.102 48,841
(8) Ophthalmologist
& Ophthalmologist
44,939 10.574 15 –0.001 –22,454 Dominated
(5) OCT
& Ophthalmologist
47,405 10.567 2481 –0.008 –293,875 Dominated
(1) FFA & OCT 62,783 10.449 17,859 –0.126 –142,229 Dominated
(7) Ophthalmologist
& OCT
62,796 10.449 17,872 –0.126 –141,627 Dominated
(4) OCT & OCT 67,424 10.442 22,500 –0.133 –168,815 Dominated
DOI: 10.3310/hta18690 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 69
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Mowatt et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
241
TABLE 70 One-way sensitivity analysis: ranibizumab unit cost (per injection)
Unit cost for
ranibizumab
(£) Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
0 (1) FFA & OCT 15,064 10.449
(7) Ophthalmologist
& OCT
15,087 10.449 23 –0.001 –36,724 Dominated
(2) FFA
& Ophthalmologist
16,110 10.575 1047 0.126 8335
(8) Ophthalmologist
& Ophthalmologist
16,133 10.574 23 –0.001 –35,089 Dominated
(4) OCT & OCT 16,226 10.442 116 –0.133 –867 Dominated
(5) OCT
& Ophthalmologist
17,364 10.567 1254 –0.008 –148,531 Dominated
(3) FFA & Nurse 17,386 10.473 1276 –0.102 –12,486 Dominated
(9) Ophthalmologist
& Nurse
17,409 10.472 1298 –0.103 –12,633 Dominated
(6) OCT & Nurse 18,647 10.465 2537 –0.110 –22,993 Dominated
50 (2) FFA
& Ophthalmologist
18,033 10.575
(8) Ophthalmologist
& Ophthalmologist
18,055 10.574 23 –0.001 –34,820 Dominated
(1) FFA & OCT 18,277 10.449 244 –0.126 –1944 Dominated
(7) Ophthalmologist
& OCT
18,300 10.449 267 –0.126 –2114 Dominated
(3) FFA & Nurse 18,894 10.473 861 –0.102 –8427 Dominated
(9) Ophthalmologist
& Nurse
18,916 10.472 884 –0.103 –8597 Dominated
(5) OCT
& Ophthalmologist
19,370 10.567 1337 –0.008 –158,327 Dominated
(4) OCT & OCT 19,675 10.442 1642 –0.133 –12,320 Dominated
(6) OCT & Nurse 20,194 10.465 2161 –0.110 –19,586 Dominated
100 (2) FFA
& Ophthalmologist
19,955 10.575
(8) Ophthalmologist
& Ophthalmologist
19,978 10.574 22 –0.001 –34,551 Dominated
(3) FFA & Nurse 20,402 10.473 446 –0.102 –4368 Dominated
(9) Ophthalmologist
& Nurse
20,424 10.472 469 –0.103 –4561 Dominated
(5) OCT
& Ophthalmologist
21,375 10.567 1420 –0.008 –168,123 Dominated
(1) FFA & OCT 21,490 10.449 1535 –0.126 –12,222 Dominated
(7) Ophthalmologist
& OCT
21,513 10.449 1557 –0.126 –12,339 Dominated
(6) OCT & Nurse 21,741 10.465 1786 –0.110 –16,180 Dominated
(4) OCT & OCT 23,124 10.442 3168 –0.133 –23,772 Dominated
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TABLE 70 One-way sensitivity analysis: ranibizumab unit cost (per injection) (continued )
Unit cost for
ranibizumab
(£) Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
250 (3) FFA & Nurse 24,926 10.473
(9) Ophthalmologist
& Nurse
24,948 10.472 22 –0.001 –35,686 Dominated
(2) FFA
& Ophthalmologist
25,723 10.575 798 0.102 7810
(8) Ophthalmologist
& Ophthalmologist
25,745 10.574 22 –0.001 –33,743 Dominated
(6) OCT & Nurse 26,381 10.465 658 –0.110 –5962 Dominated
(5) OCT
& Ophthalmologist
27,391 10.567 1668 –0.008 –197,512 Dominated
(1) FFA & OCT 31,130 10.449 5406 –0.126 –43,056 Dominated
(7) Ophthalmologist
& OCT
31,151 10.449 5428 –0.126 –43,014 Dominated
(4) OCT & OCT 33,471 10.442 7748 –0.133 –58,129 Dominated
500 (3) FFA & Nurse 32,465 10.473
(9) Ophthalmologist
& Nurse
32,487 10.472 21 –0.001 –34,442 Dominated
(6) OCT & Nurse 34,115 10.465 1650 –0.008 –201,441 Dominated
(2) FFA
& Ophthalmologist
35,337 10.575 2871 0.102 28,107
(8) Ophthalmologist
& Ophthalmologist
35,358 10.574 21 –0.001 –32,397 Dominated
(5) OCT
& Ophthalmologist
37,418 10.567 2081 –0.008 –246,492 Dominated
(1) FFA & OCT 47,196 10.449 11,859 –0.126 –94,447 Dominated
(7) Ophthalmologist
& OCT
47,216 10.449 11,879 –0.126 –94,138 Dominated
(4) OCT & OCT 50,716 10.442 15,379 –0.133 –115,391 Dominated
750 (3) FFA & Nurse 40,005 10.473
(9) Ophthalmologist
& Nurse
40,026 10.472 21 –0.001 –33,198 Dominated
(6) OCT & Nurse 41,849 10.465 1844 –0.008 –225,146 Dominated
(2) FFA
& Ophthalmologist
44,950 10.575 4945 0.102 48,404
(8) Ophthalmologist
& Ophthalmologist
44,970 10.574 20 –0.001 –31,052 Dominated
(5) OCT
& Ophthalmologist
47,445 10.567 2495 –0.008 –295,472 Dominated
(1) FFA & OCT 63,262 10.449 18,312 –0.126 –145,838 Dominated
(7) Ophthalmologist
& OCT
63,281 10.449 18,331 –0.126 –145,263 Dominated
(4) OCT & OCT 67,962 10.442 23,011 –0.133 –172,653 Dominated
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TABLE 70 One-way sensitivity analysis: ranibizumab unit cost (per injection) (continued )
Unit cost for
ranibizumab
(£) Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs ICER Dominated
1000 (3) FFA & Nurse 47,545 10.473
(9) Ophthalmologist
& Nurse
47,565 10.472 20 –0.001 –31,954 Dominated
(6) OCT & Nurse 49,583 10.465 2038 –0.008 –248,850 Dominated
(2) FFA
& Ophthalmologist
54,564 10.575 7018 0.102 68,701
(8) Ophthalmologist
& Ophthalmologist
54,583 10.574 19 –0.001 –29,706 Dominated
(5) OCT
& Ophthalmologist
57,472 10.567 2908 –0.008 –344,453 Dominated
(1) FFA & OCT 79,328 10.449 24,765 –0.126 –197,229 Dominated
(7) Ophthalmologist
& OCT
79,346 10.449 24,782 –0.126 –196,387 Dominated
(4) OCT & OCT 85,207 10.442 30,643 –0.133 –229,914 Dominated
1500 (3) FFA & Nurse 62,625 10.473
(9) Ophthalmologist
& Nurse
62,643 10.472 18 –0.001 –29,466 Dominated
(6) OCT & Nurse 65,052 10.465 2427 –0.008 –296,260 Dominated
(2) FFA
& Ophthalmologist
73,790 10.575 11,166 0.102 109,294
(8) Ophthalmologist
& Ophthalmologist
73,808 10.574 18 –0.001 –27,014 Dominated
(5) OCT
& Ophthalmologist
77,526 10.567 3735 –0.008 –442,414 Dominated
(1) FFA & OCT 111,461 10.449 37,670 –0.126 –300,011 Dominated
(7) Ophthalmologist
& OCT
111,476 10.449 37,685 –0.126 –298,636 Dominated
(4) OCT & OCT 119,697 10.442 45,907 –0.133 –344,438 Dominated
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TABLE 71 One-way sensitivity analysis: cycle number from which ranibizumab injection is assumed to have zero
unit cost
Cycle number
(month) Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs
20 (2) FFA & Ophthalmologist 20,496 10.575
(8) Ophthalmologist
& Ophthalmologist
20,516 10.574 –31,610 Dominated
(3) FFA & Nurse 21,096 10.473 –5877 Dominated
(9) Ophthalmologist & Nurse 21,117 10.472 –6046 Dominated
(1) FFA & OCT 21,383 10.449 –7064 Dominated
(7) Ophthalmologist & OCT 21,403 10.449 –7186 Dominated
(5) OCT & Ophthalmologist 21,928 10.567 –169,602 Dominated
(6) OCT & Nurse 22,455 10.465 –17,749 Dominated
(4) OCT & OCT 23,010 10.442 –18,867 Dominated
30 (2) FFA & Ophthalmologist 22,099 10.575
(8) Ophthalmologist
& Ophthalmologist
22,119 10.574 –31,597 Dominated
(3) FFA & Nurse 22,341 10.473 –2374 Dominated
(9) Ophthalmologist & Nurse 22,362 10.472 –2563 Dominated
(5) OCT & Ophthalmologist 23,608 10.567 –178,823 Dominated
(6) OCT & Nurse 23,735 10.465 –14,830 Dominated
(1) FFA & OCT 24,137 10.449 –16,237 Dominated
(7) Ophthalmologist & OCT 24,157 10.449 –16,313 Dominated
(4) OCT & OCT 25,990 10.442 –29,197 Dominated
40 (3) FFA & Nurse 23,536 10.473
(9) Ophthalmologist & Nurse 23,557 10.472 –33,809 Dominated
(2) FFA & Ophthalmologist 23,639 10.575 1004
(8) Ophthalmologist
& Ophthalmologist
23,659 10.574 –31,582 Dominated
(6) OCT & Nurse 24,964 10.465 –12,010 Dominated
(5) OCT & Ophthalmologist 25,223 10.567 –187,585 Dominated
(1) FFA & OCT 26,785 10.449 –25,054 Dominated
(7) Ophthalmologist & OCT 26,805 10.449 –25,086 Dominated
(4) OCT & OCT 28,851 10.442 –39,107 Dominated
50 (3) FFA & Nurse 24,684 10.473
(9) Ophthalmologist & Nurse 24,705 10.472 –33,789 Dominated
(2) FFA & Ophthalmologist 25,118 10.575 4251
(8) Ophthalmologist
& Ophthalmologist
25,139 10.574 –31,565 Dominated
(6) OCT & Nurse 26,144 10.465 –9296 Dominated
(5) OCT & Ophthalmologist 26,772 10.567 –195,899 Dominated
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TABLE 71 One-way sensitivity analysis: cycle number from which ranibizumab injection is assumed to have zero
unit cost (continued )
Cycle number
(month) Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs
(1) FFA & OCT 29,327 10.449 –33,518 Dominated
(7) Ophthalmologist & OCT 29,347 10.449 –33,507 Dominated
(4) OCT & OCT 31,596 10.442 –48,603 Dominated
60 (3) FFA & Nurse 25,784 10.473
(9) Ophthalmologist & Nurse 25,805 10.472 –33,766 Dominated
(2) FFA & Ophthalmologist 26,537 10.575 7368
(8) Ophthalmologist
& Ophthalmologist
26,557 10.574 –31,546 Dominated
(6) OCT & Nurse 27,275 10.465 –6686 Dominated
(5) OCT & Ophthalmologist 28,258 10.567 –203,778 Dominated
(1) FFA & OCT 31,764 10.449 –41,629 Dominated
(7) Ophthalmologist & OCT 31,784 10.449 –41,578 Dominated
(4) OCT & OCT 34,226 10.442 –57,687 Dominated
70 (3) FFA & Nurse 26,837 10.473
(9) Ophthalmologist & Nurse 26,858 10.472 –33,742 Dominated
(2) FFA & Ophthalmologist 27,895 10.575 10,356
(8) Ophthalmologist
& Ophthalmologist
27,916 10.574 –31,526 Dominated
(6) OCT & Nurse 28,357 10.465 –4181 Dominated
(5) OCT & Ophthalmologist 29,679 10.567 –211,234 Dominated
(1) FFA & OCT 34,097 10.449 –49,392 Dominated
(7) Ophthalmologist & OCT 34,117 10.449 –49,302 Dominated
(4) OCT & OCT 36,741 10.442 –66,365 Dominated
80 (3) FFA & Nurse 27,844 10.473
(9) Ophthalmologist & Nurse 27,865 10.472 –33,717 Dominated
(2) FFA & Ophthalmologist 29,194 10.575 13,217
(8) Ophthalmologist
& Ophthalmologist
29,215 10.574 –31,506 Dominated
(6) OCT & Nurse 29,391 10.465 –1780 Dominated
(5) OCT & Ophthalmologist 31,037 10.567 –218,279 Dominated
(1) FFA & OCT 36,327 10.449 –56,808 Dominated
(7) Ophthalmologist & OCT 36,347 10.449 –56,682 Dominated
(4) OCT & OCT 39,143 10.442 –74,642 Dominated
90 (3) FFA & Nurse 28,805 10.473
(9) Ophthalmologist & Nurse 28,825 10.472 –33,691 Dominated
(6) OCT & Nurse 30,377 10.465 –191,957 Dominated
(2) FFA & Ophthalmologist 30,434 10.575 15,951
(8) Ophthalmologist
& Ophthalmologist
30,454 10.574 –31,484 Dominated
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TABLE 71 One-way sensitivity analysis: cycle number from which ranibizumab injection is assumed to have zero
unit cost (continued )
Cycle number
(month) Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs
(5) OCT & Ophthalmologist 32,333 10.567 –224,925 Dominated
(1) FFA & OCT 38,455 10.449 –63,882 Dominated
(7) Ophthalmologist & OCT 38,475 10.449 –63,720 Dominated
(4) OCT & OCT 41,433 10.442 –82,523 Dominated
100 (3) FFA & Nurse 29,719 10.473
(9) Ophthalmologist & Nurse 29,740 10.472 –33,665 Dominated
(6) OCT & Nurse 31,316 10.465 –194,908 Dominated
(2) FFA & Ophthalmologist 31,615 10.575 18,559
(8) Ophthalmologist
& Ophthalmologist
31,636 10.574 –31,462 Dominated
(5) OCT & Ophthalmologist 33,567 10.567 –231,184 Dominated
(1) FFA & OCT 40,482 10.449 –70,616 Dominated
(7) Ophthalmologist & OCT 40,502 10.449 –70,420 Dominated
(4) OCT & OCT 43,612 10.442 –90,013 Dominated
110 (3) FFA & Nurse 30,589 10.473
(9) Ophthalmologist & Nurse 30,610 10.472 –33,638 Dominated
(6) OCT & Nurse 32,208 10.465 –197,680 Dominated
(2) FFA & Ophthalmologist 32,739 10.575 21,043
(8) Ophthalmologist
& Ophthalmologist
32,759 10.574 –31,439 Dominated
(5) OCT & Ophthalmologist 34,740 10.567 –237,067 Dominated
(1) FFA & OCT 42,409 10.449 –77,015 Dominated
(7) Ophthalmologist & OCT 42,428 10.449 –76,787 Dominated
(4) OCT & OCT 45,683 10.442 –97,119 Dominated
120 (3) FFA & Nurse 31,413 10.473
(9) Ophthalmologist & Nurse 31,434 10.472 –33,611 Dominated
(6) OCT & Nurse 33,054 10.465 –200,280 Dominated
(2) FFA & Ophthalmologist 33,804 10.575 23,404
(8) Ophthalmologist
& Ophthalmologist
33,825 10.574 –31,416 Dominated
(5) OCT & Ophthalmologist 35,853 10.567 –242,585 Dominated
(1) FFA & OCT 44,236 10.449 –83,080 Dominated
(7) Ophthalmologist & OCT 44,256 10.449 –82,822 Dominated
(4) OCT & OCT 47,645 10.442 –103,844 Dominated
(2) FFA & Ophthalmologist 20,496 10.575
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TABLE 72 Two-way sensitivity analysis: discount rates for cost and QALYs (NMB at £30,000)
Discount rate
Strategy
Expected
cost (£)
Expected
QALYs
NMB
(£)
Maximum
NMBCosts (%) QALYs (%)
0 0 (1) FFA & OCT 88,482 14.665 351,465
(2) FFA & Ophthalmologist 62,690 14.867 383,317
(3) FFA & Nurse 55,747 14.702 385,326 ✓
(4) OCT & OCT 94,956 14.654 344,673
(5) OCT & Ophthalmologist 66,141 14.855 379,520
(6) OCT & Nurse 58,304 14.691 382,433
(7) Ophthalmologist & OCT 88,501 14.664 351,420
(8) Ophthalmologist
& Ophthalmologist
62,711 14.866 383,270
(9) Ophthalmologist & Nurse 55,767 14.702 385,280
0.01 0.01 (1) FFA & OCT 79,586 13.211 316,729
(2) FFA & Ophthalmologist 56,451 13.385 345,109
(3) FFA & Nurse 50,221 13.243 347,070 ✓
(4) OCT & OCT 85,439 13.201 310,588
(5) OCT & Ophthalmologist 59,569 13.375 341,676
(6) OCT & Nurse 52,532 13.233 344,454
(7) Ophthalmologist & OCT 79,605 13.210 316,686
(8) Ophthalmologist
& Ophthalmologist
56,471 13.385 345,065
(9) Ophthalmologist & Nurse 50,242 13.242 347,026
0.02 0.02 (1) FFA & OCT 72,037 11.974 287,173
(2) FFA & Ophthalmologist 51,156 12.126 312,623
(3) FFA & Nurse 45,532 12.002 314,529 ✓
(4) OCT & OCT 77,358 11.965 281,589
(5) OCT & Ophthalmologist 53,990 12.116 309,502
(6) OCT & Nurse 47,631 11.993 312,151
(7) Ophthalmologist & OCT 72,056 11.973 287,133
(8) Ophthalmologist
& Ophthalmologist
51,176 12.125 312,581
(9) Ophthalmologist & Nurse 45,552 12.001 314,487
0.03 0.03 (1) FFA & OCT 65,588 10.915 261,863
(2) FFA & Ophthalmologist 46,633 11.049 284,824
(3) FFA & Nurse 41,526 10.940 286,671 ✓
(4) OCT & OCT 70,452 10.907 256,757
(5) OCT & Ophthalmologist 49,223 11.040 281,970
(6) OCT & Nurse 43,444 10.931 284,497
(7) Ophthalmologist & OCT 65,607 10.914 261,824
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TABLE 72 Two-way sensitivity analysis: discount rates for cost and QALYs (NMB at £30,000) (continued )
Discount rate
Strategy
Expected
cost (£)
Expected
QALYs
NMB
(£)
Maximum
NMBCosts (%) QALYs (%)
(8) Ophthalmologist
& Ophthalmologist
46,653 11.048 284,784
(9) Ophthalmologist & Nurse 41,547 10.939 286,631
0.04 0.04 (1) FFA & OCT 60,045 10.003 240,053
(2) FFA & Ophthalmologist 42,746 10.121 260,886
(3) FFA & Nurse 38,083 10.025 262,674 ✓
(4) OCT & OCT 64,514 9.996 235,362
(5) OCT & Ophthalmologist 45,124 10.113 258,265
(6) OCT & Nurse 39,845 10.017 260,676
(7) Ophthalmologist & OCT 60,064 10.003 240,016
(8) Ophthalmologist
& Ophthalmologist
42,766 10.120 260,848
(9) Ophthalmologist & Nurse 38,104 10.025 262,635
0.05 0.05 (1) FFA & OCT 55,252 9.213 221,149
(2) FFA & Ophthalmologist 39,384 9.318 240,151
(3) FFA & Nurse 35,106 9.233 241,879 ✓
(4) OCT & OCT 59,377 9.206 216,817
(5) OCT & Ophthalmologist 41,579 9.310 237,731
(6) OCT & Nurse 36,731 9.226 240,035
(7) Ophthalmologist & OCT 55,271 9.213 221,113
(8) Ophthalmologist
& Ophthalmologist
39,404 9.317 240,114
(9) Ophthalmologist & Nurse 35,127 9.232 241,842
0.06 0.06 (1) FFA & OCT 51,083 8.525 204,668
(2) FFA & Ophthalmologist 36,460 8.618 222,087
(3) FFA & Nurse 32,517 8.542 223,756 ✓
(4) OCT & OCT 54,908 8.519 200,652
(5) OCT & Ophthalmologist 38,495 8.611 219,843
(6) OCT & Nurse 34,023 8.536 222,047
(7) Ophthalmologist & OCT 51,102 8.525 204,634
(8) Ophthalmologist
& Ophthalmologist
36,481 8.618 222,051
(9) Ophthalmologist & Nurse 32,538 8.542 223,720
NMB, net monetary benefit.
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TABLE 73 One-way sensitivity analysis: prevalence for nAMD
nAMD
prevalence Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs Strategy
Expected
cost (£)
0.1 (9) Ophthalmologist
& Nurse
9785 11.109
(3) FFA & Nurse 9820 11.109 34 0.000 388,603
(8) Ophthalmologist
& Ophthalmologist
10,979 11.130 1159 0.021 55,404
(2) FFA
& Ophthalmologist
11,013 11.130 34 0.000 370,944
(7) Ophthalmologist
& OCT
15,389 11.106 4376 –0.024 –184,037 Dominated
(1) FFA & OCT 15,424 11.107 4411 –0.024 –186,193 Dominated
(6) OCT & Nurse 15,524 11.108 4511 –0.022 –204,863 Dominated
(5) OCT
& Ophthalmologist
18,663 11.130 7650 –0.001 –12,771,991 Dominated
(4) OCT & OCT 29,660 11.107 18,647 –0.023 –813,472 Dominated
0.2 (9) Ophthalmologist
& Nurse
14,786 11.003
(3) FFA & Nurse 14,811 11.003 25 0.000 142,530
(8) Ophthalmologist
& Ophthalmologist
16,594 11.038 1783 0.034 51,892
(2) FFA
& Ophthalmologist
16,619 11.038 25 0.000 136,422
(6) OCT & Nurse 19,871 11.001 3252 –0.037 –88,510 Dominated
(7) Ophthalmologist
& OCT
23,288 10.997 6668 –0.041 –163,248 Dominated
(1) FFA & OCT 23,313 10.997 6694 –0.041 –164,599 Dominated
(5) OCT
& Ophthalmologist
23,408 11.036 6789 –0.002 –3,561,016 Dominated
(4) OCT & OCT 35,954 10.996 19,334 –0.041 –467,969 Dominated
0.3 (9) Ophthalmologist
& Nurse
19,787 10.897
(3) FFA & Nurse 19,803 10.897 16 0.000 60,505
(8) Ophthalmologist
& Ophthalmologist
22,209 10.945 2406 0.048 50,354
(2) FFA
& Ophthalmologist
22,225 10.945 16 0.000 58,248
(6) OCT & Nurse 24,218 10.894 1993 –0.051 –38,729 Dominated
(5) OCT
& Ophthalmologist
28,152 10.942 5927 –0.003 –1,844,329 Dominated
(7) Ophthalmologist
& OCT
31,186 10.887 8960 –0.058 –154,713 Dominated
(1) FFA & OCT 31,202 10.888 8977 –0.058 –155,725 Dominated
(4) OCT & OCT 42,247 10.885 20,022 –0.060 –335,328 Dominated
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TABLE 73 One-way sensitivity analysis: prevalence for nAMD (continued )
nAMD
prevalence Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs Strategy
Expected
cost (£)
0.4 (9) Ophthalmologist
& Nurse
24,787 10.791
(3) FFA & Nurse 24,794 10.791 7 0.000 19,493
(8) Ophthalmologist
& Ophthalmologist
27,824 10.852 3030 0.061 49,491
(2) FFA
& Ophthalmologist
27,831 10.853 7 0.000 19,161
(6) OCT & Nurse 28,565 10.786 734 –0.066 –11,095 Dominated
(5) OCT
& Ophthalmologist
32,897 10.848 5066 –0.005 –1,120,483 Dominated
(7) Ophthalmologist
& OCT
39,084 10.778 11,253 –0.075 –150,064 Dominated
(1) FFA & OCT 39,091 10.778 11,260 –0.075 –150,889 Dominated
(4) OCT & OCT 48,541 10.775 20,710 –0.078 –265,161 Dominated
0.5 (3) FFA & Nurse 29,786 10.685
(9) Ophthalmologist
& Nurse
29,788 10.685 2 0.000 –5,114 Dominated
(6) OCT & Nurse 32,913 10.679 3127 –0.006 –539,595 Dominated
(2) FFA
& Ophthalmologist
33,437 10.760 3651 0.075 48,610
(8) Ophthalmologist
& Ophthalmologist
33,439 10.760 2 0.000 –4,291 Dominated
(5) OCT
& Ophthalmologist
37,642 10.754 4205 –0.006 –721,367 Dominated
(1) FFA & OCT 46,981 10.668 13,543 –0.092 –147,846 Dominated
(7) Ophthalmologist
& OCT
46,982 10.668 13,545 –0.092 –147,138 Dominated
(4) OCT & OCT 54,834 10.664 21,397 –0.096 –221,744 Dominated
0.6 (3) FFA & Nurse 34,778 10.579
(9) Ophthalmologist
& Nurse
34,789 10.578 11 –0.001 –21,519 Dominated
(6) OCT & Nurse 37,260 10.572 2482 –0.007 –354,998 Dominated
(2) FFA
& Ophthalmologist
39,043 10.668 4266 0.089 48,125
(8) Ophthalmologist
& Ophthalmologist
39,054 10.667 11 –0.001 –19,926 Dominated
(5) OCT
& Ophthalmologist
42,386 10.660 3343 –0.007 –468,497 Dominated
(1) FFA & OCT 54,870 10.559 15,827 –0.109 –145,754 Dominated
(7) Ophthalmologist
& OCT
54,880 10.558 15,837 –0.109 –145,128 Dominated
(4) OCT & OCT 61,128 10.553 22,085 –0.115 –192,228 Dominated
continued
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TABLE 73 One-way sensitivity analysis: prevalence for nAMD (continued )
nAMD
prevalence Strategy
Expected
cost (£)
Expected
QALYs
Incremental
cost (£)
Incremental
QALYs Strategy
Expected
cost (£)
0.7 (3) FFA & Nurse 39,769 10.473
(9) Ophthalmologist
& Nurse
39,790 10.472 21 –0.001 –33,237 Dominated
(6) OCT & Nurse 41,607 10.465 1838 –0.008 –224,403 Dominated
(2) FFA
& Ophthalmologist
44,649 10.575 4880 0.102 47,768
(8) Ophthalmologist
& Ophthalmologist
44,669 10.574 20 –0.001 –31,094 Dominated
(5) OCT
& Ophthalmologist
47,131 10.567 2482 –0.008 –293,938 Dominated
(1) FFA & OCT 62,759 10.449 18,110 –0.126 –144,229 Dominated
(7) Ophthalmologist
& OCT
62,778 10.449 18,129 –0.126 –143,662 Dominated
(4) OCT & OCT 67,421 10.442 22,772 –0.133 –170,859 Dominated
0.8 (3) FFA & Nurse 44,761 10.367
(9) Ophthalmologist
& Nurse
44,790 10.366 30 –0.001 –42,025 Dominated
(6) OCT & Nurse 45,954 10.357 1194 –0.009 –127,138 Dominated
(2) FFA
& Ophthalmologist
50,255 10.482 5494 0.116 47,495
(8) Ophthalmologist
& Ophthalmologist
50,284 10.482 29 –0.001 –39,470 Dominated
(5) OCT
& Ophthalmologist
51,876 10.473 1620 –0.010 –166,190 Dominated
(1) FFA & OCT 70,648 10.340 20,393 –0.143 –143,066 Dominated
(7) Ophthalmologist
& OCT
70,676 10.339 20,421 –0.143 –142,545 Dominated
(4) OCT & OCT 73,715 10.331 23,460 –0.152 –154,673 Dominated
0.9 (3) FFA & Nurse 49,752 10.261
(9) Ophthalmologist
& Nurse
49,791 10.260 39 –0.001 –48,860 Dominated
(6) OCT & Nurse 50,302 10.250 549 –0.011 –51,888 Dominated
(2) FFA
& Ophthalmologist
55,861 10.390 6109 0.129 47,279
(8) Ophthalmologist
& Ophthalmologist
55,900 10.389 38 –0.001 –45,984 Dominated
(5) OCT
& Ophthalmologist
56,620 10.379 759 –0.011 –68,648 Dominated
(1) FFA & OCT 78,537 10.230 22,676 –0.160 –142,151 Dominated
(7) Ophthalmologist
& OCT
78,574 10.230 22,713 –0.160 –141,666 Dominated
(4) OCT & OCT 80,009 10.220 24,147 –0.170 –141,988 Dominated
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TABLE 74 Alternative utility weights based on Czoski-Murray et al.78
Strategy Cost (£)
Incremental
cost (£) QALYs
Incremental
QALYs ICER (£)
(3) FFA & Nurse 39,769 – 8.582 0.000 0
(9) Ophthalmologist & Nurse 39,790 21 8.582 0.000 –51,961
(6) OCT & Nurse 41,607 1838 8.577 –0.005 –354,384
(2) FFA & Ophthalmologist 44,649 4880 8.649 0.067 72,717
(8) Ophthalmologist
& Ophthalmologist
44,669 20 8.649 0.000 –49,222
(5) OCT & Ophthalmologist 47,131 2482 8.644 –0.005 –474,382
(1) FFA & OCT 62,759 18,110 8.578 –0.071 –255,538
(7) Ophthalmologist & OCT 62,778 18,129 8.578 –0.071 –254,352
(4) OCT & OCT 67,421 22,772 8.574 –0.076 –301,288
–, there is no incremental cost in this option.
Utility weight used: > 6/12= 0.706; ≤ 6/12 to > 6/24 state= 0.681; ≤ 6/24 to > 6/60 state= 0.511; ≤ 6/60 to > 3/60
state= 0.511; ≤ 3/60= 0.314.
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